dabigatran has been researched along with rivaroxaban in 1591 studies
| Studies (dabigatran) | Trials (dabigatran) | Recent Studies (post-2010) (dabigatran) | Studies (rivaroxaban) | Trials (rivaroxaban) | Recent Studies (post-2010) (rivaroxaban) |
|---|---|---|---|---|---|
| 3,887 | 261 | 3,490 | 4,741 | 569 | 4,357 |
| Protein | Taxonomy | dabigatran (IC50) | rivaroxaban (IC50) |
|---|---|---|---|
| Coagulation factor X | Homo sapiens (human) | 0.0038 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 27 (1.70) | 29.6817 |
| 2010's | 1142 (71.78) | 24.3611 |
| 2020's | 422 (26.52) | 2.80 |
| Authors | Studies |
|---|---|
| Ilaš, J; Kikelj, D; Trstenjak, U | 1 |
| Alet, N; Altenburger, JM; Barre, G; Bocskei, Z; Bono, F; Briot, C; Dol, F; Florian, P; Follmann, M; Herault, JP; Herbert, JM; Klieber, S; Lassalle, G; Meneyrol, J; Millet, L; Petit, F; Rousseaux, T; Sadoun, F; Schaeffer, P; Schreuder, H; Wehner, V | 1 |
| Franco, FM; Han, Z; Harris, PK; Janetka, JW; Jarvis, CM; Jones, DE; Wildman, SA | 1 |
| Fischer, PM | 1 |
| Barth, M; Bendas, G; Bückreiß, N; Butov, KR; Daniliuc, CG; Humpf, HU; Imberg, L; Kalinin, DV; Kalinina, SA; Karst, U; Kastner, GA; Korff, M; Lehr, M; Ovsepyan, RA; Panteleev, MA; Poso, A; Steinmetzer, T; Wenzel, BM; Will, JM | 1 |
| Ma, Q | 1 |
| Eikelboom, JW; Hirsh, J; O'Donnell, M | 1 |
| Gross, PL; Weitz, JI | 2 |
| Harenberg, J; Wehling, M | 1 |
| Turpie, AG | 2 |
| Spyropoulos, AC | 1 |
| Hess, C | 1 |
| Eriksson, BI; Quinlan, DJ; Weitz, JI | 1 |
| Francis, CW | 1 |
| Ferrandis, R; Llau, JV; López Forte, C; Sapena, ML | 1 |
| Bounameaux, H | 1 |
| Farley, TM; Lewis, D; Macaulay, TE | 1 |
| Lassen, MR; Laux, V | 1 |
| Darius, H | 3 |
| Harenberg, J; Nitschmann, S | 1 |
| Arnaout, L; Bellamy, L; Rosencher, N | 1 |
| Kamphuisen, PW; Leebeek, FW | 1 |
| Arya, R; Roberts, LN | 1 |
| Crain, EJ; Watson, CA; Wong, PC; Xin, B | 1 |
| Crowther, MA; Lepic, K | 1 |
| Borris, LC | 1 |
| Ferrandis, R; Llau, JV | 1 |
| Eikelboom, J; O'Donnell, M; Sobieraj-Teague, M | 1 |
| Apostolakis, S; Lip, GY; Shantsila, E | 1 |
| Barry, M; McCullagh, L; Tilson, L; Walsh, C | 1 |
| Heindl, B; Spannagl, M | 1 |
| Wittkowsky, AK | 1 |
| Conard, J; Horellou, MH; Samama, MM | 1 |
| Verma, AK | 1 |
| Ufer, M | 1 |
| Gogarten, W; Pauschert, R; Quante, M | 1 |
| Becker, RC; Mackman, N | 1 |
| Banda, ZK; Benmira, S; Bhattacharya, V | 1 |
| Kolundzic, R; Trkulja, V | 1 |
| Bauer, KA | 2 |
| Weitz, JI | 3 |
| Lowenthal, DT; Sattari, M | 1 |
| Ahrens, I; Lip, GY; Peter, K | 2 |
| Fiessinger, JN | 1 |
| Adiguzel, C; Walenga, JM | 1 |
| Jiang, X; Wong, PC | 1 |
| Shakib, S; Tadros, R | 1 |
| Panchenko, EP | 1 |
| Alban, S; Völler, H; Westermann, D | 1 |
| Clemens, A; Monz, BU; Plumb, JM | 1 |
| Crowther, M; Lepic, K | 1 |
| Douketis, JD | 1 |
| Ageno, W; Rancan, E; Romualdi, E; Siragusa, S | 1 |
| Dahl, OE; Huisman, MV; Quinlan, DJ; Schulman, S | 1 |
| Giannoudis, PV; Harwood, PJ; Karadimas, EJ; Nikolaou, VS; Tan, HB | 1 |
| Morris, TA | 1 |
| Baumhäkel, M; Böhm, M; Schirmer, SH | 1 |
| Conard, J; Depasse, F; Guinet, C; Horellou, MH; Le Flem, L; Samama, M | 1 |
| Kwok, CS; Loke, YK | 1 |
| Eikelboom, JW; Eriksson, BI; Quinlan, DJ | 1 |
| Eikelboom, JW; Weitz, JI | 2 |
| Cohen Arazi, H; Di Girolamo, G; Giorgi, MA; Gonzalez, CD | 1 |
| Freyburger, G; Labrouche, S; Macouillard, G; Sztark, F | 1 |
| Diamantopoulos, A; Lees, M; Lereun, C; Rasul, F; Sengupta, N; Wells, P | 1 |
| Samama, CM | 1 |
| Ageno, W; Streif, W | 1 |
| Braunwald, E; Steffel, J | 1 |
| Cerbone, AM; Coppola, A; Franchini, M; Ruosi, C; Tufano, A | 1 |
| Fisher, WD | 1 |
| Nutescu, E | 1 |
| Friedman, RJ | 2 |
| Huisman, MV; Kooiman, J; van de Peppel, WR; van der Meer, FJ | 1 |
| Ajzenberg, N; Dumont, B; Faille, D | 1 |
| Fareed, J; Hull, R; Welzel, D | 1 |
| Keltai, K; Keltai, M | 1 |
| Gawaz, M; Geisler, T | 1 |
| Fadda, V; Maratea, D; Messori, A; Trippoli, S | 1 |
| Kazmi, RS; Lwaleed, BA | 1 |
| Stiefelhagen, P | 5 |
| del Zoppo, GJ; Eliasziw, M | 1 |
| Asmis, LM | 1 |
| Arya, R; Patel, JP; Roberts, LN | 1 |
| Fauchier, L; Le Heuzey, JY; Marijon, E | 1 |
| Büller, HR; Eerenberg, ES; Kamphuisen, PW; Sijpkens, MK; van Es, J | 1 |
| Mega, JL | 1 |
| Mousa, SA | 1 |
| Di Pasquale, G; Riva, L | 2 |
| Buller, HR; Eerenberg, ES; Kamphuisen, PW; Levi, M; Meijers, JC; Sijpkens, MK | 1 |
| Beer, JH | 1 |
| Galanis, T; Kraft, WK; Merli, GJ | 1 |
| Battinelli, EM | 1 |
| Bode, C; Diener, HC; Kaeufer, T | 1 |
| Heidinger, K; Kemkes-Matthes, B | 1 |
| Breen, KA; Hunt, BJ | 1 |
| Fürll, B; Greinacher, A; Hackbarth, C; Krauel, K | 1 |
| Jolobe, OM | 1 |
| Finsterer, J; Stöllberger, C | 4 |
| Bode, C; Moser, M | 1 |
| Combe, S; Conard, J; Flaujac, C; Horellou, MH; Samamaa, MM | 1 |
| Büller, HR; Combe, S | 1 |
| Banerjee, A; Lane, DA; Lip, GY; Torp-Pedersen, C | 1 |
| Abu-Fadel, MS; Dib, C; Golwala, H; Tafur, A | 1 |
| Biller, J; Flaster, M; Morales-Vidal, S; Schneck, MJ | 1 |
| Parma, Z; Syzdół, M; Tendera, M | 1 |
| Godier, A; Lakhdari, M; Martin, AC; Samama, CM | 1 |
| Migliaccio-Walle, K; Rublee, D; Simon, TA | 1 |
| Ageno, W; Crowther, M; Gallus, AS; Hylek, EM; Palareti, G; Wittkowsky, A | 1 |
| Goldhaber, SZ | 1 |
| Alpert, JS | 1 |
| Soff, GA | 1 |
| Mahan, C; Spyropoulos, AC | 1 |
| Cohen, A; Drost, P; Marchant, N; Mitchell, S; Orme, M; Rublee, D; Simon, TA; Sutton, A | 1 |
| Khemasuwan, D; Suramaethakul, N | 1 |
| Espada, NG; González, TC; Merino, RG; Nieto, JA | 1 |
| Palareti, G; Tripodi, A | 1 |
| Bryer, A | 1 |
| Amin, A; Deitelzweig, S; Graham, J; Jing, Y; Lin, J; Makenbaeva, D; Wiederkehr, D | 2 |
| Cohen, AT | 1 |
| Samama, MM | 1 |
| Eisenberg, MJ; Filion, KB; Grandi, SM; Miller, CS; Shimony, A | 1 |
| Haas, S; Schellong, SM; Spannagl, M | 1 |
| Larsen, TB; Lip, GY; Rasmussen, LH; Skjøth, F | 2 |
| Bommer, WJ | 1 |
| Mustonen, P; Puurunen, M | 1 |
| Halperin, JL; Varughese, CJ | 1 |
| Schulman, S | 3 |
| Lewalter, T | 1 |
| Albaladejo, P; Crackowski, JL; Cracowski, JL; Hodaj, E; Marlu, R; Paris, A; Pernod, G | 1 |
| Barry, M; McCullagh, L; Walsh, C | 1 |
| Firriolo, FJ; Hupp, WS | 1 |
| Little, JW | 1 |
| Ismael, AG; Ribowsky, JH | 1 |
| Vivancos Mora, J; Ximénez-Carrillo Rico, A; Zapata Wainberg, G | 1 |
| Licina, MM; Lip, GY; Polovina, MM; Potpara, TS; Prostran, MS; Stojanovic, RM | 1 |
| Gómez-Outes, A; Suárez-Gea, ML; Terleira-Fernández, AI; Vargas-Castrillón, E | 1 |
| Goel, R; Srivathsan, K | 1 |
| Bhatt, DL; Kar, S | 1 |
| Callahan, S; Goldsberry, A; Kim, G; Yoo, S | 1 |
| Levi, M | 1 |
| Ansell, J; Mantha, S | 2 |
| Ball, DG; Day, AG; Gibbens, SL; LaHaye, SA; Olesen, JB; Skanes, AC | 1 |
| Shafir, V; Spinler, SA | 1 |
| Agnifili, M; Bedogni, F; Brambilla, N; De Marco, F; Lanotte, S; Latib, A; Latini, RA; Laudisa, ML; Mattioli, R; Oreglia, J; Pizzocri, S; Testa, L | 1 |
| Larsen, TB; Rasmussen, LH; Skjøth, F | 1 |
| Avorn, J; Choudhry, NK; Gagne, JJ; Patrick, AR; Schneeweiss, S | 1 |
| Pollack, CV | 3 |
| Fareed, J; Kalodiki, E; Lewis, B | 1 |
| Diener, HC; Harenberg, J; Lip, GY; Marder, VJ; Marx, S; Wehling, M; Weiss, C | 1 |
| Stief, TW | 1 |
| Crippa, L; Falanga, A; Finazzi, G; Manotti, C; Marongiu, F; Moia, M; Palareti, G; Pengo, V; Poli, D; Siragusa, S; Testa, S; Tiraferri, E; Tosetto, A; Tripodi, A | 1 |
| Berthold, HK | 1 |
| Mangiafico, M; Mangiafico, RA | 1 |
| Harenberg, J; Marx, S; Wehling, M | 1 |
| Zhang, S | 1 |
| Destephan, C; Dhruvakumar, S; Gerula, C; Kaluski, E; Maher, J; Mazza, V; Patel, RJ; Waller, AH | 1 |
| Carter, KL; Kraus, PS; Ross, PA; Shermock, KM; Streiff, MB; Thomas, ML; Wellman, JC | 1 |
| Griffiths, M; Scully, C | 1 |
| Jin, M; Kamrul, R; Kosar, L; Schuster, B | 1 |
| Cannon, CP; Kohli, P | 1 |
| Bradley-Kennedy, C; Clemens, A; Kansal, AR; Monz, BU; Peng, S; Roskell, N; Sharma, M; Sorensen, SV | 1 |
| Crockett, MT; Kavanagh, EC; Moynagh, MR | 1 |
| Ahmad, Y; Lip, GY | 2 |
| Lyrer, P; Nedeltchev, K; Seiffge, D | 1 |
| Douketis, JD; Gerotziafas, G; Kaatz, S; Ortel, TL; Schulman, S; Spyropoulos, AC | 1 |
| Kopecky, S | 1 |
| Brenner, B; Hoffman, R | 1 |
| Baglin, T; Keeling, D; Kitchen, S | 1 |
| Costopoulos, C; Gorog, DA; Kukreja, N; Niespialowska-Steuden, M | 1 |
| Brouwers, PJ; Kappelle, LJ; Koudstaal, PJ; Roos, YB; van Dijk, EJ | 1 |
| Dahl, OE; Harenberg, J; Marder, VJ; Marx, S; Schulze, A; Wehling, M; Weiss, C | 1 |
| Haas, S; Kreutz, R; Llau, J; Norrving, B; Turpie, AG | 1 |
| Esmon, CT | 1 |
| Le Heuzey, JY | 1 |
| Tripodi, A | 3 |
| Graf, L; Tsakiris, DA | 1 |
| Gonzalez, MD; Naccarelli, GV | 1 |
| Koziński, M; Kubica, A; Kubica, J; Navarese, EP; Obońska, K | 1 |
| McBane, RD; Tafur, A; Wysokinski, WE | 1 |
| Merli, GJ | 1 |
| Favaloro, EJ; Lippi, G | 1 |
| Davies, R | 1 |
| Brasselet, C; Duval, S | 1 |
| Valle Bernad, R | 1 |
| Blanco-Molina, A | 1 |
| Nagler, M; Wuillemin, W | 1 |
| Haschke, M | 1 |
| Kaatz, S; Mahan, CE | 1 |
| Graungaard, T; Larsen, TB; Lip, GY; Rasmussen, LH; Skjøth, F | 1 |
| Lazo-Langner, A; Sun, D | 1 |
| Dabitz, R; Ochs, G | 1 |
| Boehlen, F; de Moerloose, P | 1 |
| Okada, Y; Yasaka, M | 1 |
| Wooten, JM | 1 |
| Martin, EN; Money, SR; Shamoun, FE | 1 |
| Crowther, MA; Siegal, DM | 1 |
| Ortel, TL | 1 |
| Pawlikowska, Z; Szponar, J | 1 |
| Coccheri, S; Orlando, D | 1 |
| Du, S; Giese, C; Harenberg, J; Krämer, R; Krämer, S; Schulze, A; Weiss, C | 1 |
| Gulseth, M; Hellwig, T | 2 |
| Deitelzweig, SB | 1 |
| Eraso, LH; Merli, GJ; Perez, A | 1 |
| Greenspon, AJ | 1 |
| Betegón Nicolás, L; de Salas-Cansado, M; Gómez Arrayas, I; Gómez Cerezo, JF; Rubio-Terrés, C; Suárez Fernández, C | 1 |
| Debue, JM; Guinet, C; Le Flem, L; Ninin, E; Samama, MM | 1 |
| Ikitimur, B; Karadağ, B; Öngen, Z | 1 |
| Brem, E; Foran, M; Koyfman, A | 1 |
| Helin, TA; Joutsi-Korhonen, L; Lassila, R; Pakkanen, A | 1 |
| Graff, J; Harder, S | 2 |
| Garcia, DA; Rojas-Hernandez, CM | 1 |
| Contractor, T; Levin, V; Marchlinski, FE; Martinez, MW | 1 |
| Douketis, JD; Faraoni, D; Levy, JH; Samama, CM; Spring, JL | 1 |
| Dyrkorn, R; Roland, PD | 1 |
| Ageno, W; Bozzato, S; Donadini, MP; Riva, N | 1 |
| Bock, F; Hartung, K; Isermann, B; Meyer, F | 1 |
| Akwaa, F; Spyropoulos, AC | 2 |
| Luettgen, J; White, A; Wong, PC | 1 |
| Galanis, T; Merli, GJ | 1 |
| Berman, JP; Halperin, JL | 1 |
| Lenchus, JD | 1 |
| Apostolakis, S; Kasmeridis, C; Lip, GY | 1 |
| Eby, CS | 1 |
| Roldán Schilling, V; Vicente García, V | 1 |
| Guijarro Merino, R; Villalobos Sánchez, A | 1 |
| Nieto Rodríguez, JA | 1 |
| Marchena Yglesias, PJ | 1 |
| Hernández, M; Suárez, C | 1 |
| Fernández, D; Heras, M; Penela, D | 1 |
| Castillo, J; de Andrés, J; Ferrandis, R; Gomar, C; Gómez-Luque, A; Hidalgo, F; Llau, JV; Torres, LM | 1 |
| Masjuan, J | 1 |
| Dalmau, FG | 1 |
| Kwok, CS; Loke, YK; Pradhan, S; Yeong, JK | 2 |
| Calvo Romero, JM; Lima Rodríguez, EM | 1 |
| Holley, AB; King, CS; Moores, LK | 1 |
| Adler, D; Beeton, A; Büller, H; de Jong, PR; Haas, S; Hsu, HC; Jacobson, BF; Louw, S; Mer, M; Rowji, P; Schapkaitz, E; Wessels, P | 1 |
| Kamphuisen, PW; Lisman, T; Northup, PG; Porte, RJ | 1 |
| Armstrong, EP; Harrington, AR; Malone, DC; Nolan, PE | 1 |
| Eby, C | 1 |
| Jeffery, SM; Ogbonna, KC | 1 |
| Badimón, JJ; Briongos Figuero, S; García Santos-Gallego, C | 1 |
| Limdi, NA; Thigpen, JL | 1 |
| Hughes, DA; Pink, J; Pirmohamed, M | 1 |
| Harris, K; Mant, J | 1 |
| Darius, H; Sommer, S | 1 |
| Bonar, R; Butler, J; Favaloro, EJ; Marsden, K | 1 |
| Gonsalves, WI; Patnaik, MM; Pruthi, RK | 1 |
| Nutescu, EA | 1 |
| Kalus, JS | 1 |
| Arachchillage, DJ; Cohen, H | 1 |
| Spyropoulos, AC; Turpie, AG | 1 |
| Kerr, R; Ogden, G; Sime, G | 1 |
| Böhm, M; Dichgans, M; Diener, HC; Ell, C; Endres, M; Epple, C; Grond, M; Laufs, U; Nickenig, G; Riess, H; Röther, J; Schellinger, PD; Spannagl, M; Steiner, T; Veltkamp, R | 1 |
| Gallego, P; Lip, GY; Roldan, V | 1 |
| Einecke, D | 1 |
| Aisenberg, J; Desai, J; Kolb, JM; Weitz, JI | 1 |
| Brardjanian, S; Coton, T; Diallo, I; Guisset, M; Jourdan, S; Mallaret, C | 1 |
| Aisenberg, J; Desai, J; Granger, CB; Weitz, JI | 1 |
| Klein, HH | 1 |
| Toth, PP | 1 |
| Hagen, G; Hamidi, V; Klemp, M; Reikvam, Å; Ringerike, T | 1 |
| Gong, IY; Kim, RB | 1 |
| Cameron, C; Coyle, D; Coyle, K; Kelly, S; Lee, K; Steiner, S; Wells, GA | 1 |
| Boos, CJ; Camm, AJ; Nam, M | 1 |
| Diener, HC | 1 |
| Douketis, J; Lang, ES; Lazo-Langner, A | 1 |
| Douketis, J; Liew, A | 1 |
| Bates, P; Culpan, P; El-Daly, I; Reidy, J | 1 |
| Baruch, L | 1 |
| Lopes, RD; Newby, LK; Truffa, AA | 1 |
| Crowther, MA; Daw, HA; Fawole, A | 1 |
| Páramo, JA | 1 |
| Rider, EB; Rider, OJ | 1 |
| Castillo, J; de Andrés, J; Ferrandis, R; Gomar, C; Gómez-Luque, A; Hidalgo, F; Llau, JV; Sierra, P; Torres, LM | 1 |
| Bhimani, AA; Hong, M | 1 |
| Kamal, AK; Kamran, SH; Muzammil, SM | 1 |
| Chana, F; Llau, JV; Marco, P; Zamorano, JL | 1 |
| Al-Majzoub, O; Assiri, A; Donovan, JL; Kanaan, AO; Silva, M | 1 |
| Aguilar, MI; Freeman, WD; Kuo, RS | 1 |
| Baumann Kreuziger, LM; Reding, MT | 1 |
| Dalen, JE | 1 |
| Fanikos, J | 1 |
| Wanat, MA | 1 |
| Baglin, T | 1 |
| Avorn, J | 1 |
| Barry, M | 1 |
| Ansell, J; Shameem, R | 1 |
| Lip, GY; Potpara, TS | 2 |
| Diener, HC; Easton, JD; Hankey, GJ; Hart, RG | 1 |
| Bennaghmouch, N; Ten Berg, JM | 1 |
| Agnelli, G; Becattini, C; Franco, L | 1 |
| den Exter, PL; Huisman, MV; Kooiman, J; van der Hulle, T | 1 |
| Eriksson, BI; Quinlan, DJ | 1 |
| Cohen, AA; Rider, T | 1 |
| Majeed, A; Schulman, S | 1 |
| Barco, S; Cheung, YW; Coppens, M; Eikelboom, JW | 1 |
| Kansal, AR; Pokora, T; Sorensen, SV; Zheng, Y | 1 |
| Hollis, S | 1 |
| Brosa, M; Diamantopoulos, A; Folkerts, K; Imberti, D; Monreal, M | 1 |
| Albaladejo, P; Blais, N; Cohen, A; de Maistre, E; Fontana, P; Godier, A; Gruel, Y; Llau, JV; Mismetti, P; Pernod, G; Rosencher, N; Samama, CM; Samama, MM; Schved, JF; Sié, P; Susen, S | 1 |
| Cameron, C; Carrier, M; Castellucci, LA; Clifford, T; Coyle, D; Gandara, E; Le Gal, G; Rodger, MA; Wells, G; Wells, PS | 1 |
| Brunkhorst, R; Foerch, C; Lindhoff-Last, E; Luger, S; Pfeilschifter, W | 1 |
| Azuma, S; Lum, CJ | 1 |
| Hughes, DA; Lane, S; Pink, J; Pirmohamed, M | 1 |
| Ando, M; Hirayama, H; Kihara, Y; Nakano, Y; Sairaku, A; Yoshida, Y | 1 |
| Atar, D; Ghanima, W; Sandset, PM | 1 |
| Dugdale, M; Fabian, TC; Gordon, JL; Lee, MD | 1 |
| Kornej, J; Lip, GY; Potpara, T | 1 |
| Sarode, R; Yates, S | 1 |
| Barbar, S; Milan, M; Pesavento, R; Prandoni, P; Vedovetto, V | 1 |
| Chandler, WL | 1 |
| Diogène, E; Troncoso, A | 1 |
| Liberato, NL; Marchetti, M; Quaglini, S; Rognoni, C | 1 |
| Eikelboom, JW; Kapral, MK; McGrath, ER; O'Donnell, MJ | 1 |
| Braun, G; Messmann, H | 1 |
| Degirmenci, SE; Steib, A | 1 |
| Adelmeijer, J; Arshad, F; Blokzijl, H; Lisman, T; Porte, RJ; Potze, W; van den Berg, AP | 1 |
| Aldin, ES; Greenberg, C; Rachidi, S; Sachs, B; Streiff, M; Zeidan, AM | 1 |
| Frölich, L; Harenberg, J; Krejczy, M; Marx, S; Obermann, K; Wehling, M | 1 |
| Avorn, J; Brennan, TA; Canestaro, WJ; Choudhry, NK; Ito, K; Matlin, OS; Patrick, AR; Shrank, WH | 1 |
| Wood, P | 1 |
| Dütsch, M; Klauser, W | 1 |
| Manning, JA | 1 |
| Kitazono, T | 1 |
| Laffan, M; Shapiro, S | 1 |
| Ragni, MV | 1 |
| Dekkers, OM; den Exter, PL; Huisman, MV; Klok, FA; Kooiman, J; van der Hulle, T | 1 |
| Avram, MJ; Benzon, HT; Bonow, RO; Green, D | 1 |
| Aumann, V; Boxberger, N; Hartung, KJ; Heim, MU; Siegemund, A | 1 |
| Baker, R; Herrmann, R; Muhammad, S; Phillips, M; Thom, J; Wood, A | 1 |
| Barillari, G; Cheng, JW | 1 |
| Crowther, MA; Garcia, DA; Siegal, DM | 1 |
| Alban, S; Birschmann, I; Busse, J; Dittrich, M; Eller, T; Flieder, T; Knabbe, C | 1 |
| Diener, HC; Weber, R | 1 |
| Chantrathammachart, P; Hebbel, RP; Key, NS; Mackman, N; Mickelson, J; Monroe, DM; Pawlinski, R; Sparkenbaugh, EM; van Ryn, J | 1 |
| Bajorek, B; Wang, Y | 1 |
| Goto, S; Tomita, A | 1 |
| Berrut, G; Chevalet, P; De Decker, L; Gegu, M; Piloquet, FX | 1 |
| Hanon, O | 1 |
| Rondina, MT; Vazquez, S; Vo, T | 1 |
| Darvish-Kazem, S; Douketis, JD; Liew, A | 1 |
| Bollmann, A; Breithardt, OA; Dinov, B; Doering, M; Hindricks, G; Kosiuk, J; Koutalas, E; Nedios, S; Richter, S; Rolf, S; Sommer, P | 1 |
| Gupta, K; Singh, D; Vacek, JL | 1 |
| Hosokawa, K; Koide, T; Maruyama, I; Miura, N; Ohnishi, T; Sameshima, H; Tanaka, KA | 1 |
| Giugliano, RP; Gonzalez-Quesada, CJ | 1 |
| Adelmeijer, J; Arshad, F; Blokzijl, H; Lisman, T; Meijers, JC; Porte, RJ; Potze, W; van den Berg, AP | 1 |
| Dorian, P; Hernandez, L; Iloeje, U; Kongnakorn, T; Kuznik, A; Lanitis, T; Lip, GY; Liu, LZ; Phatak, H | 1 |
| Bounameaux, H; Fontana, P; Goldhaber, SZ | 1 |
| Miller, MP; Nordenholz, KE; Trujillo, TC | 1 |
| Albenque, JP; Boveda, S; Combes, N; Combes, S; Hireche, H; Jourda, F; Marijon, E; Morais, J; Providência, R | 1 |
| Angiolillo, DJ; Capodanno, D | 1 |
| Chan, NC; Eikelboom, JW; Ginsberg, JS; Hirsh, J; Lauw, MN; Paikin, JS | 1 |
| Crowther, M; Pasierski, T; Undas, A; Windyga, J | 1 |
| Groh, C; Passman, R; Yadlapati, A | 1 |
| Herrmann, E; Herth, N; Kasper, A; Lindhoff-Last, E; Linnemann, B; Mani, H; Pfeilschifter, W; Schuettfort, G; Weil, Y; Wendt, T | 1 |
| Badhwar, N; Gerstenfeld, EP; Lee, BK; Lee, RJ; Marcus, GM; Olgin, J; Scheinman, M; Stepanyan, G; Tseng, ZH; Vedantham, V | 1 |
| Bassand, JP | 1 |
| Arya, R; Couchman, L; Flanagan, RJ; Gous, T; Paradzai, C; Patel, JP | 1 |
| Bolbrinker, J; Douros, A; Ebinger, M; Kreutz, R; Schlemm, L | 1 |
| Beyer-Westendorf, J; Ebertz, F; Förster, K; Gelbricht, V; Hänsel, U; Köhler, C; Kuhlisch, E; Röder, I; Röllig, D; Schreier, T; Stange, T; Thieme, C; Tittl, L; Weiss, N; Werth, S | 1 |
| Thachil, J | 1 |
| Hagen, G; Klemp, M; Wisløff, T | 1 |
| Fenger-Eriksen, C; Grove, EL; Münster, AM | 1 |
| Piccini, JP; Steinberg, BA | 1 |
| Douketis, J; Ing, E | 1 |
| Gislason, G; Sørensen, R | 1 |
| Davidson, N; Galloway, SW; Lai, A; Thachil, J | 1 |
| Brieger, D | 1 |
| Ardissino, D; Cervellin, G; Lippi, G; Quintavalla, R | 1 |
| Cohen, AT; Imfeld, S; Rider, T | 1 |
| Cotté, FE; Durand-Zaleski, I; Gaudin, AF; Kachaner, I; Kongnakorn, T; Lanitis, T | 1 |
| John, A; Michel, MS | 1 |
| Foley, J; Kirchhof, P; Lip, GY | 1 |
| Avorn, J; Brennan, TA; Brill, G; Choudhry, NK; Desai, NR; Krumme, AA; Matlin, OS; Pezalla, EJ; Schneeweiss, S; Shrank, WH; Spettell, CM | 1 |
| Dempfle, CE | 1 |
| Prandoni, P; Taher, A; Temraz, S | 1 |
| Beer, JH; Holy, EW | 1 |
| Hürlimann, D; Noll, G; Noll, S | 1 |
| Ahrens, I; Bode, C | 1 |
| Evans, RS; Fontaine, GV; Lloyd, JF; Mathews, KD; Stevens, SM; Woller, SC | 1 |
| Corelli, K; Ezekowitz, MD; Ghosh, P; Spahr, J | 1 |
| Expósito, V; Fernández-Fresnedo, G; Seras, M | 1 |
| Avendaño-Solá, C; Gómez-Outes, A; Terleira-Fernández, AI; Vargas-Castrillón, E | 1 |
| Albertson, TE; Cantrell, FL; Clark, RF; Minns, AB; Smollin, C; Stevenson, JW; Tomaszewski, C | 1 |
| Gross, PL; Weitz, JI; Yeh, CH | 1 |
| Hess, T; Konturek, P | 1 |
| Lévy, S | 1 |
| Baker, WL; Chamberlin, KW | 1 |
| Curnow, J; Joseph, J; McLintock, C; McRae, S; Nandurkar, H; Tran, H; Wood, P; Young, L | 1 |
| Kakkos, SK; Kirkilesis, GI; Tsolakis, IA | 1 |
| Angeli, F; Lip, GY; Reboldi, G; Verdecchia, P | 1 |
| Büller, HR; Coppens, M; Middeldorp, S; Schulman, S; van Es, N | 1 |
| Chatelain, C; Devalet, B; Dogné, JM; Douxfils, J; Larock, AS; Mullier, F; Sennesael, AL; Spinewine, A | 1 |
| Watson, HG | 1 |
| Chatterjee, S; Ghosh, J; Giri, JS; Mukherjee, D; Sardar, P | 1 |
| Aryal, MR; Bhandari, Y; Donato, A; Jalota, L; Karmacharya, P; Mainali, NR; Pandit, A; Pathak, R; Pradhan, R; Ukaigwe, A | 1 |
| Berthold, C; Boecher-Schwarz, H; Dooms, G; Gunness, VR; Hana, A; Hertel, F; Koy, J; Matgé, G; Standhardt, H | 1 |
| Cowell, RP | 1 |
| Askonen, K; Halinen, M; Huikuri, H; Koistinen, J; Parikka, H; Puurunen, M; Raatikainen, P; Virtanen, V | 1 |
| Gómez-Outes, A; Lecumberri, R; Suárez-Gea, ML; Terleira-Fernández, AI; Vargas-Castrillón, E | 1 |
| Rodgers, GM; Win, K | 1 |
| Alotaibi, G; Alsaleh, K; Mcmurtry, MS; Wu, C | 1 |
| Chatterjee, S; Halperin, JL; Herzog, E; Mukherjee, D; Nairooz, R; Sardar, P | 1 |
| Byrne, RW; Kasliwal, MK; Lopes, DK; Moftakhar, R; Munoz, LF; Panos, NG | 1 |
| Amin, A; Graham, J; Jing, Y; Lin, J; Lingohr-Smith, M; Trocio, J | 1 |
| Garg, P; Morris, P; Morris, PD; Saraf, K; Sheridan, P; Storey, R | 1 |
| Barucci, R; Fattirolli, F; Fracchia, S; Mannarino, G; Orso, F; Pratesi, A | 1 |
| Mitchell, AR; Page, PL; Thomas, R | 1 |
| Bongu, NR; Kocheril, AG; Turagam, MK; Velagapudi, P | 1 |
| Donovan, JL; Kanaan, AO; Rollins, BM; Silva, MA | 1 |
| Husted, SE; Thorup, SB; Vang, ML | 1 |
| Aryal, MR; Badal, M; Chaudhary, A; Donato, AA; Mege, J | 1 |
| Engel, G; Kong, MH; Mead, RH; Patrawala, RA; Winkle, RA | 1 |
| Black, DF; McBane, RD; Moder, KG; Schaefer, JK; Williams, LN; Wysokinski, WE | 1 |
| Amin, A; Lawrence, JH; Makenbaeva, D; Stokes, M; Wiederkehr, D; Wu, N | 1 |
| Boonen, K; Brunsveld, L; Emmen, JM; Schellings, MW; Schmitz, EM; van de Kerkhof, D; van den Heuvel, DJ; van der Graaf, F; van Dongen, JL | 1 |
| Steurer, J | 3 |
| Bang, OY; Chung, CS; Kim, GM; Kim, JS; Kim, SJ; Lee, KH; Lee, MJ; Park, YK; Ryoo, S; Yoon, CH | 1 |
| Hunt, BJ; Sciascia, S | 1 |
| Moorman, ML; Nash, JE; Stabi, KL | 1 |
| Levy, JH | 2 |
| Bihan, K; Ferreol, L; Funck-Brentano, C; Hulot, JS; Korostelev, M; Tissot, N; Zahr, N | 1 |
| Brueckmann, M; Clemens, A; Konstantinides, S; Lip, GY; Noack, H; Strack, A | 1 |
| Rudakova, AV; Tatarskiĭ, BA | 1 |
| Carroll, VS; Frei, J | 1 |
| Lane, DA; Lip, GY; Senoo, K | 1 |
| Eichinger, S; Gouya, G; Kapiotis, S; Kyrle, PA; Litschauer, B; Mayer, P; Smerda, L; Weisshaar, S; Wolzt, M | 1 |
| Crowther, MA; Cuker, A; Garcia, DA; Siegal, DM | 1 |
| Blann, AD; Lip, GY | 1 |
| Bailleul, E; Chatelain, B; Coucke, W; Demulder, A; Devreese, K; Douxfils, J; Jochmans, K; Mullier, F; Soumali, MR; Van Blerk, M; Van de Walle, P; Vernelen, K; Wijns, W | 1 |
| Fosbøl, EL; Gislason, GH; Hansen, ML; Køber, L; Lamberts, M; Mikkelsen, AP; Olesen, JB; Sørensen, R; Torp-Pedersen, C; Weeke, P | 1 |
| Demulder, A; Safouris, A; Triantafyllou, N; Tsivgoulis, G | 1 |
| Giugliano, RP; Plitt, A | 1 |
| Barnes, GD; Eagle, KA; Froehlich, JB | 1 |
| Madhusudhana, S; Qasem, A; Strasser, KM | 1 |
| Howell, G; Pluym, M | 1 |
| Husein, H; Samo, S; Sherid, M; Sifuentes, H; Spurr, C; Sridhar, S; Sulaiman, S; Thiruvaiyaru, D; Tupper, R | 1 |
| Kadauke, S; Khor, B; Van Cott, EM | 1 |
| Fadda, V; Maratea, D; Marinai, C; Messori, A; Trippoli, S | 1 |
| Dobesh, PP; Fanikos, J | 1 |
| Kovács, T | 1 |
| Ageno, W; Beyer-Westendorf, J | 1 |
| Ko, Y; Kong, MC; Lee, LH; Ng, HJ; Wang, Y; Xie, F | 1 |
| de Boer, A; Hasrat, F; Maitland-van der Zee, AH; Redekop, WK; Verhoef, TI | 1 |
| Ezekowitz, MD; Kent, AP | 1 |
| Berghold, A; Kemperdick, B; Mergenthal, K; Petersen, JJ; Rauck, S; Roehl, I; Schulz-Rothe, S; Siebenhofer, A; Ulrich, LR | 1 |
| Cui, J; Li, Z; Liu, C; Wu, B | 1 |
| Baber, U; Mastoris, I; Mehran, R | 1 |
| Beyer-Westendorf, J | 1 |
| Duart, M; Kauffman, C; Kusumoto, F; Ray, JC; Snipelisky, D; Ung, R | 1 |
| Bell, AD; Douketis, J; Eikelboom, J; Liew, A | 2 |
| Gierek, D; Lasek-Bal, A; Urbanek, T | 1 |
| Adcock, D; Francart, SJ; Gosselin, RC; Grant, RP; Hawes, EM; Moll, S | 1 |
| Gonschior, AK; Heinrich-Nols, J; Kansal, AR; Noack, H; Sorensen, SV; Sunderland, T; Zheng, Y | 1 |
| Andreu-Cayuelas, JM; Gallego, P; Lip, GY; Manzano-Fernández, S; Marín, F; Orenes-Piñero, E; Roldán, V; Valdés, M; Vicente, V | 1 |
| Chatterjee, S; Ghosh, J; Giri, JS; Lavie, CJ; Lip, GY; Mukherjee, D; Sardar, P | 1 |
| da Silva, RM | 1 |
| Davis, EM; Schardt, GL; Schmidt, DP; Uhlmeyer, EM | 1 |
| Allouche, E; Amara, W; Dompnier, A; Fromentin, S; Georger, F; Nguyen, C; Saoudi, N; Taieb, J | 1 |
| Cairns, JA; Weitz, JI | 1 |
| Peacock, WF | 1 |
| Feuerstein, JD; Ketwaroo, GA; Leffler, DA; Patwardhan, VR; Sengupta, N; Tapper, EB; Thaker, AM | 1 |
| Armbruster, HL; Berger, RD; Calkins, H; Habibi, M; Khurram, IM; Lindsley, JP; Marine, JE; Moranville, MP; Spragg, DD | 1 |
| Du, S; Harenberg, J; Krämer, R; Krämer, S; Wehling, M; Weiss, C | 1 |
| Broncel, M; Ciastkowska, A; Duraj, I; Gorzelak-Pabiś, P; Szlagowska, L | 1 |
| Amin, A; Deitelzweig, S | 1 |
| Blann, AD | 1 |
| Dublanchet, N; Dutheil, F; Lebreton, A; Milhaud, G; Moustafa, F; Schmidt, J | 1 |
| Forslund, T; Hjemdahl, P; Holmström, M; Johnsson, H; von Euler, M; Wettermark, B | 1 |
| Amin, A; Bruno, A; Lin, J; Lingohr-Smith, M; Trocio, J | 1 |
| Arepally, GM; Ortel, TL | 1 |
| Bruckner, T; Hess, A; Katus, HA; Kieser, M; Mereles, D; Pohlmeier, M; Scholz, E; Schweizer, PA; Thomas, D; Zitron, E; Zylla, MM | 1 |
| Chan, KE; Edelman, ER; Maddux, FW; Thadhani, RI; Wenger, JB | 1 |
| Bultas, J; Karetová, D | 1 |
| Berengo, M; Brunello, G; De Biagi, M; Pengo, V; Sivolella, S | 1 |
| Clark, B; Daw, H; Ghobrial, M; Haddad, A; Randhawa, J; Spiro, T; Thiruchelvam, N | 1 |
| Crighton, A; Gibson, J; Scott, A | 1 |
| Garg, P; Ripley, DP | 1 |
| Levasseur-Franklin, KE; Liotta, EM; Naidech, AM | 1 |
| Bultas, J | 1 |
| Bacchus, F; Schulman, S | 1 |
| Cantillon, D; Coleman, CM; Kanj, M; Khalaf, S; Mould, S; Saliba, W; Wazni, O | 1 |
| Angaran, P; Bell, AD; Berall, M; Bucci, C; Demchuk, AM; Essebag, V; Goldin, L; Goodman, SG; Green, MS; Gregoire, JC; Gross, PL; Heilbron, B; Lin, PJ; Patel, AD; Ramanathan, K; Skanes, A; Tan, MK; Wheeler, BH | 1 |
| Ferreira, J; Mirco, A | 1 |
| Becker, RC; Krishnamoorthy, A; Lopes, RD; Sherwood, MW | 1 |
| Loffredo, L; Perri, L; Violi, F | 2 |
| Oberhofer, E | 1 |
| Chatelain, B; Devalet, B; Dogné, JM; Douxfils, J; Hjemdahl, P; Mullier, F; Pohanka, A; Rönquist-Nii, Y; Sennesael, AL; Wallemacq, P | 1 |
| Powell, JR | 1 |
| Gessoni, F; Gessoni, G; Valle, R; Valverde, S | 1 |
| Friedman, RJ; Messerschmidt, C | 1 |
| Aleil, B; Krieger, C; Stephan, D | 1 |
| Hogg, K; Weitz, JI; Yeh, CH | 1 |
| Hitos, K; Kumar, N; Phan, K; Pison, L; Thomas, SP; Wang, N | 1 |
| Bovi, P; Cappellari, M | 1 |
| Castiblanco, SA; Garg, J; Jacobs, LE; Palaniswamy, C; Zak, M | 1 |
| Huh, J; Im, SI; Jeong, DS; Kim, JS; On, YK; Park, KM; Park, SJ | 1 |
| Greinacher, A; Selleng, K; Thiele, T | 1 |
| Agnelli, G; Prandoni, P; Verso, M | 1 |
| Harenberg, J; Krejczy, M; Lip, GY; Obermann, K; Wehling, M | 1 |
| Bass, AR | 1 |
| Bnouhanna, W; Cho, TH; Davenas, C; Derex, L; Farghali, A; Mechtouff, L; Nighoghossian, N; Ritzenthaler, T | 1 |
| Hsieh, CY; Hsu, JC; Lu, CY; Yang, YH | 1 |
| Lane, DA; Wood, K | 1 |
| Blaich, C; Michels, G; Müller, C; Wiesen, MH | 1 |
| Abraham, NS; Alexander, GC; Crown, W; Haas, LR; Heien, H; Shah, ND; Singh, S | 1 |
| Alexander, GC; Chang, HY; Singh, S; Tang, W; Zhou, M | 1 |
| Arentz, T; Jadidi, A; Lehrmann, H; Park, CI; Pruvot, E; Weber, R; Zimmermann, M | 1 |
| Dias, JD; Doorneweerd, DD; Norem, K; Omert, LA; Popovsky, MA; Thurer, RL | 1 |
| Gehrie, E; Tormey, C | 1 |
| Amato, A; Dentali, F; Dumonceau, JM; Paggi, S; Radaelli, F; Repici, A; Rondonotti, E | 1 |
| Beyer-Westendorf, J; Breslin, T; NiAinle, F; Werth, S | 1 |
| Cattaneo, M; Lussana, F; Squizzato, A | 1 |
| Hilpert, U | 1 |
| Arpey, CJ; Baum, CL; Brewer, JD; Chang, TW; Hochwalt, PC; Hocker, TL; Otley, CC; Roenigk, RK | 1 |
| Mateo Arranz, J; Millón Caño, JA; Souto Andrés, JC; Vilalta Setó, N | 1 |
| Lip, GY; Proietti, M | 1 |
| Singh, SM; Wijeysundera, HC | 1 |
| Chatelain, B; Devalet, B; Dogné, JM; Douxfils, J; Mani, H; Minet, V; Mullier, F | 1 |
| Beavers, C; Pahs, L; Schuler, P | 1 |
| Ge, D; Morrill, AM; Willett, KC | 1 |
| Kesteven, P; McCaslin, JE; Robertson, L | 2 |
| Butera, JN; Connell, NT | 1 |
| Alexander, GC; Barnes, GD; Goldberger, ZD; Lucas, E | 1 |
| Ganetsky, M | 1 |
| Crawford, B; Morimoto, T; Ueda, S; Wada, K | 1 |
| Du, S; Harenberg, J; Krämer, R; Walenga, J; Wehling, M; Weiss, C; Zolfaghari, S | 1 |
| Marietta, M | 1 |
| Berry, A; Ehrlich, C; Tsu, LV; Wald, E | 1 |
| Gutstein, A; Haim, M; Kadmon, E; Kornowski, R; Leshem-Lev, D; Lev, EI; Lev, EL; Mager, A; Orvin, KL; Vaduganathan, M; Zemer-Wassercug, N | 1 |
| Alla, F; Billionnet, C; Blotière, PO; Bouillon, K; Maura, G; Ricordeau, P; Zureik, M | 1 |
| Altıntaş, F; Önal, A; Özler, T; Uluçay, Ç | 1 |
| Bächli, E; Walti, C | 1 |
| Bookhart, B; Crivera, C; Germain, G; Laliberté, F; Lefebvre, P; Martin, S; Nelson, WW; Schein, J | 1 |
| Coleman, CI; Damaraju, CV; Nelson, WW; Schein, JR; Smith, DM; Song, X; Thomson, E | 1 |
| Goette, A; Hammwöhner, M | 1 |
| Lane, DA; Lee, SI; Lip, GY; Sayers, M | 1 |
| Drambarean, B; Hellenbart, E; Lee, J; Nutescu, EA | 1 |
| Aryal, MR; Donato, AA; Ghimire, S; Giri, S; Jehangir, A; Karmacharya, P; Pathak, R; Poudel, DR; Rettew, A; Shaikh, B | 1 |
| Bode, C; Kelm, M; Zeus, T | 1 |
| Birschmann, I; Blumenstock, G; Ebner, M; Härtig, F; Kuhn, J; Peter, A; Poli, S; Russo, F; Spencer, C; Winter, N; Wolf, M; Ziemann, U; Zuern, CS | 1 |
| Rondina, MT; Vazquez, S | 1 |
| Fosbøl, E; Gislason, G; Jensen, P; Jensen, T; Koeber, L; Olesen, J; Thorsberger, M; Torp-Pedersen, C; Wahlsten, L; Weeke, P | 1 |
| Gagg, J; Thachil, J | 1 |
| Rubboli, A | 2 |
| Komócsi, A | 1 |
| Flaujac, C; Godier, A; Golmard, JL; Gouin-Thibault, I; Horellou, MH; Ibrahim, F; Leblanc, I; Martin, AC; Mazoyer, E; Rosencher, N | 1 |
| Buitrago, F; Capilla Lozano, F; Gallego Fuentes, R; Rodríguez Pérez, L | 1 |
| Arellano-Rodrigo, E; Carné, X; Díaz-Ricart, M; Escolar, G; Galan, AM; Lopez-Vilchez, I; Lozano, M; Molina, P; Reverter, JC; Tassies, D; Villalta, J | 1 |
| Ang, ES; De Silva, DA; Fabiaña, N; Ramaswami, AP | 1 |
| Demir, S; Kendirli, MT; Ozdag, MF; Togrol, RE | 1 |
| Athanasakis, K; Bilitou, A; Karampli, E; Kyriopoulos, J; Tsounis, D | 1 |
| De Francesco, M; Hösel, V; Jugrin, AV; Lamotte, M; Sunderland, T; Ustyugova, A | 1 |
| Bookhart, B; Crivera, C; Deitelzweig, S; Germain, G; Laliberté, F; Lefebvre, P; Martin, S; McHorney, CA; Nelson, WW; Schein, J | 1 |
| Egami, Y; Hara, M; Makino, N; Mori, N; Nishino, M; Okamoto, N; Shutta, R; Tanaka, A; Tanouchi, J; Yano, M | 1 |
| Condliffe, R; Elliot, CA; Hurdman, J; Kiely, DG; Maclean, RM; Quadery, R; Sabroe, I; van Veen, JJ | 1 |
| Heeger, CH; Kuck, KH; Lemes, C; Lin, T; Mathew, S; Metzner, A; Ouyang, F; Plesman, J; Rillig, A; Tilz, RR; Wissner, E; Wohlmuth, P | 1 |
| Ackery, A; Sholzberg, M; Wood, B | 1 |
| Eikelboom, J; Weitz, JI | 1 |
| Afshari, F; Bösche, LI; Ewers, A; Gotzmann, M; Mügge, A; Schöne, D | 1 |
| Riess, H | 1 |
| Cairns, JA; Ciaccia, A; Fisher, WD; Kong, C; Semchuk, W; Turpie, AG; Weitz, JI | 1 |
| Anderson, E; Dyke, C; Glogoza, M; Johnke, K; Leedahl, D; Newman, R | 1 |
| Chan, NC; Dale, BJ; Eikelboom, JW | 1 |
| Goldenberg, NA; Kittelson, JM; Massicotte, MP; Takemoto, CM; Yee, DL | 1 |
| Azimi, N; Forest, CP; Holden, A | 1 |
| Bouget, J; Oger, E | 1 |
| Ageno, W; Bauersachs, R; Couturaud, F; Décousus, H; Mismetti, P | 1 |
| Kanorsky, SG; Shevelev, VI | 1 |
| Brown, KS; Dishy, V; Kochan, J; Maa, JF; Parasrampuria, DA; Shi, M; Weilert, D | 1 |
| Andreu-Cayuelas, JM; Flores-Blanco, PJ; García-Alberola, A; Lip, GY; Manzano-Fernández, S; Mateo-Martínez, A; Pastor-Pérez, FJ; Puche, CM; Roldán, V; Valdés, M | 1 |
| Anto-Michel, N; Bode, C; Diehl, P; Geisen, U; Meyer, M; Moser, M; Olivier, CB; Weber, S; Weik, P; Zhou, Q | 1 |
| Forslund, T; Hjemdahl, P; Wettermark, B | 1 |
| Gonzalez, MG; Levy, PD; Peacock, WF; Than, M | 1 |
| Beney, J; Bochatay, L; Jordan-von Gunten, V; Petignat, PA; Roulet, L | 1 |
| Cuker, A; Siegal, D | 1 |
| Roca, B; Roca, M | 1 |
| Barake, W; Baranchuk, A; Chu, K; Lamb, T; Lamba, J; Marr, JN; McIntyre, WF; Mohajer, K; Oqab, Z; Quadros, K; Quinn, KL; van Oosten, E; Yazdan-Ashoori, P | 1 |
| Bruno, A; Deitelzweig, S; Gupta, K; Lin, J; Lingohr-Smith, M; Tate, N; Trocio, J | 1 |
| Bajalan, M; Biggs, TC; Jayaram, S; Mainwaring, J; Salib, R | 1 |
| Batson, S; Kachroo, S; Lip, GY; Liu, LZ; Liu, X; Mitchell, SA; Phatak, H | 1 |
| Noguez, JH; Ritchie, JC | 1 |
| Bertrand, M; Blotière, PO; Bouillon, K; Maura, G; Ricordeau, P; Zureik, M | 1 |
| Smith, LL | 1 |
| Hussein, A; Saliba, W; Wazni, OM | 1 |
| Birschmann, I; Busse, J; Dittrich, M; Flieder, T; Gripp, T; Hendig, D; Knabbe, C; Kuhn, J | 1 |
| How, CH | 1 |
| Dechering, DG; Eckardt, L; Foraita, P; Güner, F; Kochhäuser, S; Lange, PS; Leitz, P; Mönnig, G; Pott, C; Wasmer, K; Zellerhoff, S | 1 |
| Batson, S; Bird, A; Cohen, AT; Hamilton, M; Liu, X; Mitchell, SA; Phatak, H; Tushabe, D | 1 |
| Rostagno, C | 1 |
| Cheung, BM; Kumana, CR; Lauder, IJ; Siu, DC; Tse, HF | 1 |
| Benöhr, P; Hohmann, C; Neumann-Haefelin, T; Radziwill, R | 1 |
| Hendrix, P; Keiner, D; Oertel, J; Senger, S | 1 |
| Huang, B; Shao, X; Wan, H; Wang, J; Wu, S; Yang, Y; Zhang, H; Zhou, Z; Zhu, J | 1 |
| Al-Khalili, F; Benson, L; Lindström, C | 1 |
| Gellér, L; Merkely, B; Szegedi, N; Széplaki, G; Tahin, T | 1 |
| Johnston, S | 1 |
| Amylidi, AL; Exadaktylos, AK; Lehmann, B; Ricklin, ME; Sauter, TC | 1 |
| Adcock, DM; Gosselin, RC | 1 |
| Shao, XH; Wan, HB; Wang, J; Wu, S; Yang, YM; Zhang, H; Zhu, J | 1 |
| Baldelli, S; Cattaneo, D; Clementi, E; Pastori, D; Perrone, V; Pignatelli, P; Radice, S; Violi, F | 1 |
| Costantinides, F; Maglione, M; Pascazio, L; Rizzo, R | 1 |
| Ammollo, CT; Colucci, M; Dellanoce, C; Incampo, F; Paoletti, O; Semeraro, F; Testa, S | 1 |
| Beyer-Westendorf, J; Ehlken, B; Evers, T | 1 |
| Hansen, PS; Sanchez, R; Walfridsson, H | 1 |
| Alamneh, EA; Bereznicki, LR; Chalmers, L | 1 |
| Smolewski, P; Witkowska, M; Witkowski, M | 1 |
| Greaves, M; Lurie, B; McDonald, L; Olaiya, A; Watson, HG; Watt, B | 1 |
| Caughey, GE; Pratt, NL; Ramsay, EN; Roughead, EE; Shakib, S | 1 |
| Ageno, W; Finazzi, G | 1 |
| Dahmen, A; Gorr, E; Hoppe, C; Horlitz, M; Keskin, K; Koektuerk, B; Schoett, M; Turan, CH; Turan, RG; Yang, A; Yorgun, H | 1 |
| Anand, S; Chan, EW; He, Y; Leung, WK; Li, X; Siu, CW; Wong, IC | 1 |
| Doolin, M; Isaacs, AN; Morse, C; Nisly, SA; Shiltz, E | 1 |
| Besselaar, A; Boonen, K; Hendriks, JG; Jonkers, F; Schellings, MW; Schmitz, EM; van de Kerkhof, D; van den Heuvel, DJ | 1 |
| Dobesh, PP; Finks, SW; Trujillo, TC | 1 |
| Ayala-Paredes, F; Birnie, DH; Coutu, B; Coyle, D; Eikelboom, J; Essebag, V; Healey, JS; Kalfon, E; Nery, P; Philippon, F; Sandhu, RK; Sapp, J; Verma, A; Wells, G | 1 |
| Browne, C; Cohen, AT; Hamilton, M; Lanitis, T; Leipold, R; Quon, P; Rublee, D | 1 |
| Alcocer, L | 1 |
| Francart, S; Francis, CW; Gosselin, RC; Gudmundsdottir, BR; Hawes, E; Letertre, LR; Malmstrom, RE; Moll, S; Onundarson, PT; Skeppholm, M | 1 |
| Ferreira, J; Silva Miguel, L | 1 |
| Åsberg, S; Hijazi, Z; Norrving, B; Oldgren, J; Terent, A | 1 |
| Kaufner, L; Rosenthal, C; Sander, M; von Heymann, C | 1 |
| Blum, RA; Lindfield, D | 1 |
| Acin, F; Bleda, S; Cañibano, C; De Haro, J; Varela, C | 1 |
| Andreotti, F; Arnesen, H; Bachmann, F; Baigent, C; Collet, JP; De Caterina, R; Halvorsen, S; Huber, K; Husted, S; Jespersen, J; Kristensen, SD; Lip, GY; Morais, J; Rasmussen, LH; Ricci, F; Sibbing, D; Siegbahn, A; Storey, RF; Ten Berg, J; Verheugt, FW; Wallentin, L; Weitz, JI | 1 |
| Bode, C; Diehl, P; Meyer, M; Moser, M; Olivier, CB; Weber, S; Weik, P; Zhou, Q | 1 |
| Boehlen, F; Bounameaux, H; Fontana, P; Righini, M; Robert-Ebadi, H | 1 |
| Myers, B; Webster, A | 1 |
| Boda, Z | 1 |
| Aita, A; Angeli, F; Bartolini, C; Reboldi, G; Verdecchia, P | 1 |
| Garg, AX; Gomes, T; Harel, Z; Juurlink, DN; Mamdani, M; Wald, R; Yao, Z | 1 |
| Feng, Y; Li, PJ; Liang, ZA; Liu, GJ; Wang, T; Xiao, J; Yang, Q | 1 |
| Baik, SH; Hernandez, I; Zhang, Y | 1 |
| Munson, CF; Reid, AJ | 1 |
| Pan, EY; Sobieraj, DM | 1 |
| Coleman, CI; Evers, T; Tangirala, M | 2 |
| Baker, D; Narasimhan, S; Wilsmore, B | 1 |
| Bonovas, S; Douramani, P; Ikonomidis, I; Kapsimali, V; Katogiannis, K; Kopterides, P; Kyriakou, E; Lekakis, J; Papadakis, I; Tsangaris, I; Tsantes, AE | 1 |
| Harenberg, J | 1 |
| Belik, S; Haslacher, H; Jilma-Stohlawetz, P; Lang, M; Perkmann, T; Quehenberger, P; Ratzinger, F; Schmetterer, KG | 1 |
| Agnelli, G; Becattini, C | 1 |
| Hayes, CJ; Martin, BC; Shah, A; Shewale, A | 1 |
| Marra, A; Perrone, A; Servillo, G; Vargas, M | 1 |
| Ellinghaus, P; Gerdes, C; Hauenschild, P; Heitmeier, S; Laux, V; Perzborn, E; Summer, H; Visser, M | 1 |
| Fonarow, GC; Gersh, BJ; Kim, S; Kowey, PR; Mahaffey, KW; O'Brien, EC; Peterson, ED; Piccini, JP; Thomas, L | 1 |
| Kuperan, P; Lee, LH; Ng, HJ; Sum, CL; Tan, CW; Ting, WC; Wong, WH; Yap, ES; Yip, CY | 1 |
| Aoyagi, H; Asano, M; Hirao, K; Kawaguchi, N; Kurabayashi, M; Nakamura, T; Okishige, K; Sasano, T; Shimura, T; Suzuki, H; Yamashita, M; Yamauchi, Y | 1 |
| Pasechnik, IN | 1 |
| Alves Júnior, JL; Fernandes, CJ; Gavilanes, F; Morinaga, LK; Prada, LF; Souza, R | 1 |
| Aronow, WS; Chatterjee, S; Kundu, A; Owan, T; Ryan, JJ; Sardar, P | 1 |
| Martin, K; Moll, S | 1 |
| Bereczki, D; Mirolovics, Á; Papp, C; Zsuga, J | 1 |
| Lesko, LJ | 1 |
| Cigarroa, J; Henrikson, CA; Steinberg, JS; Tereshchenko, LG | 1 |
| Bjerregaard Larsen, T; Gorst-Rasmussen, A; Lip, GY | 1 |
| Bair, TL; Bunch, TJ; Crandall, BG; Cutler, MJ; Day, JD; Jacobs, V; Mallender, C; May, HT; Osborn, JS; Stevens, SM; Weiss, JP; Woller, SC | 1 |
| Arachchillage, DR; Baglin, T; Besser, M; Maclean, R; van Veen, JJ | 1 |
| Hart, C; Schmid, S | 1 |
| Boey, JP; Gallus, A | 1 |
| Cappato, R; De Caterina, R; Ezekowitz, MD; Giugliano, RP; Patel, MR; Piccini, JP; Renda, G; Ricci, F; Zimarino, M | 1 |
| Brouns, R; Cornu, P; Desmaele, S; Dupont, AG; Steurbaut, S | 1 |
| Blinc, A; Gubenšek, M; Mavri, A; Pohar Perme, M; Tratar, G; Vene, N; Vižintin Cuderman, T | 1 |
| Abe, H; Aizawa, Y; Fujii, Y; Jimbo, Y; Sato, M; Takahashi, H; Takano, H | 1 |
| Battat, E; Bitterman, H; Dotan, SG; Eikelboom, JW; Ellis, MH; Ginsberg, JS; Hammerman, A; Hirsh, J; Neuman, T | 1 |
| Kaminskas, E; Reiffel, JA; Reilly, P; Sager, P; Sarich, T; Seltzer, J; Weitz, JI | 1 |
| Abramson, S; Chan, KE; Giugliano, RP; Jardine, M; Maddux, FW; Patel, MR; Perkovic, V; Piccini, JP; Zhao, S | 1 |
| Kjældgaard, JN; Larsen, TB; Lip, GY; Nielsen, PB; Skjøth, F | 1 |
| Mizoguchi, T; Yasaka, M | 1 |
| Kuwashiro, T; Okada, Y; Sahara, N | 1 |
| Barra, ME; Connors, JM; Fanikos, J; Goldhaber, SZ; Piazza, G; Sylvester, KW | 1 |
| Chiang, A; Ho, AC; Hong, BK; Hsu, J; Maguire, JI; Rahimy, E; Regillo, CD; Shahlaee, A; Shieh, WS; Sridhar, J | 1 |
| Higashiya, S; Hina, K; Kamikawa, S; Kawamura, H; Komtasubara, I; Kusachi, S; Murakami, M; Murakami, T; Yamaji, H | 1 |
| Agnelli, G; Becattini, C; Cianella, F; Conti, S; Filippucci, E; Giustozzi, M; Marchesini, E; Pierpaoli, L; Vedovati, MC; Verdecchia, P; Verso, M | 1 |
| G Andersson, N | 1 |
| Abraham, NS; Bellolio, MF; McBane, RD; Noseworthy, PA; Sangaralingham, LR; Shah, ND; Yao, X | 1 |
| Antman, EM; Giugliano, RP; Ruff, CT | 1 |
| Bhattacharya, B; Davis, KA; Maung, AA; Schuster, KM | 1 |
| Chen, D; Hsu, P; Meijer, P; Smock, KJ; Van Cott, EM; Zantek, ND | 1 |
| Colquhoun, D; Freedman, SB; Ortiz, M; Simons, LA; Thomas, G; Waterhouse, BJ | 1 |
| Batson, S; Bird, A; Cohen, AT; Hamilton, M; Horblyuk, R; Li, S; Mitchell, SA | 1 |
| Ageno, W; Büller, HR; Camm, AJ; Falanga, A; Hacke, W; Hendriks, J; Lobban, T; Merino, J; Milojevic, IS; Moya, F; Randall, G; Tsioufis, K; van der Worp, HB; Verhamme, P | 1 |
| Calmette, L; Flaujac, C; Gouin-Thibault, I; Horellou, MH; Ibrahim, F; Layka, A; Mazoyer, É | 1 |
| Fosbøl, EL; Gadsbøll, K; Gislason, GH; Lamberts, M; Lip, GY; Olesen, JB; Pallisgaard, JL; Sindet-Pedersen, C; Staerk, L; Torp-Pedersen, C | 1 |
| Hamilton, M; Horblyuk, R; Kamble, S; Keshishian, A; Lip, GY; Mardekian, J; Pan, X | 1 |
| Berger, K; Lesch, CA; Sin, JH | 1 |
| Schwartz, JB | 2 |
| Bruno, A; Kamble, S; Kawabata, H; Lip, GY; Mardekian, J; Masseria, C; Pan, X; Phatak, H | 1 |
| Benedetti, R; Fenoglio, L; Imberti, D; Pomero, F | 1 |
| Abbate, R; Bassi, L; Carraro, P; Cini, M; Legnani, C; Palareti, G; Paniccia, R; Paoletti, O; Pengo, V; Poli, D; Testa, S; Tripodi, A | 1 |
| Milling, TJ; Spyropoulos, AC | 1 |
| Peacock, WF; Villines, TC | 2 |
| Fanikos, J; Huisman, MV | 2 |
| Kawasugi, K; Kita, H; Kuyama, Y; Shirai, T; Yamamoto, T | 1 |
| Eikelboom, J; Merli, G | 2 |
| Musgrave, KM; Powell, J | 1 |
| Jaffer, IH; Weitz, JI | 1 |
| Granger, CB; Hawkins, NM; Jhund, PS; McMurray, JJ; O'Meara, E; Petrie, MC; Pfeffer, MA; Pozzi, A; Solomon, SD; Swedberg, K; Virani, S; Yusuf, S | 1 |
| Davies, RA; Orr, Y; Perera, NK | 1 |
| Dellegrottaglie, S; Filippatos, G; Giugliano, RP; Lund, LH; Magnani, G; McMurray, J; Perrone-Filardi, P; Rosano, GM; Savarese, G; Trimarco, B | 1 |
| Davies, AH; Lim, CS; Ravikumar, R | 1 |
| Steed, MB; Swanson, MT | 1 |
| Cuker, A; Samuelson, BT | 1 |
| Hernandez, I; Zhang, Y | 1 |
| Chan, YH; Chang, SH; Kuo, CT; Lee, HF; See, LC; Tu, HT; Wu, LS; Yeh, YH | 1 |
| Falck, P; Fride Tvete, I; Ghanima, W; Halvorsen, S; Hoxmark, C; Jonasson, C; Solli, O | 1 |
| Chillarige, Y; Goulding, MR; Graham, DJ; Hsueh, YH; Izem, R; Kelman, JA; Liao, J; MaCurdy, TE; Mott, K; Reichman, ME; Southworth, MR; Wei, Y; Wernecke, M; Worrall, C | 1 |
| Torjesen, I | 1 |
| Bajorek, BV; Pandya, E | 1 |
| Koyfman, A; Long, B | 1 |
| Dyrkorn, R; Lundgaard, H; Molden, E; Spigset, O; Stokes, CL | 1 |
| Barrios, V; Masjuan, J | 1 |
| Bonde, AN; Fosbøl, EL; Gerds, TA; Gislason, GH; Lamberts, M; Lip, GYH; Olesen, JB; Ozenne, B; Staerk, L; Torp-Pedersen, C | 2 |
| Agdirlioglu, T; Borowski, M; Kellner, M; Reers, S; Reppel, M; Thiele, H; Waltenberger, J | 1 |
| Hernandez, I; Smith, KJ; Zhang, Y | 1 |
| Chapman, K; Enjeti, AK; Lim, MS; Swanepoel, P | 1 |
| Brown, JD; Shewale, AR; Talbert, JC | 2 |
| Butala, NM; Kartoun, U; Kennedy, KF; Mahmood, S; Secemsky, EA; Shaw, SY; Wasfy, JH; Yeh, RW | 1 |
| Assar, MD; Ball, T; Cox, KM; McCullough, PA | 1 |
| Keskar, V; Sood, MM | 1 |
| Horiuchi, D; Ishida, Y; Itoh, T; Kimura, M; Kinjo, T; Nishizaki, K; Okumura, K; Sasaki, K; Sasaki, S; Shoji, Y; Tomita, H; Tsushima, Y | 1 |
| Gage, BF; Ganti, BR; Lee, ED; Lin, H; Nunley, RM; Venker, BT | 1 |
| Al-Kahlili, F; Gilstring, Å; Haeggström, A; Risberg, D; Tullberg, U; Wallén, H | 1 |
| Grove, EL; Hvas, AM; McGrail, R; Nissen, PH; Revsholm, J | 1 |
| Boehr, S; Haen, E | 1 |
| Doukky, R; Jaffer, AK; Moseley, A; Volgman, AS; Williams, KA | 1 |
| Alonso, A; Bengtson, LGS; Chen, LY; Lutsey, PL; MacLehose, RF | 1 |
| Chan, EW; Chan, PH; Chiang, CE; Huang, D; Lau, CP; Li, WH; Lip, GYH; Siu, CW; Tse, HF; Wong, ICK | 1 |
| Azizi, M; Beaune, P; Blanchard, A; Delavenne, X; Funck-Brentano, C; Gaussem, P; Gouin-Thibault, I; Loriot, MA; Mismetti, P; Narjoz, C; Salem, JE; Siguret, V | 1 |
| Douglas, JS; Gauthier-Lewis, ML; Riley, TR; Sanchez, CK | 1 |
| Crowther, MA; Shih, AW | 1 |
| Bhatt, DL; Fonarow, GC; Harding, T; Hernandez, AF; Khan, Y; Peterson, ED; Schwamm, LH; Suter, RE; Xian, Y | 1 |
| Kawada, T | 2 |
| Abraham, NS; McBane, RD; Noseworthy, PA; Sangaralingham, LR; Shah, ND; Yao, X | 1 |
| Heard, LK; Maggio, KL; Shanahan, C | 1 |
| Banzato, A; Hoxha, A; Pengo, V; Ruffatti, A | 1 |
| Chen, HC; Liu, CY | 1 |
| Guo, L; Hong, Y; Li, S; Wang, P; Zhong, X | 1 |
| Góralczyk, T; Malec, K; Undas, A | 1 |
| Etminan, M; Guo, M; Talany, G | 1 |
| Abraham, NS; Noseworthy, PA; Sangaralingham, LR; Shah, ND; Yao, X | 1 |
| Alban, S; Birschmann, I; Dittrich, M; Eller, T; Flieder, T; Fox, V; Gripp, T; Knabbe, C; Kuhn, J | 1 |
| Al-Sanea, N; Hakeam, HA | 1 |
| Bhurtu, A; Bundhun, PK; Huang, WQ; Pursun, M; Soogund, MZ; Teeluck, AR | 1 |
| Biagi, C; Conti, V; Donati, M; Melis, M; Monaco, L; Motola, D; Vaccheri, A; Venegoni, M | 1 |
| Buerke, M; Hoffmeister, HM | 1 |
| Goralczyk, T; Undas, A | 1 |
| Weißbach, L; Zotz, RB | 1 |
| Ayyagari, P; Chrischilles, E; Cram, P; Jones, M; Mazur, A; Vaughan Sarrazin, MS | 1 |
| Bhatt, DL; Federspiel, JJ; Fonarow, GC; Hernandez, AF; Laskowitz, DT; Peterson, ED; Schwamm, LH; Smith, EE; Xian, Y | 1 |
| Bluecher, A; Ferreirós, N; Harder, S; Labocha, S; Meyer Dos Santos, IM; Meyer Dos Santos, S; Picard-Willems, B; Singer, OC | 1 |
| Agnelli, G; Aita, A; Becattini, C; Conti, S; Giustozzi, M; Molini, G; Pierpaoli, L; Valecchi, F; Vedovati, MC; Verdecchia, P | 1 |
| Al-Rawi, S; Alhaddad, A; Elewa, H; Mahmoud, H; Nounou, A; Singh, R | 1 |
| Broscaru, L; Gulba, DC | 1 |
| Bowrin, K; Briere, JB; Roberts, J; Tatarsky, B; Wood, R | 1 |
| Terayama, Y | 1 |
| Ageno, W; Becattini, C; D'Angelo, A; Davì, G; De Cristofaro, R; Dentali, F; Di Minno, G; Falanga, A; Gussoni, G; Masotti, L; Palareti, G; Pignatelli, P; Prisco, D; Santi, RM; Santilli, F; Silingardi, M; Tufano, A; Violi, F | 1 |
| Birschmann, I; Blumenstock, G; Ebner, M; Härtig, F; Kuhn, J; Peter, A; Poli, S; Spencer, C; Ziemann, U; Zuern, CS | 2 |
| Bhagirath, VC; Eikelboom, JW; Monagle, S; Ng, KH | 1 |
| Bai, Y; Deng, H; Lip, GY; Shantsila, A | 1 |
| EncisoSilva, J; Greenberg, B; Schlueter, M; Thomas, I | 1 |
| Cangemi, DJ; Cipher, DJ; Feagins, LA; Krill, T; Spechler, SJ; Weideman, R | 1 |
| Bliden, KP; Chaudhary, R; Cohen, E; Doubleday, M; Gurbel, PA; Lopez-Espina, CG; Mathew, B; Mohammed, N; Muresan, AA; Raviv, G; Tantry, US; Zaman, F | 1 |
| Brand, S; Crespo, C; Kansal, A; Monreal-Bosch, M; Soulard, S | 1 |
| Atzema, C; Behlouli, H; Eisenberg, MJ; Essebag, V; Ho, PM; Humphries, KH; Jackevicius, CA; Lu, L; Pilote, L; Rahme, E; Tsadok, MA; Tu, JV; Turakhia, M; Zhou, L | 1 |
| Coluccia, A; Margaglione, M; Schiavoni, M | 1 |
| Gaudio, C; Greco, C; Pelliccia, F; Schiariti, M; Tanzilli, G; Viceconte, N | 1 |
| Kolegova, II; Koziolova, NA; Polyanskaya, EA | 1 |
| Fujisaki, J; Hirasawa, T; Horiuchi, Y; Igarashi, M; Ishiyama, A; Iwasaki, R; Michitaka, K; Mita, E; Ninomiya, T; Omae, M; Tomida, H; Tsuchida, T; Yamada, T; Yamamoto, Y; Yoshio, T | 1 |
| Carrier, M; de Wit, C; Le Gal, G; Shaw, J | 1 |
| Breithardt, G | 1 |
| Gkiatas, I; Korompilias, AV; Kostas-Agnantis, I; Papadopoulos, DV; Tsantes, AG; Ziara, P | 1 |
| Ammann, P; Blum, S; Conen, D; Di Valentino, M; Erne, P; Kühne, M; Moschovitis, G; Osswald, S; Schläpfer, J; Shah, D; Sticherling, C; Tabord, A; Vogt, C; Zimny, M | 1 |
| Burden, AM; de Boer, A; de Vries, F; Ebbelaar, C; Schalekamp, T; Souverein, P; Stolk, LM; Ten Cate-Hoek, A | 1 |
| Blaich, C; Michels, G; Müller, C; Streichert, T; Wiesen, MHJ | 1 |
| Connolly, SJ; Eikelboom, JW; Hirsh, J; Quinlan, DJ; Weitz, JI | 1 |
| Al Khalili, F | 1 |
| Adachi, T; Fujioka, S; Hoshino, H; Takagi, M | 1 |
| Dell'Aniello, S; Huiart, L; Loo, SY; Renoux, C | 1 |
| Bhave, PD; Chrischilles, E; Girotra, S; Giudici, M; Hodgson-Zingman, D; Mazur, A; Palamaner Subash Shantha, G; Vaughan Sarrazin, MS | 1 |
| Albaladejo, P; Bellamy, L; Bosson, JL; David, JS; de Maistre, E; Gruel, Y; Kauffmann, S; Mémier, V; Pernod, G; Romegoux, P; Samama, CM; Sié, P; Suchon, P; Thoret, S; Viallon, A | 1 |
| Colquhoun, D; Freedman, B; Ortiz, M; Simons, LA; Waterhouse, BJ | 1 |
| Nathwani, S; Wanis, C | 1 |
| Barmparas, G; Bosarge, P; Brown, CV; Bukur, M; Carrick, MM; Catalano, RD; Coimbra, R; Holly-Nicolas, J; Inaba, K; Kaminski, S; Klein, AL; Kobayashi, L; Kopelman, T; Ley, EJ; Martinez, EM; Moore, FO; Murry, J; Nirula, R; Paul, D; Quick, J; Rivera, O; Schreiber, M | 1 |
| Chan, KA; Chen, HM; Lai, CL; Liao, MT; Lin, TT | 1 |
| Bai, Y; Lip, GYH; Shantsila, A | 1 |
| Arias-Jaramillo, DR; Gaviria-Mendoza, A; Machado-Alba, JE | 1 |
| Ebner, T; Ikukawa, K; Ishiguro, N; Ito, S; Kishimoto, W; Kito, T; Komori, H; Kusuhara, H; Nakanishi, T; Schaefer, O; Tamai, I; Tsuruya, Y; Wang, X; Yamamura, N | 1 |
| Barkun, AN; Dorreen, A; Huynh, T; Martel, M; Miller, CS | 1 |
| Beauchesne, MF; Blais, L; Brais, C; Farand, P; Larochelle, J; Letemplier, G; Perreault, S; Turgeon, MH | 1 |
| Alexander, JH; Lopes, RD; Vora, AN | 1 |
| Lim, WS; Zhao, YJ | 1 |
| Graham, DJ; Kelman, JA; Wernecke, M | 1 |
| Parks, AL; Redberg, RF | 1 |
| Gotoh, S; Kuwashiro, T; Nakamura, A; Nakanishi, Y; Okada, Y; Takaguchi, G; Tomoda, M; Yasaka, M | 1 |
| Bonde, AN; Fosbøl, EL; Gadsbøll, K; Gislason, GH; Gundlund, A; Olesen, JB; Sindet-Pedersen, C; Staerk, L | 1 |
| Barbera, V; Bellasi, A; Campana, C; Cozzolino, M; De Pascalis, A; Di Iorio, B; Di Lullo, L; Galliani, M; Ronco, C; Russo, D; Russo, L; Santoboni, F; Vitaliano, E | 1 |
| Burnett, AE; Dobesh, PP; Fanikos, J; Mahan, CE | 1 |
| Langer, F; Voigtlaender, M | 1 |
| Cifu, AS; Jain, A | 1 |
| Churilov, L; Hardidge, AJ; Suen, K; Westh, RN | 1 |
| Abugattas de Torres, JP; Brugada, P; Chierchia, GB; Choudhury, R; Coutino-Moreno, HE; de Asmundis, C; De Regibus, V; Iacopino, S; Longobardi, M; Mugnai, G; Storti, C; Stroker, E; Takarada, K | 1 |
| Asvestas, D; Bazoukis, G; Efremidis, M; Efremidis, T; Georgopoulos, S; Karamichalakis, N; Kolokathis, AM; Letsas, KP; Rokiza, A; Sakellaropoulou, A; Saplaouras, A; Sideris, A; Vlachos, K | 1 |
| Gersh, BJ; Noseworthy, PA; Sangaralingham, LR; Shah, ND; Yao, X | 1 |
| Blennerhassett, R; Favaloro, EJ; Pasalic, L | 1 |
| Gupta, K; Lin, J; Lingohr-Smith, M; Mardekian, J; Menges, B; Nadkarni, A; Trocio, J; You, M | 1 |
| Kjældgaard, JN; Larsen, TB; Lip, GYH; Nielsen, PB; Skjøth, F | 1 |
| Ansell, J; Fonarow, GC; Gersh, BJ; Hylek, E; Kowey, PR; Mahaffey, KW; O'Brien, EC; Peterson, ED; Piccini, JP; Shrader, P; Singer, DE; Steinberg, BA; Thomas, L | 1 |
| Aiello, A; Aspromonte, N; Colivicchi, F; Di Fusco, SA; Santini, M; Tubaro, M | 1 |
| Amin, A; Baser, O; Dina, O; Keshishian, A; Le, H; Liu, X; Mardekian, J; Rosenblatt, L; Trocio, J; Vo, L; Zhang, Q | 1 |
| Kido, K; Scalese, MJ | 1 |
| Antovic, A; Antovic, J; Berndtsson, M; Malmström, RE; Norberg, EM; Rasmuson, A; Skeppholm, M | 1 |
| Andreozzi, GM; Bignamini, AA; Kuca, P; Tomkowski, W | 1 |
| Ashaye, A; Deitelzweig, S; Farmer, C; Hamilton, M; Horblyuk, R; Li, X; Luo, X; Vo, L | 1 |
| Imberti, D; Mastroiacovo, D | 1 |
| Alberts, MJ; Bunz, TJ; Coleman, CI; Peacock, WF | 1 |
| Fosbøl, EL; Gadsbøll, K; Gislason, GH; Gundlund, A; Køber, L; Lamberts, M; Olesen, JB; Staerk, L; Vinding, NE | 1 |
| Fischer, AM; Godier, A; Martin, AC; Mauge, L; Smadja, DM | 1 |
| Casson, RJ; Chan, W; Sanders, P; Selva, D; Sun, MT; Wong, CX; Wood, MK | 1 |
| Nasir, U | 1 |
| Byström, B; Norrving, B; Oldgren, J; Renlund, H; Själander, A; Sjögren, V; Svensson, PJ | 1 |
| Jolobe, OMP | 1 |
| Lip, GYH; Rivera-Caravaca, JM | 1 |
| Lip, GYH; Makaritsis, K; Michel, P; Ntaios, G; Papavasileiou, V; Vemmos, K | 1 |
| Gersh, BJ; Hargraves, I; Montori, VM; Noseworthy, PA; Shah, ND; Yao, X | 1 |
| Ariansen, I; Ellekjær, H; Furu, K; Kjerpeseth, LJ; Selmer, R; Skovlund, E | 2 |
| Alonso, A; Norby, FL | 1 |
| Bell, JS; Dārziņš, P; Fanning, L; Ilomäki, J | 1 |
| Alla, F; Billionnet, C; Maura, G; Pariente, A | 1 |
| Alvarez-Madrazo, S; Bennie, M; Mueller, T; Robertson, C | 1 |
| Valent, F | 1 |
| Fukuoka, H; Hoshida, S; Ikeoka, K; Inui, H; Minamisaka, T; Shinoda, Y; Watanabe, T | 1 |
| Arima, Y; Hokimoto, S; Ishii, M; Ito, M; Izumiya, Y; Kaikita, K; Kojima, S; Ogawa, H; Sueta, D; Takashio, S; Tsujita, K; Yamabe, H; Yamamoto, E; Yamamuro, M | 1 |
| Davis, DO; Davis, KA | 1 |
| Douxfils, J; Gosselin, RC | 1 |
| Fogerty, AE; Oertel, LB | 1 |
| Petrasko, M; Petraskova, T; Raizada, A | 1 |
| Koretz, RL | 1 |
| Favaloro, EJ; Lippi, G; Pasalic, L | 1 |
| An, SJ; Kim, CK; Kim, TJ; Ko, SB; Nam, KW; Oh, K; Yoon, BW | 1 |
| Bellmann, B; Landmesser, U; Lenz, K; Lin, T; Lsharaf, AK; Nagel, P; Rillig, A; Roser, M; Tscholl, V | 1 |
| Curtice, T; Deitelzweig, S; Gupta, K; Lin, J; Lingohr-Smith, M; Luo, X; Mardekian, J; Menges, B; Trocio, J | 1 |
| Abarca, J; Adeboyeje, G; Barron, JJ; Crawford, G; Redberg, R; Rosenberg, A; Sylwestrzak, G; White, J | 1 |
| Ashton, V; Crivera, C; Germain, G; Laliberté, F; Lefebvre, P; McHorney, CA; Peterson, ED; Schein, JR; Wynant, W | 1 |
| Davis, MDP; El-Azhary, RA; King, BJ; McBane, RD; McCarthy, JT; McEvoy, MT; Shields, RC | 1 |
| Izumi, N; Katada, J; Kohsaka, S; Murata, T; Terayama, Y; Wang, F | 1 |
| Deger, KA; Gandhi, P; Kansal, AR; Peng, S; Qiao, N; Ustyugova, A; Wang, C | 1 |
| Bhave, PD; Bhise, V; Chaikriangkrai, K; Deshmukh, A; Giudici, M; Horwitz, PA; Inampudi, C; Kumar, AA; Mentias, A; Mickelsen, S; Oral, H; Palamaner Subash Shantha, G; Pancholy, S; Patel, N; Vaughan Sarrazin, MS | 1 |
| Hernandez, I; Saba, S; Zhang, Y | 2 |
| Borne, RT; Hess, PL; Ho, PM; Jackevicius, CA; Maddox, TM; Marzec, LN; Masoudi, FA; O'Donnell, C; Turakhia, MP; Varosy, PD | 1 |
| Alonso, A; Bengtson, LGS; Chamberlain, AM; Chen, LY; Lutsey, PL; MacLehose, RF; Norby, FL; Rapson, I | 1 |
| Carley, B; Draper, E; Griesbach, S; Krueger, K; Larson, T; Parkhurst, B | 1 |
| de Maistre, E; Delavenne, X; Freyburger, G; Golmard, JL; Gouin-Thibault, I; Gruel, Y; Sié, P; Susen, S | 1 |
| Baldovino, S; Fenoglio, R; Radin, M; Roccatello, D; Schreiber, K; Sciascia, S | 1 |
| Bansal, VK; Choi, MJ; Herzog, CA; Jaar, BG; Kramer, H; Mehta, R; Rocco, MV; Sarnak, MJ | 1 |
| Griffiths, CL; Hicks, S; Livengood, SJ; Vestal, ML | 1 |
| Akyüz, A; Başaran, Ö; Berilgen, R; Çelik, O; Çetin, N; Coşar, S; Dereli, Y; Doğan, T; Doğan, V; Emren, SV; Enhoş, A; Ergene, O; Gürsul, E; İnci, S; Karaca, I; Karaca, Ö; Köseoğlu, C; Levent, F; Onrat, E; Otlu, YÖ; Özdemir, İH; Özmen, Ç; Sümerkan, M; Zoghi, M | 1 |
| Babiarz, A; Bodys, A; Budnik, M; Filipiak, KJ; Gawałko, M; Kapłon-Cieślicka, A; Kochanowski, J; Opolski, G; Peller, M; Scisło, P; Uliński, R; Żochowski, M | 1 |
| Ali, Z; El-Makaty, H; Elewa, H | 1 |
| Chu, XC; Gao, JH; Ning, B; Wang, LL; Zhao, CX | 1 |
| Collings, SL; Evans, D; Hack, G; Johnson, ME; Lefèvre, C; Maguire, A; Stynes, G | 1 |
| Basto, AN; Gibson, CM; Howard, ML | 1 |
| Galanter, WL; Lee, TA; Manzoor, BS; Nutescu, EA; Sharp, LK; Walton, SM | 1 |
| Alla, F; Billionnet, C; Gagne, JJ; Maura, G; Pariente, A | 1 |
| Antia, C; Gloster, H; Hone, N | 1 |
| Boulouis, G; Charidimou, A; Goldstein, JN; Gurol, ME; Morotti, A; Pasi, M | 1 |
| Kanai, Y; Matsuda, H; Mitaki, S; Oguro, H; Onoda, K; Tahara, N; Takayoshi, H; Yamaguchi, S | 1 |
| Ahuja, T; Cirrone, F; Green, D; Papadopoulos, J; Raco, V; Xiang, E | 1 |
| Ali, M; Gunasekaran, K; Kaatz, S; Lavender, R; Mahan, CE; Nakhle, A; Paje, DG | 1 |
| Basto, AN; Fewel, NP; Stock, EM; Ta, M; Vo, K | 1 |
| Fukuhara, S; Fukuma, S; Furukawa, TA; Goto, Y; Kimachi, K; Kimachi, M | 1 |
| Beer, TM; Daughety, MM; DeLoughery, TG; Olson, SR; Shatzel, JJ | 1 |
| Grove, EL; Hellfritzsch, M; Pottegård, A | 1 |
| Eek, AK; Granas, AG; Øie, E | 1 |
| Gersh, BJ; Nath, KA; Noseworthy, PA; Sangaralingham, LR; Shah, ND; Tangri, N; Yao, X | 1 |
| Pazmiño, PA | 1 |
| Brodie, MM; Newman, JC; Rockey, DC; Smith, T | 1 |
| Anguita, M; Asunción Esteve-Pastor, M; Bertomeu, V; Cequier, A; Marín, F; Martínez-Sellés, M; Muñiz, J; Raña Míguez, P; Roldán, I; Ruiz Ortiz, M | 1 |
| Bhatt, NR; Davis, NF; Flynn, RJ; Manecksha, RP; McDermott, T; Nolan, WJ; Thomas, AZ | 1 |
| Arshad, A; Kaluski, E; Khan, SU; Nasir, F; Riaz, IB; Talluri, S | 1 |
| Anderson, JM; Arnold, DM; Bates, SM; Blostein, M; Caprini, JA; Carrier, M; Clark, NP; Coppens, M; Dentali, F; Douketis, JD; Duncan, J; Gross, PL; Kassis, J; Kowalski, S; Le Gal, G; Le Templier, G; Lee, AY; Li, N; MacKay, E; Schulman, S; Shah, V; Shivakumar, S; Solymoss, S; Spencer, FA; Spyropoulos, AC; Syed, S; Tafur, AJ; Thiele, T; Vanassche, T; Wu, C; Yeo, E | 1 |
| Abdul-Rahim, AH; Acampa, M; Acciarresi, M; Ageno, W; Agnelli, G; Alberti, A; Athanasakis, G; Bandini, F; Becattini, C; Bellesini, M; Bono, G; Bovi, P; Cappellari, M; Carletti, M; Carolei, A; Caso, V; Chiti, A; Chondrogianni, M; Ciccone, A; Cimini, LA; Colombo, G; Consoli, D; Corea, F; D'Amore, C; De Lodovici, ML; Denti, L; Falocci, N; Flomin, Y; Furie, KL; Galati, F; Gialdini, G; Giannini, N; Giorli, E; Giuntini, M; Gourbali, V; Guideri, F; Karagkiozi, E; Karapanayiotides, T; Kargiotis, O; Lanari, A; Lees, KR; Letteri, F; Liantinioti, C; Lorenzini, G; Lotti, EM; Maccarrone, M; Maimone Baronello, M; Makaritsis, K; Mancuso, M; Marcheselli, S; Martini, G; Masotti, L; Monaco, S; Mosconi, MG; Mumoli, N; Ntaios, G; Orlandi, G; Paciaroni, M; Padovani, A; Pezzini, A; Poli, L; Putaala, J; Sacco, S; Scoditti, U; Silvestrelli, G; Sohn, SI; Soloperto, R; Tadi, P; Tassi, R; Tassinari, T; Tatlisumak, T; Tiseo, C; Tomppo, L; Toni, D; Tsivgoulis, G; Vadikolias, K; Vannucchi, V; Venti, M; Yaghi, S; Zedde, M | 1 |
| Cao, F; Henk, HJ; Mardekian, J; Odell, K; Patel, C; Price, K; Sands, GH; Singh, P; Singhal, S; Tan, W; Trocio, J; Tuell, K; Vo, L | 1 |
| Miano, T; Pan, W; Uyhazi, KE; VanderBeek, BL | 1 |
| Avorn, J; Choudhry, NK; Gagne, JJ; Glynn, RJ; Krumme, AA; Kulldorff, M; Ortiz, AS; Pawar, A; Schneeweiss, S | 1 |
| Ishikawa, T; Moroi, J; Nakase, T | 1 |
| Levanov, AN; Sinitsina, II; Sychev, DA; Tsomaya, IV; Vardanyan, AV | 1 |
| Franco Moreno, AI; García Navarro, MJ; Martín Díaz, RM | 1 |
| Steuber, T | 1 |
| Chinushi, M; Fuse, I; Hasegawa, Y; Iijima, K; Izumi, D; Minamino, T; Otuki, S; Sato, A; Suda, M; Yagihara, N | 1 |
| Cheng, HM; Hsu, CC; Hsu, PF; Huang, CJ; Sung, SH; Tu, ST; Yu, BH | 1 |
| Bayer, N; Geidel, S; Hassan, K; Oberhoffer, M; Schlingloff, F; Schmoeckel, M; Wohlmuth, P | 1 |
| Flaujac, C; Golmard, JL; Gouin-Thibault, I; Jabet, A; Joly, BS; Siguret, V; Stepanian, A | 1 |
| Chantarangkul, V; Legnani, C; Testa, S; Tosetto, A; Tripodi, A | 1 |
| Balsam, P; Bednarski, J; Filipiak, KJ; Grabowski, M; Kowalczuk, A; Kołtowski, Ł; Lodziński, P; Maciejewski, K; Opolski, G; Ozierański, K; Peller, M; Praska-Ogińska, A; Szepietowska, K; Tymińska, A; Zaboyska, I; Zaleska, M; Żukowska, K | 1 |
| Basic, E; Hohmann, C; Hohnloser, SH; Nabauer, M | 1 |
| De Maistre, E; Derex, L; Gouin-Thibault, I; Gruel, Y; Sie, P; Susen, S; Touzé, E | 1 |
| Gil, M; Webster, E | 1 |
| Alonso, A; Chen, LY; Datta, YH; Lutsey, PL; MacLehose, RF; Norby, FL; Shah, S | 1 |
| Asmar, J; Bizouard, G; Collings, SL; Duhot, D; Fauchier, L; Johnson, ME; Lefèvre, C; Maguire, A; Mouquet, F; Stynes, G; Vannier-Moreau, V | 1 |
| Atar, D; Ghanima, W; König, MSS; Raouf, N; Risnes, K; Rutherford, OW | 1 |
| Ay, C; Königsbrügge, O; Pabinger, I; Quehenberger, P; Weigel, G | 1 |
| Albendin Iglesias, H; Andreu Cayuelas, JM; Bailen Lorenzo, JL; Caro Martínez, C; Cerezo Manchado, JJ; Elvira Ruiz, G; Flores Blanco, PJ; García Alberola, A; Januzzi, JL; Manzano-Fernández, S | 1 |
| Adcock, DM; Bates, SM; Douxfils, J; Favaloro, EJ; Gosselin, RC; Gouin-Thibault, I; Guillermo, C; Kawai, Y; Kitchen, S; Lindhoff-Last, E | 1 |
| Bączek, M; Gorczyca, I; Jelonek, O; Kośmider, P; Wożakowska-Kapłon, B | 1 |
| Crispin, P; Pratt, J | 1 |
| Fortier, K; Reebye, UN; Shroff, D | 1 |
| Battistella, M; Cameron, K; Farrell, A; Feldberg, J; Ma, J; Patel, P; Sivarajahkumar, S | 1 |
| Antonucci, E; Cosmi, B; Dellanoce, C; Legnani, C; Morandini, R; Palareti, G; Paoletti, O; Pengo, V; Poli, D; Testa, R; Testa, S; Tripodi, A | 2 |
| Angelillo-Scherrer, A; Cuker, A; Eberle, B; Erdoes, G; Exadaktylos, AK; Nagler, M; Sauter, TC; Thiele, T; Wuillemin, WA | 1 |
| Howard, LS | 1 |
| Balsam, P; Bednarski, J; Maciejewski, K; Opolski, G; Ozierański, K; Peller, M; Praska-Oginska, A; Szepietowska, K; Tymińska, A; Zaboyska, I; Zaleska, M; Żukowska, K | 1 |
| Ashley, J; Sood, MM | 1 |
| Dyrkorn, R; Hegstad, S; Lindahl, S; Spigset, O | 1 |
| Koscielny, J; Rosenthal, C; von Heymann, C | 1 |
| Adeboyeje, G; Barron, JJ; Charlton, B; Grady, D; Redberg, RF; Shin, J | 1 |
| de Boer, PT; Hoffmann, M; Jacobs, MS; Levin, LÅ; Postma, MJ; Schouten, JF | 1 |
| Aguinaco, MR; Bustins, A; Campoy, D; Canals, T; Cerdá, M; Constans, M; Ene, G; Gabilondo, M; Jiménez, C; Johansson, E; Las Heras, G; López, M; Marzo, C; Mateo, J; Moya, Á; Oliver, A; Olivera, P; Perea, G; Plensa, E; Pons, V; Reverter, JC; Sánchez, E; Santamaría, A; Santos, N; Sorigue, M; Tàssies, D; Varela, A; Vicente, L | 1 |
| Cheung, JW; D'Amato, S; Gabriels, J; Ip, JE; Khan, M; Lerman, B; Liu, CF; Markowitz, SM; Patel, A; Shaban, N; Singh, P; Thomas, G; Wu, M | 1 |
| Escobar, C; Martí-Almor, J; Martínez-Zapata, MJ; Pérez Cabeza, A | 1 |
| Leow, AS; Loh, JP; Sia, CH; Tan, BY | 1 |
| Beyer-Westendorf, I; Beyer-Westendorf, J; Endig, S; Marten, S; Reitter, A; Tittl, L | 1 |
| Chan, YH; Chang, SH; Kuo, CF; Kuo, CT; Lee, HF; See, LC; Tu, HT; Wang, CL; Wu, LS; Yeh, YH | 1 |
| Akintoye, E; Alvarez, P; Briasoulis, A; Inampudi, C; Panaich, S; Vaughan-Sarrazin, M | 1 |
| Bunz, TJ; Coleman, CI; Martinez, BK; Sood, NA | 1 |
| Armeni, M; Bendini, MG; Caldarone, E; D'Emidio, S; Fusco, A; Leggio, M; Lombardi, M; Mazza, A; Mereu, D; Severi, P | 1 |
| Haas, K; Heuschmann, PU; Khan, S; Purrucker, JC; Rizos, T; Siedler, T; Veltkamp, R; Wolf, M | 1 |
| Dülgeroglu, J; Schmidt, D | 1 |
| Kamble, S; Kawabata, H; Lip, GYH; Mardekian, J; Masseria, C; Pan, X; Phatak, H | 1 |
| Boswell, R; Pearson, GJ | 1 |
| Garzon, J; Jaramillo, L; Mendoza, L; Mendoza-Sanchez, J; Quiroga, A; Rangel, L; Silva, F | 1 |
| Khan, SU; Lash, B; Nasir, F; Raghu Subramanian, C; Wolfe, Z | 1 |
| Hart, A; Shroff, GR; Stoecker, R | 1 |
| Anstee, QM; Dhar, A; Goldin, RD; Levene, AP; Sadiq, F; Thursz, MR | 1 |
| Hernandez, I; Hospodar, AR; Smith, KJ; Zhang, Y | 1 |
| Facchinetti, R; Fantin, F; Ferrari, E; Masciocchi, E; Mazzali, G; Nori, N; Rossi, AP; Sant, S; Zamboni, M; Zoico, E | 1 |
| Ašić, A; Marjanović, D; Mirat, J; Primorac, D | 1 |
| Adelmeijer, J; Bernal, W; Bos, S; Fisher, C; Kleiss, S; Lisman, T; Patel, VC; Shawcross, DL; Singanayagam, A; Stoy, SH | 1 |
| Belenkov, YN; Khabarova, NV; SHakaryants, GA | 1 |
| Banach, M; Covic, A; Lopatowska, P; Malyszko, J; Mlodawska, E; Sobkowicz, B; Tomaszuk-Kazberuk, A | 1 |
| Ageno, W; Antonucci, E; Beyer-Westendorf, J; Morandini, R; Paciaroni, M; Palareti, G; Pengo, V; Poli, D; Righini, M; Sivera, P; Testa, S; Verhamme, P | 1 |
| Jain, N; Reilly, RF | 1 |
| Norrving, B; Renlund, H; Själander, A; Själander, S; Sjögren, V | 1 |
| Baser, O; Di Fusco, M; Friend, K; Gupta, K; Hamilton, M; Jones, WS; Keshishian, A; Li, X; Lopes, RD; Luo, X; Mardekian, J; Masseria, C; Pan, X; Steffel, J | 1 |
| Cornelius, CC; Cripps, MW; Gales, PE; Nakonezny, PA; Vazquez, N; Wey, JC | 1 |
| Kim, M; Kim, MS; Kim, S; Ko, YJ; Lee, J; Park, BJ; Park, K; Yang, BR | 1 |
| Burke, C; Collins, R; Coughlan, T; Egom, EE; McAuliffe, C; McHugh, J; Moore, D; Morrissey, E; O'Brien, J; Pharithi, RB; Ranganathan, D; Ryan, D; Vaughan, M | 1 |
| Bittinger, L; Curtis, C; Pol, D; Ramkumar, S | 1 |
| Durand, M; Johnson, S; Matteau, A; Sinyavskaya, L | 1 |
| Cavallari, I; De Caterina, R; Hanon, O; Patti, G | 1 |
| Chan, YH; Chang, CY; Chang, SH; Hsieh, MY; Kuo, CF; Kuo, CT; See, LC; Tu, HT; Yeh, YH | 1 |
| Abe, K; Aoyagi, H; Isono, A; Kita, H; Kodashima, S; Kozuma, K; Maruyama, K; Watari, Y; Yamamoto, T | 1 |
| Basalo, MC; Ferrero-Martínez, AI; Gómez-Quintanilla, A; Guitián, A; Montero-Magan, M; Olcoz-Chiva, MT; Paredes-Galán, E; Rodríguez-Artalejo, F; Rodríguez-Pascual, C; Sharma, J; Torres-Torres, I; Vilches-Moraga, A | 1 |
| Barden, S; Campbell, T; Condliffe, R; Connolly, V; Davies, CWH; Donaldson, J; Everett, B; Free, C; Horner, D; Howard, LSGE; Hunter, L; Kaler, J; Nelson-Piercy, C; O-Dowd, E; Patel, R; Preston, W; Sheares, K | 1 |
| Chen, S; Hou, K; Li, Y; Liu, J; Wang, Y; Xia, N; Xu, D | 1 |
| Mohebbi, N | 1 |
| Andersson, NW; Lund, M; Melbye, M; Pasternak, B; Svanström, H | 1 |
| Chang, Y; Crowther, M; Holbrook, A; Larsen, TB; Levine, MAH; Li, G; Lip, GYH; Mbuagbaw, L; Sun, X; Tang, J; Thabane, L; Witt, DM | 1 |
| Atkinson, H; Chan, AKC; Gantioqui, J; Stevic, I | 1 |
| Coupland, C; Hill, T; Hippisley-Cox, J; Vinogradova, Y | 1 |
| Chen, HM; Lai, CL; Liao, MT; Lin, TT | 1 |
| Alviz, I; Avendano, R; Cerna, L; Cerrud-Rodriguez, RC; Di Biase, L; Diaz, JC; Grupposo, V; Kirchhof, P; Kumar, S; Michaud, GF; Natale, A; Romero, J; Taveras, J | 1 |
| Chrapek, M; Janion-Sadowska, A; Papuga-Szela, E; Undas, A; Łukaszuk, R | 1 |
| Karakas-Torgut, A; Mo, Y; Pham, AQ | 1 |
| Azboy, I; Groff, H; Parvizi, J | 1 |
| Krug, K; Laux, G; Peters-Klimm, F; Schwill, S; Szecsenyi, J; van Lieshout, J; Wensing, M | 1 |
| Carrier, M; Khorana, AA; Lee, AYY; Meyer, G; Noble, S; O'Connell, C; Soff, G | 1 |
| Moore, KT | 1 |
| Arena, G; Baratta, A; Bianchi, S; Catarzi, S; Conti, A; Covelli, A; Dell'Amico, I; Mazzucchelli, M; Molesti, D; Orlandi, G; Pampana, A; Perrotta, ME; Tognarelli, A; Torri, T | 1 |
| Bai, Y; Carmo, J; Esteve-Pastor, MA; Lip, GYH; Marín, F; Orenes-Piñero, E; Proietti, M; Rivera-Caravaca, JM; Roldán, V; Romanazzi, I; Romiti, GF | 1 |
| Avnery, O; Battat, E; Derazne, E; Dotan, SG; Ellis, MH; Hammerman, A | 1 |
| Adam, TJ; Alonso, A; Lutsey, PL; MacLehose, RF; Roetker, NS; Zakai, NA | 1 |
| Birschmann, I; Faust, I; Flieder, T; Gripp, T; Hammerschmidt, A; Hendig, D; Knabbe, C; Kuhn, J | 1 |
| Aizawa, Y; Fujita, S; Fuse, K; Ikeda, Y; Kitazawa, H; Okabe, M; Sato, T; Takahashi, M | 1 |
| Domanovits, H; Frossard, M; Gremmel, T; Niessner, A; Pabinger, I; Sengölge, G; Steinlechner, B; Sycha, T; Wolzt, M | 1 |
| Kido, K; Ngorsuraches, S | 1 |
| Bakkehøi, G; Eek, AK; Stenberg-Nilsen, H; Strøm, BO | 1 |
| Calabrese, V; Colaiori, I; Creta, A; Di Sciascio, G; Ioannou, A; Picarelli, F; Providência, R; Ragni, L; Ricciardi, D; Scordino, D | 1 |
| Carlsen, SM; Giannadakis, C; Gulati, AM; Gulati, S; Jakola, AS; Jensberg, H; Madsbu, MA; Salvesen, Ø; Solheim, O; Øie, LR | 1 |
| Bawa, H; Dirschl, DR; Luu, HH; Weick, JW | 1 |
| Padrini, R | 1 |
| Bowrin, K; Briere, JB; Coleman, C; Fauchier, L; Folkerts, K; Levy, P; Millier, A; Taieb, V; Toumi, M; Wu, O | 1 |
| Hirsh Raccah, B; Kalish, Y; Matok, I; Muszkat, M; Perlman, A; Rottenstreich, A; Zacks, N | 1 |
| Atia, R; Bonnel, S; Borderie, V; Bouheraoua, N; Laroche, L; Vallos, M | 1 |
| Endo, S; Kishi, H; Kogiku, M; Noda, M; Notsu, Y; Ota, M; Shimizu, M; Takekawa, M; Yamazaki, H; Yamazaki-Nishioka, M | 1 |
| Al Yami, MS; Alfayez, OM; Alsheikh, R | 1 |
| Franchino-Elder, J; Gilligan, AM; Henriques, C; Sainski-Nguyen, A; Sander, S; Smith, DM; Song, X; Wang, C; Wilson, K | 1 |
| Di Lullo, L; Terranova, A; Uguccioni, M | 1 |
| Bertlich, M; Bootz, F; Eichhorn, KW; Freytag, S; Gräff, I; Horlbeck, F; Jakob, M; Schafigh, D; Send, T | 1 |
| Davani, S; Girard, A; Lagoutte-Renosi, J; Le Poupon, J; Montange, D | 1 |
| Biehle, L; Trierweiler, D | 1 |
| Corsi Romanelli, MM; Costa, E; Prinzivalli, M; Rampoldi, B; Sammarco, G | 1 |
| Lip, GYH | 1 |
| Friedecky, D; Hlusi, A; Lukes, J; Nemcova, M; Palova, M; Prochazkova, J; Slavik, L; Ulehlova, J; Vaclavik, J; Zhanelova, M | 1 |
| Barmparas, G; Coimbra, R; Dhillon, NK; Kobayashi, L; Ley, EJ; Margulies, DR; Patel, KA | 1 |
| Bhatt, DL; Federspiel, JJ; Fonarow, GC; Hernandez, AF; Huang, RJ; Jin, C; Laskowitz, DT; Peterson, ED; Schwamm, LH; Smith, EE; Xian, Y | 1 |
| Andersen, M; Braunschweig, F; Forslund, T; Hjemdahl, P; Komen, JJ; Mantel-Teeuwisse, AK; von Euler, M; Wettermark, B | 1 |
| An, GV; Belenkov, YN; Khabarova, NV; SHakaryants, GA | 1 |
| Alonso, A; Chen, LY; Datta, YH; Lutsey, PL; MacLehose, RF; Norby, FL; Shah, S; Zakai, NA | 1 |
| Aoki, J; Kanamaru, T; Kimura, K; Matsumoto, N; Mishina, M; Nishiyama, Y; Nito, C; Okubo, S; Sakamoto, Y; Sekine, T; Shimoyama, T; Suda, S; Suzuki, K | 1 |
| Chang, SH; Chu, PH; Kuo, CF; Tseng, HJ; Wang, CL; Wen, MS; Wu, VC | 1 |
| Birschmann, I; Blumenstock, G; Ebner, M; Härtig, F; Kuhn, J; Peter, A; Poli, S; Rupp, A; Spencer, C; Ziemann, U; Zuern, CS | 1 |
| Braunschweig, F; Forslund, T; Hjemdahl, P; Holmström, M; Johnsson, H; von Euler, M; Wallén, H | 1 |
| Eckert, R; Fleddermann, A; Hayes, C; Magalski, A; Main, ML; Muskala, P | 1 |
| Abdulsattar, Y; Kamble, S; Lip, GYH; Mardekian, J; Masseria, C; Petkun, W; Phatak, H; Tepper, PG | 1 |
| Batistatou, A; Gkiatas, I; Korompilias, AV; Kostas, I; Papadopoulos, D; Papoudou-Bai, A; Tsantes, AG | 1 |
| Lehre, I; Molden, E; Ranhoff, AH; Viktil, KK | 1 |
| Antunovic, M; Dzudovic, B; Dzudovic, J; Obradovic, S; Stavric, M; Subota, V; Subotic, B | 1 |
| Hu, A; Niu, J; Winkelmayer, WC | 1 |
| Carli, G; Chiarini, F; Cortellini, G; Farsi, A; Lippolis, D | 1 |
| Dei, A; Grifoni, E; Landini, G; Masotti, L; Moroni, F; Panigada, G; Spolveri, S; Vannucchi, V | 1 |
| Alcusky, M; Fisher, M; Goldberg, RJ; Hume, AL; Lapane, KL; McManus, DD; Tjia, J | 1 |
| Alvarez-Madrazo, S; Bennie, M; Mueller, T; Robertson, C; Wu, O | 1 |
| Cannegieter, SC; Huisman, MV; Klok, FA; Lijfering, WM; Rosendaal, FR; Teichert, M; Zielinski, GD | 1 |
| Cheon, K; Cho, HJ; Choi, HY; Han, SW; Heo, JH; Jung, YH; Kim, YD; Lee, HS; Lee, KY; Nam, HS; Park, HJ; Park, JH | 1 |
| Ayala-Paredes, F; Becker, G; Birnie, DH; Connolly, SJ; Coutu, B; Eikelboom, J; Essebag, V; Healey, JS; Kalfon, E; Lellouche, N; Nery, PB; Philippon, F; Sandhu, RK; Sapp, J; Sumner, GL; Verma, A; Wells, GA | 1 |
| Dager, WE; Nishijima, DK; Roberts, AJ | 1 |
| Fanaroff, AC; Ohman, EM | 1 |
| Baker, CL; Dhamane, AD; Dina, O; Lin, J; Lingohr-Smith, M; Mardekian, J; Menges, B; Nadkarni, A; Rosenblatt, L; Russ, C | 1 |
| Abouelfath, A; Bénichou, J; Blin, P; Cottin, Y; Droz, C; Dureau-Pournin, C; Lassalle, R; Mismetti, P; Moore, N | 2 |
| Ahmad, A; Evans, A; Oh, K; Petrini, M; Rush, T; Schwartzman, E; Tang, W; Thompson, D; Villines, TC | 1 |
| Ackery, A; Chaudhry, H; Mahamad, S; McFarlan, A; Nisenbaum, R; Rizoli, S; Sholzberg, M | 1 |
| Bonde, AN; Fosbøl, EL; Gislason, GH; Køber, L; Lamberts, M; Olesen, JB; Rørth, R; Torp-Pedersen, C; Vinding, NE | 1 |
| Chung, CP; Daugherty, JR; Dupont, WD; Murray, KT; Ray, WA; Smalley, WE; Stein, CM | 1 |
| Gottsäter, A | 1 |
| Själander, A; Själander, S | 1 |
| Oldgren, J | 1 |
| Strandberg, K | 1 |
| Baser, O; Deitelzweig, S; Friend, K; Gupta, K; Hamilton, M; Keshishian, A; Li, X; Lip, GYH; Luo, X; Mardekian, J; Masseria, C; Nadkarni, A; Pan, X | 1 |
| Cowperthwaite, M; Fanale, C; Nadasdy, Z; Ramakrishnan, A; Shpak, M | 1 |
| Cipriano, LE; Hachinski, V; Lee, SAW; Ruiz Vargas, E; Sposato, LA | 1 |
| Jafari, M; MacKay, J; Stecker, EC; Warden, BA; Willman, A | 1 |
| Chen, W; Gao, D; Gao, G; He, Y; Lakin, R; Liu, X; Sun, H; Wang, Y; Yan, M; Yang, H; Yang, P; Yu, M; Zhao, Q | 1 |
| Campodonico, P; Guiddo, G; Lerza, R; Malerba, M; Minuto, P; Motta, G; Riccardi, A; Spinola, MB | 1 |
| Bae, HJ; Chung, I; Gwak, DS; Han, MK; Kang, JH; Kim, BJ; Kim, BK; Woo, HG | 1 |
| Guo, X; Liu, Y; Sun, Z; Xu, Y; Zhang, Y | 1 |
| Joung, B; Kim, JY; Kim, TH; Kim, YH; Lee, MH; Pak, HN; Park, J; Shim, J; Uhm, JS; Yu, HT | 1 |
| Gouin-Thibault, I; Jourdi, G; Le Bonniec, B | 1 |
| Ageno, W; Agnelli, G; Chan, NC; De Caterina, R; Diener, HC; Hylek, E; Lip, GYH; Raskob, GE; Siegal, DM; Verheugt, FWA; Weitz, JI | 1 |
| Arakawa, K; Endo, T; Fukui, K; Himeno, H; Ishikawa, T; Kikuchi, S; Kimura, K; Kobayashi, S; Mochida, Y; Morita, Y; Okuda, J; Sakamaki, K; Sawada, R; Shigemasa, T; Shimizu, M; Sugano, T; Takamura, T; Tamura, K; Tsukahara, K; Tsunematsu, T | 1 |
| Garcia, DA; Gu, TM; Sabath, DE | 1 |
| Aslan, U; Aydın, A; Dağdeviren, B; Gürol, T; Kemaloğlu Öz, T; Kobegenova, M; Sarıgül, NU; Soylu, Ö | 1 |
| Banchelli, F; Boriani, G; D'Amico, R; Guazzaloca, G; Magrini, N; Malavasi, VL; Manotti, C; Marietta, M; Pattacini, C; Pavesi, P; Quintavalla, R; Sinigaglia, T; Urbinati, S; Voci, C | 1 |
| Chaudhury, P; Mentias, A; Shantha, G; Vaughan Sarrazin, MS | 1 |
| Bosch, F; Cerdá, M; Cerezo-Manchado, JJ; Fernández, M; Johansson, E; Martínez, F; Rodríguez, S; Santamaría, A; Varela, A | 1 |
| Curnow, J; Favaloro, EJ; Mohammed, S; Pasalic, L | 1 |
| Huang, Y; Que, D; Wang, L; Wu, S; Xie, S; Xu, Y; Yau, TO | 1 |
| Aldouby-Bier, G; Fisher Negev, T; Hirsh-Raccah, B; Hochberg-Klein, S; Horwitz, E; Kalish, Y; Muszkat, M; Perlman, A | 1 |
| Amiya, R; Higuchi, Y; Hirata, A; Hirayama, A; Kobayashi, T; Sakata, Y; Sotomi, Y | 1 |
| Gressenberger, P | 1 |
| Ahmad, A; Al-Khatib, SM; Blank, M; Coylewright, M; DiBattiste, P; Gersh, BJ; Granger, CB; Healey, JS; Hedrich, O; Hylek, EM; Kline-Rogers, E; Mendys, P; Mirro, MJ; Naccarelli, G; Patel, P; Peterson, ED; Pokorney, SD; Ruff, CT; Rutman, H; Stockbridge, N; Temple, R | 1 |
| Young, M | 1 |
| Kopytek, M; Natorska, J; Undas, A; Ząbczyk, M | 1 |
| Ay, C; Beer, R; Haushofer, A; Kwasny, O; Leitgeb, J; Ortler, M; Schaden, E; Schöchl, H; Wiegele, M | 1 |
| Cha, MJ; Choi, EK; Joung, B; Kang, KW; Kim, C; Kim, J; Kim, JB; Kim, TH; Lee, JM; Lee, SR; Lee, YS; Park, HW; Park, J; Park, JK; Park, JS; Shim, J; Uhm, JS | 1 |
| Ariano, C; De Vecchis, R | 1 |
| Chan, YH; Chang, SH; Chen, SW; Kuo, CF; Kuo, CT; Lee, HF; See, LC; Tu, HT; Wu, LS; Yeh, YH | 1 |
| Bryk, AH; Chrapek, M; Dębski, M; Desteghe, L; Heidbuchel, H; Janion-Sadowska, A; Konieczyńska, M; Małecka, B; Metzgier-Gumiela, A; Podolec, P; Sadowski, M; Skonieczny, G; Sobieraj, E; Undas, A | 1 |
| Cha, MJ; Choi, EK; Kim, HM; Kwon, JM; Lee, SY; Oh, S; Park, CS | 1 |
| Baranchuk, A; Corbalán, R; Enríquez, A | 1 |
| Breuer, L; Engelhorn, T; Kallmünzer, B; Macha, K; Marsch, A; Schwab, S; Siedler, G; Strasser, EF | 1 |
| Deitelzweig, S; Lip, GYH | 1 |
| Brown, JD; Pham, PN | 1 |
| Basic, E; Hohnloser, SH; Nabauer, M | 1 |
| Baldus, S; Hohmann, C; Hohnloser, SH; Jacob, J; Pfister, R; Walker, J | 1 |
| Oo, TH; Rojas-Hernandez, CM | 1 |
| Ferenci, T; Finta, E; Gasparics, R; Medvegy, M; Simonyi, G | 1 |
| Amin, A; Dhamane, A; Di Fusco, M; Friend, K; Garcia Reeves, AB; Keshishian, A; Li, X; Luo, X; Mardekian, J; Nadkarni, A; Pan, X; Rosenblatt, L; Yuce, H | 1 |
| Amin, A; Baker, CL; Carda, E; Dhamane, A; Dina, O; Keshishian, A; Mardekian, J; Nadkarni, A; Rosenblatt, L; Russ, C; Yuce, H | 1 |
| Buijs, JT; Crooijmans, JJ; Kroone, C; Laghmani, EH; Le Dévédec, SE; Tieken, C; van den Akker, RFP; van der Molen, KM; van der Pluijm, G; Versteeg, HH; Vletter, EM | 1 |
| Pickett, JD | 1 |
| Al-Khaffaf, A; Franchini, M; Frattini, F; Mimiola, E; Sissa, C | 1 |
| Caughey, G; Duszynski, K; Kalisch Ellett, LM; Kerr, M; Pratt, NL; Ramsay, E; Roughead, EE; Shakib, S | 1 |
| Arrigoni, L; Cappelletti, A; Cera, M; Colombo, A; Della Bella, P; Godino, C; Margonato, A; Mattiello, P; Mazzone, P; Melillo, F; Rubino, F; Salerno, A | 1 |
| Chan, YH; Chang, SH; Chao, TF; Kuo, CT; Lee, HF; Lip, GYH; See, LC; Tu, HT; Wu, LS; Yeh, YH | 1 |
| Balachander, N; Deitelzweig, S; Dhamane, AD; Di Fusco, M; Garcia Reeves, AB; Kang, A; Keshishian, A; Li, X; Lip, GYH; Luo, X; Mardekian, J; Nadkarni, A; Pan, X; Rosenblatt, L; Yuce, H | 1 |
| Fleddermann, AM; Hayes, CH; Magalski, A; Main, ML | 1 |
| Boling, B; Nestor, MA | 1 |
| Nowak, K; Pac, A; Stepien, K; Undas, A; Zalewski, J | 1 |
| Crijns, HJ; Gulpen, AJW; Henskens, YMC; Schalla, S; Ten Cate, H; Ten Cate-Hoek, AJ; van Oerle, R; Wetzels, R | 1 |
| Imberti, D; Mastroiacovo, D; Pomero, F | 1 |
| Dina, O; Gupta, K; Keshishian, A; Mardekian, J; Nadkarni, A; Shank, TC; Trocio, J; Zhang, Q | 1 |
| Cha, MJ; Choi, EK; Han, KD; Jung, JH; Kwon, S; Lee, SR; Lip, GYH; Oh, S | 1 |
| Batiushin, MM | 1 |
| Pastori, D; Violi, F | 1 |
| Chen, YT; Lin, HJ | 1 |
| Chen, H; Deng, Y; Li, S; Tong, Y; Zou, L | 1 |
| Aakjaer, M; Andersen, M; Ballarin, E; De Bruin, ML; Droz, C; Gardarsdottir, H; Gasse, C; Groenwold, R; Heeke, A; Huerta, C; Ibáñez, L; Klungel, O; Lassalle, R; Leon-Muñoz, LM; Martin Merino, E; Montero, D; Moore, N; Rottenkolber, M; Sabaté, M; Schmiedl, S; Souverein, P; van den Ham, HA; Vidal, X | 1 |
| Bowrin, K; Briere, JB; Coleman, CI; Levy, P; Millier, A; Taieb, V; Toumi, M; Wu, O | 1 |
| Butt, JH; Fosbøl, EL; Garcia, D; Køber, L; Li, A; Peterson, ED; Torp-Pedersen, C; Xian, Y | 1 |
| Behdarvand, B; Bero, L; Karanges, EA | 1 |
| Ariansen, I; Ellekjær, H; Karlstad, Ø; Kjerpeseth, LJ; Selmer, R; Skovlund, E | 1 |
| Albendín Iglesias, H; Arregui Montoya, F; Bailén Lorenzo, JL; Caro Martínez, C; Cerezo Manchado, JJ; Elvira Ruiz, G; Flores Blanco, PJ; García Alberola, A; Lova Navarro, A; Manzano-Fernández, S; Pascual Figal, DA | 1 |
| Papuga-Szela, E; Rusin, G; Undas, A; Wypasek, E; Żuk, J | 1 |
| Buscarini, E; Coote, N; Droege, F; Dupuis-Girod, S; Fialla, AD; Geisthoff, U; Kjeldsen, A; Lenato, GM; Mager, HJ; Manfredi, G; Millar, CM; Pagella, F; Post, MC; Sabbà, C; Shovlin, CL; Suppressa, P; Sure, U; Torring, PM; Ugolini, S | 1 |
| Agnelli, G; Becattini, C; Isidori, F; Mosconi, MG; Vedovati, MC | 1 |
| Barben, J; d'Athis, P; Manckoundia, P; Menu, D; Mihai, AM; Nuss, V; Putot, A; Rosay, C; Vovelle, J | 1 |
| Balabanova, Y; Brobert, G; Fatoba, S; García Rodríguez, LA; Martín-Pérez, M; Roberts, L; Ruigomez, A; Schaefer, B; Suzart-Woischnik, K; Vora, P | 1 |
| Dong, J; Du, X; Ma, C; Yang, Y | 1 |
| Löser, C; Nast, A; Zeymer, U | 1 |
| Balabanova, Y; Brobert, G; Fatoba, S; Fernandez, O; García Rodríguez, LA; Roberts, L; Ruigómez, A; Vora, P | 1 |
| Bernard, MA; Blin, P; Dallongeville, J; Droz-Perroteau, C; Dureau-Pournin, C; Fauchier, L; Lassalle, R; Moore, N; Sacher, F | 1 |
| Barequet, IS; Bourla, N; Moisseiev, J; Salomon, O; Tamarin, I; Zehavi-Dorin, T | 1 |
| Blin, P; de Pouvourville, G; Karam, P | 1 |
| Bae, HJ; Cho, YK; Choi, SW; Han, S; Hur, SH; Hwang, J; Jun, SW; Kim, H; Kim, IC; Lee, CH; Lee, SH; Nam, CW; Park, HS; Yoon, HJ | 1 |
| Eschler, CM; Exadaktylos, AK; Funk, GC; Lindner, G; Maier, V; Walter, P; Woitok, BK | 1 |
| Bachelot-Loza, C; Duchemin, J; Fontenay, M; Gaussem, P; Jourdi, G; Mazoyer, E; Poirault-Chassac, S | 1 |
| Aboutanos, M; Anand, RJ; Bachmann, L; Bennett, JD; Broering, B; Chenault, G; Chou, C; Contaifer, D; DeAntonio, JH; Doan, D; Feeser, VR; Ferrada, P; Goldberg, S; Han, J; Hobgood, S; Jayaraman, S; Kumar, NG; Leichtle, SW; Liebrecht, L; Mangino, M; Nguyen, T; Procter, LD; Rodas, EB; Rossi, AP; Staschen, J; Vitto, MJ; Whelan, JF; Wijesinghe, DS; Wolfe, L; Young, C | 1 |
| Prentice, A; Ruiz, I; Weeda, ER | 1 |
| Higashiya, S; Hina, K; Hirohata, S; Kamikawa, S; Kawamura, H; Kusachi, S; Murakami, M; Murakami, T; Yamaji, H | 1 |
| Bailey, E; Bollu, PC; Dyer, N; Govindarajan, R; Nagarajan, E; Sivaraman, M; Yelam, A | 1 |
| Adabala, N; Bommana, S; Di Biase, L; Gianni, C; Gopinathannair, R; Khalafi, M; Lakkireddy, D; Lakkireddy, P; Maybrook, R; Mohanty, S; Natale, A; Parikh, V; Pillarisetti, J; Reddy, MY; Reddy, S; Saksena, S | 1 |
| Alonso, A; Chen, LY; Diem, SJ; Ensrud, KE; Lutsey, PL; MacLehose, RF; Norby, FL | 1 |
| Jairam, A; Jha, VK; Mahapatra, D | 1 |
| Chao, TF; Chen, SA; Chen, TJ; Chiang, CE; Liao, JN; Lip, GYH | 1 |
| Carlucci, G; Carlucci, M; Ferrone, V; Fontana, A; Milanetti, E; Todaro, S; Ventrella, A | 1 |
| Jansson, M; Norrving, B; Renlund, H; Själander, A; Själander, S; Sjögren, V | 1 |
| Liao, YWB; Wang, TKM | 1 |
| Kanorskii, SG | 2 |
| Bartels, DB; Gopalakrishnan, C; Gurusamy, VK; Huybrechts, KF; Landon, J; Schneeweiss, S; Zint, K | 1 |
| Fredenburgh, JC; Jaffer, IH; Stafford, A; Weitz, JI; Whitlock, RP | 1 |
| Lip, GYH; Mujovic, N; Potpara, TS | 1 |
| Chao, HC; Jeng, JS; Jhang, RS; Kuo, CH; Liao, HW; Lin, SY; Lin, YT; Peng, YF; Tang, SC; Tsai, IL | 1 |
| Hsu, JY; Huang, HK; Lin, SM; Liu, PP; Loh, CH; Peng, CC; Wang, JH; Yeh, JI | 1 |
| Adademir, T; Aksoy, R; Baş, T; Başaran, EK; Çevirme, D; Elibol, A; Keser, S; Savluk, ÖF; Yılmaz, B | 1 |
| Chu, YB; Dong, SJ; Gupta, P; Li, YH; Wu, B; Zhai, SD; Zhang, YJ | 1 |
| Drabik, L; Potpara, T; Undas, A | 2 |
| Ghanima, W; Halvorsen, S; Jonasson, C; Rutherford, OW; Söderdahl, F | 2 |
| Buijs, JT; Najidh, S; Versteeg, HH | 1 |
| Boissier, E; Bourcier, R; Dargazanli, C; Desal, H; Gory, B; Kyheng, M; L'Allinec, V; Labreuche, J; Lapergue, B; Mazighi, M; Roy, M; Sibon, I | 1 |
| Aimo, A; De Caterina, R; Petricciuolo, S | 1 |
| Buda, S; Degli Esposti, L; Perrone, V; Piovaccari, G; Saragoni, S | 1 |
| Albert, L; Bejjani, A; Coons, JC; Iasella, CJ | 1 |
| Bao, Y; Hua, W; Jin, Q; Ke, M; Lin, C; Ling, T; Pan, W; Quan, J; Wei, Y; Wu, L; Xie, Y; Zhang, N | 1 |
| Alves, G; Bicker, J; Falcão, A; Fortuna, A; Gouveia, F; Rocha, M; Santos, J | 1 |
| Hsu, JY; Huang, HK; Lin, SM; Liu, PP; Loh, CH; Peng, CC; Wang, JH | 1 |
| Alvarez, P; Asleh, R; Briasoulis, A; Chrischilles, E; Gao, Y; Inampudi, C; Leira, EC; Vaughan-Sarrazin, M | 1 |
| de Boer, A; Gardarsdottir, H; Maitland-van der Zee, AH; Souverein, PC; van den Ham, HA; Zhang, Y | 1 |
| Ali, H; Hanley, DF; Marsh, EB; Nyquist, PA; Shin, SS; Ziai, WC | 1 |
| Chen, N; Holbrook, A; Lee, M; Leenus, A; Liu, J; Mbuagbaw, L; Thabane, L; Wang, M | 1 |
| Chin, PKL; Moore, GA; Zhang, M | 1 |
| Brčić, M; Ćelap, I; Margetić, S; Mihić, R | 1 |
| Al-Khalili, F; Ammar, M; Antovic, A; Antovic, JP; Jakovljevic, V; Malmström, RE; Petkovic, A; Pruner, I; Soutari, N; Vranic, A; Zdravkovic, N | 1 |
| MacGillivray, TE | 1 |
| Shan, C; Yu, L; Yu, Z | 1 |
| Broncel, M; Bukowska, B; Gorzelak-Pabiś, P; Woźniak, E | 1 |
| Albrecht, H; Hagel, AF; Konturek, PC; Maass, LS; Neurath, MF; Raithel, M | 1 |
| Fosbøl, EL; Køber, L; Vinding, NE | 1 |
| Heinrich-Nols, J; van Ryn, J | 1 |
| Ho, KH; Leng, G; van Hove, M | 1 |
| Auditeau, C; Blandinières, A; Gendron, N; Smadja, DM; Talbot, A | 1 |
| Bari, N; Ho, JPK; Riffat, F | 1 |
| Acar, RD; Akgün, T; Camm, AJ; Emren, V; Kanat, S; Karacağlar, E; Kepez, A; Kul, Ş; Özel, E; Şimşek, E; Tülüce, K; Türk, UÖ; Yakar Tülüce, S | 1 |
| Liu, X; Xu, ZX; Yu, P; Yuan, P; Zhu, WG | 1 |
| Agosti, S; Di Brigida, G; Morelli, N; Risso, R; Rota, E; Rovere, ME; Testa, L | 1 |
| Ageno, W; Casella, IB; Chee, KH; Desch, M; Donado, E; Goldhaber, SZ; Reilly, PA; Schellong, S; Schulman, S; Singer, DE; Tang, W; Voccia, I | 1 |
| Ashley, J; Badve, SV; Battistella, M; Bota, S; Garg, AX; Harel, Z; Jun, M; Manuel, D; Mavrakanas, T; McArthur, E; Molnar, AO; Rhodes, E; Sood, MM; Tanuseputro, P; Wells, P | 1 |
| Jenkins, A; Katada, J; Kohsaka, S; Li, B; Mardekian, J; Saito, K; Terayama, Y | 1 |
| Bauersachs, J; Berliner, D; Flierl, U; Schäfer, A | 1 |
| Brooks, MM; Glynn, NW; Hernandez, I; Saba, S; Yang, L; Zhang, Y | 1 |
| Berteotti, M; Casciaro, MA; Ettorre, E; Godino, C; Lip, GYH; Marcucci, R; Melillo, F; Menafra, V; Menichelli, D; Pastori, D; Perticone, F; Pignatelli, P; Saliola, M; Sciacqua, A; Violi, F | 1 |
| Modukuru, VR; Naderan, M; Shoar, N; Shoar, S | 1 |
| Gawęda, B; Iwaniec, T; Kapelak, B; Kapusta, P; Kopytek, M; Madeja, J; Mazur, P; Natorska, J; Undas, A; Wypasek, E | 1 |
| Ashurov, AB; Khagush, AL; Kiseleva, MV; Novikova, TN; Plotnikova, MO; Podoprigora, EA; Sayganov, SA | 1 |
| De Kesel, PM; Devreese, KMJ | 1 |
| Han, X; Ma, L; Nie, X; Peng, L; Wang, J; Zan, X; Zheng, N | 1 |
| Balusson, F; Bouget, J; Lacut, K; Maignan, M; Nowak, E; Oger, E; Pavageau, L; Roy, PM; Scailteux, LM | 1 |
| Chan, EW; Cheung, CL; Lam, JKY; Lau, WCY; Lee, ACH; Lip, GYH; Man, KKC; Sing, CW; Siu, CW; Wong, ICK | 1 |
| Branam, DL; Covert, K | 1 |
| Alexandre, J; Chrétien, B; Dolladille, C; Fedrizzi, S; Lelong-Boulouard, V; Sassier, M | 1 |
| Chaudhary, R; Garg, J; McBane, RD; Murad, MH; Pagali, S; Wysokinski, WE | 1 |
| Mastroroberto, P; Santarpino, G | 1 |
| Liu, X; Sun, Y; Xu, Y | 1 |
| Hironobe, N; Kihara, Y; Matsumura, H; Nakano, Y; Onohara, Y; Sairaku, A | 1 |
| Son, KB | 1 |
| Blais, JE; Chan, EW; Chen, EYH; Chui, CSL; Lau, WCY; Mok, MT; Seto, WK; Suh, IH; Wong, ICK; Yan, VKC; Zhao, J | 1 |
| Collins, R; Gil, VM; Hanon, O; Hardt, R; Hoffmeister, M; Monteiro, P; Pazan, F; Quinn, TJ; Ropers, D; Sergi, G; Verheugt, FWA; Wehling, M | 1 |
| Douketis, J; Kaplovitch, E; Shaw, JR | 1 |
| Carrier, M; Clark, EG; Garg, AX; Harel, Z; Hill, K; Hundemer, GL; Knoll, G; McArthur, E; Rhodes, E; Sood, MM; Sucha, E | 1 |
| García-Sempere, A; Hurtado, I; Peiró, S; Rodríguez-Bernal, CL; Sanfélix-Gimeno, G; Santa-Ana-Téllez, Y | 1 |
| Belhassen, M; Cotté, FE; Dalon, F; Danchin, N; Falissard, B; Gollety, S; Hanon, O; Jacoud, F; Lefevre, C; Mahé, I; Nolin, M; Steg, PG; Van Ganse, E | 1 |
| Cipriano, A; Parollo, M; Santini, M; Taurino, E; Venturi, E | 1 |
| Abdelmaseeh, P; Asinger, R; Megaly, M; Sedhom, R | 1 |
| Budnik, M; Chrapek, M; Filipiak, KJ; Gawałko, M; Gielerak, G; Gorczyca, I; Jelonek, O; Jurek, A; Kapłon-Cieślicka, A; Kiliszek, M; Kochanowski, J; Krzesiński, P; Michalska, A; Opolski, G; Scisło, P; Starzyk, K; Uziębło-Życzkowska, B; Wożakowska-Kapłon, B | 1 |
| Fomin, VV; Kogay, VV; Listratov, AI; Napalkov, DA; Skripka, AI; Sokolova, AA | 1 |
| Balachander, N; Deitelzweig, S; Dhamane, AD; Di Fusco, M; Garcia Reeves, AB; Kang, AL; Keshishian, AV; Li, X; Lip, GYH; Luo, X; Mardekian, J; Pan, X; Rosenblatt, L; Yuce, H | 1 |
| Le, T; Pasciolla, S; Wright, K; Zizza, LF | 1 |
| Aakjaer, M; Andersen, M; De Bruin, ML; Gardarsdottir, H; Heeke, A; Huerta, C; Klungel, OH; León-Muñoz, LM; Merino, EM; Montero, D; Rottenkolber, M; Schmiedl, S; Souverein, PC; van den Ham, HA | 1 |
| Adelmeijer, J; Bontemps, STH; de Kleine, RHJ; de Meijer, VE; Hulscher, JBF; Lisman, T; Porte, RJ; Reyntjens, KMEM; Scheenstra, R; Werner, MJM | 1 |
| Huang, M; Liu, X; Ma, J; Ye, C; Zeng, C; Zeng, J | 1 |
| Afriyie, A; Berger, SE; Deshpande, S; Di Fusco, M; Earley, A; Kang, A; Lopes, RD; Mantovani, LG; Russ, C | 1 |
| Buyukdere, H; Carrier, M; Castellucci, LA; Chakraborty, S; Dowlatshahi, D; Shaw, JR; Tokessy, M | 1 |
| Bardou, M; Billionnet, C; Drouin, J; Maura, G; Neumann, A; Weill, A | 1 |
| As-Sultany, M; Donnachie, NJ; Finley, R; Highcock, AJ | 1 |
| Katus, HA; Kraft, M; Nietfeld, J; Schlund, D; Schmidt, C; Thomas, D; Wiedmann, F | 1 |
| Doyama, H; Fujishiro, M; Fujita, T; Hasatani, K; Hatta, W; Hiasa, Y; Hikichi, T; Igarashi, K; Iguchi, M; Inoue, T; Kawaguchi, K; Kitamura, K; Kuribayashi, S; Mikami, T; Morita, Y; Nishida, T; Nishikawa, J; Oda, I; Sumiyama, K; Sumiyoshi, T; Tomida, H; Tsuji, Y; Uraoka, T; Yada, T; Yamamoto, K; Yanagitani, A; Yoshio, T | 1 |
| Cui, Y; Gong, Y; Hu, K; Jiang, J; Liu, Z; Ma, L; Mu, G; Wang, Z; Xiang, Q; Xie, Q; Zhang, H; Zhou, S | 2 |
| Lobastov, KV; Schastlivtsev, IV | 1 |
| Coppens, M; Douketis, JD; Duncan, J; Li, N; Radwi, M; Schulman, S; Shaw, JR; Spyropoulos, AC; Syed, S; Vanassche, T | 1 |
| Amioka, M; Maeda, J; Matsumura, H; Morishima, N; Nakano, Y; Sairaku, A; Watanabe, Y | 1 |
| Jin, H; Wang, L; Zhi, H; Zhou, W; Zhu, K | 1 |
| Bane, KL; Maji, D; Mohseni, P; Opneja, A; Stavrou, EX; Suster, MA; Wilson, BM | 1 |
| Frol, S; Hudnik, LK; Oblak, JP; Šabovič, M; Sernec, LP | 2 |
| DU, LP; Liu, B; Liu, XM | 1 |
| Cui, Y; Jiang, J; Liu, Z; Mu, G; Wang, Z; Xiang, Q; Xie, Q; Zhang, H; Zhou, S | 1 |
| Goya, M; Hirao, K; Kawabata, M; Maeda, S; Sasano, T; Takahashi, Y; Yagishita, A | 1 |
| Bazan-Socha, S; Dropiński, J; Pacholczak-Madej, R; Undas, A; Zaręba, L | 1 |
| Dannenberg, L; Hohlfeld, T; Kelm, M; Orban, M; Petzold, T; Polzin, A; Thienel, M; Wolff, G; Zeus, T | 1 |
| Brüggenjürgen, B; Darius, H; De Caterina, R; Duytschaever, M; Huber, K; Kirchhof, P; Kotecha, D; Le Heuzey, JY; Lucerna, M; Patti, G; Pecen, L; Renda, G; Ricci, F; Rohla, M; Schilling, RJ; Schnabel, RB; Sellal, JM; Siller-Matula, JM; Verheugt, FWA; Wachter, R; Zamorano, JL | 1 |
| Caprini, JA; Clark, NP; Douketis, J; Kaplovitch, E; Li, N; MacDougall, K; Schulman, S; Spyropoulos, AC; Tafur, AJ | 1 |
| Aucella, F; Barcellona, D; Brunori, G; Forneris, G; Genovesi, SC; Grandone, E; Gresele, P; Marietta, M; Poli, D; Testa, S; Tripodi, A | 1 |
| Amano, Y; Fujishiro, H; Harada, H; Hayasaka, K; Iwaki, T; Katsuyama, Y; Kushiyama, Y; Maeda, G; Miyaoka, Y; Murakami, D; Nakahara, R; Ujihara, T; Yuki, T | 1 |
| Bernier, M; Drici, MD; Lancrerot, SL; Lavrut, T; Parassol, N; Rocher, F; Viotti, J | 1 |
| Aakjaer, M; Andersen, M; Ballarín, E; De Bruin, ML; Gardarsdottir, H; Gasse, C; Gerlach, R; Huerta, C; Ibánez, L; Klungel, O; Leon-Muñoz, LM; Martin Merino, E; Montero, D; Rottenkolber, M; Sabaté, M; Schmiedl, S; Souverein, PC; Tauscher, M; van den Ham, R; Vidal, X | 1 |
| Ahn, SH; Cho, HJ; Choi, HY; Choi, JK; Han, SW; Heo, JH; Jung, YH; Kang, YJ; Kim, WJ; Kim, YD; Kwon, JH; Lee, KY; Nam, HS; Park, HJ; Park, JH; Seo, JH; Sung, SM | 1 |
| Hocker, TLH; Neill, BC; Singh, AH; Siscos, SM | 1 |
| Haas, S; Patti, G | 1 |
| Jang, E; Joung, B; Kim, D; Kim, JY; Kim, TH; Lee, MH; Lip, GYH; Pak, HN; Sung, JH; Uhm, JS; Yang, PS; Yu, HT | 1 |
| Fanning, L; Lau, WCY; Man, KKC; Mongkhon, P; Wong, ICK; Wong, KHTW | 1 |
| Davis, KA; Valanejad, SM | 1 |
| Andreoli, L; Barcellona, D; Cafolla, A; De Micheli, V; Denas, G; Falanga, A; Fierro, T; Gerosa, M; Ghirarduzzi, A; Gresele, P; Hoxha, A; Martinelli, I; Pengo, V; Prisco, D; Silvestri, E; Testa, S; Tincani, A; Tosetto, A | 1 |
| Gerasimenko, AS; Gorbatenko, VS; Shatalova, OV | 1 |
| Atić, A; Hadžibegović, I; Hulak Karlak, V; Jurin, I; Lucijanić, M; Magličić, A; Šakić, Z; Starčević, B | 1 |
| Bertoletti, L; Cucherat, M; Durieu, I; Grange, C; Grenet, G; Gueyffier, F; Kilo, R; Laporte, S; Lega, JC; Mainbourg, S; Mismetti, P; Nony, P; Provencher, S | 1 |
| Bernardini, F; Marchetti, G; Romoli, M; Urbinati, S | 2 |
| Hardy, LJ; Khan, AA; Lau, YC; Lip, GYH; Philippou, H; Shantsila, E | 1 |
| Baldwin, MK; Chi, V; Edelman, AB; McCarty, OJT; Samuelson Bannow, BT; Sochacki, P | 1 |
| Cho, HJ; Choi, HY; Choi, S; Jang, HJ; Jang, SS; Jeon, S; Kim, DE; Kim, H; Kim, J; Kim, K; Kim, YD; Kwon, IC; Lee, KY; Lee, SK; Nahrendorf, M; Ryu, WS; Schellingerhout, D | 1 |
| Bereznicki, LR; Bezabhe, WM; Curtain, C; Peterson, GM; Radford, J; Salahudeen, MS; Wimmer, BC | 1 |
| Carney, G; Durand, M; Eltonsy, S; Filion, KB; Fisher, A; Jun, M; Kuo, IF; Matteau, A; Pang, M; Paterson, JM; Quail, J; Renoux, C; Schnitzer, ME | 1 |
| Chan, N; Eikelboom, JW; Sobieraj-Teague, M | 1 |
| Bang, OY; Choi, HY; Han, S; Jang, SW; Kang, S; Kim, YH; Lee, JM; Lee, MY; On, YK; Park, YJ; Suh, HS; Won, MM | 1 |
| Ishizawa, K; Mitsuboshi, S; Niimura, T; Zamami, Y | 1 |
| Del Sole, F; Menichelli, D; Pastori, D; Pignatelli, P; Violi, F | 1 |
| Avorn, J; Gagne, JJ; Kesselheim, AS; Rome, BN | 1 |
| Egred, M; Farag, M; Gorog, DA; Gue, YX; Spinthakis, N | 1 |
| Lee, EM; Tan, VH; Tan, YC; Tiew, WJ; Wong, VL | 1 |
| Qu, R; Song, R; Wang, Y; Zhang, A; Zhou, D | 1 |
| Brouwer, RW; Gerritsma-Bleeker, CL; Segers, M; van der Veen, L; van Hulst, M; van Raay, JJ; Veeger, NJ | 1 |
| Brahmbhatt, B; Devani, K; Radadiya, D; Reddy, C | 1 |
| Cui, C; Cui, X; Li, D; Liu, Y; Wei, H | 1 |
| Hung, CS; Li, HJ; Lin, FJ; Lin, SY; Wang, CC | 1 |
| Ghaznavi, Z; Jackevicius, CA; Lu, L; Warner, AL | 1 |
| Aletti, M; Caré, W; Daban, JL; Doutrelon, C; Foissaud, V; Lefeuvre, L; Vodovar, D | 1 |
| Lorenzoni, V; Pirri, S; Turchetti, G | 1 |
| Chen, S; Dong, Y; He, J; Lip, GYH; Liu, C; Wu, D; Ye, Z; Zhu, W | 1 |
| Chan, FK; Guo, CL; Lam, KL; Lau, LH; Mak, JW; Ng, SC; Wong, GL; Wong, SH; Yip, TC | 1 |
| Barnathan, E; Freedman, A; Larbi, L; Rao, G; Shoaibi, A; Truong, HQ; Wang, L; Weaver, J; Wildgoose, P; Wu, S; Yuan, Z | 1 |
| Côté, R; Dorais, M; Martel, MJ; Perreault, S; Qazi, JZ; Schnitzer, ME | 1 |
| Arita, T; Nagahama, T; Nagai, K; Otsuka, T; Suzuki, S; Tanaka, T; Yagi, N; Yamashita, T | 1 |
| Luna, JD; Manzano-Gamero, V; Pardo-Cabello, AJ | 1 |
| Di Fusco, M; Friend, K; Jones, WS; Keshishian, A; Li, X; Lopes, RD; Luo, X; Mardekian, J; Masseria, C; Pan, X; Thomas, L; Yuce, H | 1 |
| Chukhliaev, PV; Garbuzov, AA; Khavkina, DA; Ploskireva, AA; Ruzhentsova, TA | 1 |
| De Souza, S; Goddard, R; Hargreaves, IP; Porter, KMF | 1 |
| Cappelleri, JC; Deitelzweig, S; Di Fusco, M; Gutierrez, C; Kang, A; Keshishian, A; Mokgokong, R; Savone, M | 1 |
| Altay, S; Aşkın, L; Beşli, F; Çakmak, HA; Canpolat, U; Gedikli, Ö; Pehlivanoğlu, S; Şahin, M; Sinan, ÜY; Ünlü, S; Yanık, A | 1 |
| Oh, HJ; Park, BJ; Ryu, KH; Yoon, BH | 1 |
| Xu, J; Zhu, J | 1 |
| Choi, EK; Han, KD; Jung, JH; Kwon, S; Lee, SR; Lip, GYH; Oh, S | 1 |
| Ashton, V; Berger, JS; Jung, Y; Kharat, A; Laliberté, F; Lefebvre, P; Lejeune, D; Moore, KT | 1 |
| Feng, L; Liu, X; Wang, L; Zhou, M | 1 |
| Chan, EWY; Cheung, BMY; Cheung, CL; Lau, WCY; Li, GHY; Lip, GYH; Sing, CW; Tan, KCB; Wong, ICK | 1 |
| Barnes, GD; Cuker, A; Dawwas, GK; Dietrich, E; Leonard, CE; Lewis, JD | 1 |
| de Brouwer, B; Egea, M; Eggington, S; Franco, N; Huynh, M; Ismyrloglou, E; Joglekar, R; Liu, S; Lyon, J; Reynolds, MR; Rosemas, SC; Thijs, V; Tsintzos, SI; Tsivgoulis, G; Witte, KK; Ziegler, PD | 1 |
| Bo, M; Brunetti, E | 1 |
| Cannegieter, SC; Huisman, MV; Klok, FA; Lijfering, WM; Rosendaal, FR; Teichert, M; van der Meer, FJM; van Rein, N; Zielinski, GD | 1 |
| Duvanova, SP; Filimonov, KM; Gorbunova, EV; Makarov, SA; Mamchur, SE | 1 |
| Alexandris-Souphis, T; Ali, MA; Barnes, GD; Decamillo, D; Errickson, J; Froehlich, JB; Haymart, B; Kaatz, S; Kline-Rogers, E; Kong, X; Kozlowski, JH; Krol, GD; Li, Y; Schaefer, JK; Shankar, SR; Sood, SL | 1 |
| Antz, M; Camm, AJ; Collins, R; Cornu, P; Desteghe, L; Haeusler, KG; Heidbüchel, H; Oldgren, J; Potpara, T; Reinecke, H; Roldan-Schilling, V; Rowell, N; Sinnaeve, P; Steffel, J; Vanassche, T | 1 |
| Dong, YX; Gao, LJ; Li, WW; Ma, CM; Wang, N; Xia, YL; Xiao, XJ; Yang, MH; Yin, XM; Yu, XH; Zhang, RF | 1 |
| Munasinghe, A; Rao, V | 1 |
| Pos, L | 1 |
| Cuccia, C; Enea, I; Fresco, C; Paciaroni, M; Patti, G; Pecora, D; Rocca, B; Rubboli, A | 1 |
| Anoopkumar-Dukie, S; Badrick, T; Bernaitis, N | 1 |
| Deitelzweig, S; Dhamane, AD; Jiang, J; Kang, A; Keshishian, A; Klem, C; Lip, GYH; Luo, X; Mardekian, J; Rosenblatt, L; Yuce, H | 1 |
| Daei, M; Heidari, Z; Khalili, H | 1 |
| Agudo-Fernández, S; Calvo Morillas, I; Castaño Milla, C; González Blanco, A; Olmos Jerez, JA; Sancho Del Val, L | 1 |
| Alatawi, Y; Alghamdi, BS; Alshehri, FS; Balabagno, AO; Chen, Y; Durmanova, V; Evangelista, LS; Hromadka, T; Javor, J; Ji, Q; Jiao, J; Kralova, M; Kurdi, M; Labban, S; Li, X; Li, Y; Lv, Q; Minarik, G; Ocenasova, A; Pagsibigan, JS; Parnicka, Z; Reznakova, V; Shawkatova, I; Shen, ZJ; Tian, X; Tu, S; Tuazon, JA; Vaseckova, B; Wang, XY; Wang, Z; Xue, Y; Zeng, LX; Zhang, S; Zhang, ZH; Zuo, C | 1 |
| Dasgupta, K; Godin, R; Nedjar, H; Rahme, E; Tagalakis, V | 1 |
| Anderson, A; Eworuke, E; Gassman, A; Hou, L; Huang, TY; Moeny, D; Waldron, P; Wong, HL; Zhang, R | 1 |
| Akpan, IJ; Cuker, A | 1 |
| Bradley, SM; Gosch, KL; Hess, PL; Jani, SM; Maddox, TM; Michael Ho, P; Varosy, PD; Virani, SS | 1 |
| Cook, BM; Kanaan, DM; Kelly, J; Malloy, R | 1 |
| Atar, D; Rubboli, A | 1 |
| Bennie, M; Forslund, T; Hallas, J; Haug, U; Hellfritzsch, M; Hjemdahl, P; Karlstad, Ø; Kjerpeseth, LJ; Klungel, OH; Kollhorst, B; Komen, JJ; Mantel-Teeuwisse, AK; Mueller, T; Olesen, M; Pottegård, A; Schink, T; Voss, A; Wettermark, B | 1 |
| Cui, X; Guo, M; Thai, S; Wang, T; Wei, J; Xu, W; Zhao, Y; Zhou, J | 1 |
| Grove, EL; Larsen, TB; Lip, GYH; Nielsen, PB; Ording, AG; Skjøth, F; Søgaard, M | 1 |
| Dilcher, B; Hayward, I; Kline, J; Pagenhardt, J; Quedado, K | 1 |
| Boscolo-Anzoletti, M; Chantarangkul, V; Clerici, M; Novembrino, C; Paoletti, O; Peyvandi, F; Scalambrino, E; Testa, S; Tripodi, A | 1 |
| Chandler, WL; Chen, D; Goodwin, AJ; Harris, NS; Higgins, RA; Isom, JA; Long, T; Moser, K; Olson, JD; Pham, HP; Rollins-Raval, M; Smock, KJ; VanSandt, A; Volod, O; Wool, G | 1 |
| Burns, C; Garwood, CL; Liu, Q; Smythe, MA | 1 |
| Han, KD; Kim, BS; Kim, HK; Kim, YJ; Lee, H; Lee, HJ; Lee, SP; Park, JB | 1 |
| Benamouzig, R; Deutsch, D; Fauchier, L; Guenoun, M | 1 |
| Chaudhry, UA; Ezekowitz, MD; George, WT; Gracely, EJ; Harper, G; Harper, GR; Wolfe, CM | 1 |
| Abdelgawwad, K; Brescia, CW; Coleman, CI; Costa, OS; O'Donnell, B; Sood, N; Vardar, B | 1 |
| Bolek, T; Galajda, P; Kamenišťáková, A; Kubisz, P; Mokáň, M; Samoš, M; Škorňová, I; Stančiaková, L; Staško, J | 1 |
| Anic, A; Bakotic, Z; Benko, I; Bojko, A; Brusich, S; Jan, M; Manola, S; Pavlovic, N; Pernat, A; Pezo Nikolic, B; Radeljic, V; Scherr, D; Szavits Nossan, J; Traykov, V; Velagic, V; Zeljkovic, I | 1 |
| Al-Khalili, F; Ehrenstein, V; Ghanima, W; Gislason, G; Halvorsen, S; Hohnloser, SH; Jenkins, A; Johnsen, SP; Linder, M; Madsen, M; Sulo, G; Tell, GS | 1 |
| Beyer-Westendorf, J; Birschmann, I; Greinacher, A; Grottke, O; Herrmann, E; Konstantinides, S; Kuhn, J; Lindau, S; Lindhoff-Last, E; Lucks, J; Meybohm, P; Nowak-Göttl, U; Schellong, S; Sümnig, A; von Heymann, C; Zydek, B | 1 |
| Ma, S; Mei, H; Wang, J | 1 |
| Giacomuzzi, K; Jani, E; Marschang, P; Mueller, T; Thuile, K | 1 |
| Bessette, LG; Gagne, JJ; Glynn, RJ; Kim, DH; Lee, H; Pawar, A; Schneeweiss, S | 1 |
| Caughey, GE; Li, RJ; Shakib, S | 1 |
| Jiang, H; Jiang, Y; Lv, J; Ma, H; Zeng, H | 1 |
| Broniatowska, E; Papuga-Szela, E; Undas, A; Weronska, A | 1 |
| Jiang, J; Li, W; Wang, M; Wang, S; Wang, X; Wu, T; Xie, J; Xue, E; Zhan, S; Zheng, H; Zhou, R | 1 |
| Chen, CY; Chu, CC; Huang, YL | 1 |
| Cornu, P; Dupont, A; Moudallel, S; Steurbaut, S | 1 |
| Atripaldi, U; Bottino, R; Cattaneo, D; Clementi, E; Giannetti, L; Laezza, N; Russo, V | 1 |
| Benipal, H; Douketis, J; Foster, G; Holbrook, A; Ma, J; Paterson, JM; Thabane, L | 1 |
| Deitelzweig, S; Dhamane, AD; Ferri, M; Jiang, J; Kang, A; Keshishian, AV; Klem, C; Lip, GYH; Luo, X; Yuce, H; Zhang, Y | 1 |
| Ikusaka, M; Ishizuka, K; Mori, T; Yokokawa, D | 1 |
| Badve, SV; Beaubien-Souligny, W; Blum, D; Dorian, P; Garg, AX; Harel, Z; Jandoc, R; Jeyakumar, N; Jun, M; Kitchlu, A; McArthur, E; Silver, SA; Smyth, B; Sood, MM; Wald, R; Yan, AT | 1 |
| Biais, M; Cavaillez, T; Delassasseigne, C; James, C; Mouton, C; Roullet, S; Sesay, M; Weinmann, L | 1 |
| Chen, J; Chen, M; Fang, Z; Jiang, S; Lv, M; Qian, J; Wu, S; Xu, W; Zeng, Z; Zhang, J | 2 |
| Biss, TT; Chalmers, EA | 1 |
| Chao, TF; Chen, MC; Chen, SW; Chu, PH; Chung, CM; Kuan, FC; Lin, YS; Lip, GYH; Wu, M; Wu, VC | 1 |
| Aoyama, T; Enomoto, A; Kawano, Y; Mano, Y; Nagata, M; Nishikawa, T; Sasaki, Y; Takahashi, H | 1 |
| Cavillon Decaestecker, M; Decaestecker, K; Ferret, L; Gautier, S; Tsogli, ES; Verdun, S | 1 |
| Abdulsattar, W; Al-Abdouh, A; Alom, M; Assaly, R; Ayesh, H; Beran, A; Hamouda, D; Khuder, SA; Mhanna, M; Sajdeya, O; Srour, O | 1 |
| Ansell, J; Bakhru, S; Freedman, D; Laulicht, BE; Tracey, G; Villano, S | 1 |
| Barnett-Griness, O; Gronich, N; Kotler, A; Saliba, W; Stein, N | 1 |
| Barnes, GD; DeCamillo, D; Haymart, B | 1 |
| Ashton, V; Bunz, TJ; Coleman, CI | 1 |
| Gromov, K; Jensen, TB; Jimenez-Solem, E; Olesen, JB; Overgaard, S; Petersen, J; Schelde, AB | 1 |
| Ágústsson, AS; Björnsson, ES; Guðmundsdóttir, BR; Hreinsson, JP; Ingason, AB; Lund, SH; Önundarson, PT; Pálsson, DA; Reynisson, IE; Rumba, E | 2 |
| Everington, T; Husted, M; McKeague, L; Sly, D | 1 |
| Amin, AN; Auladell-Rispau, A; Barrios, V; Escobar, C; Lip, GYH; Requeijo, C; Salazar, J; Santero, M | 1 |
| Avery, P; Biss, T; Kamali, F; Kampouraki, E; Wynne, H | 1 |
| Cannegieter, SC; Huisman, MV; Lijfering, WM; Nierman, MC; Toorop, MMA; van der Meer, FJM; van Rein, N; Vermaas, HW | 1 |
| Dhamane, AD; Di Fusco, M; Emir, B; Ferri, M; Gutierrez, C; Hernandez, I; Keshishian, A; Russ, C; Tsai, WL; Yuce, H | 1 |
| Albisetti, M; Brandão, LR; Male, C; Monagle, P; Young, G | 1 |
| Durand, M; Renoux, C; Sinyavskaya, L | 1 |
| Guo, CL; Lee, APW; Shahzada, TS | 1 |
| Chu, H; Du, X; Feng, M; Fu, G; He, B; Liu, J; Wang, B; Wang, Z; Yu, Y; Zhuo, W | 1 |
| Beyer-Westendorf, J; Brückner, L; Pietsch, J; Tiebel, O | 1 |
| Li, J; Qian, Y; Weng, Z; Zhang, J | 1 |
| Brüggenjürgen, B; Gao, X; Marston, XL; Unverdorben, M; Wang, R; Ye, X; Yeh, YC; Zimmermann, L | 1 |
| Dong, W; Jiang, M; Nie, X; Zhou, H | 1 |
| Abe, K; Amano, H; Asaoka, Y; Honda, T; Kodashima, S; Komatsuda, S; Kozuma, K; Manabe, D; Tanaka, A; Yamamoto, H; Yamamoto, T; Yanagisawa, D | 1 |
| Caldarola, P; Cipriani, M; Colivicchi, F; Corda, M; De Luca, L; De Nardo, A; Di Fusco, SA; Di Lenarda, A; Francese, GM; Gabrielli, D; Gulizia, MM; Mocini, D; Napoletano, C; Navazio, A; Oliva, F; Riccio, C; Roncon, L; Tizzani, E; Urbinati, S; Valente, S | 1 |
| Alvarez, P; Chaudhury, P; Desai, MY; Hanna, M; Kanj, M; Mentias, A; Moudgil, R; Nakhla, M | 1 |
| Blanche, P; Gislason, GH; Hansen, ML; Holt, A; Jensen, MH; Lamberts, M; McGettigan, P; Nouhravesh, N; Rasmussen, PV; Schjerning, AM; Schou, M; Strange, JE; Torp-Pedersen, C | 1 |
| Huang, CF; Huang, TM; Jeng, JS; Kuo, CH; Lin, SY; Peng, YF; Tang, SC | 1 |
| Groll, A; Haefeli, WE; Meid, AD; Wirbka, L | 1 |
| Hill-McManus, D; Hughes, DA | 1 |
| Aizawa, T; Hojo, S; Kaneda, K; Kato, M; Kawaji, T; Kimura, T; Kushiyama, A; Miki, S; Morimoto, T; Nakatsuma, K; Yaku, H; Yokomatsu, T | 1 |
| Berlowitz, DR; Lee, JS; Liu, W; Mitra, A; Rose, AJ; Yu, H | 1 |
| Ammollo, CT; Colucci, M; Dellanoce, C; Dirienzo, L; Mancazzo, F; Paoletti, O; Testa, S; Vitulli, A | 1 |
| Camoin-Jau, L; Chevillard, L; Delrue, M; Deye, N; Dragoni, A; Gainnier, M; Malissin, I; Mégarbane, B; Siguret, V; Stépanian, A; Voicu, S | 1 |
| Lip, GYH; Morici, N; Rubboli, A | 1 |
| Jaffray, J; Young, G | 1 |
| An, Y; Ieko, M; Kumano, O; Suzuki, S; Yamazaki, M; Yasaka, M | 1 |
| Agten, SM; Bos, MHA; de Boer, HC; Dólleman, SC; Hackeng, TM; Spronk, HMH; van Zonneveld, AJ; Versteeg, HH | 1 |
| Davis, K; Khouli, C; Mihm, A; Nisly, SA; Sebaaly, J; Wooten, L | 1 |
| Male, C | 1 |
| Aakerøy, R; Ellekjær, H; Hegstad, S; Helland, A; Kristoffersen, AH; Schjøtt, J; Spigset, O; Stokes, CL; Tomić, M | 1 |
| Babálová, L; Bolek, T; Dluhá, J; Hajaš, G; Kubisz, P; Kurča, E; Mokáň, M; Nosáľ, V; Petrovičová, A; Samoš, M; Sivák, Š; Škorňová, I; Stančiaková, L; Staško, J | 1 |
| Aslan, S | 1 |
| Brkljačić, DD; Ćelap, I; Glojnarić, AČ; Goreta, SŠ; Harenberg, J; Hetjens, S; Huzjan, AL; Margetić, S; Mioč, P; Puretić, MB; Weiss, C | 1 |
| Cook, HE; Hewitt, JH; Patterson, EP; Randolph, AE | 1 |
| Lomakina, V; Sozio, SJ; Tekle, J | 1 |
| Barnes, GD; Connors, JM; Cuker, A; Dawwas, GK | 1 |
| Gerner, ST; Kallmünzer, B; Macha, K; Plechschmidt, J; Schwab, S; Siedler, G; Stoll, S; Strasser, E; Wang, R | 1 |
| Bertoletti, L; Bin, V; Delavenne, X; Hodin, S; Lafaie, L; Saïb, S | 1 |
| Bereznicki, LR; Bezabhe, WM; Kefale, AT; Peterson, GM | 1 |
| Zakrocka, I; Załuska, W | 1 |
| Cui, YM; Hu, K; Liu, ZY; Ma, LY; Mu, GY; Wang, Z; Wang, ZN; Xiang, Q; Xie, QF; Zhang, HX; Zhou, S | 1 |
| Diener, HC; Dubner, SJ; Gurusamy, VK; Halperin, JL; Huisman, MV; Kotalczyk, A; Lip, GYH; Ma, CS; Marler, S; Rothman, KJ; Teutsch, C | 1 |
| Horwitz, H; Jimenez-Solem, E; Nyeland, ME; Schelde, AB; von Osmanski, BI | 1 |
| da Silva, RMFL | 1 |
| Celestino Sobral Filho, D; de Barros Guimarães, AA; do Rego Barros, MC; Lima Filho, AIN | 1 |
| Caldeira, TG; de Andrade, RP; de Souza, J; Morais Ruela, AL; Vasques, BV | 1 |
| Murray, KT; Ray, WA | 1 |
| Gu, HQ | 1 |
| Angona, RE; Baldzizhar, A; Eaton, MP; Feng, C; Lebedko, N; Nadtochiy, SM; Stefanos, T | 1 |
| Hirohisa, I; Hiroshi, I; Hiroyuki, N; Masayori, S; Natsuko, SY; Yutaka, I | 1 |
| Agustsson, AS; Bjornsson, ES; Gudmundsdottir, BR; Hreinsson, JP; Ingason, AB; Lund, SH; Onundarson, PT; Palsson, DA; Reynisson, IE; Rumba, E; Tryggvason, G | 1 |
| Caravelli, P; Casini, M; De Caterina, R; Morganti, R; Negro, F; Ruocco, L; Tripodi, A | 1 |
| Bowrin, K; Briere, JB; Cabeza, AIP; Escobar Cervantes, C; Gasche, D; Genís Gironès, M; Llorac Moix, A; Martí-Almor, J; Millier, A; Tardu, J; Toumi, M | 1 |
| Atzema, CL; Austin, PC; Borgundvaag, B; de Wit, K; Grewal, K; McLeod, SL; Mittmann, N; Sharma, S | 1 |
| Halimeh, S; Male, C; Nowak-Goettl, U | 1 |
| Honmou, O; Kataoka-Sasaki, Y; Kiyose, R; Magota, H; Nakazaki, M; Oka, S; Onodera, R; Sasaki, M; Ukai, R | 1 |
| Bang, OY; Han, S; Jang, SW; Kang, S; Kim, YH; Lee, MY; On, YK; Park, YJ; Ryu, J; Suh, HS | 1 |
| Chan, ECY; Soh, XQ; Tan, DS | 1 |
| Broncel, M; Gorzelak-Pabiś, P; Pawlos, A; Wojdan, K; Woźniak, E | 1 |
| Atreja, N; Deitelzweig, S; Jiang, J; Kang, A; Keshishian, A; Lip, GYH; Luo, X; Schuler, P; Yuce, H; Zhang, Y | 1 |
| Alkhameys, S; Barrett, R | 1 |
| Csajka, C; Daali, Y; Fontana, P; Gaspar, F; Guidi, M; Reny, JL; Terrier, J | 1 |
| Chung, MK; Dukes, J; Ezekowitz, MD; Gengler, BE; Gopinathannair, R; Lakkireddy, D; Lip, GYH; Mar, PL; Miletello, M; Noseworthy, PA; Olshansky, B; Perez, A; Reiffel, J; Tisdale, JE | 1 |
| Chandrasegaram, A; Peters, CD | 1 |
| Brito, NC; de Brito, AFS; Ferreira Júnior, ABS; Ferreira, VL; Nita, ME; Riveros, BS; Tanaka, SKT | 1 |
| Ageno, W; Angiolillo, DJ; Barnes, GD; Bhatt, DL; Bikdeli, B; Connors, JM; Eikelboom, JW; Fanikos, J; Goldhaber, SZ; Jimenez, D; Kirtane, AJ; Krumholz, HM; Lip, GYH; Lippi, G; Lopes, RD; Mehran, R; Monreal, M; Parikh, SA; Piazza, G; Sadeghipour, P; Siegal, DM; Talasaz, AH; Weitz, JI; Zahedi Tajrishi, F | 1 |
| Emmens, W; Mitrovic, D; Naimi, A; van den Bemt, P; van der Mijle, A; van Roon, E; Veeger, N | 1 |
| Asiimwe, A; Brobert, G; Morgan Stewart, H; Russell, B; Vora, P | 1 |
| Chang, A; Harper, P; Stephens, M | 1 |
| Bögl, MS; Buchtele, N; Douxfils, J; Harenberg, J; Herkner, H; Jilma, B; Merrelaar, AE; Merrelaar, M; Schoergenhofer, C; Schwameis, M; Siriez, R; Spiel, AO | 1 |
| Li, X; Lv, Q; Wang, Z; Xu, Q; Yu, M; Zong, L | 1 |
| Archontakis-Barakakis, P; Batsidis, A; Giamouzis, G; Giannakoulas, G; Giannopoulos, S; Kalaitzoglou, D; Kokkinidis, DG; Li, W; Lip, GYH; Manolopoulos, A; Ntaios, G; Palaiodimos, L; Tzelves, L | 1 |
| Cao, S; He, T; Wu, X; Yu, B | 1 |
| Ajao, A; Connolly, JG; Cosgrove, A; Eworuke, E; Kolonoski, J; Mohamoud, M; Shapira, O; Zhang, R | 1 |
| Budnik, M; Ciba-Stemplewska, A; Filipiak, KJ; Gawałko, M; Gorczyca-Głowacka, I; Jurek, A; Kapłon-Cieślicka, A; Krzesiński, P; Opolski, G; Scisło, P; Uziębło-Życzkowska, B; Wożakowska-Kapłon, B | 1 |
| Anguita, M; Badimón, L; Bertomeu-Martínez, V; Cequier, Á; Esteve-Pastor, MA; Lip, GYH; López-Gálvez, R; Marín, F; Muñiz, J; Otero, D; Rivera-Caravaca, JM; Roldán-Rabadán, I; Ruiz-Ortiz, M | 1 |
| Chen, C; Chen, X; Huang, N; Jiang, S; Lv, M; Wu, T; Zhang, J | 1 |
| Amin, A; Dina, O; Hines, DM; Keshishian, A; Le, H; Liu, X; Rosenblatt, L; Vo, L; Zhang, Q | 1 |
| Chaudhury, P; Desai, MY; Harb, S; Johnston, D; Kapadia, S; Menon, V; Mentias, A; Michael, M; Nakhla, S; Saad, M; Saliba, W; Svensson, L; Wazni, O | 1 |
| Belhassen, M; Cotté, FE; Dalon, F; Danchin, N; Guitard-Dehoux, D; Hanon, O; Jacoud, F; Mahé, I; Marant-Micallef, C; Née, M; Steg, PG; Van Ganse, E | 1 |
| Bansal, A; Eisele, CD; Jain, R; Julian, K; Mausteller, KG; Patel, P | 1 |
| Bai, Z; Chen, H; Cheng, G; Ning, H; Yang, N; Zhao, Y; Zou, M | 1 |
| Arora, P; Jayasekare, R; Muehrcke, M; Russell, M | 1 |
| Bi, G; Chen, J; Qin, X; Wu, F | 1 |
| Lameijer, H; Meijer, K; Mitrovic, D; Stapel, L; van Roon, E; Veeger, N | 1 |
| Chiba, T; Egashira, S; Ihara, M; Inoue, M; Kimura, S; Koga, M; Okada, T; Shiozawa, M; Takashima, H; Toyoda, K; Wada, S; Yoshimoto, T; Yoshimura, S | 1 |
| Ktenopoulos, N; Lionaki, S; Rallidis, LS; Sagris, M; Theofilis, P | 1 |
| Amico, F; Colivicchi, F; Di Fusco, SA; Giubilato, S; Gulizia, MM; Lucà, F | 1 |
| Artang, R; Brod, C; Nielsen, JD | 1 |
| Burgos-Gonzalez, A; Huerta, C; Peñalver, MJ; Pulido, J; Sordo, L; Soriano, LC | 1 |
| Bloom, B; Cohen-Aubart, F; Freund, Y | 1 |
| Douketis, JD; Li, N; Moffat, KA; Nixon, J; Schulman, S; Shaw, JR; Spyropoulos, AC | 1 |
| Beyene, K; Chan, AHY; Gong, J; Hayes, M; Munevar Aquite, O; Schauer, C; Wei, H | 1 |
| Bani Hani, Z; S H Abrahim, M; Sofola-James, O | 1 |
| Björnsson, ES; Hreinsson, JP; Ingason, AB | 1 |
| Cho, MS; Choi, KJ; Kang, DH | 1 |
| Bielecka, B; Gorczyca-Głowacka, I; Wożakowska-Kapłon, B | 1 |
| Bakuła, E; Bednarski, J; Bil, J; Błaszczyk, R; Gawałko, M; Gorczyca-Głowacka, I; Jelonek, O; Kapłon-Cieślicka, A; Krzciuk, M; Krzesiński, P; Kuźma, Ł; Mamcarz, A; Rajtar-Salwa, R; Szpotowicz, A; Szyszkowska, A; Tokarek, T; Tomaszuk-Kazberuk, A; Uziębło-Życzkowska, B; Wełnicki, M; Wójcik, M; Wojewódzki, M; Wożakowska-Kapłon, B | 1 |
| Arioli, D; Athanasiou, A; Ballestri, S; Capitelli, M; Cappi, C; Coluccio, V; Di Girolamo, M; Marietta, M; Marrazzo, A; Romagnoli, E | 1 |
| Ali, AK; Duffield, S; Gatto, N; Gibbs, L; Govil, P; Jaksa, A; Jonsson, P; Kent, S; Kincaid, L; Patrick, AR; Rowark, S; Sharma, M | 1 |
| Belhassen, M; Cotte, FE; Dalon, F; Danchin, N; Gollety, S; Hanon, O; Jacoud, F; Mahé, I; Nolin, M; Steg, G; Van Ganse, E | 1 |
| Lameijer, H; Meijer, K; Mitrovic, D; van Elp, M; van Roon, E; Veeger, N | 1 |
| Brewster, J; Hingorani, AD; Lau, WCY; Li, J; Lip, GYH; Man, KKC; Reich, C; Seager, S; Stewart, HM; Torre, CO; Van Zandt, M; Wei, L; Wong, ICK | 1 |
| Chen, J; Chen, M; Fang, Z; Guan, C; Jiang, S; Lv, M; Qian, J; Wu, S; Xu, W; Zeng, Z; Zhang, J | 1 |
| Gosselin, L; Lévy, C; Steichen, O; Vilcu, AM | 1 |
| Badve, SV; Deague, J; Dundon, BK; Hammett, C; Joseph, JE; Kerr, PG; Lo, S; Perkovic, V; Tran, HA; Wong, A | 1 |
| Kalka, I; Kornowski, R; Rossman, H; Segal, E; Talmor-Barkan, Y; Witberg, G; Yacovzada, NS | 1 |
| Buonocore, M; Degezelle, K; Meyns, B; Rex, S | 1 |
| Arora, J; de Lusignan, S; Delanerolle, G; Emanuel, S; Fan, X; Feher, M; Field, BC; Heiss, C; Hobbs, FR; Joy, M; Kar, D; Pollock, KG; Sandler, B; Sheppard, JP; Williams, J | 1 |
| Ha, N; Hess, R; Mouland, E; Renner, E; Sutter-Long, D | 1 |
| Curis, E; Delrue, M; Foulon-Pinto, G; Gaussem, P; Gouin-Thibault, I; Guen, JL; Jourdi, G; Ketz, F; Lafuente-Lafuente, C; Lecompte, T; Mullier, F; Pautas, E; Puymirat, E; Rivière, L; Siguret, V; Tall, F | 1 |
| Anastassopoulou, A; Doobaree, IU; Fay, M; Gusto, G; Khachatryan, A; Manu, M; Mughal, F; Spentzouris, G; Zawaneh, Y | 1 |
| Alsultan, MM; Costa, LSD; Guo, JJ; Hincapie, AL | 1 |
| Borhani-Haghighi, A; Ghafari Darab, M; Goudarzi, Z; Hayatbakhsh, A; Jafari, M; Karimzadeh, I; Keshavarz, K; Vazin, A | 1 |
| Boivin Proulx, LA; Dorais, M; Legault, C; Lenglet, A; Perreault, S; Qazi, JZ | 1 |
| Antoniolli, M; Barrionuevo, B; Bernal, MI; Cigalini, IM; Lerech, E; Morcos, L; Scatularo, CE; Zaidel, EJ | 1 |
| Bortman, LV; Di Girolamo, G; Giorgi, MA; Gonzalez, CD; Mitchell, F; Naveiro, S; Pérez Morales, J | 1 |
| Abraham, NS; Barkun, AN; Douketis, J; Hansen-Barkun, C; Kaplovitch, E; Liederman, Z; Majid, A; Martel, M; Schulman, S; Spyropoulos, AC | 1 |
| Boussery, K; Capiau, A; De Backer, T; De Bolle, L; Mehuys, E; Van Tongelen, I | 1 |
| Atreja, N; Deitelzweig, S; Jenkins, A; Jiang, J; Kang, A; Keshishian, A; Lip, GYH; Schuler, P; Sun, X; Yuce, H | 1 |
| Ansell, J; Freedman, D; Siegal, DM | 1 |
| Matre, NB; McLaughlin, EM; Naik, KD; Rozycki, AJ; Whitson, BA | 1 |
| Acosta-Isaac, R; Corrochano, M; Mojal, S; Moret, C; Muñoz, R; Plaza, M; Souto, JC | 1 |
| Albiges, L; Baudin, E; Besse, B; Boileve, A; Ducreux, M; Hadoux, J; Leary, A; Malka, D; Maulard, A; Mir, O; Rieutord, A; Scotté, F | 1 |
| Atreja, N; Dhamane, AD; Di Fusco, M; Emir, B; Ferri, M; Gutierrez, C; Keshishian, A; Russ, C; Yuce, H | 1 |
| Klöter, T; Laufs, U; Metze, M; Petros, S; Pfrepper, C; Siegemund, A; Siegemund, T; Stöbe, S | 1 |
| Agustsson, AS; Bjornsson, ES; Gudmundsdottir, BR; Hreinsson, JP; Ingason, AB; Lund, SH; Onundarson, PT; Palsson, DA; Reynisson, IE; Rumba, E | 1 |
| Alexander, GC; Andersen, KM; Boyce, RD; Gomez-Lumbreras, A; Kocis, PT; Kravchenko, OV; Leonard, CE; Malone, DC; Mehta, H; Tan, M; Villa Zapata, L | 1 |
| Aktan, A; Arslan, B; Aslan, B; Demir, M; Ertaş, F; Günlü, S; Güzel, T; Kılıç, R; Özbek, M | 1 |
| Björck, F; Jansson, M; Norrving, B; Renlund, H; Själander, A; Själander, S; Sjögren, V | 1 |
| Aigami, T; Fujii, S; Fukudo, M; Ishigo, T; Katano, S; Koyama, M; Takada, R; Yano, T | 1 |
| Cober, MP; Fenn, NE; Hill, C; King, M; Mills, K; Omecene, NE; Pauley, JL; Sierra, CM; Smith, T | 1 |
| Cui, C; Lai, X; Li, H; Liu, D; Sia, JEV; Wu, X; Zhang, F | 1 |
| Cohen, D; Lavon, O | 1 |
| Malý, J; Moudallel, S; Rydant, S; Steurbaut, S; van den Eynde, C | 1 |
| Ashton, V; Berger, JS; Bookhart, B; Boudreau, J; Germain, G; Laliberté, F; Lefebvre, P; Lejeune, D; Weir, MR | 1 |
| Chaiyakunapruk, N; Nathisuwan, S; Nelson, RE; Nonthasawadsri, T; Syeed, MS | 1 |
| Aronow, HD; Hume, AL; Lawal, OD; Matson, KL; Shobayo, F; Taveira, TH; Wen, X; Zhang, Y | 1 |
| Dilokthornsakul, P; Nimworapan, M; Niyomsri, S; Wongcharoen, W | 1 |
| Chan, EW; Knapp, MRJ; Li, HL; Wei, L; Wong, ICK; Yan, VKC | 1 |
| Dia, N; Dreesen, E; Edwina, AE; Spriet, I; Tournoy, J; Van der Linden, L; Vanassche, T; Verhamme, P | 1 |
| Andrade, JG; Fordyce, CB; Holmes, DN; Levin, A; Piccini, JP; Yao, RJR | 1 |
| Desai, NR; Dhruva, SS; Graham, DJ; Inselman, JW; Lee, JY; Ngufor, C; Noseworthy, PA; Polley, E; Ross, JS; Shah, ND; Siontis, KC; Yao, X | 1 |
| Altın, C; Aslan, O; Bilgel, ZG; Boyraz, B; Çakal, S; Çayırlı, S; Çoner, A; Coşgun, MS; Dal, A; Dalgıç, O; Demir, M; Doğduş, M; Erdoğan, A; Ergin, I; Genç, Ö; Güler, A; Güvendi Şengör, B; İbişoğlu, E; İlkay Yüce, E; Kaplan, M; Karabulut, D; Karabulut, U; Keskin Meriç, B; Kıvrak, T; Kocabaş, U; Murat, B; Murat, S; Naki Tekin, DD; Özçalık, E; Özdemir, I; Özgeyik, M; Özyurtlu, F; Şahin, Ş; Şen, T; Tüner, H; Urgun, ÖD; Uzman, O; Yavuz, V | 1 |
| Nakano, Y; Sairaku, A | 1 |
| De Backer, TL; Grymonprez, M; Ikram, MA; Lahousse, L; Petrovic, M; Steurbaut, S | 1 |
| Bessette, LG; Bykov, K; Cervone, A; Kim, DH; Lin, KJ; Mastrorilli, JM; Singer, DE | 1 |
| De Caterina, R; van Es, N; Weitz, JI | 1 |
| Bae, YJ; Hwang, HJ; Jin, ES; Sohn, IS | 1 |
| Babálová, L; Bolek, T; Brisudová, K; Kertys, M; Kurča, E; Mokrý, J; Nosáľ, V; Pršo, K; Samoš, M; Sivák, Š; Žideková, N | 1 |
| Al Qaraghuli, F; Fiedler-Kelly, J; Gonzalez, D; Powell, JR; Weiner, D | 1 |
| Chan, EW; Li, X; Li, Y; Peng, K; Wong, ICK | 1 |
| Chen, X; Dai, H; Du, X; Gu, P; Guan, C; Huang, N; Huang, X; Li, R; Lin, X; Liu, X; Liu, Y; Lv, M; Wu, T; Xu, W; Zhang, J; Zhang, M; Zhang, W; Zheng, Q; Zhu, Z | 1 |
| Hui, X; Li, J; Li, M; Ma, Y; Tian, J; Wang, Q; Wang, X; Xie, P; Yan, P; Yang, K; Yao, L | 1 |
| Fredenburgh, JC; Weitz, JI | 1 |
| Hayat, A; Själander, A; Wallvik, J | 1 |
| Ho, LT; Huang, CF; Jeng, JS; Kuo, CH; Lin, SY; Liu, YB; Peng, YF; Tang, SC; Tsai, LK | 1 |
| Kwon, HM; Lee, YS; Moon, HS; Nam, KW; Won, SH | 1 |
| Last-Koopmans, S; Mooij, R; Neeteson, M | 1 |
| Achanta, A; Bhalodia, NJ; Cheng, J; Coons, JC; Deri, CR; Heiney, H; Iasella, CJ; Marchionda, O; Stahl, K; White, EM | 1 |
| Blanchon, T; Conte, C; Gosselin, L; Hanslik, T; Lapeyre-Mestre, M; Launay, T; Rossignol, L; Saint-Salvi, B; Sarazin, M; Souty, C; Steichen, O; Turbelin, C; Vilcu, AM | 1 |
| Apolinario, M; Firth, C; Keddis, MT; Lim, ES; Shamoun, F; Zhang, N | 1 |
| Bakhtiari, K; Meijers, JCM; Peters, SLM; Zwiers, A | 1 |
| Chung, CP; Daugherty, JR; Dickson, AL; Dupont, WD; Hung, AM; Murray, KT; Ray, WA; Smalley, W; Stein, CM; Zimmerman, E | 1 |
| Ilc, S; Mavri, A | 1 |
| Atreja, N; Bell, G; Cato, M; Cheng, D; DeKoven, M; Divino, V; Hernandez, I; Hines, DM; Hood, DW; Kariuki, W; Russ, C; Xie, L | 1 |
| Chen, J; Ma, F; Xu, W; Zhang, J | 1 |
| Levy, JH; Mamoun, N | 1 |
| Chen, K; Chen, X; Chen, Z; Ju, J; Li, Q; Ma, D; Tian, W; Wang, T; Wang, X; Xu, H; Zhang, J | 1 |
| An, J; Cheetham, TC; Lang, DT; Lee, MS; Luong, T; Reynolds, K | 1 |
| Brunetti, ND; D'Angelo, A; De Gennaro, L; Derosa, G; Gaudio, G; Gavazzoni, M; Maffioli, P; Maggi, A; Pasini, G; Raddino, R; Rizzo, M | 1 |
| Arora, P; Ghanekar, S; Muehrcke, M; Russell, M | 1 |
| Baiardi, G; Cafaro, A; Cangemi, G; Caviglia, MC; Mattioli, F; Poeta, MG; Stella, M | 1 |
| Chilbert, MR; Goriacko, P; Jacobs, D; Saber, M; Sinnet, M; Woodruff, AE | 1 |
| Gao, J; Miao, L; Shi, D; Shi, J; Song, L; Yu, H; Zhu, C | 1 |
| Cera, M; Comi, G; Cozzani, G; Della Bella, P; Gaspardone, C; Godino, C; Leo, G; Maisano, F; Margonato, A; Mattiello, P; Melillo, F; Montorfano, M; Nemola, G; Parlati, AL; Russi, A; Salerno, A; Sparasci, FM; Tresoldi, M; Vetrugno, L; Zangrillo, A | 1 |
| Akerman, M; Chin-Hon, J; Davenport, L; Hindenburg, A; Huang, J | 1 |
| Chen, Y; Huang, K; Wu, M; Xia, H; Yu, S; Yu, W; Zhou, H | 1 |
| Gu, ZC; Lin, HW; Liu, BL; Ma, EL; Pan, MM; Wang, J; Wang, X; Wu, B; Zhang, C | 1 |
| Bang, SM; Jeong, HE; Park, S; Shin, JY; Yoon, D; You, SC | 1 |
| Assouline, S; Cohen, C; Cohen, S; Dhanjal, TS; Dib, JC; Dievart, F; Durand, P; Garban, T; Guedj-Meynier, D; Guenoun, M; Hoffman, O; Lellouche, N; Lequeux, B; Ouazana, L; Parrens, E; Pradeau, V; Sabouret, P; Schwartz, J; Sharareh, A; Villaceque, M | 1 |
| Alghamdi, B; Alhuwail, A; Alkhathami, S; Alkredees, M; Almalki, T; AlNasser, M; Alotaibi, W; Alqahtani, B; Alsaeed, O; Alsalem, T; Alshahrani, F; Alshreem, A; Alzahrani, Y; Asiri, A; Assiri, A; Ayoub, M; Bakkari, A; Basndwah, H; Ibrahim, ARN; Khudari, A; Mustafa, M; Sultan, H; Tawhari, F; Zaitoun, M | 1 |
| Berry, SD; Daiello, LA; Hayes, KN; Kiel, DP; Kim, DH; Lee, Y; Zhang, T; Zullo, AR | 1 |
| Al-Hussainy, N; Kragholm, KH; Lip, GYH; Lundbye-Christensen, S; Pareek, M; Riahi, S; Therkelsen, SK; Torp-Pedersen, C | 1 |
| Huang, KC; Lee, JK; Lin, DS; Lin, TT; Lo, HY | 1 |
| Chang, YM; Chen, CH; Hsieh, MT; Lin, PY; Lin, SH; Liu, CH; Sung, PS; Wang, CM | 1 |
563 review(s) available for dabigatran and rivaroxaban
| Article | Year |
|---|---|
Design of Small-Molecule Active-Site Inhibitors of the S1A Family Proteases as Procoagulant and Anticoagulant Drugs.
Topics: Amino Acid Sequence; Animals; Anticoagulants; Blood Coagulation; Catalytic Domain; Humans; Peptide Hydrolases; Protease Inhibitors; Small Molecule Libraries | 2018 |
Beyond unfractionated heparin and warfarin: current and future advances.
Topics: Angina, Unstable; Anticoagulants; Azetidines; Benzimidazoles; Benzylamines; Brain Ischemia; Clinical Trials as Topic; Coumarins; Dabigatran; Factor Xa Inhibitors; Fibrinolytic Agents; Fondaparinux; Forecasting; Hemorrhage; Heparin; Heparin, Low-Molecular-Weight; Hirudins; Humans; Morpholines; Myocardial Infarction; Peptide Fragments; Polysaccharides; Prothrombin; Pyrazoles; Pyridines; Pyridones; Recombinant Proteins; Rivaroxaban; Thiophenes; Thrombin; Thrombophilia; Thrombosis; Warfarin | 2007 |
New anticoagulants for treatment of venous thromboembolism.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dabigatran; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Injections, Subcutaneous; Male; Maximum Tolerated Dose; Morpholines; Oligosaccharides; Postphlebitic Syndrome; Prognosis; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Survival Analysis; Thiophenes; Treatment Outcome; Venous Thromboembolism | 2008 |
Current and future prospects for anticoagulant therapy: inhibitors of factor Xa and factor IIa.
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Atrial Fibrillation; Azetidines; Benzimidazoles; Benzylamines; Clinical Trials as Topic; Dabigatran; Factor Xa Inhibitors; Glycine; Humans; Infusions, Parenteral; Morpholines; Oligosaccharides; Piperazines; Prothrombin; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiophenes; Thrombin; Thrombosis; Venous Thromboembolism | 2008 |
The top 4 advances in antithrombotic care in the last year.
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Benzimidazoles; Clinical Trials as Topic; Dabigatran; Humans; Morpholines; Practice Guidelines as Topic; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2008 |
Brave new world: the current and future use of novel anticoagulants.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Drug Discovery; Factor Xa Inhibitors; Humans; Morpholines; Oligosaccharides; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism | 2008 |
Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor xa inhibitors in development.
Topics: Animals; Antithrombin III; Benzimidazoles; Dabigatran; Drug Discovery; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiophenes; Thrombin | 2009 |
[Anaesthesia and thromboembolic disease].
Topics: Acenocoumarol; Administration, Oral; Anesthesia, Conduction; Anticoagulants; Benzimidazoles; Clinical Protocols; Dabigatran; Early Ambulation; Fibrinolytic Agents; Fondaparinux; Heparin; Heparin, Low-Molecular-Weight; Humans; Morpholines; Polysaccharides; Postoperative Complications; Pyridines; Risk Factors; Rivaroxaban; Safety; Surgical Procedures, Operative; Thiophenes; Venous Thromboembolism; Venous Thrombosis | 2008 |
Emergence of new oral antithrombotics: a critical appraisal of their clinical potential.
Topics: Administration, Oral; Benzimidazoles; Blood Coagulation; Dabigatran; Fibrinolytic Agents; Hemorrhage; History, 20th Century; History, 21st Century; Humans; Medication Adherence; Morpholines; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Rivaroxaban; Thiophenes; Treatment Outcome; Venous Thromboembolism | 2008 |
Should new oral anticoagulants replace low-molecular-weight heparin for thromboprophylaxis in orthopaedic surgery?
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; Dabigatran; Drug Administration Schedule; Factor Xa Inhibitors; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Morpholines; Orthopedic Procedures; Prothrombin; Pyridines; Risk Assessment; Rivaroxaban; Thiophenes; Thrombosis; Vitamin K | 2009 |
New anticoagulants for prevention and treatment of venous thromboembolism.
Topics: Animals; Anticoagulants; Benzimidazoles; Clinical Trials as Topic; Dabigatran; Drugs, Investigational; Humans; Morpholines; Oligosaccharides; Pyridines; Rivaroxaban; Thiophenes; Treatment Outcome; Venous Thromboembolism | 2010 |
A logical approach to surgical thromboprophylaxis.
Topics: Benzimidazoles; Dabigatran; Humans; Morpholines; Postoperative Complications; Premedication; Pyridines; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2009 |
New anticoagulants and regional anesthesia.
Topics: Anesthesia, Epidural; Anesthesia, Spinal; Anticoagulants; Benzimidazoles; Dabigatran; Hematoma, Epidural, Spinal; Humans; Morpholines; Nerve Block; Platelet Aggregation Inhibitors; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiophenes | 2009 |
New anticoagulants for atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzamides; Benzimidazoles; Biotin; Clinical Trials, Phase III as Topic; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Oligosaccharides; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Vitamin K | 2009 |
Anticoagulation with {blacktriangledown}dabigatran or{blacktriangledown}rivaroxaban.
Topics: Adult; Anticoagulants; Benzimidazoles; Cost-Benefit Analysis; Dabigatran; Humans; Morpholines; Pyridines; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; Treatment Outcome; Venous Thromboembolism | 2009 |
[New oral anticoagulants. Consequences for perioperative coagulation diagnostics and therapy].
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; Blood Coagulation Disorders; Dabigatran; Factor Xa Inhibitors; Humans; International Normalized Ratio; Intraoperative Complications; Morpholines; Partial Thromboplastin Time; Pyridines; Rivaroxaban; Thiophenes; Thrombin; Thromboembolism | 2009 |
New oral anticoagulants: a practical guide for clinicians.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; Clinical Trials, Phase III as Topic; Dabigatran; Drugs, Investigational; Evidence-Based Medicine; Humans; Morpholines; Orthopedic Procedures; Practice Guidelines as Topic; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2010 |
Comparative efficacy and safety of the novel oral anticoagulants dabigatran, rivaroxaban and apixaban in preclinical and clinical development.
Topics: Anticoagulants; Benzimidazoles; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiophenes; Treatment Outcome | 2010 |
[Oral prevention of thromboembolism with rivaroxaban and dabigatran: are the newly approved drugs innovations in orthopaedic and trauma surgery? ].
Topics: Administration, Oral; Benzimidazoles; beta-Alanine; Dabigatran; Fibrinolytic Agents; Humans; Morpholines; Orthopedic Procedures; Orthopedics; Practice Guidelines as Topic; Rivaroxaban; Thiophenes; Thromboembolism; Traumatology; Treatment Outcome | 2010 |
Old versus new anticoagulants: focus on pharmacology.
Topics: Animals; Anticoagulants; Azetidines; Benzimidazoles; Benzylamines; Dabigatran; Factor Xa; Factor Xa Inhibitors; Fondaparinux; Heparin; Heparin, Low-Molecular-Weight; Humans; Morpholines; Oligosaccharides; Polysaccharides; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiophenes; Thrombin; Warfarin | 2010 |
Rivaroxaban vs dabigatran for thromboprophylaxis after joint-replacement surgery: exploratory indirect comparison based on meta-analysis of pivotal clinical trials.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; Dabigatran; Enoxaparin; Hemorrhage; Humans; Morpholines; Postoperative Care; Pyridines; Randomized Controlled Trials as Topic; Rivaroxaban; Safety; Survival Analysis; Thiophenes; Venous Thromboembolism | 2010 |
New oral anticoagulants in development: potential for improved safety profiles.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; Blood Coagulation; Dabigatran; Drug Evaluation; Factor Xa; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiophenes; Thrombin; Venous Thromboembolism | 2010 |
Potential of new anticoagulants in patients with cancer.
Topics: Anticoagulants; Benzimidazoles; Biotin; Clinical Trials as Topic; Dabigatran; Humans; Morpholines; Neoplasms; Oligosaccharides; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiophenes; Thrombosis | 2010 |
Novel oral anticoagulants in development: Dabigatran, Rivaroxaban, and Apixaban.
Topics: Administration, Oral; Anticoagulants; Azetidines; Benzimidazoles; Benzylamines; Dabigatran; Drug Approval; Humans; Morpholines; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiophenes; United States; Venous Thrombosis | 2011 |
New oral anticoagulant drugs in cardiovascular disease.
Topics: Administration, Oral; Animals; Anticoagulants; Benzimidazoles; Cardiovascular Diseases; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Prothrombin; Pyridines; Rivaroxaban; Thiophenes; Vitamin K | 2010 |
Drug and dietary interactions of the new and emerging oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Cytochrome P-450 Enzyme System; Dabigatran; Drug Interactions; Food-Drug Interactions; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes | 2010 |
Clot prevention--common questions about medications.
Topics: Anticoagulants; Aspirin; Benzimidazoles; Dabigatran; Factor Xa Inhibitors; Fibrinolytic Agents; Humans; International Normalized Ratio; Morpholines; Pharmacogenetics; Pyridines; Risk Factors; Rivaroxaban; Thiophenes; Thrombosis; Venous Thromboembolism | 2010 |
[New oral anticoagulants: better than vitamin K antagonists?].
Topics: Anticoagulants; Antithrombin Proteins; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Atrial Fibrillation; Benzimidazoles; Dabigatran; Humans; Morpholines; Postoperative Complications; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiophenes; Venous Thrombosis; Vitamin K | 2010 |
New anticoagulants for the prevention of thromboembolism.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; Dabigatran; Humans; Morpholines; Postoperative Complications; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2010 |
Pharmacologic properties of the new oral anticoagulants: a clinician-oriented review with a focus on perioperative management.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Interactions; Drugs, Investigational; Humans; Morpholines; Perioperative Care; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes | 2010 |
Managing bleeding complications in patients treated with the old and the new anticoagulants.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Factor VIIa; Fondaparinux; Hemorrhage; Heparin; Humans; Morpholines; Polysaccharides; Protamines; Recombinant Proteins; Risk Factors; Rivaroxaban; Thiophenes; Vitamin K | 2010 |
New synthetic antithrombotic agents for venous thromboembolism: pentasaccharides, direct thrombin inhibitors, direct Xa inhibitors.
Topics: Anticoagulants; Benzamides; Benzimidazoles; beta-Alanine; Dabigatran; Fondaparinux; Humans; Morpholines; Oligosaccharides; Polysaccharides; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2010 |
[Novel anticoagulants for stroke prevention in atrial fibrillation].
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Azetidines; Benzimidazoles; Benzylamines; Clinical Trials, Phase III as Topic; Dabigatran; Factor Xa Inhibitors; Fibrinolytic Agents; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiophenes; Thromboembolism | 2010 |
[Two new anticoagulants available in 2010--Dabigatran Etexilate and Rivaroxaban: expected progresses--raised problems].
Topics: Anticoagulants; Benzimidazoles; Blood Coagulation Tests; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Pyridines; Rivaroxaban; Thiophenes; Thrombin | 2010 |
Dabigatran and rivaroxaban for prevention of venous thromboembolism--systematic review and adjusted indirect comparison.
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Enoxaparin; Factor Xa Inhibitors; Hemorrhage; Humans; Morpholines; Orthopedic Procedures; Postoperative Complications; Pulmonary Embolism; Rivaroxaban; Thiophenes; Venous Thromboembolism; Venous Thrombosis | 2011 |
Novel oral factor Xa and thrombin inhibitors in the management of thromboembolism.
Topics: Acute Coronary Syndrome; Amidines; Anticoagulants; Atrial Fibrillation; Azetidines; Benzimidazoles; Clinical Trials as Topic; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Thrombin; Thromboembolism; Treatment Outcome; Vitamin K | 2011 |
Changing anticoagulant paradigms for atrial fibrillation: dabigatran, apixaban and rivaroxaban.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Design; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thromboembolism; Vitamin K | 2011 |
New anticoagulants: pharmacology and clinical studies.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Biological Availability; Clinical Trials as Topic; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; Morpholines; Postoperative Complications; Prothrombin; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2011 |
Direct thrombin and factor Xa inhibitors in children: a quest for new anticoagulants for children.
Topics: Adolescent; Anticoagulants; Arginine; Benzimidazoles; beta-Alanine; Child; Child, Preschool; Dabigatran; Drug Approval; Factor Xa Inhibitors; Fondaparinux; Hirudins; Humans; Infant; Infant, Newborn; Morpholines; Peptide Fragments; Pipecolic Acids; Polysaccharides; Recombinant Proteins; Risk Factors; Rivaroxaban; Sulfonamides; Thiophenes; Thrombin; Venous Thromboembolism | 2011 |
Novel oral anticoagulants: focus on stroke prevention and treatment of venous thrombo-embolism.
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Cost-Benefit Analysis; Dabigatran; Drug Approval; Factor X; Humans; Morpholines; Off-Label Use; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism | 2011 |
Preventing postsurgical venous thromboembolism: pharmacological approaches.
Topics: Aged; Anticoagulants; Antithrombins; Arthroscopy; Bariatric Surgery; Benzimidazoles; Blood Coagulation Disorders, Inherited; Dabigatran; Fondaparinux; Heparin; Heparin, Low-Molecular-Weight; Hip Fractures; Humans; Kidney; Knee; Laparoscopy; Morpholines; Neoplasms; Orthopedic Procedures; Polysaccharides; Postoperative Complications; Pyridines; Rivaroxaban; Thiophenes; Thrombophilia; Venous Thromboembolism | 2011 |
New oral anticoagulants and outpatient prophylaxis of venous thromboembolism.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Dabigatran; Guideline Adherence; Heparin, Low-Molecular-Weight; Humans; Morpholines; Outpatients; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Time Factors; Venous Thromboembolism; Warfarin | 2011 |
Characteristics of novel anticoagulants and potential economic implications.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Cost Savings; Dabigatran; Health Care Costs; Humans; Medication Adherence; Morpholines; Rivaroxaban; Thiophenes; United States; Venous Thromboembolism; Vitamin K | 2011 |
[New oral anticoagulant drugs: dabigatran, rivaroxaban and apixaban. Present and future].
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Drug Approval; Drug Monitoring; Factor Xa Inhibitors; Fibrinolytic Agents; Forecasting; France; Humans; Morpholines; Orthopedic Procedures; Postoperative Complications; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Thrombin; Thromboembolism; Thrombophilia; Venous Thromboembolism | 2011 |
Prophylaxis of venous thromboembolism: low molecular weight heparin compared to the selective anticoagulants rivaroxaban, dabigatran and fondaparinux.
Topics: Animals; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Evidence-Based Medicine; Fondaparinux; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Morpholines; Polysaccharides; Practice Guidelines as Topic; Rivaroxaban; Thiophenes; Treatment Outcome; Venous Thromboembolism | 2011 |
Prevention of venous thromboembolism after major orthopedic surgery: indirect comparison of three new oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Enoxaparin; Humans; Morpholines; Orthopedic Procedures; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Risk Factors; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2011 |
New anticoagulants: how to deal with treatment failure and bleeding complications.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Morpholines; Rivaroxaban; Thiophenes; Thromboembolism; Thrombosis; Treatment Failure | 2011 |
[The new Anticoagulants - Relevant Facts for the GP].
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Biological Availability; Clinical Trials, Phase III as Topic; Dabigatran; Dose-Response Relationship, Drug; Drug Administration Schedule; Evidence-Based Medicine; Factor Xa Inhibitors; General Practice; Humans; Metabolic Clearance Rate; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2011 |
Anticoagulating obese patients in the modern era.
Topics: Acute Coronary Syndrome; Anticoagulants; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Double-Blind Method; Factor Xa Inhibitors; Fondaparinux; Hemorrhage; Heparin; Humans; Morpholines; Multicenter Studies as Topic; Obesity; Polysaccharides; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; Thrombin; Thrombophilia; Venous Thrombosis; Warfarin | 2011 |
Rivaroxaban for the prevention and treatment of venous thromboembolism.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; Clinical Trials, Phase III as Topic; Dabigatran; Humans; Medication Adherence; Morpholines; Practice Guidelines as Topic; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiophenes; Thromboembolism | 2012 |
[Thromboembolic prophylaxis 2011: is warfarin on the wane?].
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzamides; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Evidence-Based Medicine; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Rivaroxaban; Thiazoles; Thiophenes; Thromboembolism; Treatment Outcome; Warfarin | 2011 |
Prophylaxis for deep vein thrombosis and pulmonary embolism in the surgical patient.
Topics: Anticoagulants; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Heparin; Heparin, Low-Molecular-Weight; Humans; Intermittent Pneumatic Compression Devices; Morpholines; Neurosurgical Procedures; Orthopedic Procedures; Postoperative Complications; Pulmonary Embolism; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Stockings, Compression; Surgical Procedures, Operative; Thiophenes; Urologic Surgical Procedures; Venous Thrombosis | 2011 |
Novel oral anticoagulants for VTE prevention in orthopedic surgery: overview of phase 3 trials.
Topics: Administration, Oral; Anticoagulants; Arthroplasty, Replacement; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Enoxaparin; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Treatment Outcome; Venous Thromboembolism | 2011 |
[Atrial fibrillation: what the GP needs to know].
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Comorbidity; Dabigatran; General Practice; Humans; International Normalized Ratio; Medication Adherence; Morpholines; Partial Thromboplastin Time; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Stroke; Thiophenes | 2011 |
[New anticoagulants. Characteristics, monitoring and management of bleeding].
Topics: Administration, Oral; Antithrombins; Arthroplasty, Replacement, Hip; Atrial Fibrillation; Benzimidazoles; Blood Coagulation Tests; Critical Care; Dabigatran; Drug Approval; Factor Xa Inhibitors; Fibrinolytic Agents; Hemorrhage; Heparin; Humans; Morpholines; Postoperative Complications; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiophenes; Thrombophilia; Vitamin K | 2011 |
A new era of antithrombotic therapy in patients with atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Fibrinolytic Agents; Humans; Morpholines; Platelet Aggregation Inhibitors; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2012 |
Direct thrombin inhibitors and factor Xa inhibitors in patients with cerebrovascular disease.
Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes | 2012 |
ARISTOTLE RE-LYs on the ROCKET. What's new in stroke prevention in patients with atrial fibrillation?
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Evidence-Based Medicine; Hemorrhage; Humans; Morpholines; Patient Selection; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Time Factors; Treatment Outcome; Warfarin | 2012 |
Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Benzimidazoles; Dabigatran; Dose-Response Relationship, Drug; Evidence-Based Medicine; Factor Xa; Factor Xa Inhibitors; Humans; Morpholines; Practice Guidelines as Topic; Pyridines; Rivaroxaban; Societies, Medical; Thiophenes; Thrombosis; United States; Vitamin K | 2012 |
A new generation of oral direct anticoagulants.
Topics: Acute Coronary Syndrome; Administration, Oral; Animals; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Hemorrhage; Humans; Morpholines; Orthopedic Procedures; Pyrazoles; Pyridones; Risk Assessment; Risk Factors; Rivaroxaban; Thiophenes; Thrombosis; Treatment Outcome | 2012 |
Improving prevention and treatment of venous thromboembolism: clinical trial results.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Economics, Pharmaceutical; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2012 |
The efficacy and safety of pharmacological prophylaxis of venous thromboembolism following elective knee or hip replacement: systematic review and network meta-analysis.
Topics: Antithrombins; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Dabigatran; Female; Hemorrhage; Humans; Male; Morpholines; Postoperative Complications; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2012 |
Novel oral anticoagulation in management of venous thromboembolism, atrial fibrillation, and acute coronary syndrome.
Topics: Acute Coronary Syndrome; Administration, Oral; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism; Vitamin K; Warfarin | 2012 |
New anticoagulant drugs for treatment of venous thromboembolism and stroke prevention in atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Dabigatran; Drugs, Investigational; Heparin; Humans; International Normalized Ratio; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Venous Thromboembolism; Vitamin K | 2012 |
Long-term benefits of preventing venous thromboembolic events.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Follow-Up Studies; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Risk Assessment; Rivaroxaban; Thiazoles; Thiophenes; Venous Thromboembolism | 2012 |
Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Embolism; Humans; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2012 |
Novel oral anticoagulants--key messages for the angiologist.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; Blood Coagulation; Blood Coagulation Tests; Dabigatran; Drug Monitoring; Evidence-Based Medicine; Factor Xa Inhibitors; Hemorrhage; Humans; Morpholines; Practice Guidelines as Topic; Predictive Value of Tests; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiophenes; Thrombin; Thromboembolism | 2012 |
Current and future alternatives to warfarin for the prevention of stroke in atrial fibrillation.
Topics: Anticoagulants; Antithrombin Proteins; Atrial Appendage; Atrial Fibrillation; Benzimidazoles; Chemoprevention; Dabigatran; Fibrinolytic Agents; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Warfarin | 2012 |
[New antithrombotic drugs].
Topics: Adenosine; Anticoagulants; Benzimidazoles; beta-Alanine; Clopidogrel; Dabigatran; Hemorrhage; Humans; Morpholines; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Ticagrelor; Ticlopidine; Warfarin | 2012 |
Prevention of stroke in patients with atrial fibrillation: anticoagulant and antiplatelet options.
Topics: Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clopidogrel; Dabigatran; Hemorrhage; Humans; Morpholines; Practice Guidelines as Topic; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Thrombolytic Therapy; Ticlopidine; Warfarin | 2012 |
Treatment of venous thromboembolism with dabigatran.
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Rivaroxaban; Secondary Prevention; Thiophenes; Treatment Outcome; Venous Thromboembolism; Warfarin | 2012 |
[Prophylaxis of stroke and embolisms in atrial fibrillation--what is new in the guidelines?].
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Evidence-Based Medicine; Factor Xa Inhibitors; Guideline Adherence; Hemorrhage; Humans; Intracranial Embolism; Morpholines; Randomized Controlled Trials as Topic; Risk Factors; Rivaroxaban; Stroke; Thiophenes | 2012 |
New oral anticoagulants: will they replace warfarin?
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Hypersensitivity; Drug Interactions; Factor Xa Inhibitors; Gastritis; Hemorrhage; Humans; Liver; Morpholines; Rivaroxaban; Thiophenes; Thromboembolism | 2012 |
[Clinical management of the new anticoagulants].
Topics: Administration, Oral; Anticoagulants; Azetidines; Benzimidazoles; Benzylamines; beta-Alanine; Clinical Trials as Topic; Dabigatran; Drug Monitoring; Drugs, Investigational; Hemorrhage; Humans; Morpholines; Multicenter Studies as Topic; Patient Care Planning; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Thrombophilia; Vitamin K | 2012 |
Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2012 |
Dabigatran, rivaroxaban, or apixaban versus enoxaparin for thromboprophylaxis after total hip or knee replacement: systematic review, meta-analysis, and indirect treatment comparisons.
Topics: Administration, Oral; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Dabigatran; Enoxaparin; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2012 |
Newer oral anticoagulant agents: a new era in medicine.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thromboembolism | 2012 |
Anticoagulants for the treatment of acute coronary syndrome in the era of new oral agents.
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Antithrombins; Aspirin; Benzimidazoles; beta-Alanine; Clopidogrel; Dabigatran; Drug Therapy, Combination; Factor Xa Inhibitors; Hemorrhage; Heparin; Humans; Morpholines; Platelet Aggregation Inhibitors; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Ticlopidine; Warfarin | 2012 |
The management of antithrombotic medication in skin surgery.
Topics: Anticoagulants; Antithrombins; Aspirin; Benzimidazoles; beta-Alanine; Dabigatran; Dermatologic Surgical Procedures; Fibrinolytic Agents; Fondaparinux; Heparin, Low-Molecular-Weight; Humans; Morpholines; Platelet Aggregation Inhibitors; Polysaccharides; Risk Assessment; Rivaroxaban; Thienopyridines; Thiophenes; Vitamin K; Warfarin | 2012 |
An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation.
Topics: Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Embolism; Factor Xa Inhibitors; Female; Heart Valve Diseases; Hemorrhage; Humans; Ischemic Attack, Transient; Male; Morpholines; Multicenter Studies as Topic; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Secondary Prevention; Severity of Illness Index; Stroke; Thiophenes; Thrombophilia; Vitamin K; Warfarin | 2012 |
New oral anticoagulants for atrial fibrillation.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Drug Substitution; Female; Humans; Male; Morpholines; Practice Guidelines as Topic; Pyridines; Rivaroxaban; Thiophenes | 2012 |
Adjusted indirect comparison of new oral anticoagulants for stroke prevention in atrial fibrillation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Biological Availability; Comparative Effectiveness Research; Dabigatran; Drug Monitoring; Embolism; Female; Humans; Male; Middle Aged; Morpholines; Outcome and Process Assessment, Health Care; Pharmacovigilance; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2012 |
New oral anticoagulants in the ED setting: a review.
Topics: Acute Coronary Syndrome; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Emergency Service, Hospital; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism | 2012 |
Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cerebral Hemorrhage; Chi-Square Distribution; Dabigatran; Embolism; Female; Humans; Male; Middle Aged; Morpholines; Myocardial Infarction; Odds Ratio; Pyrazoles; Pyridones; Risk Assessment; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome | 2012 |
Phase III studies on novel oral anticoagulants for stroke prevention in atrial fibrillation: a look beyond the excellent results.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Evidence-Based Medicine; Female; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Patient Safety; Preventive Health Services; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin | 2012 |
[New oral anticoagulants for the prevention of stroke. Open questions in geriatric patients].
Topics: Administration, Oral; Aged; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Evidence-Based Medicine; Female; Humans; Morpholines; Rivaroxaban; Stroke; Thiophenes | 2012 |
Emerging anticoagulant therapies for atrial fibrillation: new options, new challenges.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; Benzoates; Clinical Trials as Topic; Coumarins; Dabigatran; Factor Xa; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiophenes; Thrombin; Warfarin | 2012 |
Clinical considerations of anticoagulation therapy for patients with atrial fibrillation.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cardiology; Dabigatran; Female; Humans; Male; Middle Aged; Morpholines; Pyrazoles; Pyridones; Risk; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2012 |
Emerging oral anticoagulants for stroke prevention in patients with non-valvular atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin | 2012 |
Oral anticoagulation in atrial fibrillation: balancing the risk of stroke with the risk of bleed.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Decision Support Techniques; Health Status Indicators; Hemorrhage; Humans; Morpholines; Practice Guidelines as Topic; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2012 |
The novel oral anticoagulants: an update for the interventional radiologist.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridones; Radiography, Interventional; Rivaroxaban; Thiophenes; Thromboembolism | 2012 |
Stroke prevention in atrial fibrillation: concepts and controversies.
Topics: Administration, Oral; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Dronedarone; Drug Design; Humans; Morpholines; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin | 2012 |
[The new anticoagulants - their role in secondary prevention of thromboembolism after stroke].
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; International Normalized Ratio; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Secondary Prevention; Stroke; Thiophenes; Thromboembolism; Vitamin K | 2012 |
Periprocedural antithrombotic and bridging therapy: recommendations for standardized reporting in patients with arterial indications for chronic oral anticoagulant therapy.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Elective Surgical Procedures; Factor Xa Inhibitors; Fibrinolytic Agents; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Ischemic Attack, Transient; Medical Records; Morpholines; Perioperative Period; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Thromboembolism | 2012 |
New anticoagulants for stroke prophylaxis in atrial fibrillation: assessing the impact on medication adherence.
Topics: Administration, Oral; Animals; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Drug Administration Schedule; Humans; Medication Adherence; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2012 |
The promise of novel direct oral anticoagulants.
Topics: Anticoagulants; Antithrombins; Azetidines; Benzimidazoles; Benzylamines; Clinical Trials, Phase III as Topic; Dabigatran; Factor Xa Inhibitors; Heparin, Low-Molecular-Weight; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Thrombin; Thromboembolism; Warfarin | 2012 |
Novel oral anticoagulants in acute coronary syndrome.
Topics: Acute Coronary Syndrome; Administration, Oral; Animals; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes | 2013 |
[New oral anticoagulants for atrial fibrillation: a neurologist's view].
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiophenes | 2012 |
Interpretation of endpoints in a network meta-analysis of new oral anticoagulants following total hip or total knee replacement surgery.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Endpoint Determination; Enoxaparin; Factor Xa Inhibitors; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2012 |
Management consensus guidance for the use of rivaroxaban--an oral, direct factor Xa inhibitor.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Loss, Surgical; Clinical Trials as Topic; Dabigatran; Factor Xa Inhibitors; Female; Humans; Male; Morpholines; Practice Guidelines as Topic; Pregnancy; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism; Venous Thrombosis; Warfarin | 2012 |
What did we learn from new oral anticoagulant treatment?
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Drug Interactions; Factor Xa Inhibitors; Half-Life; Hemorrhage; Humans; Metabolic Clearance Rate; Morpholines; Rivaroxaban; Stroke; Thiophenes; Venous Thrombosis | 2012 |
Antithrombotic treatment of atrial fibrillation: new insights.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Fibrinolytic Agents; Hemorrhage; Humans; Kidney; Morpholines; Pyrazoles; Pyridones; Risk Assessment; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Vitamin K | 2012 |
Laboratory tests and the new oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation; Blood Coagulation Tests; Dabigatran; Dose-Response Relationship, Drug; Drug Monitoring; Hemorrhage; Humans; Morpholines; Predictive Value of Tests; Pyrazoles; Pyridones; Risk Assessment; Risk Factors; Rivaroxaban; Thiophenes | 2012 |
Anticoagulant treatment: the end of the old agents?
Topics: Acute Coronary Syndrome; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Drug Interactions; Factor Xa Inhibitors; Humans; Morpholines; Prothrombin; Rivaroxaban; Stroke; Thiophenes; Thromboembolism | 2012 |
The laboratory and the new oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation Tests; Dabigatran; Dose-Response Relationship, Drug; Drug Interactions; Drug Monitoring; Hemostasis; Humans; Liver Diseases; Morpholines; Pyrazoles; Pyridones; Renal Insufficiency; Rivaroxaban; Thiophenes | 2013 |
[New oral anticoagulants - sunset for warfarin in therapy of atrial fibrillation].
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Electric Countershock; Factor Xa Inhibitors; Humans; Kidney Failure, Chronic; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Warfarin | 2012 |
The new oral anticoagulants and the future of haemostasis laboratory testing.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Hemostasis; Humans; Laboratories; Morpholines; Rivaroxaban; Thiophenes | 2012 |
[Laboratory diagnostic with regard to new anticoagulants - monitoring and influence on coagulation tests].
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation; Blood Coagulation Tests; Dabigatran; Dose-Response Relationship, Drug; Drug Interactions; Drug Monitoring; Food-Drug Interactions; Hemostasis; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Switzerland; Thiophenes; Thromboembolism | 2012 |
[Clinical pharmacological aspects of new oral anticoagulants].
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Dabigatran; Dose-Response Relationship, Drug; Drug Interactions; Drug Monitoring; Factor Xa Inhibitors; Hemorrhage; Humans; Metabolic Clearance Rate; Morpholines; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Thiophenes; Thromboembolism; Vitamin K | 2012 |
Performance of new anticoagulants for thromboprophylaxis in patients undergoing hip and knee replacement surgery.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Evidence-Based Medicine; Humans; Morpholines; Practice Guidelines as Topic; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Societies, Medical; Thiazoles; Thiophenes; Venous Thromboembolism | 2012 |
[Stroke risk--atrial fibrillation].
Topics: Aged; Anticoagulants; Atrial Appendage; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cross-Sectional Studies; Dabigatran; Humans; International Normalized Ratio; Minimally Invasive Surgical Procedures; Morpholines; Population Dynamics; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Risk Factors; Rivaroxaban; Stroke; Thiophenes | 2012 |
Comparing new anticoagulants.
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Rivaroxaban; Thiophenes; United States; United States Food and Drug Administration; Warfarin | 2012 |
The novel anticoagulants: the surgeons' prospective.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Loss, Surgical; Clinical Trials as Topic; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Surgical Procedures, Operative; Thiazoles; Thiophenes; Venous Thromboembolism; Warfarin | 2013 |
Acute management of bleeding in patients on novel oral anticoagulants.
Topics: Acute Disease; Administration, Oral; Aged; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Blood Coagulation Tests; Dabigatran; Drug Therapy, Combination; Factor Xa Inhibitors; Hemorrhage; Hemostatics; Humans; Morpholines; Plasma; Platelet Aggregation Inhibitors; Pyrazoles; Pyridones; Renal Dialysis; Renal Insufficiency; Risk Factors; Rivaroxaban; Thiophenes | 2013 |
Perioperative management of patients on chronic antithrombotic therapy.
Topics: Administration, Oral; Aged; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Fibrinolytic Agents; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; International Normalized Ratio; Middle Aged; Morpholines; Perioperative Care; Risk; Rivaroxaban; Thiophenes; Thromboembolism; Thrombosis; Vitamin K | 2012 |
New oral anticoagulants: which one should my patient use?
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Chemistry, Pharmaceutical; Clinical Trials as Topic; Dabigatran; Factor Xa Inhibitors; Hematology; Humans; Morpholines; Rivaroxaban; Thiophenes; Thrombin; Thrombosis; Warfarin | 2012 |
[New anticoagulants--are we prepared?].
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; Morpholines; Prothrombin; Rivaroxaban; Thiophenes; Thromboembolism | 2012 |
New oral anticoagulants in atrial fibrillation: a reappraisal of trial results looking at absolute figures.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Venous Thrombosis | 2013 |
New oral therapies for the prevention and treatment of venous thromboembolism.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Benzimidazoles; Dabigatran; Drug Monitoring; Evidence-Based Medicine; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiophenes; Treatment Outcome; Venous Thromboembolism | 2013 |
Implications of new anticoagulants in primary practice.
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism | 2013 |
A review of oral anticoagulants in patients with atrial fibrillation.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Platelet Aggregation Inhibitors; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2012 |
Review of recently approved alternatives to anticoagulation with warfarin for emergency clinicians.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Approval; Emergencies; Hemorrhage; Humans; Morpholines; Rivaroxaban; Stroke; Thiophenes; United States; United States Food and Drug Administration; Warfarin | 2013 |
Anticoagulant therapy with the oral direct factor Xa inhibitors rivaroxaban, apixaban and edoxaban and the thrombin inhibitor dabigatran etexilate in patients with hepatic impairment.
Topics: Absorption; Anticoagulants; Benzimidazoles; Dabigatran; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Humans; Liver Diseases; Metabolic Clearance Rate; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Thrombin; Tissue Distribution; Venous Thromboembolism | 2013 |
The novel oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2013 |
Novel oral anticoagulants for stroke prevention in patients with atrial fibrillation: dawn of a new era.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Stroke; Thiophenes | 2013 |
Managing new oral anticoagulants in the perioperative and intensive care unit setting.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Critical Care; Dabigatran; Hemorrhage; Humans; Intensive Care Units; Morpholines; Perioperative Care; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Warfarin | 2013 |
[From heparin to apixaban: anticoagulants cut both ways?].
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; Blood Coagulation Tests; Dabigatran; Drug Interactions; Factor Xa Inhibitors; Fondaparinux; Heparin; Humans; International Normalized Ratio; Liver Failure; Metabolic Clearance Rate; Morpholines; Perioperative Care; Polysaccharides; Pyrazoles; Pyridines; Pyridones; Renal Insufficiency; Rivaroxaban; Thiophenes; Thrombocytopenia; Thrombosis; Vitamin K | 2014 |
Novel oral anticoagulants: a review of the literature and considerations in special clinical situations.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Clinical Trials as Topic; Dabigatran; Drug Approval; Europe; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Therapeutic Equivalency; Thiophenes; United States; United States Food and Drug Administration; Venous Thromboembolism; Warfarin | 2013 |
Direct thrombin and factor Xa inhibition for stroke prevention in patients with atrial fibrillation.
Topics: Age Factors; Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; Comorbidity; Dabigatran; Factor Xa; Factor Xa Inhibitors; Female; Humans; Male; Morpholines; Pyridines; Risk Factors; Rivaroxaban; Sex Factors; Stroke; Thiophenes; Warfarin | 2013 |
Novel oral anticoagulants for stroke prevention in patients with atrial fibrillation.
Topics: Administration, Oral; Aging; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Comorbidity; Dabigatran; Hemorrhage; Humans; Meta-Analysis as Topic; Morpholines; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2013 |
A new era of oral anticoagulation in atrial fibrillation: implications in clinical practice.
Topics: Administration, Oral; Adult; Age Distribution; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Hemorrhage; Humans; Middle Aged; Morpholines; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Thromboembolism; Warfarin | 2013 |
[Pharmacodynamic and pharmacokinetic characteristics. Mechanism of action of the new oral anticoagulants].
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes | 2012 |
[Prophylaxis of venous thromboembolism in orthopedic surgery. Role of the new anticoagulants].
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Postoperative Complications; Pulmonary Embolism; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2012 |
[New approaches in the treatment of deep vein thrombosis].
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Biotin; Clinical Trials, Phase III as Topic; Dabigatran; Drug Administration Schedule; Humans; Morpholines; Oligosaccharides; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Venous Thrombosis | 2012 |
[New evidence in the secondary prevention of thromboembolic disease].
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Biomarkers; Dabigatran; Fibrin Fibrinogen Degradation Products; Humans; Morpholines; Prognosis; Risk Factors; Rivaroxaban; Secondary Prevention; Thiophenes; Venous Thromboembolism | 2012 |
[The role of internal medicine in preventing stroke in atrial fibrillation].
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Decision Support Techniques; Humans; Internal Medicine; Morpholines; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes | 2012 |
[Contribution of the new oral anticoagulants to the treatment of acute coronary syndrome].
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Azepines; Azetidines; Benzamides; Benzimidazoles; Benzylamines; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Drug Administration Schedule; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes | 2012 |
[Recommendations on use of direct oral anticoagulants in the perioperative period].
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Loss, Surgical; Dabigatran; Humans; Morpholines; Perioperative Care; Postoperative Hemorrhage; Practice Guidelines as Topic; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism; Withholding Treatment | 2012 |
[Advances in the secondary prevention of cardioembolic stroke].
Topics: Anticoagulants; Atrial Appendage; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Contraindications; Dabigatran; Endovascular Procedures; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Secondary Prevention; Spain; Stroke; Thiophenes | 2012 |
[The new oral anticoagulants in special populations].
Topics: Administration, Oral; Age Factors; Anticoagulants; Benzimidazoles; Contraindications; Dabigatran; Embolism; Humans; Morpholines; Obesity; Pyrazoles; Pyridines; Pyridones; Renal Insufficiency; Rivaroxaban; Stroke; Thiophenes; Thrombosis | 2012 |
Relative effects of two different enoxaparin regimens as comparators against newer oral anticoagulants: meta-analysis and adjusted indirect comparison.
Topics: Administration, Oral; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Dabigatran; Enoxaparin; Humans; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2013 |
Moving toward a more ideal anticoagulant: the oral direct thrombin and factor Xa inhibitors.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Pulmonary Embolism; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thrombin | 2013 |
Established and new-generation antithrombotic drugs in patients with cirrhosis - possibilities and caveats.
Topics: Animals; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Disease Progression; Fibrinolytic Agents; Hemorrhage; Heparin; Humans; Liver Cirrhosis; Morpholines; Platelet Aggregation Inhibitors; Rivaroxaban; Thiophenes; Thrombosis; Vitamin K | 2013 |
The laboratory and the direct oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation Tests; Dabigatran; Humans; Morpholines; Rivaroxaban; Thiophenes | 2013 |
Novel anticoagulants and laboratory testing.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation; Blood Coagulation Tests; Dabigatran; Humans; Morpholines; Outcome Assessment, Health Care; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thrombosis | 2013 |
Risk versus benefit of non-vitamin K dependent anticoagulants compared to warfarin for the management of atrial fibrillation in the elderly.
Topics: Aged; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Interactions; Fibrinolytic Agents; Humans; Morpholines; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Thiophenes; Warfarin | 2013 |
[Improvements in oral anticoagulant therapy for atrial fibrillation].
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Azetidines; Benzimidazoles; Benzylamines; beta-Alanine; Dabigatran; Embolism; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Treatment Outcome; Warfarin | 2013 |
Reversal of oral anticoagulation.
Topics: Administration, Oral; Animals; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Hemorrhage; Humans; Morpholines; Rivaroxaban; Thiophenes; Warfarin | 2013 |
Novel oral anticoagulants: clinical pharmacology, indications and practical considerations.
Topics: Administration, Oral; Animals; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes | 2013 |
Potential impact of new oral anticoagulants on the management of atrial fibrillation-related stroke in primary care.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Dabigatran; Female; Hemorrhage; Humans; Male; Morpholines; Primary Health Care; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Workload | 2013 |
The new oral anticoagulants in clinical practice.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Treatment Outcome | 2013 |
Use of new oral anticoagulants in antiphospholipid syndrome.
Topics: Administration, Oral; Adult; Animals; Anticoagulants; Antiphospholipid Syndrome; Benzimidazoles; beta-Alanine; Breast Feeding; Clinical Trials, Phase III as Topic; Contraindications; Dabigatran; Drug Monitoring; Female; Humans; Infant, Newborn; Maternal Exposure; Morpholines; Pregnancy; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiazoles; Thiophenes | 2013 |
Preventing stroke and systemic embolism in renal patients with atrial fibrillation: focus on anticoagulation.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Comorbidity; Dabigatran; Disease Management; Embolism; Female; Fibrinolytic Agents; Hemorrhage; Humans; Hypertension; Intracranial Embolism; Male; Morpholines; Patient Selection; Pyrazoles; Pyridones; Renal Insufficiency, Chronic; Risk; Risk Factors; Rivaroxaban; Severity of Illness Index; Stroke; Thiophenes; Thrombophilia; Warfarin | 2013 |
Venous thromboembolism management: where do novel anticoagulants fit?
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Factor X; Heparin; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Thrombin; Venous Thromboembolism; Vitamin K; Warfarin | 2013 |
Recommendations for the emergency management of complications associated with the new direct oral anticoagulants (DOACs), apixaban, dabigatran and rivaroxaban.
Topics: Administration, Oral; Animals; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Dose-Response Relationship, Drug; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Renal Insufficiency; Rivaroxaban; Thiophenes | 2013 |
Gastrointestinal bleeding with the new oral anticoagulants--defining the issues and the management strategies.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Endoscopy; Gastrointestinal Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2013 |
Dabigatran, ROCKET atrial fibrillation, and beyond: basic science, mechanisms of agents, monitoring, and reversal.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation Factors; Cerebral Hemorrhage; Dabigatran; Factor Xa Inhibitors; Humans; Monitoring, Physiologic; Morpholines; Prodrugs; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Thrombin; Thromboembolism; Vitamin K; Warfarin | 2013 |
Novel oral anticoagulants in gastroenterology practice.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; Dabigatran; Gastrointestinal Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiophenes | 2013 |
[Electrical cardioversion for non-valvular atrial fibrillation--underestimated risk for thromboembolic complications?].
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Administration Schedule; Electric Countershock; Enoxaparin; Heparin; Humans; International Normalized Ratio; Morpholines; Phenprocoumon; Practice Guidelines as Topic; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Thromboembolism; Warfarin | 2013 |
Stroke prevention in patients with atrial fibrillation: focus on new oral anticoagulants.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Humans; International Normalized Ratio; Morpholines; Pyrazoles; Pyridines; Pyridones; Risk Factors; Rivaroxaban; Stroke; Thiophenes | 2013 |
New anticoagulants as thromboprophylaxis after total hip or knee replacement.
Topics: Anticoagulants; Antithrombins; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Humans; Morpholines; Outcome Assessment, Health Care; Patient Safety; Premedication; Rivaroxaban; Thiophenes; Thromboembolism | 2013 |
Managing bleeding in anticoagulated patients in the emergency care setting.
Topics: Anticoagulants; Antidotes; Benzimidazoles; beta-Alanine; Dabigatran; Emergency Service, Hospital; Hemorrhage; Hemostasis; Humans; Morpholines; Rivaroxaban; Thiophenes; Warfarin | 2013 |
Importance of pharmacokinetic profile and variability as determinants of dose and response to dabigatran, rivaroxaban, and apixaban.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Biological Availability; Blood Coagulation; Dabigatran; Dose-Response Relationship, Drug; Drug Interactions; Drug Monitoring; Humans; Morpholines; Outcome Assessment, Health Care; Patient Selection; Polymorphism, Genetic; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2013 |
Cost-effectiveness of new oral anticoagulants compared with warfarin in preventing stroke and other cardiovascular events in patients with atrial fibrillation.
Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cardiovascular Diseases; Cost-Benefit Analysis; Dabigatran; Drug Costs; Hemorrhage; Humans; Markov Chains; Middle Aged; Morpholines; Pyrazoles; Pyridones; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Time Factors; Warfarin | 2013 |
Novel oral anticoagulants and stroke prevention in atrial fibrillation and chronic heart failure.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Chronic Disease; Dabigatran; Drug Monitoring; Heart Failure; Hemorrhage; Humans; Morpholines; Outcome Assessment, Health Care; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Severity of Illness Index; Stroke; Thiophenes; Warfarin | 2014 |
Clinical review: Clinical management of new oral anticoagulants: a structured review with emphasis on the reversal of bleeding complications.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Disease Management; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes | 2013 |
Thromboprophylaxis in patients with pelvic and acetabular fractures: A short review and recommendations.
Topics: Acetabulum; Anticoagulants; Aspirin; Benzimidazoles; beta-Alanine; Coumarins; Dabigatran; Fondaparinux; Fractures, Bone; Heparin; Humans; Mass Screening; Morpholines; Multiple Trauma; Pelvis; Polysaccharides; Pulmonary Embolism; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Thiophenes; Vena Cava Filters; Venous Thromboembolism | 2013 |
Laboratory monitoring of anticoagulant medications: focus on novel oral anticoagulants.
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Blood Coagulation Tests; Dabigatran; Drug Monitoring; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Thrombosis | 2013 |
Alternatives to warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a look back at the state of the field in 2012.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Warfarin | 2013 |
Practical management of bleeding due to the anticoagulants dabigatran, rivaroxaban, and apixaban.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation Tests; Dabigatran; Drug Monitoring; Hemorrhage; Hemostatic Techniques; Humans; Morpholines; Perioperative Care; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes | 2013 |
The changing face of oral anticoagulants.
Topics: Anticoagulants; Antithrombin Proteins; Benzimidazoles; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Prodrugs; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiophenes; Thromboembolism; Warfarin | 2013 |
The perioperative management of new direct oral anticoagulants: a question without answers.
Topics: Administration, Oral; Aged; Anesthesiology; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Dabigatran; Female; Hemorrhage; Hemostasis; Heparin, Low-Molecular-Weight; Humans; Male; Morpholines; Patient Safety; Perioperative Period; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thromboembolism | 2013 |
New alternative anticoagulants in atrial fibrillation: the move beyond warfarin.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Humans; Morpholines; Prognosis; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2013 |
What are the new therapeutic alternatives to warfarin in atrial fibrillation?
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pakistan; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2013 |
Bleeding with dabigatran, rivaroxaban, apixaban. No antidote, and little clinical experience.
Topics: Anticoagulants; Antidotes; Benzimidazoles; beta-Alanine; Blood Coagulation Tests; Dabigatran; Drug Overdose; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes | 2013 |
[New clinical perspectives in the management of oral direct anticoagulant agents].
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Elective Surgical Procedures; Emergencies; Factor Xa Inhibitors; Hemorrhage; Humans; Kidney Diseases; Morpholines; Orthopedic Procedures; Postoperative Complications; Premedication; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Risk; Rivaroxaban; Thiophenes; Thrombophilia; Vitamin K | 2014 |
Mixed treatment comparison meta-analysis of aspirin, warfarin, and new anticoagulants for stroke prevention in patients with nonvalvular atrial fibrillation.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Data Interpretation, Statistical; Databases, Bibliographic; Double-Blind Method; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2013 |
New anticoagulants (dabigatran, apixaban, rivaroxaban) for stroke prevention in atrial fibrillation.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Male; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes | 2013 |
Novel oral anticoagulants: a review of new agents.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Administration Schedule; Humans; Morpholines; Postoperative Complications; Practice Guidelines as Topic; Pulmonary Embolism; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism; Venous Thrombosis | 2013 |
Clinical use of new oral anticoagulant drugs: dabigatran and rivaroxaban.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Drug Interactions; Embolism; Factor Xa Inhibitors; Hemorrhage; Humans; Morpholines; Rivaroxaban; Stroke; Thiophenes | 2013 |
Disadvantages of VKA and requirements for novel anticoagulants.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Dosage Calculations; Drug Interactions; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; Thrombin; Thrombosis; Vitamin K; Warfarin | 2013 |
Novel oral anticoagulants in non-valvular atrial fibrillation.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Drug Administration Schedule; Humans; Intracranial Hemorrhages; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Thromboembolism | 2013 |
Novel oral anticoagulants in secondary prevention of stroke.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Guidelines as Topic; Humans; Intracranial Hemorrhages; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Thromboembolism; Warfarin | 2013 |
New oral anticoagulants after acute coronary syndrome.
Topics: Acute Coronary Syndrome; Administration, Oral; Aged; Anticoagulants; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Factor Xa Inhibitors; Humans; Intracranial Hemorrhages; Morpholines; Platelet Aggregation Inhibitors; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thrombin; Thromboembolism | 2013 |
New oral anticoagulants for the treatment of venous thromboembolism.
Topics: Administration, Oral; Adult; Aged; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Administration Schedule; Humans; Middle Aged; Morpholines; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiazoles; Thiophenes; Venous Thromboembolism; Warfarin | 2013 |
New anticoagulants in the treatment of patients with cancer-associated venous thromboembolism.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Administration Schedule; Heparin, Low-Molecular-Weight; Humans; Morpholines; Neoplasms; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; Treatment Outcome; Venous Thromboembolism; Warfarin | 2013 |
Novel oral anticoagulants for thromboprophylaxis after orthopaedic surgery.
Topics: Administration, Oral; Anticoagulants; Arthroplasty, Replacement; Benzimidazoles; beta-Alanine; Dabigatran; Drug Administration Schedule; Heparin, Low-Molecular-Weight; Humans; Morpholines; Postoperative Hemorrhage; Pulmonary Embolism; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; Venous Thromboembolism; Warfarin | 2013 |
NOACs for thromboprophylaxis in medical patients.
Topics: Administration, Oral; Aged; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Administration Schedule; Enoxaparin; Humans; Morpholines; Postoperative Hemorrhage; Pulmonary Embolism; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Surgical Procedures, Operative; Thiophenes; Venous Thromboembolism; Warfarin | 2013 |
Bleeding and antidotes in new oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation Factors; Dabigatran; Drug Administration Schedule; Hemorrhage; Hemostatics; Humans; Morpholines; Prothrombin; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiazoles; Thiophenes; Thromboembolism | 2013 |
New oral anticoagulants in elderly patients.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Drug Administration Schedule; Humans; Intracranial Hemorrhages; Morpholines; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism; Vitamin K; Warfarin | 2013 |
Cost-effectiveness of new oral anticoagulants in the prevention of stroke in patients with atrial fibrillation.
Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; Cost-Benefit Analysis; Dabigatran; Drug Administration Schedule; Humans; Intracranial Hemorrhages; Morpholines; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism; Warfarin | 2013 |
[Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors. Proposals of the Working Group on Perioperative Haemostasis (GIHP) - March 2013].
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Emergencies; Emergency Medical Services; Factor Xa Inhibitors; Hemorrhage; Hemostasis; Humans; Morpholines; Perioperative Care; Rivaroxaban; Surgical Procedures, Operative; Thiophenes; Thrombin | 2013 |
Efficacy and safety outcomes of oral anticoagulants and antiplatelet drugs in the secondary prevention of venous thromboembolism: systematic review and network meta-analysis.
Topics: Anticoagulants; Aspirin; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Morpholines; Platelet Aggregation Inhibitors; Pyrazoles; Pyridones; Recurrence; Rivaroxaban; Thiophenes; Venous Thromboembolism; Vitamin K | 2013 |
Cost-effectiveness of pharmacogenetics-guided warfarin therapy vs. alternative anticoagulation in atrial fibrillation.
Topics: Algorithms; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Drug Costs; Drug Dosage Calculations; Humans; Morpholines; Pharmacogenetics; Pyrazoles; Pyridones; Quality-Adjusted Life Years; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2014 |
New oral anticoagulants--a review.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Medication Adherence; Morpholines; Practice Guidelines as Topic; Pulmonary Embolism; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism; Venous Thrombosis | 2013 |
Anticoagulant and antiplatelet medications encountered in emergency surgery patients: a review of reversal strategies.
Topics: Anticoagulants; Aspirin; Benzimidazoles; Clopidogrel; Dabigatran; Emergencies; Enoxaparin; Fondaparinux; Heparin; Humans; Morpholines; Platelet Aggregation Inhibitors; Platelet Transfusion; Polysaccharides; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Surgical Procedures, Operative; Thiophenes; Ticlopidine; Warfarin | 2013 |
Anticoagulation management in nonvalvular atrial fibrillation: current and future directions.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatran; Drug Administration Schedule; Fibrinolytic Agents; Forecasting; Humans; Morpholines; Percutaneous Coronary Intervention; Postoperative Care; Postoperative Hemorrhage; Premedication; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Thromboembolism; Warfarin | 2013 |
Novel thrombin and factor Xa inhibitors: challenges to reversal of their anticoagulation effects.
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Factor Xa Inhibitors; Hemorrhagic Disorders; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes | 2013 |
Advantages and limitations of the new anticoagulants.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Disease Management; Dose-Response Relationship, Drug; Drug Interactions; Drug Monitoring; Factor Xa Inhibitors; Humans; Intracranial Hemorrhages; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Thromboembolism | 2014 |
The risk of recurrent thromboembolic disorders in patients with unprovoked venous thromboembolism: new scenarios and opportunities.
Topics: Age Factors; Anticoagulants; Aspirin; Benzimidazoles; beta-Alanine; Dabigatran; Disease Management; Female; Fibrin Fibrinogen Degradation Products; Fibrinolytic Agents; Fondaparinux; Humans; Male; Morpholines; Obesity; Polysaccharides; Postthrombotic Syndrome; Pulmonary Embolism; Risk Assessment; Risk Factors; Rivaroxaban; Secondary Prevention; Sex Factors; Thiophenes; Thrombophilia; Ultrasonography; Venous Thromboembolism; Venous Thrombosis; Warfarin | 2014 |
Novel oral anticoagulants: a focused review for stroke physicians.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; Child; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiophenes | 2014 |
[Gastrointestinal bleeding in cardiological patients].
Topics: Algorithms; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation Factors; Dabigatran; Drug Monitoring; Gastrointestinal Hemorrhage; Heart Diseases; Humans; Metabolic Clearance Rate; Morpholines; Phenprocoumon; Platelet Aggregation Inhibitors; Platelet Transfusion; Rivaroxaban; Thiophenes; Vitamin K | 2013 |
The use of novel oral anticoagulants for thromboprophylaxis after elective major orthopedic surgery.
Topics: Administration, Oral; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Humans; Morpholines; Postoperative Complications; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2013 |
Practical management of new oral anticoagulants after total hip or total knee arthroplasty.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; Blood Coagulation Tests; Clinical Trials, Phase III as Topic; Contraindications; Dabigatran; Drug Administration Schedule; Drug Interactions; Drug Monitoring; Hematoma, Epidural, Spinal; Humans; Morpholines; Platelet Aggregation Inhibitors; Postoperative Complications; Postoperative Hemorrhage; Postoperative Nausea and Vomiting; Practice Guidelines as Topic; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2013 |
Pharmacokinetic and pharmacodynamic drug interactions with new oral anticoagulants: what do they mean for patients with atrial fibrillation?
Topics: Anticoagulants; ATP Binding Cassette Transporter, Subfamily B, Member 1; Atrial Fibrillation; Benzimidazoles; Cytochrome P-450 Enzyme System; Dabigatran; Drug Interactions; Drug Therapy, Combination; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiophenes | 2013 |
Outpatient management of oral anticoagulation in atrial fibrillation.
Topics: Ambulatory Care; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2013 |
[Evidence of novel oral anticoagulants (NOAC)].
Topics: Administration, Ophthalmic; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cerebral Infarction; Clinical Trials, Phase III as Topic; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2013 |
The old and new: PCCs, VIIa, and long-lasting clotting factors for hemophilia and other bleeding disorders.
Topics: Antibodies; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation Factors; Clinical Trials as Topic; Dabigatran; Factor VIIa; Female; Half-Life; Hemophilia A; Hemorrhage; Hemostatics; Humans; Male; Morpholines; Rivaroxaban; RNA Interference; Thiophenes | 2013 |
Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Female; Hemorrhage; Humans; Male; Morpholines; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Risk Factors; Rivaroxaban; Thiazoles; Thiophenes; Treatment Outcome; Venous Thromboembolism; Vitamin K | 2014 |
New oral anticoagulants and regional anaesthesia.
Topics: Administration, Oral; Anesthesia, Conduction; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Platelet Aggregation Inhibitors; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thrombosis | 2013 |
Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.
Topics: Administration, Oral; Animals; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cardiovascular Diseases; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes | 2014 |
{blacktriangledown} Apixaban and {blacktriangledown} rivaroxaban for stroke prevention in AF.
Topics: Adult; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Embolism; Factor Xa Inhibitors; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes | 2014 |
[New anticoagulants in patients with atrial fibrillation].
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Brain Infarction; Dabigatran; Humans; Intracranial Embolism; Ischemic Attack, Transient; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Vitamin K | 2013 |
New oral anticoagulants in practice: pharmacological and practical considerations.
Topics: Administration, Oral; Aging; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Complementary Therapies; Dabigatran; Drug Interactions; Drug Monitoring; Humans; International Normalized Ratio; Kidney Diseases; Liver Diseases; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Sex Factors; Stroke; Thiophenes; Warfarin | 2014 |
New antithrombotics for secondary prevention of acute coronary syndrome.
Topics: Acute Coronary Syndrome; Anticoagulants; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Coronary Thrombosis; Dabigatran; Hemorrhage; Humans; Imines; Lactones; Morpholines; Platelet Activation; Platelet Aggregation Inhibitors; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Secondary Prevention; Thiophenes; Thrombin | 2014 |
New oral anticoagulant agents - general features and outcomes in subsets of patients.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Hemorrhage; Humans; Morpholines; Patient Selection; Pyrazoles; Pyridines; Pyridones; Risk; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Treatment Outcome; Venous Thromboembolism; Warfarin | 2014 |
[General characteristics of the new oral anticoagulants].
Topics: Administration, Oral; Aged; Anticoagulants; Benzimidazoles; beta-Alanine; Cerebral Infarction; Dabigatran; Dose-Response Relationship, Drug; Drug Interactions; Drugs, Investigational; Humans; Iatrogenic Disease; Intracranial Hemorrhages; Morpholines; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Vitamin K | 2013 |
[Novel oral anticoagulants and atrial fibrillation in the elderly].
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cerebral Hemorrhage; Dabigatran; Drugs, Investigational; Half-Life; Humans; Intracranial Embolism; Metabolic Clearance Rate; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Vitamin K | 2013 |
Current state of anticoagulants to treat deep venous thrombosis.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Medication Adherence; Morpholines; Patient Selection; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Venous Thrombosis | 2014 |
Is there a role for novel oral anticoagulants in patients with an acute coronary syndrome? A review of the clinical trials.
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes | 2013 |
Anticoagulation and antiplatelet therapy in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Anticoagulants; Aspirin; Benzimidazoles; beta-Alanine; Clopidogrel; Dabigatran; Enoxaparin; Fondaparinux; Heparin; Hirudins; Humans; Morpholines; Peptide Fragments; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Polysaccharides; Prasugrel Hydrochloride; Pyrazoles; Pyridones; Recombinant Proteins; Rivaroxaban; Thiophenes; Ticagrelor; Ticlopidine; Warfarin | 2014 |
Direct oral anticoagulants in the treatment and long-term prevention of venous thrombo-embolism.
Topics: Acute Disease; Administration, Oral; Antithrombins; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Hemorrhage; Humans; Long-Term Care; Morpholines; Perioperative Care; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Treatment Outcome; Venous Thromboembolism; Vitamin K | 2014 |
Practical considerations in emergency management of bleeding in the setting of target-specific oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Emergency Treatment; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes | 2014 |
Management of antiplatelet and anticoagulant therapy in patients with atrial fibrillation in the setting of acute coronary syndromes or percutaneous coronary interventions.
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Morpholines; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Postoperative Complications; Prasugrel Hydrochloride; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thrombosis; Ticagrelor | 2014 |
New oral anticoagulants for stroke prevention in atrial fibrillation: impact of study design, double counting and unexpected findings on interpretation of study results and conclusions.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Data Interpretation, Statistical; Humans; Morpholines; Practice Guidelines as Topic; Pyrazoles; Pyridines; Pyridones; Research Design; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Treatment Outcome | 2014 |
Practical aspects of new oral anticoagulant use in atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2014 |
Comparative coronary risks of apixaban, rivaroxaban and dabigatran: a meta-analysis and adjusted indirect comparison.
Topics: Acute Coronary Syndrome; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes | 2014 |
Novel oral anticoagulants in acute coronary syndrome: re-evaluating the thrombin hypothesis.
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Azepines; Azetidines; Benzamides; Benzimidazoles; Benzylamines; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thrombin; Vitamin K | 2014 |
The newer direct oral anticoagulants: a practical guide.
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism; Warfarin | 2014 |
New oral anticoagulants: clinical indications, monitoring and treatment of acute bleeding complications.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation Tests; Dabigatran; Drug Monitoring; Factor Xa Inhibitors; Hemorrhage; Hemostatic Techniques; Hemostatics; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thrombin; Thromboembolism; Thrombophilia | 2014 |
Anticoagulation in atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Medication Adherence; Morpholines; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2014 |
New oral anticoagulants and oculoplastic surgery.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Cardiovascular Diseases; Cataract Extraction; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Surgery, Plastic; Thiophenes | 2014 |
Anticoagulation: a GP primer on the new oral anticoagulants.
Topics: Anticoagulants; Antithrombins; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation Tests; Dabigatran; Drug Monitoring; Factor Xa Inhibitors; General Practice; Hemorrhage; Humans; Kidney; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism; Warfarin | 2014 |
Phase III trials of new oral anticoagulants in the acute treatment and secondary prevention of VTE: comparison and critique of study methodology and results.
Topics: Anticoagulants; Clinical Trials, Phase III as Topic; Dabigatran; Hemorrhage; Humans; Outcome Assessment, Health Care; Patient Acuity; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Secondary Prevention; Thiazoles; Venous Thromboembolism | 2014 |
Primary prevention of ischaemic stroke in atrial fibrillation: new oral anticoagulant drugs for all?
Topics: Administration, Oral; Age Factors; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Brain Ischemia; Clinical Trials, Phase III as Topic; Dabigatran; Humans; Morpholines; Practice Guidelines as Topic; Primary Prevention; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Stroke; Thiophenes | 2014 |
Direct oral anticoagulants in the prevention of venous thromboembolism: evidence from major clinical trials.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Half-Life; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Venous Thromboembolism; Vitamin K | 2014 |
Direct oral anticoagulants in the management of venous thromboembolism--evidence from major clinical trials.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Humans; Morpholines; Neoplasms; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Venous Thromboembolism | 2014 |
Stroke prevention in atrial fibrillation: established oral anticoagulants versus novel anticoagulants-translating clinical trial data into practice.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Translational Research, Biomedical; Treatment Outcome | 2014 |
[Oral anticoagulation in chronic kidney disease with atrial fibrillation].
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; Hemorrhage; Humans; Renal Insufficiency, Chronic; Risk Assessment; Risk Factors; Rivaroxaban; Stroke | 2015 |
Evolving use of new oral anticoagulants for treatment of venous thromboembolism.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Therapy; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Treatment Outcome; Venous Thromboembolism | 2014 |
[Gastrointestinal bleeding under treatment with new oral anticoagulants].
Topics: Administration, Oral; Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cerebral Hemorrhage; Dabigatran; Gastrointestinal Hemorrhage; Humans; Intracranial Embolism; Morpholines; Postoperative Complications; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Thiophenes; Thrombosis; Vitamin K; Warfarin | 2014 |
Newer clinically available antithrombotics and their antidotes.
Topics: Animals; Antidotes; Antithrombins; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Elective Surgical Procedures; Factor Xa Inhibitors; Hemorrhage; Hemostatics; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism | 2014 |
Editor's Choice - efficacy and safety of the new oral anticoagulants dabigatran, rivaroxaban, apixaban, and edoxaban in the treatment and secondary prevention of venous thromboembolism: a systematic review and meta-analysis of phase III trials.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Secondary Prevention; Thiazoles; Thiophenes; Venous Thromboembolism | 2014 |
Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials.
Topics: Acute Disease; Administration, Oral; Anticoagulants; Benzimidazoles; Clinical Trials, Phase III as Topic; Dabigatran; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Morpholines; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiazoles; Thiophenes; Venous Thromboembolism; Vitamin K | 2014 |
Indirect comparison of dabigatran, rivaroxaban, apixaban and edoxaban for the treatment of acute venous thromboembolism.
Topics: Acute Disease; Adult; Aged; Anticoagulants; Clinical Trials, Phase III as Topic; Dabigatran; Female; Hemorrhage; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Recurrence; Risk Assessment; Rivaroxaban; Survival Analysis; Thiazoles; Venous Thrombosis | 2015 |
Oral direct inhibitors of coagulation.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiophenes | 2014 |
Treatment discontinuations with new oral agents for long-term anticoagulation: insights from a meta-analysis of 18 randomized trials including 101,801 patients.
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Medication Adherence; Morpholines; Pulmonary Embolism; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism | 2014 |
Meta-analysis of efficacy and safety of rivaroxaban compared with warfarin or dabigatran in patients undergoing catheter ablation for atrial fibrillation.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Rivaroxaban; Thiophenes; Thromboembolism; Treatment Outcome; Warfarin | 2014 |
NOAC and intracerebral bleeding--presentation of four cases and review of the literature.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cerebral Hemorrhage; Dabigatran; Female; Humans; Hypertension; Male; Morpholines; Rivaroxaban; Thiophenes | 2014 |
Direct oral anticoagulants: integration into clinical practice.
Topics: Acute Kidney Injury; Administration, Oral; Anticoagulants; Atrial Fibrillation; Clinical Trials, Phase III as Topic; Dabigatran; Drug Administration Schedule; Hemorrhage; Humans; Medication Adherence; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thromboembolism; Treatment Outcome | 2014 |
[Update on current care guideline: atrial fibrillation].
Topics: Administration, Oral; Anti-Arrhythmia Agents; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Incidence; Morpholines; Practice Guidelines as Topic; Prevalence; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Warfarin | 2014 |
Direct oral anticoagulants in the treatment of acute venous thromboembolism: a systematic review and meta-analysis.
Topics: Administration, Oral; Animals; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Venous Thromboembolism | 2014 |
Dabigatran, rivaroxaban and apixaban for extended venous thromboembolism treatment: network meta-analysis.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Chi-Square Distribution; Dabigatran; Hemorrhage; Humans; Morpholines; Odds Ratio; Pyrazoles; Pyridones; Recurrence; Risk Assessment; Risk Factors; Rivaroxaban; Thiophenes; Time Factors; Treatment Outcome; Venous Thromboembolism | 2014 |
Novel oral anticoagulants in patients with renal insufficiency: a meta-analysis of randomized trials.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Renal Insufficiency; Rivaroxaban; Stroke; Thiophenes; Thromboembolism | 2014 |
Non-vitamin K antagonist oral anticoagulants (NOACs): clinical evidence and therapeutic considerations.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Cost-Benefit Analysis; Dabigatran; Drug Administration Schedule; Evidence-Based Medicine; Factor Xa Inhibitors; Humans; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Venous Thromboembolism; Vitamin K; Warfarin | 2014 |
[Treatment of very old patients with non valvular atrial fibrillation. The valuable opportunity offered by new oral anticoagulants, to be cautiously used].
Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes | 2013 |
Atrial fibrillation - new frontiers in anticoagulation.
Topics: Administration, Oral; Animals; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes | 2014 |
Novel anticoagulants vs warfarin for stroke prevention in atrial fibrillation.
Topics: Animals; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Discovery; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Warfarin | 2014 |
Evaluation of oral anticoagulants for the extended treatment of venous thromboembolism using a mixed-treatment comparison, meta-analytic approach.
Topics: Administration, Oral; Anticoagulants; Dabigatran; Hemorrhage; Humans; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Venous Thromboembolism; Warfarin | 2014 |
[Monitoring options and reversal agents for oral anticoagulants].
Topics: Administration, Oral; Anticoagulants; Antithrombins; Blood Coagulation Factors; Blood Coagulation Tests; Dabigatran; Drug Monitoring; Factor Xa Inhibitors; Hemorrhage; Humans; Plasma; Pyrazoles; Pyridones; Rivaroxaban; Vitamin K | 2014 |
The potential of target-specific oral anticoagulants for the acute and long-term treatment of venous thromboembolism.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Heparin; Humans; Morpholines; Pulmonary Embolism; Rivaroxaban; Thiophenes; Venous Thromboembolism; Venous Thrombosis | 2014 |
Emergency surgery and trauma in patients treated with the new oral anticoagulants: dabigatran, rivaroxaban, and apixaban.
Topics: Anticoagulants; Antidotes; Benzimidazoles; beta-Alanine; Dabigatran; Emergencies; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Surgical Procedures, Operative; Thiophenes; Wounds and Injuries | 2014 |
Pharmacology and safety of new oral anticoagulants: the challenge of bleeding persists.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Monitoring; Evidence-Based Medicine; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes | 2014 |
Oral anticoagulants: the move beyond warfarin.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Approval; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thrombosis; Warfarin | 2014 |
Oral anticoagulants for stroke prevention in atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Administration Schedule; Drug Therapy, Combination; Humans; Morpholines; Patient Preference; Platelet Aggregation Inhibitors; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Research Design; Rivaroxaban; Stroke; Thiazoles; Thiophenes | 2014 |
Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Drug Monitoring; Factor Xa Inhibitors; Humans; Morpholines; Partial Thromboplastin Time; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes | 2014 |
Target-specific oral anticoagulants: practice issues for the clinician.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Interactions; Humans; Medication Adherence; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Venous Thromboembolism; Warfarin | 2014 |
Perioperative management of oral anticoagulants: a focus on target-specific oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Monitoring; Humans; Kidney Function Tests; Morpholines; Perioperative Period; Practice Guidelines as Topic; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thromboembolism; Warfarin | 2014 |
Switching between oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; United States; Warfarin | 2014 |
Management of hemorrhage with the target-specific oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Transfusion; Charcoal; Dabigatran; Drug Monitoring; Factor Xa Inhibitors; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Renal Dialysis; Rivaroxaban; Thiophenes | 2014 |
Testing the therapeutic equivalence of novel oral anticoagulants for thromboprophylaxis in orthopedic surgery and for prevention of stroke in atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Humans; Morpholines; Orthopedic Procedures; Patient Safety; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Therapeutic Equivalency; Thiazoles; Thiophenes; Treatment Outcome; Venous Thromboembolism | 2015 |
New oral anticoagulants for the treatment of venous thromboembolism: understanding differences and similarities.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Venous Thromboembolism | 2014 |
[Stroke prevention after stroke in patients with atrial fibrillation: a case-based review].
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Administration Schedule; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Secondary Prevention; Stroke; Thiophenes; Vitamin K; Warfarin | 2014 |
Benefit-risk profile of non-vitamin K antagonist oral anticoagulants in the management of venous thromboembolism.
Topics: Administration, Oral; Anticoagulants; Blood Coagulation; Clinical Trials as Topic; Dabigatran; Factor Xa Inhibitors; Female; Hemorrhage; Heparin; Humans; Male; Orthopedic Procedures; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Rivaroxaban; Thiazoles; Thromboembolism; Treatment Outcome; Venous Thromboembolism; Vitamin K | 2015 |
A systematic review and adjusted indirect comparison of oral anticoagulants.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Heparin, Low-Molecular-Weight; Humans; Morpholines; Orthopedic Procedures; Postoperative Complications; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2014 |
Balancing ischaemia and bleeding risks with novel oral anticoagulants.
Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; Ischemia; Morpholines; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Venous Thromboembolism | 2014 |
[Bleeding complications under oral anticoagulation].
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation Tests; Dabigatran; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Thiophenes; Vitamin K | 2014 |
Approach to the new oral anticoagulants in family practice: part 1: comparing the options.
Topics: Acute Disease; Administration, Oral; Anticoagulants; Antidotes; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Monitoring; Family Practice; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism; Warfarin | 2014 |
Risk of major bleeding in different indications for new oral anticoagulants: insights from a meta-analysis of approved dosages from 50 randomized trials.
Topics: Administration, Oral; Antithrombins; Azepines; Benzamides; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Risk; Rivaroxaban; Thiazoles; Thiophenes | 2015 |
Novel oral anticoagulants in non-valvular atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Chemistry, Pharmaceutical; Dabigatran; Humans; Morpholines; Rivaroxaban; Thiophenes | 2014 |
Strategies for urgent reversal of target-specific oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation Factors; Charcoal; Dabigatran; Factor VIIa; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Recombinant Proteins; Renal Dialysis; Rivaroxaban; Thiazoles; Thiophenes | 2014 |
Target-specific oral anticoagulants and the hospitalist.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Clinical Trials, Phase III as Topic; Dabigatran; Factor Xa Inhibitors; Hospitalists; Humans; International Normalized Ratio; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Venous Thrombosis; Warfarin | 2015 |
Non-vitamin K antagonist oral anticoagulants (NOACs): a view from the laboratory.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Dose-Response Relationship, Drug; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Thrombosis; Treatment Outcome; Vitamin K | 2014 |
[More with atrial fibrillation, anticoagulants since the coming of NOAK ].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cohort Studies; Dabigatran; Drug Prescriptions; Drug Utilization; Factor Xa Inhibitors; Female; Humans; Male; Middle Aged; Morpholines; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Thiophenes; Warfarin | 2015 |
Changing practice of anticoagulation: will target-specific anticoagulants replace warfarin?
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Venous Thromboembolism; Warfarin | 2015 |
Relevance of P-glycoprotein in stroke prevention with dabigatran, rivaroxaban, and apixaban.
Topics: Administration, Oral; Antithrombins; ATP Binding Cassette Transporter, Subfamily B, Member 1; Atrial Fibrillation; Dabigatran; Drug Interactions; Factor Xa Inhibitors; Humans; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Treatment Outcome | 2015 |
Managing dentoalveolar surgical procedures in patients taking new oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Dabigatran; Dental Care for Chronically Ill; Factor Xa Inhibitors; Humans; Oral Hemorrhage; Oral Surgical Procedures; Pyrazoles; Pyridones; Rivaroxaban; Warfarin | 2015 |
Practical recommendations on incorporating new oral anticoagulants into routine practice.
Topics: Administration, Oral; Anticoagulants; Blood Coagulation; Dabigatran; Drug Interactions; Humans; Pyrazoles; Pyridones; Rivaroxaban; Thrombosis | 2014 |
Reversal of the novel oral anticoagulants dabigatran, rivoraxaban, and apixaban.
Topics: Animals; Antidotes; Antithrombins; Benzimidazoles; beta-Alanine; Coagulants; Dabigatran; Factor Xa Inhibitors; Fibrinolytic Agents; Hemorrhage; Humans; Models, Animal; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thromboembolism | 2015 |
[Anticoagulant therapy in secondary prevention of coronary events].
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Aspirin; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Clopidogrel; Dabigatran; Hemorrhage; Humans; Morpholines; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyrazoles; Pyridones; Rivaroxaban; Secondary Prevention; Thiophenes; Ticlopidine; Warfarin | 2014 |
Clinical experience with the new oral anticoagulants for treatment of venous thromboembolism.
Topics: Administration, Oral; Animals; Anticoagulants; Clinical Trials, Phase III as Topic; Dabigatran; Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Risk Factors; Rivaroxaban; Thiazoles; Time Factors; Treatment Outcome; Venous Thromboembolism | 2015 |
Systematic review of cost-effectiveness analyses of novel oral anticoagulants for stroke prevention in atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Cost-Benefit Analysis; Dabigatran; Humans; Pyrazoles; Pyridones; Rivaroxaban; Stroke | 2015 |
The periprocedural management of novel oral anticoagulants in patients with nonvalvular atrial fibrillation: rationale and a summary of the available evidence from phase 3 clinical trials.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Rivaroxaban; Thiophenes; Treatment Outcome | 2015 |
Impact of new oral anticoagulants on gastrointestinal bleeding in atrial fibrillation: A meta-analysis of interventional trials.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Gastrointestinal Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Risk Factors; Rivaroxaban; Thiazoles; Warfarin | 2015 |
Clinical experience with novel oral anticoagulants for thromboprophylaxis after elective hip and knee arthroplasty.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Dabigatran; Drug Administration Schedule; Elective Surgical Procedures; Factor Xa Inhibitors; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Thiophenes; Thromboembolism; Treatment Outcome | 2015 |
Overview of the new oral anticoagulants: opportunities and challenges.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dabigatran; Dose-Response Relationship, Drug; Drug Administration Schedule; Factor Xa Inhibitors; Female; Humans; Male; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Sensitivity and Specificity; Stroke; Thiazoles; Thiophenes; Thromboembolism; Warfarin | 2015 |
Intravenous thrombolysis for stroke in patients taking non-VKA oral anticoagulants: an update.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cerebral Hemorrhage; Contraindications; Dabigatran; Drug Administration Schedule; Drug Interactions; Endovascular Procedures; Factor Xa Inhibitors; Female; Humans; Infusions, Intravenous; Kidney Function Tests; Male; Middle Aged; Practice Guidelines as Topic; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Thrombectomy; Thrombolytic Therapy; Tissue Plasminogen Activator | 2015 |
Periprocedural Management of New Oral Anticoagulants in Atrial Fibrillation Ablation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Cardiac Catheterization; Catheter Ablation; Dabigatran; Factor Xa Inhibitors; Humans; Meta-Analysis as Topic; Rivaroxaban; Thromboembolism; Treatment Outcome; Warfarin | 2015 |
Reversal of anticoagulants: an overview of current developments.
Topics: Administration, Oral; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticoagulants; Antithrombins; Benzamides; Clinical Trials as Topic; Dabigatran; Factor Xa; Factor Xa Inhibitors; Fondaparinux; Hemorrhage; Hemostatics; Heparin; Humans; Infusions, Parenteral; Intracranial Hemorrhages; Polysaccharides; Protamines; Pyrazoles; Pyridines; Pyridones; Recombinant Proteins; Rivaroxaban; Thiazoles; Thrombosis; Vitamin K | 2015 |
Using new oral anticoagulants in patients undergoing major orthopedic surgery.
Topics: Administration, Oral; Anticoagulants; Dabigatran; Humans; Orthopedic Procedures; Postoperative Care; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Venous Thromboembolism | 2015 |
Novel oral anticoagulants: efficacy, laboratory measurement, and approaches to emergent reversal.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Drug Monitoring; Factor Xa Inhibitors; Hemorrhage; Humans; Laboratories; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thromboembolism; Treatment Outcome; Warfarin | 2015 |
Management of anticoagulation in patients with acute gastrointestinal bleeding.
Topics: Acenocoumarol; Acute Disease; Algorithms; Anticoagulants; Coagulants; Dabigatran; Endoscopy, Gastrointestinal; Gastrointestinal Hemorrhage; Humans; Rivaroxaban; Vitamin K; Warfarin | 2015 |
Bleeding Risk, Management and Outcome in Patients Receiving Non-VKA Oral Anticoagulants (NOACs).
Topics: Antithrombins; Clinical Trials as Topic; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; Outcome Assessment, Health Care; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Thromboembolism; Vitamin K | 2015 |
Post-operative arterial thrombosis with non-vitamin K antagonist oral anticoagulants after total hip or knee arthroplasty.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Brain Ischemia; Clinical Trials, Phase III as Topic; Dabigatran; Enoxaparin; Factor Xa Inhibitors; Female; Humans; Incidence; Male; Middle Aged; Multicenter Studies as Topic; Myocardial Infarction; Postoperative Complications; Postoperative Hemorrhage; Prothrombin; Pulmonary Embolism; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Treatment Outcome | 2015 |
Antidotes to non-vitamin K oral anticoagulants: necessary or not?
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Venous Thromboembolism | 2015 |
Cost-Effectiveness of Novel Oral Anticoagulants for Stroke Prevention in Non-Valvular Atrial Fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Cost-Benefit Analysis; Dabigatran; Humans; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Treatment Outcome; Warfarin | 2015 |
Non-VKA Oral Anticoagulants: Accurate Measurement of Plasma Drug Concentrations.
Topics: Anticoagulants; Blood Coagulation; Dabigatran; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Thiophenes; Thromboembolism | 2015 |
Dosing of Target-Specific Oral Anticoagulants in Special Populations.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Clinical Trials as Topic; Dabigatran; Humans; Kidney Diseases; Liver Diseases; Obesity; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiazoles; Venous Thromboembolism | 2015 |
Oral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of deep vein thrombosis.
Topics: Administration, Oral; Antithrombins; Azetidines; Benzylamines; Dabigatran; Factor Xa Inhibitors; Humans; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiazoles; Venous Thrombosis | 2015 |
Comparative efficacy and safety of novel oral anticoagulants in patients with atrial fibrillation: A network meta-analysis with the adjustment for the possible bias from open label studies.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Azetidines; Benzylamines; Dabigatran; Hemorrhage; Humans; Myocardial Infarction; Odds Ratio; Oligosaccharides; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiazoles; Thromboembolism; Treatment Outcome; Vitamin K | 2015 |
[Direct acting oral anticoagulants in venous thromboembolism].
Topics: Administration, Oral; Aged; Anticoagulants; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Contraindications; Dabigatran; Drug Interactions; Humans; International Normalized Ratio; Male; Morpholines; Pulmonary Embolism; Pyrazoles; Pyridones; Recurrence; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2015 |
The Impact of Novel Anticoagulants: Should All AF Patients Now Be Anticoagulated?
Topics: Animals; Anticoagulants; Antithrombins; Atrial Fibrillation; Blood Coagulation; Dabigatran; Hemorrhage; Humans; Rivaroxaban; Thromboembolism; Treatment Outcome; Warfarin | 2015 |
Meta-analysis on efficacy and safety of new oral anticoagulants for venous thromboembolism prophylaxis in elderly elective postarthroplasty patients.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Dabigatran; Female; Heparin, Low-Molecular-Weight; Humans; Male; Odds Ratio; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Survival Analysis; Treatment Outcome; Venous Thromboembolism | 2015 |
[Prophylaxis of thromboembolism in atrial fibrillation: new oral anticoagulants and left atrial appendage closure].
Topics: Anticoagulants; Atrial Appendage; Atrial Fibrillation; Atrial Flutter; Benzimidazoles; beta-Alanine; Combined Modality Therapy; Contraindications; Dabigatran; Hemorrhage; Morpholines; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Thiophenes; Thromboembolism; Vitamin K | 2015 |
Problem-Based Review: Non Vitamin K Antagonist Oral Anticoagulants for the Acute Physician.
Topics: Anticoagulants; Dabigatran; Emergency Medicine; Humans; Pyrazoles; Pyridones; Rivaroxaban; Stroke; United Kingdom | 2015 |
Incorporating edoxaban into the choice of anticoagulants for atrial fibrillation.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Cardiovascular Diseases; Clinical Trials, Phase III as Topic; Dabigatran; Embolism; Factor Xa Inhibitors; Female; Humans; Intracranial Hemorrhages; Male; Pyrazoles; Pyridines; Pyridones; Research Design; Rivaroxaban; Stroke; Thiazoles; Warfarin | 2016 |
[Treatment of bleeding complications due to oral anticoagulant drugs].
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thromboembolism; Vitamin K | 2015 |
Laboratory measurement of the direct oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Blood Coagulation; Blood Coagulation Tests; Chromatography, High Pressure Liquid; Dabigatran; Drug Monitoring; Humans; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles | 2016 |
New oral anticoagulants for patients with nonvalvular atrial fibrillation.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Factor Xa Inhibitors; Gastrointestinal Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles | 2015 |
Treatment of pulmonary embolism.
Topics: Antithrombins; Clinical Trials as Topic; Dabigatran; Factor Xa Inhibitors; Humans; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Rivaroxaban; Thiazoles; Venous Thromboembolism | 2015 |
Target-specific Oral Anticoagulants in the Emergency Department.
Topics: Acute Disease; Administration, Oral; Anticoagulants; Blood Coagulation Tests; Dabigatran; Drug Interactions; Drug Monitoring; Emergency Service, Hospital; Factor Xa Inhibitors; Hemorrhage; Humans; Practice Guidelines as Topic; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Venous Thromboembolism | 2016 |
Oral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of pulmonary embolism.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Dabigatran; Factor Xa Inhibitors; Humans; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Recurrence; Rivaroxaban; Secondary Prevention; Thiazoles; Venous Thromboembolism; Venous Thrombosis | 2015 |
Monitoring and reversal of direct oral anticoagulants.
Topics: Administration, Oral; Antibodies, Monoclonal, Humanized; Anticoagulants; Arginine; Blood Coagulation Factors; Blood Coagulation Tests; Dabigatran; Factor VIIa; Factor Xa; Factor Xa Inhibitors; Hemorrhage; Hemostasis; Humans; Partial Thromboplastin Time; Piperazines; Prothrombin; Pyrazoles; Pyridines; Pyridones; Recombinant Proteins; Rivaroxaban; Thiazoles; Thrombin Time | 2015 |
The new oral anticoagulants: Reasonable alternatives to warfarin.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Venous Thrombosis | 2015 |
A guide to new anticoagulant medications for ENT surgeons.
Topics: Administration, Oral; Adult; Anticoagulants; Clinical Competence; Cross-Sectional Studies; Dabigatran; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Hemorrhage; Humans; Male; Middle Aged; Otolaryngology; Practice Guidelines as Topic; Practice Patterns, Physicians'; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Surveys and Questionnaires; United Kingdom | 2015 |
Relative efficacy and safety of non-Vitamin K oral anticoagulants for non-valvular atrial fibrillation: Network meta-analysis comparing apixaban, dabigatran, rivaroxaban and edoxaban in three patient subgroups.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Clinical Trials, Phase III as Topic; Dabigatran; Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiazoles; Vitamin K | 2016 |
Evolving strategies to prevent stroke and thromboembolism in nonvalvular atrial fibrillation.
Topics: Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Dabigatran; Equipment and Supplies; Hemorrhage; Humans; Ligation; Platelet Aggregation Inhibitors; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thromboembolism; Warfarin | 2015 |
Comparison of the Novel Oral Anticoagulants Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in the Initial and Long-Term Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis.
Topics: Administration, Oral; Anticoagulants; Dabigatran; Humans; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Time Factors; Treatment Outcome; Venous Thromboembolism | 2015 |
New Oral Anticoagulants in Prophylaxis of Venous Thromboembolic Disease in Major Orthopedic Surgery.
Topics: Administration, Oral; Anticoagulants; Dabigatran; Enoxaparin; Fondaparinux; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Orthopedic Procedures; Polysaccharides; Rivaroxaban; Venous Thromboembolism | 2016 |
Non-vitamin K Oral Anticoagulants Versus Warfarin for Patients with Atrial Fibrillation: Absolute Benefit and Harm Assessments Yield Novel Insights.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Humans; Male; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiazoles; Warfarin | 2016 |
[Novel oral anticoagulants--issues in clinical practice].
Topics: Administration, Oral; Anticoagulants; Dabigatran; Humans; Perioperative Care; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thrombosis | 2015 |
An evidence summary of the management of patients taking direct oral anticoagulants (DOACs) undergoing dental surgery.
Topics: Administration, Oral; Antithrombins; Dabigatran; Factor Xa Inhibitors; Humans; Oral Surgical Procedures; Pyrazoles; Pyridones; Rivaroxaban | 2016 |
The laboratory's 2015 perspective on direct oral anticoagulant testing.
Topics: Administration, Oral; Algorithms; Anticoagulants; Antithrombins; Blood Coagulation; Blood Coagulation Tests; Calibration; Chemistry, Clinical; Dabigatran; Dose-Response Relationship, Drug; Humans; Partial Thromboplastin Time; Prothrombin Time; Pyrazoles; Pyridones; Rivaroxaban | 2016 |
Meta-Analysis of Efficacy and Safety of New Oral Anticoagulants Compared With Uninterrupted Vitamin K Antagonists in Patients Undergoing Catheter Ablation for Atrial Fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Catheter Ablation; Dabigatran; Factor Xa Inhibitors; Humans; Ischemic Attack, Transient; Observational Studies as Topic; Prothrombin; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Time Factors; Treatment Outcome; Vitamin K; Warfarin | 2016 |
Suboptimal Use of Oral Anticoagulants in Atrial Fibrillation: Has the Introduction of Direct Oral Anticoagulants Improved Prescribing Practices?
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Blood Coagulation Factors; Dabigatran; Dose-Response Relationship, Drug; Evidence-Based Medicine; Factor Xa Inhibitors; Humans; Medication Errors; Practice Guidelines as Topic; Practice Patterns, Physicians'; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Risk Factors; Rivaroxaban; Stroke; Thiazoles; Warfarin | 2016 |
[The latest recommendations on the use of new oral anticoagulants in routine practice].
Topics: Administration, Oral; Anticoagulants; Dabigatran; Humans; Practice Patterns, Physicians'; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles | 2016 |
The association between non-vitamin K antagonist oral anticoagulants and gastrointestinal bleeding: a meta-analysis of observational studies.
Topics: Administration, Oral; Anticoagulants; Dabigatran; Dose-Response Relationship, Drug; Gastrointestinal Hemorrhage; Histamine H2 Antagonists; Humans; Proton Pump Inhibitors; Rivaroxaban; Warfarin | 2016 |
Management of Venous Thromboembolism: Recent Advances in Oral Anticoagulation Therapy.
Topics: Administration, Oral; Anticoagulants; Dabigatran; Drug Interactions; Humans; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiazoles; Treatment Outcome; Venous Thromboembolism; Venous Thrombosis | 2016 |
Cost-effectiveness of Apixaban Versus Other Oral Anticoagulants for the Initial Treatment of Venous Thromboembolism and Prevention of Recurrence.
Topics: Anticoagulants; Cost-Benefit Analysis; Dabigatran; Female; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Male; Middle Aged; Pyrazoles; Pyridones; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Recurrence; Rivaroxaban; Secondary Prevention; United Kingdom; Venous Thromboembolism | 2016 |
Challenges and Treatment for Stroke Prophylaxis in Patients with Atrial Fibrillation in Mexico: A Review.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Drug Administration Schedule; Drugs, Investigational; Evidence-Based Medicine; Humans; Mexico; Practice Guidelines as Topic; Precision Medicine; Pyrazoles; Pyridines; Pyridones; Risk Factors; Rivaroxaban; Stroke; Thiazoles; Vitamin K | 2016 |
Management of direct oral anticoagulants-associated bleeding in the trauma patient.
Topics: Administration, Oral; Antifibrinolytic Agents; Antithrombins; Atrial Fibrillation; Clinical Protocols; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; Plasma; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; United States; Wounds and Injuries | 2016 |
Meta-analysis and adjusted indirect comparison of direct oral anticoagulants in prevention of acute limb ischemia in patients with atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; Humans; Ischemia; Leg; Odds Ratio; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Warfarin | 2016 |
Oral anticoagulants in coronary heart disease (Section IV). Position paper of the ESC Working Group on Thrombosis - Task Force on Anticoagulants in Heart Disease.
Topics: Administration, Oral; Animals; Anticoagulants; Clinical Trials as Topic; Coronary Artery Disease; Dabigatran; Drug Interactions; Humans; Platelet Aggregation Inhibitors; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles | 2016 |
Direct oral anticoagulants: a guide for daily practice.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Factor Xa Inhibitors; Humans; Practice Guidelines as Topic; Pyrazoles; Pyridines; Pyridones; Recurrence; Rivaroxaban; Stroke; Thiazoles; Venous Thromboembolism | 2016 |
[Treatment with inhibitors of new oral direct anticoagulants in patients with severe bleedings or urgent surgical procedures. The new dabigatran antidote: the place of idarucizumab in clinical practice].
Topics: Acute Disease; Administration, Oral; Ambulatory Care; Antibodies, Monoclonal, Humanized; Anticoagulants; Antidotes; Antithrombins; Dabigatran; Factor Xa; Factor Xa Inhibitors; Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Recombinant Proteins; Rivaroxaban; Severity of Illness Index; Surgical Procedures, Operative; Thiazoles | 2016 |
Why switch from warfarin to NOACs?
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Evidence-Based Medicine; Female; Humans; Intracranial Hemorrhages; Male; Randomized Controlled Trials as Topic; Risk Assessment; Rivaroxaban; Severity of Illness Index; Survival Rate; Treatment Outcome; Vitamin K; Warfarin | 2016 |
Network meta-analysis of efficacy and safety of competitive oral anticoagulants in patients undergoing radiofrequency catheter ablation of atrial fibrillation.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Catheter Ablation; Causality; Comorbidity; Dabigatran; Female; Humans; Incidence; Male; Middle Aged; Postoperative Complications; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Thromboembolism; Treatment Outcome; Vitamin K | 2016 |
Novel oral anticoagulants in plastic surgery.
Topics: Administration, Oral; Algorithms; Anticoagulants; Dabigatran; Elective Surgical Procedures; Emergencies; Humans; Kidney; Liver; Perioperative Care; Plastic Surgery Procedures; Postoperative Hemorrhage; Practice Guidelines as Topic; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles | 2016 |
Considerations for Prescribing Target-Specific Oral Anticoagulants in the Setting of Renal Dysfunction or Drug Interactions.
Topics: Administration, Oral; Anticoagulants; Dabigatran; Drug Interactions; Humans; Outpatients; Pyrazoles; Pyridines; Pyridones; Renal Insufficiency, Chronic; Rivaroxaban; Thiazoles; Venous Thromboembolism | 2016 |
Sex related differences in patients with acute venous thromboembolism treated with new oral anticoagulants. A meta-analysis of the interventional trials.
Topics: Administration, Oral; Anticoagulants; Dabigatran; Double-Blind Method; Female; Hemorrhage; Humans; Male; Middle Aged; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Sex Characteristics; Thiazoles; Treatment Outcome; Venous Thromboembolism | 2016 |
Treatment of Venous Thromboembolism With New Anticoagulant Agents.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Clinical Trials, Phase III as Topic; Dabigatran; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Heparin, Low-Molecular-Weight; Humans; Infusions, Intravenous; Male; Middle Aged; Phlebography; Prognosis; Pulmonary Embolism; Pyridines; Randomized Controlled Trials as Topic; Rivaroxaban; Severity of Illness Index; Survival Analysis; Thiazoles; Treatment Outcome; Venous Thromboembolism | 2016 |
Bleeding management in patients with new oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Clinical Trials, Phase III as Topic; Dabigatran; Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles | 2016 |
A Practical Guide to Ordering and Interpreting Coagulation Tests for Patients on Direct Oral Anticoagulants in Singapore.
Topics: Antithrombins; Blood Coagulation Tests; Dabigatran; Factor Xa Inhibitors; Humans; Partial Thromboplastin Time; Practice Guidelines as Topic; Prothrombin Time; Pyrazoles; Pyridones; Rivaroxaban; Singapore | 2016 |
[The use of new oral anticoagulants in surgery. Part 1].
Topics: Anticoagulants; Dabigatran; Humans; Postoperative Complications; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Surgical Procedures, Operative | 2016 |
New anticoagulants for the treatment of venous thromboembolism.
Topics: Anticoagulants; Dabigatran; Humans; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Time Factors; Venous Thromboembolism; Warfarin | 2016 |
Minimizing the Risk of Bleeding with NOACs in the Elderly.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Meta-Analysis as Topic; Precision Medicine; Pyrazoles; Pyridones; Risk; Rivaroxaban; Stroke; Warfarin | 2016 |
[THE IMPORTANCE OF ANTICOAGULANT THERAPY IN PATIENTS WITH ARTIAL FIBRILLATION IN STROKE PREVENTION--SUMMARY OF INTERNATIONAL DATA AND NOVEL THERAPEUTIC MODALITIES].
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Prevalence; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles | 2016 |
Comparative Effectiveness of Interventions for Stroke Prevention in Atrial Fibrillation: A Network Meta-Analysis.
Topics: Anticoagulants; Atrial Appendage; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Intracranial Hemorrhages; Network Meta-Analysis; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Warfarin | 2016 |
[Coagulation disorders in the intensive care unit - what is new?].
Topics: Anticoagulants; Dabigatran; Hemophilia A; Hemorrhage; Heparin; Humans; Intensive Care Units; Rivaroxaban; Thrombocytopenia; Thrombosis; Warfarin | 2016 |
Drug Treatment of Venous Thromboembolism in the Elderly.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Clinical Trials as Topic; Dabigatran; Drug Interactions; Factor Xa Inhibitors; Hemorrhage; Humans; Practice Guidelines as Topic; Pyrazoles; Pyridones; Rivaroxaban; Venous Thromboembolism; Warfarin | 2016 |
Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants After Cardioversion for Nonvalvular Atrial Fibrillation.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Electric Countershock; Hemorrhage; Humans; Odds Ratio; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thromboembolism; Treatment Outcome; Warfarin | 2016 |
NOAC monitoring, reversal agents, and post-approval safety and effectiveness evaluation: A cardiac safety research consortium think tank.
Topics: Antibodies, Monoclonal, Humanized; Antidotes; Antithrombins; Arginine; Atrial Fibrillation; Congresses as Topic; Dabigatran; Drug Monitoring; Factor Xa; Factor Xa Inhibitors; Humans; Partial Thromboplastin Time; Piperazines; Product Surveillance, Postmarketing; Pyrazoles; Pyridines; Pyridones; Recombinant Proteins; Rivaroxaban; Stroke; Thiazoles; Thrombin Time; Venous Thromboembolism | 2016 |
Nonvitamin K Anticoagulant Agents in Patients With Advanced Chronic Kidney Disease or on Dialysis With AF.
Topics: Anticoagulants; Atrial Fibrillation; Creatinine; Dabigatran; Glomerular Filtration Rate; Hemorrhage; Humans; Kidney; Kidney Failure, Chronic; Pyrazoles; Pyridines; Pyridones; Renal Dialysis; Renal Insufficiency, Chronic; Rivaroxaban; Stroke; Thiazoles; Warfarin | 2016 |
[Anticoagulation for patients with non-valvular atrial fibrillation].
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Factor Xa Inhibitors; Humans; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thrombolytic Therapy; Warfarin | 2016 |
[Cerebral infarction and transient ischemic attack].
Topics: Acute-Phase Reaction; Anticoagulants; Cerebral Infarction; Dabigatran; Endovascular Procedures; Factor Xa Inhibitors; Humans; Ischemic Attack, Transient; Japan; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Recombinant Proteins; Recurrence; Rivaroxaban; Tissue Plasminogen Activator; Warfarin | 2016 |
Management of Bleeding With Non-Vitamin K Antagonist Oral Anticoagulants in the Era of Specific Reversal Agents.
Topics: Administration, Oral; Antibodies, Monoclonal, Humanized; Antithrombins; Arginine; Blood Coagulation Factors; Dabigatran; Factor VIIa; Factor Xa; Factor Xa Inhibitors; Hemorrhage; Hemostatics; Humans; Piperazines; Plasma; Pyrazoles; Pyridines; Pyridones; Recombinant Proteins; Rivaroxaban; Thiazoles | 2016 |
Comparison of the Non-VKA Oral Anticoagulants Apixaban, Dabigatran, and Rivaroxaban in the Extended Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis.
Topics: Administration, Oral; Anticoagulants; Clinical Trials, Phase III as Topic; Dabigatran; Humans; Long-Term Care; Network Meta-Analysis; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Treatment Outcome; Venous Thromboembolism | 2016 |
Re-Initiation of Dabigatran and Direct Factor Xa Antagonists After a Major Bleed.
Topics: Antithrombins; Atrial Fibrillation; Dabigatran; Factor Xa Inhibitors; Gastrointestinal Hemorrhage; Hemorrhage; Humans; Intracranial Hemorrhages; Pyrazoles; Pyridones; Recurrence; Risk Assessment; Rivaroxaban; Stroke; Thromboembolism | 2016 |
Safety of Direct Oral Anticoagulants: Insights from Postmarketing Studies.
Topics: Administration, Oral; Antithrombins; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Product Surveillance, Postmarketing; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thromboembolism | 2016 |
Idarucizumab and Factor Xa Reversal Agents: Role in Hospital Guidelines and Protocols.
Topics: Antibodies, Monoclonal, Humanized; Antidotes; Antithrombins; Arginine; Blood Coagulation Factors; Clinical Protocols; Dabigatran; Factor Xa; Factor Xa Inhibitors; Hemorrhage; Hospitals; Humans; Piperazines; Practice Guidelines as Topic; Pyrazoles; Pyridones; Recombinant Proteins; Rivaroxaban | 2016 |
Discontinuation and Management of Direct-Acting Anticoagulants for Emergency Procedures.
Topics: Antibodies, Monoclonal, Humanized; Anticoagulants; Antidotes; Antithrombins; Arginine; Dabigatran; Deprescriptions; Emergencies; Factor Xa; Factor Xa Inhibitors; Hemorrhage; Heparin; Heparin, Low-Molecular-Weight; Humans; International Normalized Ratio; Piperazines; Prothrombin Time; Pyrazoles; Pyridones; Recombinant Proteins; Rivaroxaban; Surgical Procedures, Operative | 2016 |
Bleeding with Direct Oral Anticoagulants vs Warfarin: Clinical Experience.
Topics: Administration, Oral; Anticoagulants; Antidotes; Atrial Fibrillation; Clinical Trials, Phase III as Topic; Dabigatran; Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Warfarin | 2016 |
A systematic review of anti-thrombotic therapy in epistaxis.
Topics: Anticoagulants; Antifibrinolytic Agents; Aspirin; Clopidogrel; Dabigatran; Disease Management; Epistaxis; Humans; Platelet Aggregation Inhibitors; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Ticlopidine; Tranexamic Acid; Warfarin | 2016 |
Optimizing the safety of treatment for venous thromboembolism in the era of direct oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Blood Coagulation; Clinical Trials, Phase III as Topic; Coagulants; Dabigatran; Humans; Patient Safety; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Venous Thromboembolism | 2016 |
Do novel anticoagulant agents increase the risk of perioperative complications during implantable cardiac rhythm device insertion?
Topics: Aged, 80 and over; Anticoagulants; Cardiac Surgical Procedures; Dabigatran; Defibrillators, Implantable; Humans; Intraoperative Complications; Male; Pacemaker, Artificial; Postoperative Complications; Rivaroxaban; Thromboembolism; Warfarin | 2017 |
Efficacy and Safety of Novel Oral Anticoagulants in Patients With Atrial Fibrillation and Heart Failure: A Meta-Analysis.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Cardiovascular Diseases; Cause of Death; Dabigatran; Embolism; Factor Xa Inhibitors; Heart Failure; Hemorrhage; Humans; Intracranial Hemorrhages; Mortality; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Treatment Outcome; Warfarin | 2016 |
The Role of New Oral Anticoagulants (NOACs) in Cancer Patients.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Catheters, Indwelling; Dabigatran; Drug Administration Schedule; Drug Dosage Calculations; Humans; Neoplasms; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiazoles; Venous Thromboembolism; Venous Thrombosis | 2017 |
Warfarin and Newer Agents: What the Oral Surgeon Needs to Know.
Topics: Administration, Oral; Anticoagulants; Antidotes; Antithrombins; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Hemostasis, Surgical; Humans; Oral Surgical Procedures; Pyrazoles; Pyridones; Rivaroxaban; Warfarin | 2016 |
Measurement and reversal of the direct oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Blood Coagulation; Blood Coagulation Tests; Dabigatran; Factor Xa Inhibitors; Humans; International Normalized Ratio; Rivaroxaban | 2017 |
Idarucizumab and factor Xa reversal agents: role in hospital guidelines and protocols.
Topics: Antibodies, Monoclonal, Humanized; Anticoagulants; Arginine; Clinical Protocols; Dabigatran; Emergency Treatment; Factor Xa; Factor Xa Inhibitors; Hemorrhage; Hospitals; Humans; Patient Selection; Piperazines; Practice Guidelines as Topic; Pyrazoles; Pyridines; Pyridones; Recombinant Proteins; Rivaroxaban; Surgical Procedures, Operative; Thiazoles | 2016 |
Bleeding with direct oral anticoagulants vs warfarin: clinical experience.
Topics: Anticoagulants; Clinical Trials, Phase III as Topic; Dabigatran; Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Warfarin | 2016 |
Safety of direct oral anticoagulants: insights from postmarketing studies.
Topics: Anticoagulants; Dabigatran; Hemorrhage; Humans; Product Surveillance, Postmarketing; Pyrazoles; Pyridones; Rivaroxaban | 2016 |
Best Clinical Practice: Current Controversies in Pulmonary Embolism Imaging and Treatment of Subsegmental Thromboembolic Disease.
Topics: Anticoagulants; Dabigatran; Decision Making; Humans; Patient Outcome Assessment; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Risk Factors; Rivaroxaban; Thiazoles; Tomography, X-Ray Computed; Venous Thromboembolism | 2017 |
Use of direct oral anticoagulants in patients with nonvalvular atrial fibrillation according to clinical profile.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Clinical Trials, Phase III as Topic; Dabigatran; Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiazoles | 2017 |
Use of Oral Anticoagulation in the Management of Atrial Fibrillation in Patients with ESRD: Con.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Kidney Failure, Chronic; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Warfarin | 2016 |
Safety and Efficacy of New Anticoagulants for the Prevention of Venous Thromboembolism After Hip and Knee Arthroplasty: A Meta-Analysis.
Topics: Anticoagulants; Arthroplasty, Replacement, Knee; Dabigatran; Enoxaparin; Fondaparinux; Hemorrhage; Humans; Morpholines; Polysaccharides; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2017 |
Role of agents for reversing the effects of target-specific oral anticoagulants.
Topics: Administration, Oral; Antithrombins; Dabigatran; Drug Evaluation; Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; United States; United States Food and Drug Administration | 2017 |
Reversal of direct oral anticoagulants: a practical approach.
Topics: Administration, Oral; Antibodies, Monoclonal, Humanized; Anticoagulants; Antidotes; Dabigatran; Factor Xa; Hemorrhage; Humans; Partial Thromboplastin Time; Prothrombin Time; Recombinant Proteins; Rivaroxaban | 2016 |
Detection of lupus anticoagulant in the era of direct oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Antiphospholipid Syndrome; Dabigatran; Humans; Lupus Coagulation Inhibitor; Rivaroxaban | 2017 |
Comparative Efficacy of Clinical Events Prevention of Five Anticoagulants in Patients With Atrial Fibrillation (A Network Meta-Analysis).
Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Mortality; Myocardial Infarction; Network Meta-Analysis; Odds Ratio; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Warfarin | 2017 |
Effect of major gastrointestinal tract surgery on the absorption and efficacy of direct acting oral anticoagulants (DOACs).
Topics: Administration, Oral; Anticoagulants; Contraindications; Dabigatran; Digestive System Surgical Procedures; Gastrointestinal Tract; Humans; Rivaroxaban; Treatment Outcome | 2017 |
Bleeding outcomes associated with rivaroxaban and dabigatran in patients treated for atrial fibrillation: a systematic review and meta-analysis.
Topics: Antithrombins; Atrial Fibrillation; Dabigatran; Factor Xa Inhibitors; Global Health; Hemorrhage; Humans; Incidence; Rivaroxaban; Secondary Prevention; Stroke | 2017 |
[Management of NOAK administration during invasive or surgical interventions : When and how to pause and when to restart?]
Topics: Administration, Oral; Antibodies, Monoclonal, Humanized; Anticoagulants; Blood Loss, Surgical; Dabigatran; Drug Interactions; Half-Life; Humans; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Surgical Procedures, Operative; Thiazoles; Thromboembolism; Vitamin K | 2017 |
[NOAC: Real-life data and the role of antidotes for the treatment of bleeding].
Topics: Aged; Antibodies, Monoclonal, Humanized; Anticoagulants; Antidotes; Dabigatran; Factor Xa; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Pyrazoles; Pyridones; Recombinant Proteins; Rivaroxaban; Stroke; Thromboembolism; Vitamin K; Warfarin | 2017 |
Clinical implications of reversal agents for direct oral anticoagulants.
Topics: Antibodies, Monoclonal, Humanized; Anticoagulants; Antithrombins; Arginine; Dabigatran; Factor Xa; Factor Xa Inhibitors; Hemorrhage; Humans; Piperazines; Pyrazoles; Pyridines; Pyridones; Recombinant Proteins; Rivaroxaban; Thiazoles; Venous Thromboembolism | 2017 |
Reversal of Direct Oral Anticoagulants: Current Status and Future Directions.
Topics: Administration, Oral; Antibodies, Monoclonal, Humanized; Anticoagulants; Atrial Fibrillation; Clinical Trials, Phase III as Topic; Dabigatran; Factor Xa; Forecasting; Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Recombinant Proteins; Rivaroxaban; Stroke; Thiazoles; Venous Thromboembolism | 2017 |
Rivaroxaban Versus Dabigatran or Warfarin in Real-World Studies of Stroke Prevention in Atrial Fibrillation: Systematic Review and Meta-Analysis.
Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Intracranial Embolism; Intracranial Thrombosis; Rivaroxaban; Stroke; Warfarin | 2017 |
Anticoagulation Therapy and NOACs in Heart Failure.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Clinical Trials as Topic; Dabigatran; Factor Xa Inhibitors; Heart Failure; Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Venous Thromboembolism; Warfarin | 2017 |
The role of new oral anticoagulants in orthopaedics: an update of recent evidence.
Topics: Administration, Oral; Antibodies, Monoclonal, Humanized; Anticoagulants; Arginine; Blood Coagulation Tests; Dabigatran; Factor Xa; Hemorrhage; Humans; Orthopedic Procedures; Piperazines; Practice Guidelines as Topic; Pyrazoles; Pyridines; Pyridones; Recombinant Proteins; Rivaroxaban; Thiazoles; Venous Thromboembolism | 2017 |
Laboratory Monitoring of Non-Vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation: A Review.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Chromatography, High Pressure Liquid; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; Intracranial Hemorrhages; Partial Thromboplastin Time; Prothrombin Time; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Tandem Mass Spectrometry; Thiazoles; Thrombin Time; Warfarin | 2017 |
[New oral anticoagulants in patients with atrial fibrillation: efficacy and safety data from the real world].
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Pyrazoles; Pyridines; Pyridones; Registries; Rivaroxaban; Thiazoles; Thromboembolism; Treatment Outcome | 2017 |
Novel oral anticoagulants and exodontia: the evidence.
Topics: Administration, Oral; Anticoagulants; Dabigatran; Humans; Oral Surgical Procedures; Postoperative Hemorrhage; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban | 2017 |
Risk of Gastrointestinal Bleeding in Patients Taking Non-Vitamin K Antagonist Oral Anticoagulants: A Systematic Review and Meta-analysis.
Topics: Anticoagulants; Dabigatran; Gastrointestinal Hemorrhage; Humans; Risk Assessment; Rivaroxaban; Stroke; Thromboembolism | 2017 |
Nonvitamin K-dependent oral anticoagulants (NOACs) in chronic kidney disease patients with atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Prospective Studies; Pyrazoles; Pyridines; Pyridones; Renal Insufficiency, Chronic; Rivaroxaban; Stroke; Thiazoles; Thromboembolism; Warfarin | 2017 |
Renal Function Considerations for Stroke Prevention in Atrial Fibrillation.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Embolism; Factor Xa Inhibitors; Hemorrhage; Humans; Pharmaceutical Research; Pyrazoles; Pyridines; Pyridones; Renal Insufficiency; Risk Assessment; Rivaroxaban; Stroke; Therapeutic Equivalency; Thiazoles; Warfarin | 2017 |
Direct oral anticoagulants for the treatment of cancer-associated venous thromboembolism. What do we know so far?
Topics: Acute Disease; Administration, Oral; Anticoagulants; Clinical Trials, Phase III as Topic; Dabigatran; Guideline Adherence; Heparin, Low-Molecular-Weight; Humans; Long-Term Care; Neoplasms; Pyrazoles; Pyridines; Pyridones; Risk Factors; Rivaroxaban; Secondary Prevention; Thiazoles; Venous Thromboembolism | 2017 |
Low-Molecular-Weight Heparin and the Relative Risk of Surgical Site Bleeding Complications: Results of a Systematic Review and Meta-Analysis of Randomized Controlled Trials of Venous Thromboprophylaxis in Patients After Total Joint Arthroplasty.
Topics: Anticoagulants; Arthroplasty; Arthroplasty, Replacement, Knee; Aspirin; Dabigatran; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Incidence; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Risk; Rivaroxaban; Treatment Outcome; Venous Thromboembolism; Warfarin | 2017 |
Novel (Oral) Anticoagulant Challenges in Surgery.
Topics: Administration, Oral; Anticoagulants; Dabigatran; Humans; Perioperative Period; Postoperative Complications; Pyrazoles; Pyridones; Rivaroxaban; Thromboembolism | 2017 |
Direct oral anticoagulants in patients undergoing cardioversion: insight from randomized clinical trials.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Electric Countershock; Factor Xa Inhibitors; Hemorrhage; Humans; Incidence; Prospective Studies; Rivaroxaban; Stroke; Thromboembolism; Warfarin | 2017 |
Management of Oral Anticoagulation Therapy After Gastrointestinal Bleeding: Whether to, When to, and How to Restart an Anticoagulation Therapy.
Topics: Anticoagulants; Dabigatran; Gastrointestinal Hemorrhage; Humans; Pyrazoles; Pyridones; Rivaroxaban; Thromboembolism; Warfarin | 2017 |
Risk of major bleeding in patients with non-valvular atrial fibrillation treated with oral anticoagulants: a systematic review of real-world observational studies.
Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Risk; Rivaroxaban; Thiazoles; Warfarin | 2017 |
[State of the art: Direct oral anticoagulants and transfusion].
Topics: Administration, Oral; Antibodies, Monoclonal, Humanized; Antidotes; Antithrombins; Arginine; Blood Coagulation Factors; Blood Transfusion; Dabigatran; Factor Xa; Factor Xa Inhibitors; Hemorrhage; Hemostatics; Humans; Piperazines; Pyrazoles; Pyridones; Recombinant Proteins; Rivaroxaban; Stroke; Thrombophilia | 2017 |
Risk of Intraocular Bleeding With Novel Oral Anticoagulants Compared With Warfarin: A Systematic Review and Meta-analysis.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Eye Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Risk Assessment; Rivaroxaban; Thiazoles; Venous Thromboembolism; Warfarin | 2017 |
Real-World Setting Comparison of Nonvitamin-K Antagonist Oral Anticoagulants Versus Vitamin-K Antagonists for Stroke Prevention in Atrial Fibrillation: A Systematic Review and Meta-Analysis.
Topics: Anticoagulants; Atrial Fibrillation; Brain Ischemia; Dabigatran; Gastrointestinal Hemorrhage; Hemorrhage; Humans; Myocardial Infarction; Proportional Hazards Models; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Warfarin | 2017 |
Comparative effectiveness of rivaroxaban in the treatment of nonvalvular atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Drug Administration Schedule; Epidemiologic Methods; Factor Xa Inhibitors; Female; Humans; Male; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Treatment Outcome; Warfarin | 2017 |
Use of direct oral anticoagulants for stroke prevention in elderly patients with nonvalvular atrial fibrillation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Warfarin | 2017 |
Chronic kidney disease and anticoagulation: from vitamin K antagonists and heparins to direct oral anticoagulant agents.
Topics: Administration, Oral; Anticoagulants; Dabigatran; Hemorrhage; Heparin; Humans; Pyrazoles; Pyridones; Renal Insufficiency, Chronic; Rivaroxaban; Thrombosis; Vitamin K | 2017 |
Reversal agents for oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Clinical Trials, Phase III as Topic; Dabigatran; Humans; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Warfarin | 2017 |
Effects of different anticoagulant drugs on the prevention of complications in patients after arthroplasty: A network meta-analysis.
Topics: Anticoagulants; Arthroplasty; Azetidines; Benzylamines; Dabigatran; Enoxaparin; Heparin; Heparin, Low-Molecular-Weight; Humans; Network Meta-Analysis; Postoperative Complications; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Treatment Outcome; Venous Thromboembolism; Warfarin | 2017 |
Direct Oral Anticoagulants in Cardioversion: A Review of Current Evidence.
Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Electric Countershock; Humans; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles | 2018 |
Outcome of intracerebral haemorrhage related to non-vitamin K antagonists oral anticoagulants versus vitamin K antagonists: a comprehensive systematic review and meta-analysis.
Topics: Anticoagulants; Antithrombins; Cerebral Hemorrhage; Dabigatran; Factor Xa Inhibitors; Hematoma; Humans; Mortality; Odds Ratio; Phenprocoumon; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Severity of Illness Index; Thiazoles; Vitamin K; Warfarin | 2018 |
Management of Elective Surgery and Emergent Bleeding with Direct Oral Anticoagulants.
Topics: Administration, Oral; Antibodies, Monoclonal, Humanized; Anticoagulants; Antidotes; Antithrombins; Benzamides; Blood Loss, Surgical; Dabigatran; Deprescriptions; Elective Surgical Procedures; Factor Xa; Factor Xa Inhibitors; Hemorrhage; Humans; Practice Guidelines as Topic; Pyrazoles; Pyridines; Pyridones; Recombinant Proteins; Rivaroxaban; Thiazoles | 2017 |
Direct oral anticoagulants versus warfarin for preventing stroke and systemic embolic events among atrial fibrillation patients with chronic kidney disease.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Embolism; Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Rivaroxaban; Stroke; Thiazoles; Warfarin | 2017 |
An update on the bleeding risks associated with DOACs.
Topics: Administration, Oral; Anticoagulants; Dabigatran; Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Risk Factors; Rivaroxaban; Thiazoles | 2017 |
Management of Anticoagulation in Patients With Prostate Cancer Receiving Enzalutamide.
Topics: Androgen Receptor Antagonists; Anticoagulants; Atrial Fibrillation; Benzamides; Dabigatran; Drug Interactions; Embolism; Heart Valve Prosthesis; Heparin, Low-Molecular-Weight; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Venous Thromboembolism; Warfarin | 2017 |
Incidence of Visible Hematuria Among Antithrombotic Agents: A Systematic Review of Over 175,000 Patients.
Topics: Age Factors; Anticoagulants; Dabigatran; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Hematuria; Humans; Incidence; Male; Patient Safety; Prognosis; Risk Assessment; Rivaroxaban; Sex Factors; Warfarin | 2018 |
Meta-Analysis of the Safety and Efficacy of the Oral Anticoagulant Agents (Apixaban, Rivaroxaban, Dabigatran) in Patients With Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Administration, Oral; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; Pyrazoles; Pyridones; Rivaroxaban | 2018 |
[Clinico-Pharmacological and Clinical Basis of Multiplicity of Intake of Novel Oral Anticoagulants].
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Rivaroxaban; Stroke | 2017 |
Direct oral anticoagulants: An update.
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Clinical Trials as Topic; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; Postoperative Complications; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Secondary Prevention; Stroke; Thiazoles; Venous Thromboembolism; Withholding Treatment | 2018 |
The role of direct oral anticoagulants in the management of venous thromboembolism.
Topics: Administration, Oral; Anticoagulants; Benzamides; Dabigatran; Female; Humans; Incidence; Male; Prognosis; Pyridines; Risk Assessment; Rivaroxaban; Severity of Illness Index; Survival Rate; Treatment Outcome; Venous Thromboembolism; Warfarin | 2017 |
Advances in anticoagulation therapy.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Humans; Male; Middle Aged; Pyrazoles; Pyridines; Pyridones; Risk Factors; Rivaroxaban; Stroke; Thiazoles; Thrombosis | 2018 |
[Antidote treatment during use of direct anticoagulants].
Topics: Aged; Antibodies, Monoclonal, Humanized; Anticoagulants; Antidotes; Dabigatran; Female; Hemorrhage; Humans; Male; Pyrazoles; Pyridines; Pyridones; Risk; Rivaroxaban; Thiazoles | 2018 |
Review: An overview and analysis of novel oral anticoagulants and their dental implications.
Topics: Administration, Oral; Anticoagulants; Dabigatran; Dental Care; Humans; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles | 2018 |
A systematic review of direct oral anticoagulant use in chronic kidney disease and dialysis patients with atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Dabigatran; Embolism; Glomerular Filtration Rate; Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Renal Dialysis; Renal Insufficiency, Chronic; Risk Factors; Rivaroxaban; Stroke; Thiazoles; Treatment Outcome; Warfarin | 2019 |
How I manage patients with anticoagulation-associated bleeding or urgent surgery.
Topics: Administration, Oral; Anticoagulants; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; Rivaroxaban | 2018 |
Non-vitamin K antagonist oral anticoagulants for pulmonary embolism: who, where and for how long?
Topics: Administration, Oral; Anticoagulants; Dabigatran; Humans; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Secondary Prevention; Thiazoles; Venous Thromboembolism | 2018 |
Novel oral anticoagulants in chronic kidney disease: ready for prime time?
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Pyrazoles; Pyridones; Renal Insufficiency, Chronic; Risk Factors; Rivaroxaban; Stroke; Venous Thromboembolism | 2018 |
Update on Direct Oral AntiCoagulants (DOACs).
Topics: Administration, Oral; Anticoagulants; Dabigatran; Drug Interactions; Drug Substitution; Heparin, Low-Molecular-Weight; Humans; Kidney Function Tests; Liver Function Tests; Metabolic Clearance Rate; Perioperative Care; Pyrazoles; Pyridines; Pyridones; Risk Factors; Rivaroxaban; Thiazoles; Venous Thromboembolism | 2017 |
Direct Oral Anticoagulants Versus Vitamin K Antagonists in Real-life Patients With Atrial Fibrillation. A Systematic Review and Meta-analysis.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Brain Ischemia; Case-Control Studies; Dabigatran; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Middle Aged; Observational Studies as Topic; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Stroke; Treatment Outcome; Vitamin K; Warfarin | 2019 |
A meta-summary of case reports of non-vitamin K antagonist oral anticoagulant use in patients with left ventricular thrombus.
Topics: Administration, Oral; Anticoagulants; Dabigatran; Hemorrhage; Humans; Myocardial Infarction; Pyrazoles; Pyridones; Rivaroxaban; Thrombosis; Ventricular Dysfunction, Left | 2018 |
[Peri-Interventional Management of Direct Oral Anticoagulants - Balancing Benefits and Risks].
Topics: Administration, Oral; Aged; Antibodies, Monoclonal, Humanized; Anticoagulants; Atrial Fibrillation; Blood Coagulation Factors; Blood Coagulation Tests; Colonoscopy; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; Male; Premedication; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Rivaroxaban; Thiazoles; Thromboembolism | 2018 |
A review of the use of direct oral anticoagulant use in orthotopic heart transplantation recipients.
Topics: Administration, Oral; Anticoagulants; Dabigatran; Heart Transplantation; Humans; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Warfarin | 2018 |
A systematic review and Bayesian network meta-analysis of risk of intracranial hemorrhage with direct oral anticoagulants.
Topics: Administration, Oral; Antithrombins; Bayes Theorem; Dabigatran; Factor Xa Inhibitors; Humans; Intracranial Hemorrhages; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Risk Factors; Rivaroxaban; Thiazoles; Treatment Outcome | 2018 |
Non-Vitamin K-Dependent Oral Anticoagulants for Nonvalvular Atrial Fibrillation in Patients With CKD: Pragmatic Considerations for the Clinician.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Cyclophosphamide; Dabigatran; Diabetes Mellitus; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Hypertension; Male; Multimorbidity; Obesity; Prognosis; Pyrazoles; Pyridones; Renal Insufficiency, Chronic; Risk Assessment; Rivaroxaban; Thromboembolism | 2018 |
Pharmacogenetics of novel oral anticoagulants: a review of identified gene variants & future perspectives.
Topics: Administration, Oral; Anticoagulants; Dabigatran; Enzymes; Humans; Pharmacogenomic Testing; Pharmacogenomic Variants; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles | 2018 |
Atrial fibrillation in dialysis patients: is there a place for non-vitamin K antagonist oral anticoagulants?
Topics: Anticoagulants; Atrial Fibrillation; Brain Ischemia; Dabigatran; Humans; Practice Guidelines as Topic; Pyrazoles; Pyridines; Pyridones; Renal Dialysis; Renal Insufficiency, Chronic; Rivaroxaban; Stroke; Thiazoles | 2018 |
Clinical Pharmacology of Oral Anticoagulants in Patients with Kidney Disease.
Topics: Administration, Oral; Anticoagulants; Antidotes; Antithrombins; Dabigatran; Factor Xa Inhibitors; Humans; International Normalized Ratio; Pyrazoles; Pyridines; Pyridones; Renal Insufficiency, Chronic; Rivaroxaban; Thiazoles; Warfarin | 2019 |
The safety and efficacy of non-vitamin K antagonist oral anticoagulants in atrial fibrillation in the elderly.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Hemorrhage; Humans; Rivaroxaban; Treatment Outcome; Vitamin K | 2018 |
British Thoracic Society Guideline for the initial outpatient management of pulmonary embolism (PE).
Topics: Ambulatory Care; Anticoagulants; Dabigatran; Female; Hemorrhage; Humans; Length of Stay; Male; Neoplasms; Patient Discharge; Patient Selection; Pregnancy; Pregnancy Complications, Cardiovascular; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Rivaroxaban; Severity of Illness Index; Substance Abuse, Intravenous; Thiazoles | 2018 |
[The Multimorbid Patient: Use of New Oral Anticoagulants in Patients with Chronic Kidney Disease].
Topics: Anticoagulants; Arterial Occlusive Diseases; Atrial Fibrillation; Comorbidity; Contraindications; Coronary Disease; Dabigatran; Glomerular Filtration Rate; Kidney Failure, Chronic; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thromboembolism; Vitamin K | 2018 |
Direct comparative effectiveness and safety between non-vitamin K antagonist oral anticoagulants for stroke prevention in nonvalvular atrial fibrillation: a systematic review and meta-analysis of observational studies.
Topics: Administration, Oral; Aged; Antithrombins; Atrial Fibrillation; Dabigatran; Embolism; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Observational Studies as Topic; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Treatment Outcome | 2019 |
Uninterrupted direct oral anticoagulants vs. uninterrupted vitamin K antagonists during catheter ablation of non-valvular atrial fibrillation: a systematic review and meta-analysis of randomized controlled trials.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Catheter Ablation; Cerebral Infarction; Dabigatran; Drug Administration Schedule; Factor Xa Inhibitors; Hemorrhage; Humans; Postoperative Complications; Postoperative Hemorrhage; Risk Factors; Rivaroxaban; Severity of Illness Index; Thromboembolism; Warfarin | 2018 |
Clinical Pharmacokinetics and Pharmacodynamics of Direct Oral Anticoagulants in Patients with Renal Failure.
Topics: Administration, Oral; Animals; Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Renal Insufficiency; Rivaroxaban | 2019 |
[Spontaneous choroidal hemorrhage associated with novel oral anticoagulants: A report of two cases and literature review].
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Choroid Hemorrhage; Dabigatran; Drugs, Investigational; Female; Humans; Rivaroxaban | 2018 |
Insights From Practice With Use of Direct Oral Anticoagulants in Transplantation.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Female; Humans; Male; Middle Aged; Organ Transplantation; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Venous Thromboembolism | 2018 |
The safety of NOACs in atrial fibrillation patient subgroups: A narrative review.
Topics: Administration, Oral; Age Factors; Anticoagulants; Atrial Fibrillation; Clinical Trials, Phase III as Topic; Dabigatran; Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Risk Factors; Rivaroxaban; Stroke; Thiazoles; Warfarin | 2019 |
Intravenous tPA (Tissue-Type Plasminogen Activator) in Patients With Acute Ischemic Stroke Taking Non-Vitamin K Antagonist Oral Anticoagulants Preceding Stroke.
Topics: Administration, Intravenous; Administration, Oral; Antibodies, Monoclonal, Humanized; Anticoagulants; Antidotes; Antithrombins; Brain Ischemia; Dabigatran; Factor Xa Inhibitors; Fibrinolytic Agents; Humans; Intracranial Hemorrhages; Odds Ratio; Practice Guidelines as Topic; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Tissue Plasminogen Activator | 2018 |
[Improved stroke prevention in atrial fibrillation: the Stockholm experience of the introduction of NOACs].
Topics: Aged, 80 and over; Antithrombins; Atrial Fibrillation; Dabigatran; Humans; Ischemic Attack, Transient; Observational Studies as Topic; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Sweden; Thiazoles; Warfarin | 2018 |
Oral Anticoagulation in Patients With End-Stage Kidney Disease on Dialysis and Atrial Fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Kidney Failure, Chronic; Pyrazoles; Pyridines; Pyridones; Renal Dialysis; Rivaroxaban; Thiazoles; Thromboembolism; Warfarin | 2018 |
Hypersensitivity reactions to non-vitamin K oral anticoagulants - a review of literature and diagnostic work-up proposal.
Topics: Anticoagulants; Dabigatran; Drug Hypersensitivity; Humans; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles | 2019 |
Non-Vitamin K Antagonist Oral Anticoagulants in the Treatment of Atrial Fibrillation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Female; Hemorrhage; Humans; Male; Middle Aged; Prognosis; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Risk Assessment; Rivaroxaban; Stroke; Survival Rate; Treatment Outcome; Warfarin | 2019 |
Use of Direct Oral Anticoagulants Among Patients Undergoing Cardioversion: The Importance of Timing Before Cardioversion.
Topics: Administration, Oral; Anticoagulants; Dabigatran; Electric Countershock; Humans; Pyrazoles; Pyridines; Pyridones; Risk Factors; Rivaroxaban; Thiazoles; Thromboembolism; Time Factors | 2018 |
Differences in safety and efficacy of oral anticoagulants in patients with non-valvular atrial fibrillation: A Bayesian analysis.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Bayes Theorem; Dabigatran; Female; Gastrointestinal Hemorrhage; Humans; Male; Middle Aged; Proportional Hazards Models; Pyrazoles; Pyridones; Risk; Rivaroxaban; Stroke; Warfarin | 2019 |
Strategies of neutralization of the direct oral anticoagulants effect: review of the literature.
Topics: Administration, Oral; Anticoagulants; Antidotes; Antithrombins; Dabigatran; Factor Xa; Factor Xa Inhibitors; Hemorrhage; Humans; Recombinant Proteins; Rivaroxaban | 2019 |
The Non-Vitamin K Antagonist Oral Anticoagulants in Heart Disease: Section V-Special Situations.
Topics: Administration, Oral; Antibodies, Monoclonal, Humanized; Anticoagulants; Arginine; Atrial Fibrillation; Benzamides; Biomarkers; Blood Coagulation; Clinical Trials as Topic; Dabigatran; Drug Administration Schedule; Factor Xa; Heart Diseases; Humans; Piperazines; Pyrazoles; Pyridines; Pyridones; Recombinant Proteins; Risk; Rivaroxaban; Stroke; Thiazoles; Thrombin; Venous Thromboembolism; Vitamin K; Warfarin | 2019 |
Atrial Fibrillation.
Topics: Antithrombins; Atrial Fibrillation; Critical Care Nursing; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; Pyrazoles; Pyridones; Rivaroxaban; Stroke | 2019 |
[Management of bleeding associated with direct oral anticoagulants: update on reversal strategies].
Topics: Administration, Oral; Antibodies, Monoclonal, Humanized; Antidotes; Antithrombins; Blood Coagulation Factors; Dabigatran; Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Risk Factors; Rivaroxaban; Thiazoles | 2019 |
Direct Oral Anticoagulants in the Prevention and Treatment of Venous Thromboembolism in Patients with Cancer: New Insights from Randomized Controlled Trials.
Topics: Administration, Oral; Anticoagulants; Benzamides; Dabigatran; Heparin, Low-Molecular-Weight; Humans; Neoplasms; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiazoles; Venous Thromboembolism | 2019 |
Reversing Direct Oral Anticoagulants in Acute Intracranial Hemorrhage.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Benzamides; Dabigatran; Humans; Intracranial Hemorrhages; Practice Guidelines as Topic; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Rivaroxaban; Thromboembolism; Treatment Outcome | 2019 |
Direct oral anticoagulants for extended treatment of venous thromboembolism: insights from the EINSTEIN CHOICE study.
Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Dabigatran; Glycosaminoglycans; Hemorrhage; Humans; Middle Aged; Pyrazoles; Pyridones; Recurrence; Risk Factors; Rivaroxaban; Treatment Outcome; Venous Thromboembolism; Vitamin K | 2020 |
Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients With Cancer and Atrial Fibrillation: A Systematic Review and Meta-Analysis.
Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; Factor Xa Inhibitors; Gastrointestinal Hemorrhage; Hemorrhage; Humans; Intracranial Hemorrhages; Neoplasms; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Venous Thromboembolism; Warfarin | 2019 |
Impact of methodological choices on a meta-analysis of real-world evidence comparing non-vitamin-K antagonist oral anticoagulants with vitamin K antagonists for the treatment of patients with non-valvular atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Rivaroxaban; Vitamin K | 2019 |
[Dermatosurgery in the age of novel oral anticoagulants/direct oral anticoagulants].
Topics: Administration, Oral; Anticoagulants; Dabigatran; Dermatologic Surgical Procedures; Humans; Postoperative Hemorrhage; Practice Guidelines as Topic; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban | 2019 |
Drugs for atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Animals; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Calcium Channel Blockers; Clinical Trials as Topic; Dabigatran; Humans; Rivaroxaban | 2019 |
Medication adherence to rivaroxaban and dabigatran in patients with non-valvular atrial fibrillation: a meta-analysis.
Topics: Adult; Atrial Fibrillation; Dabigatran; Female; Humans; Male; Medication Adherence; Rivaroxaban; United States | 2020 |
Newer Oral Anticoagulant in Chronic Kidney Disease: What we Should Know.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Factor Xa Inhibitors; Humans; Renal Insufficiency, Chronic; Rivaroxaban | 2019 |
Antithrombotic regimen for patients with cardiac indication for dual antiplatelet therapy and anticoagulation: a meta-analysis of randomized trials.
Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Dabigatran; Drug Therapy, Combination; Dual Anti-Platelet Therapy; Factor Xa Inhibitors; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Ticagrelor; Warfarin | 2020 |
Bleeding in anticoagulated patients with atrial fibrillation: practical considerations.
Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles | 2020 |
A systematic review on the effects of direct oral anticoagulants on cancer growth and metastasis in animal models.
Topics: Administration, Oral; Animals; Anticoagulants; Antithrombins; Dabigatran; Humans; Mice; Models, Animal; Neoplasms; Pyrazoles; Pyridones; Rats; Rivaroxaban; Venous Thromboembolism | 2020 |
[Oral anticoagulation in patients with atrial fibrillation and stage 4 or 5 chronic kidney disease].
Topics: Administration, Oral; Age Factors; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Diabetes Complications; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Hypertension; Male; Middle Aged; Off-Label Use; Prevalence; Pyrazoles; Pyridines; Pyridones; Renal Insufficiency, Chronic; Risk Factors; Rivaroxaban; Sex Factors; Sleep Apnea, Obstructive; Stroke; Thiazoles; Thromboembolism | 2020 |
Barriers and facilitators to optimal oral anticoagulant management: a scoping review.
Topics: Anticoagulants; Dabigatran; Disease Management; Factor Xa Inhibitors; Humans; Quality of Health Care; Rivaroxaban; Thromboembolism; Vitamin K; Warfarin | 2020 |
Bleeding in anticoagulated patients with atrial fibrillation: practical considerations.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Pyridones; Rivaroxaban; Stroke | 2020 |
[The role of direct oral anticoagulants in the management of cancer-associated thrombosis in 2020].
Topics: Anticoagulants; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; Cytochrome P-450 Enzyme System; Dabigatran; Drug Interactions; Factor Xa Inhibitors; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Neoplasm Proteins; Neoplasms; Pyrazoles; Pyridines; Pyridones; Recurrence; Rivaroxaban; Secondary Prevention; Thiazoles; Thrombosis; Venous Thromboembolism | 2020 |
Non-Vitamin K Antagonist Oral Anticoagulants in Secondary Stroke Prevention in Atrial Fibrillation Patients: An Updated Analysis by Adding Observational Studies.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Factor Xa Inhibitors; Humans; Intracranial Hemorrhages; Observational Studies as Topic; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Risk Factors; Rivaroxaban; Secondary Prevention; Stroke; Thiazoles; Treatment Outcome; Vitamin K; Warfarin | 2020 |
Anticoagulants for Stroke Prevention in Atrial Fibrillation in Elderly Patients.
Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Factor Xa Inhibitors; Female; Humans; Intracranial Hemorrhages; Male; Pyrazoles; Pyridines; Pyridones; Risk Factors; Rivaroxaban; Stroke; Thiazoles; Treatment Outcome; Vitamin K; Warfarin | 2020 |
Direct oral anticoagulant adsorption: Impact on lupus anticoagulant testing-Review of the literature and evaluation on spiked and patient samples.
Topics: Administration, Oral; Adsorption; Anticoagulants; Antiphospholipid Syndrome; Dabigatran; Humans; Lupus Coagulation Inhibitor; Pyridones; Rivaroxaban | 2020 |
Direct-acting oral anticoagulant use at extremes of body weight: Literature review and recommendations.
Topics: Anticoagulants; Body Weight; Dabigatran; Drug Dosage Calculations; Factor Xa Inhibitors; Humans; Obesity; Overweight; Pyrazoles; Pyridones; Rivaroxaban; Venous Thromboembolism | 2020 |
DOACs Versus VKAs in Older Adults Treated for Acute Venous Thromboembolism: Systematic Review and Meta-Analysis.
Topics: Administration, Oral; Aged; Anticoagulants; Antifibrinolytic Agents; Antithrombins; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; Randomized Controlled Trials as Topic; Rivaroxaban; Venous Thromboembolism; Vitamin K | 2020 |
Meta-analysis of efficacy and safety of new oral anticoagulants compared with warfarin in Japanese patients undergoing catheter ablation for atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Catheter Ablation; Dabigatran; Humans; Japan; Rivaroxaban; Stroke; Warfarin | 2020 |
A Structured Literature Review and International Consensus Validation of FORTA Labels of Oral Anticoagulants for Long-Term Treatment of Atrial Fibrillation in Older Patients (OAC-FORTA 2019).
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Consensus Development Conferences as Topic; Dabigatran; Europe; Female; Humans; Long-Term Care; Male; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Vitamin K; Warfarin | 2020 |
Periprocedural Management of Oral Anticoagulation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Perioperative Care; Postoperative Complications; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Rivaroxaban; Stroke; Surgical Procedures, Operative; Warfarin | 2020 |
Use of Direct Oral Anticoagulants in the Treatment of Left Ventricular Thrombi: A Systematic Review.
Topics: Dabigatran; Factor Xa Inhibitors; Heart Diseases; Heart Ventricles; Humans; Off-Label Use; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thrombosis; Treatment Outcome | 2020 |
[Personalized approach for direct oral anticoagulant prescription: from theory to practice].
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Precision Medicine; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Treatment Outcome | 2019 |
The role of non-vitamin K antagonist oral anticoagulants in Asian patients with atrial fibrillation: A PRISMA-compliant article.
Topics: Administration, Oral; Aged; Anticoagulants; Antithrombins; Asia; Asian People; Atrial Fibrillation; Cost of Illness; Dabigatran; Embolism; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Network Meta-Analysis; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Safety; Stroke; Thiazoles; Warfarin | 2020 |
A review of global health technology assessments of non-VKA oral anticoagulants in non-valvular atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Pyridones; Rivaroxaban; Stroke; Technology Assessment, Biomedical | 2020 |
Diagnostic performance of coagulation indices for direct oral anticoagulant concentration.
Topics: Administration, Oral; Anticoagulants; Blood Coagulation Tests; Dabigatran; Factor Xa Inhibitors; Humans; Pyridones; Rivaroxaban | 2020 |
[Peculiarities of the treatment of venous thromboembolism with direct oral anticoagulants in challenging patients: senile age, renal failure, fragility].
Topics: Administration, Oral; Age Factors; Aged; Antithrombins; Dabigatran; Frail Elderly; Humans; Pyrazoles; Pyridones; Renal Insufficiency; Rivaroxaban; Venous Thromboembolism | 2020 |
Efficacy and safety of non-vitamin K anticoagulants and warfarin in patients with atrial fibrillation and heart failure: A network meta-analysis.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Heart Failure; Humans; Network Meta-Analysis; Pyridones; Rivaroxaban; Stroke; Warfarin | 2020 |
Different Coagulation Indicators in Predicting Clinical Outcomes for Patients With Direct Oral Anticoagulants: A Systematic Review and Meta-analysis.
Topics: Administration, Oral; Blood Coagulation; Blood Coagulation Tests; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; Prothrombin Time; Pyrazoles; Pyridones; Rivaroxaban; Venous Thromboembolism | 2020 |
Noncanonical Effects of Oral Thrombin and Factor Xa Inhibitors in Platelet Activation and Arterial Thrombosis.
Topics: Animals; Blood Coagulation; Dabigatran; Factor Xa Inhibitors; Humans; Platelet Activation; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thrombosis | 2021 |
Non-Vitamin K Antagonist Oral Anticoagulants and Factors Influencing the Ischemic and Bleeding Risk in Elderly Patients With Atrial Fibrillation: A Review of Current Evidence.
Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Dabigatran; Drug Administration Schedule; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Ischemic Stroke; Male; Medication Adherence; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Risk Factors; Rivaroxaban; Thiazoles; Time Factors; Treatment Outcome | 2020 |
Non-vitamin K oral anticoagulants and risk of fractures: a systematic review and meta-analysis.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Rivaroxaban; Stroke; Vitamin K | 2021 |
Direct Oral Anticoagulants in Select Patients With Hypercoagulable Disorders.
Topics: Administration, Oral; Anticoagulants; Dabigatran; Hemorrhage; Humans; Rivaroxaban; Thrombophilia; Venous Thromboembolism | 2021 |
Twice- or Once-Daily Dosing of Direct Oral Anticoagulants, a systematic review and meta-analysis.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Pyridones; Rivaroxaban; Stroke; Treatment Outcome | 2021 |
Effectiveness and safety among direct oral anticoagulants in nonvalvular atrial fibrillation: A multi-database cohort study with meta-analysis.
Topics: Administration, Oral; Adult; Anticoagulants; Atrial Fibrillation; Brain Ischemia; Cohort Studies; Dabigatran; Humans; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Treatment Outcome; Warfarin | 2021 |
Direct oral anticoagulants: evidence and unresolved issues.
Topics: Administration, Oral; Anticoagulants; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Venous Thromboembolism | 2020 |
Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin for Patients With Left Ventricular Thrombus: A Systematic Review and Meta-Analysis.
Topics: Anticoagulants; Antithrombins; Dabigatran; Embolism; Factor Xa Inhibitors; Heart Diseases; Heart Ventricles; Hemorrhage; Humans; Odds Ratio; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thrombosis; Warfarin | 2021 |
Switching between direct oral anticoagulants: a systematic review and meta-analysis.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Pyridones; Retrospective Studies; Rivaroxaban; Stroke | 2021 |
Major gastrointestinal bleeding risk with direct oral anticoagulants: Does type and dose matter? - A systematic review and network meta-analysis.
Topics: Administration, Oral; Anticoagulants; Dabigatran; Gastrointestinal Hemorrhage; Humans; Network Meta-Analysis; Rivaroxaban; Stroke; Warfarin | 2021 |
Cost-Effectiveness of Direct Non-Vitamin K Oral Anticoagulants Versus Vitamin K Antagonists for the Management of Patients with Non-Valvular Atrial Fibrillation Based on Available "Real-World" Evidence: The Italian National Health System Perspective.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Cost-Benefit Analysis; Dabigatran; Female; Hemorrhage; Humans; Italy; Male; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Vitamin K | 2021 |
Comparative Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Observational Studies as Topic; Propensity Score; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thromboembolism | 2021 |
Comparative Risk Assessment of Severe Uterine Bleeding Following Exposure to Direct Oral Anticoagulants: A Network Study Across Four Observational Databases in the USA.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Humans; Male; Observational Studies as Topic; Pyridones; Risk Assessment; Rivaroxaban; Uterine Hemorrhage; Venous Thromboembolism; Warfarin | 2021 |
Real-world persistence to direct oral anticoagulants in patients with atrial fibrillation: a systematic review and network meta-analysis.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Network Meta-Analysis; Pyridones; Rivaroxaban; Stroke | 2021 |
The risk of gastrointestinal hemorrhage with non-vitamin K antagonist oral anticoagulants: A network meta-analysis.
Topics: Administration, Oral; Adult; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Enoxaparin; Female; Gastrointestinal Hemorrhage; Humans; Male; Middle Aged; Network Meta-Analysis; Observational Studies as Topic; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Risk Factors; Rivaroxaban; Stroke; Thiazoles; Venous Thromboembolism; Warfarin | 2021 |
Direct oral anticoagulant safety during breastfeeding: a narrative review.
Topics: Anticoagulants; Breast Feeding; Dabigatran; Factor Xa Inhibitors; Female; Humans; Milk, Human; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles | 2021 |
Review Article: Gastrointestinal Bleeding Risk with Direct Oral Anticoagulants.
Topics: Administration, Oral; Anticoagulants; Dabigatran; Gastrointestinal Hemorrhage; Humans; Rivaroxaban; Vitamin K | 2022 |
Effects of rivaroxaban and warfarin on the risk of gastrointestinal bleeding and intracranial hemorrhage in patients with atrial fibrillation: Systematic review and meta-analysis.
Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Gastrointestinal Hemorrhage; Humans; Intracranial Hemorrhages; Rivaroxaban; Stroke; Warfarin | 2021 |
Wound complications and bleeding with new oral anticoagulants in patients undergoing total joint arthroplasty: A systematic review and meta-analysis of randomized controlled trials.
Topics: Administration, Oral; Anticoagulants; Arthroplasty; Dabigatran; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Randomized Controlled Trials as Topic; Rivaroxaban; Venous Thromboembolism | 2022 |
Severe Bleeding Risk of Direct Oral Anticoagulants Versus Vitamin K Antagonists for Stroke Prevention and Treatment in Patients with Atrial Fibrillation: A Systematic Review and Network Meta-Analysis.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Factor Xa Inhibitors; Gastrointestinal Hemorrhage; Humans; Intracranial Hemorrhages; Network Meta-Analysis; Rivaroxaban; Stroke; Vitamin K | 2023 |
Comparison of non-vitamin K antagonist oral anticoagulants on bleeding and thrombosis.
Topics: Anticoagulants; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; Ischemic Stroke; Pyrazoles; Pyridones; Rivaroxaban; Thrombosis | 2021 |
Direct Oral Anticoagulants Versus Warfarin in Morbidly Obese Patients With Nonvalvular Atrial Fibrillation: A Systematic Review and Meta-analysis.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Obesity, Morbid; Retrospective Studies; Rivaroxaban; Stroke; Warfarin | 2021 |
Effectiveness and Safety of Dabigatran Compared to Vitamin K Antagonists in Non-Asian Patients with Atrial Fibrillation: A Systematic Review and Meta-Analysis.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Rivaroxaban; Stroke; Vitamin K | 2021 |
Editor's Choice - Severe Bleeding Risks of Direct Oral Anticoagulants in the Prevention and Treatment of Venous Thromboembolism: A Network Meta-Analysis of Randomised Controlled Trials.
Topics: Administration, Oral; Anticoagulants; Dabigatran; Humans; Network Meta-Analysis; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Venous Thromboembolism | 2022 |
Direct oral anticoagulants for use in paediatrics.
Topics: Antithrombins; Child; Clinical Trials as Topic; Dabigatran; Factor Xa Inhibitors; Humans; Pediatrics; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles | 2022 |
Anticoagulant-related nephropathy: Focus on novel agents. A review.
Topics: Acute Kidney Injury; Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Renal Insufficiency, Chronic; Rivaroxaban; Warfarin | 2022 |
Non-vitamin K antagonist oral anticoagulants in venous thromboembolism patients: a meta-analysis of real-world studies.
Topics: Administration, Oral; Anticoagulants; Dabigatran; Hemorrhage; Humans; Rivaroxaban; Venous Thromboembolism | 2022 |
Biopharmaceutics considerations for direct oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Biopharmaceutics; Dabigatran; Rivaroxaban | 2021 |
Real-world cost-effectiveness analysis of NOACs versus VKA for stroke prevention in Spain.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Cost-Benefit Analysis; Dabigatran; Humans; Pyridones; Rivaroxaban; Spain; Stroke; Vitamin K | 2022 |
New Anticoagulants in Neonates, Children, and Adolescents.
Topics: Administration, Oral; Adolescent; Anticoagulants; Child; Dabigatran; Humans; Infant, Newborn; Rivaroxaban; Thrombosis | 2022 |
Population Pharmacokinetic Models for Direct Oral Anticoagulants: A Systematic Review and Clinical Appraisal Using Exposure Simulation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Pyridones; Rivaroxaban; Stroke | 2022 |
Drug Interactions Affecting Oral Anticoagulant Use.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Cytochrome P-450 CYP3A; Dabigatran; Drug Interactions; Hemorrhage; Humans; Pyridones; Rivaroxaban; Warfarin | 2022 |
The use of non-vitamin K oral anticoagulants in dialysis patients-A systematic review.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Renal Dialysis; Rivaroxaban; Stroke; Vitamin K | 2022 |
Thromboprophylaxis of Patients Submitted to Total Hip and Knee Arthroplasty: A Cost-Effectiveness Assessment From the Perspective of the Brazilian National Health System.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Brazil; Cost-Benefit Analysis; Dabigatran; Enoxaparin; Humans; Rivaroxaban; Venous Thromboembolism | 2022 |
Efficacy and Safety Considerations With Dose-Reduced Direct Oral Anticoagulants: A Review.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Rivaroxaban; Stroke; Venous Thromboembolism | 2022 |
Effectiveness and safety of intracranial events associated with the use of direct oral anticoagulants for atrial fibrillation: A systematic review and meta-analysis of 92 studies.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Brain Ischemia; Dabigatran; Humans; Intracranial Hemorrhages; Ischemic Stroke; Pyridones; Rivaroxaban; Stroke; Thromboembolism; Vitamin K | 2022 |
Comparing the efficacy and safety of direct oral anticoagulants versus Vitamin K antagonists in patients with antiphospholipid syndrome: a systematic review and meta-analysis.
Topics: Administration, Oral; Anticoagulants; Antiphospholipid Syndrome; Dabigatran; Fibrinolytic Agents; Hemorrhage; Humans; Rivaroxaban; Thrombosis; Venous Thromboembolism; Vitamin K | 2022 |
A comparison of front-line oral anticoagulants for the treatment of non-valvular atrial fibrillation: effectiveness and safety of direct oral anticoagulants in the FANTASIIA registry.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Pyridones; Registries; Rivaroxaban; Stroke; Vitamin K | 2022 |
Anticoagulation and BMI: effect of high body weight on the safety and efficacy of direct oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Body Mass Index; Body Weight; Dabigatran; Hemorrhage; Humans; Obesity; Pyridones; Rivaroxaban; Stroke; Vitamin K | 2022 |
The association of non-vitamin K antagonist oral anticoagulants
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Osteoporotic Fractures; Rivaroxaban; Stroke; Warfarin | 2023 |
Impact of comparative effectiveness research on Medicare coverage of direct oral anticoagulants.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Comparative Effectiveness Research; Dabigatran; Humans; Medicare; Pyridones; Rivaroxaban; Stroke; United States | 2022 |
Direct oral anticoagulants versus standard anticoagulation in children treated for acute venous thromboembolism.
Topics: Administration, Oral; Anticoagulants; Blood Coagulation; Child; Dabigatran; Hemorrhage; Humans; Randomized Controlled Trials as Topic; Rivaroxaban; Venous Thromboembolism | 2023 |
Direct Oral Anticoagulants in Patients on Chronic Dialysis and Concomitant Atrial Fibrillation: A Common Clinical Impasse.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Renal Dialysis; Rivaroxaban; Stroke; Warfarin | 2022 |
Acute Pulmonary Embolism: A Review.
Topics: Acute Disease; Administration, Oral; Anticoagulants; Dabigatran; Fibrin Fibrinogen Degradation Products; Heparin; Humans; Pulmonary Embolism; Risk; Rivaroxaban; United States; Vitamin K; Warfarin | 2022 |
Gastrointestinal Bleeding on Oral Anticoagulation: What is Currently Known.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Gastrointestinal Hemorrhage; Humans; Pyridones; Rivaroxaban; Stroke; Warfarin | 2022 |
Risk and Management of Bleeding Complications with Direct Oral Anticoagulants in Patients with Atrial Fibrillation and Venous Thromboembolism: a Narrative Review.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Cerebral Hemorrhage; Dabigatran; Gastrointestinal Hemorrhage; Humans; Rivaroxaban; Stroke; Venous Thromboembolism | 2023 |
Direct oral anticoagulants for venous thromboembolism in cancer patients: a systematic review and network meta-analysis.
Topics: Administration, Oral; Anticoagulants; Dabigatran; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Neoplasms; Network Meta-Analysis; Rivaroxaban; Venous Thromboembolism; Warfarin | 2022 |
Use of tramadol and the risk of bleeding complications in patients on oral anticoagulants: a systematic review and meta-analysis.
Topics: Administration, Oral; Adult; Anticoagulants; Atrial Fibrillation; Case-Control Studies; Dabigatran; Fibrinolytic Agents; Hemorrhage; Humans; Rivaroxaban; Tramadol; Vitamin K | 2022 |
Oral Anticoagulant Use in Patients With Atrial Fibrillation and Chronic Kidney Disease: A Review of the Evidence With Recommendations for Australian Clinical Practice.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Australia; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; Renal Insufficiency, Chronic; Rivaroxaban; Stroke; Warfarin | 2022 |
Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation: A Systematic Review of Economic Evaluations.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Cost-Benefit Analysis; Dabigatran; Humans; Rivaroxaban; Stroke; Warfarin | 2023 |
Direct Oral Anticoagulants: An Updated Systematic Review of Their Clinical Pharmacology and Clinical Effectiveness and Safety in Patients With Nonvalvular Atrial Fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Pharmacology, Clinical; Rivaroxaban; Stroke; Treatment Outcome; Vitamin K | 2023 |
Urgent procedures or surgeries in patients receiving oral anticoagulants: a systematic literature review.
Topics: Administration, Oral; Adult; Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Pyridones; Rivaroxaban; Stroke; Warfarin | 2023 |
Economic Evaluation of Direct Oral Anticoagulants Compared to Warfarin for Venous Thromboembolism in Thailand: A Cost-Utility Analysis.
Topics: Anticoagulants; Cost-Benefit Analysis; Dabigatran; Humans; Pyridones; Quality-Adjusted Life Years; Rivaroxaban; Thailand; Venous Thromboembolism; Warfarin | 2023 |
Insights into the Pharmacokinetics and Pharmacodynamics of Direct Oral Anticoagulants in Older Adults with Atrial Fibrillation: A Structured Narrative Review.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Pyridones; Rivaroxaban | 2023 |
Increased major bleeding incidence in atrial fibrillation patients with apixaban: a review of Japanese post-marketing surveillance studies of direct oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Incidence; Japan; Product Surveillance, Postmarketing; Pyridones; Rivaroxaban; Stroke | 2023 |
Oral direct thrombin inhibitors or oral factor Xa inhibitors versus conventional anticoagulants for the treatment of deep vein thrombosis.
Topics: Anticoagulants; Antithrombins; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; Neoplasm Recurrence, Local; Pulmonary Embolism; Rivaroxaban; Venous Thromboembolism; Venous Thrombosis | 2023 |
News at XI: moving beyond factor Xa inhibitors.
Topics: Administration, Oral; Anticoagulants; Dabigatran; Factor Xa Inhibitors; Factor XI; Humans; Rivaroxaban | 2023 |
Non-major bleeding risk of direct oral anticoagulants versus vitamin K antagonists for stroke prevention with atrial fibrillation: a systematic review and network meta-analysis.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Fibrinolytic Agents; Hemorrhage; Humans; Network Meta-Analysis; Rivaroxaban; Stroke; Vitamin K | 2023 |
Direct oral anticoagulants and their antagonists in perioperative practice.
Topics: Administration, Oral; Anticoagulants; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; Rivaroxaban | 2023 |
Efficacy and Safety of Oral Anticoagulants in Older Adult Patients With Atrial Fibrillation: Pairwise and Network Meta-Analyses.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Ischemic Stroke; Network Meta-Analysis; Rivaroxaban; Stroke; Warfarin | 2023 |
Warfarin faring better: vitamin K antagonists beat rivaroxaban and apixaban in the INVICTUS and PROACT Xa trials.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Fibrinolytic Agents; Humans; Pyridones; Rheumatic Heart Disease; Rivaroxaban; Stroke; Vitamin K; Warfarin | 2023 |
Altered plasma levels of apixaban in major gastrointestinal tract surgery: A case report and review of the literature.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Gastrointestinal Tract; Hemorrhage; Humans; Rivaroxaban; Stroke | 2023 |
Studies on Atrial Fibrillation and Venous Thromboembolism in the Past 20 Years: A Bibliometric Analysis Via CiteSpace and VOSviewer.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Venous Thromboembolism; Warfarin | 2023 |
Efficacy and Safety of Direct Oral Anticoagulants for Stroke Prevention in Older Patients With Atrial Fibrillation: A Network Meta-Analysis of Randomized Controlled Trials.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; Hemorrhage; Humans; Intracranial Hemorrhages; Network Meta-Analysis; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke | 2023 |
53 trial(s) available for dabigatran and rivaroxaban
| Article | Year |
|---|---|
Enoxaparin versus dabigatran or rivaroxaban for thromboprophylaxis after hip or knee arthroplasty: Results of separate pooled analyses of phase III multicenter randomized trials.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Dabigatran; Enoxaparin; Follow-Up Studies; Hemorrhage; Humans; Morpholines; Postoperative Complications; Prospective Studies; Rivaroxaban; Thiophenes; Treatment Outcome; Venous Thromboembolism; Withholding Treatment | 2010 |
Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects.
Topics: Adult; Anticoagulants; Antidotes; Benzimidazoles; beta-Alanine; Blood Coagulation; Blood Coagulation Factors; Cross-Over Studies; Dabigatran; Double-Blind Method; Endopeptidases; Factor Xa Inhibitors; Humans; Male; Morpholines; Partial Thromboplastin Time; Prothrombin Time; Rivaroxaban; Thiophenes; Thrombin; Thrombin Time; Young Adult | 2011 |
Dabigatran, rivaroxaban and apixaban versus enoxaparin for thomboprophylaxis after total knee or hip arthroplasty: pool-analysis of phase III randomized clinical trials.
Topics: Adult; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Dabigatran; Enoxaparin; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Treatment Outcome; Venous Thromboembolism | 2012 |
Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers.
Topics: Administration, Oral; Adolescent; Adult; Anticoagulants; Area Under Curve; Benzimidazoles; beta-Alanine; Blood Coagulation Factors; Cross-Over Studies; Dabigatran; Factor VIIa; Humans; Kinetics; Male; Middle Aged; Morpholines; Prothrombin; Recombinant Proteins; Risk; Rivaroxaban; Thiophenes; Thrombin | 2012 |
Analysis of the projected utility of dabigatran, rivaroxaban, and apixaban and their future impact on existing Hematology and Cardiology Anticoagulation Clinics at The Johns Hopkins Hospital.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Female; Hospitals, University; Humans; Kidney Function Tests; Liver Function Tests; Male; Middle Aged; Morpholines; Practice Guidelines as Topic; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Thiophenes | 2012 |
Mixed treatment comparison meta-analysis of aspirin, warfarin, and new anticoagulants for stroke prevention in patients with nonvalvular atrial fibrillation.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Data Interpretation, Statistical; Databases, Bibliographic; Double-Blind Method; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2013 |
Cost-effectiveness impact of rivaroxaban versus new and existing prophylaxis for the prevention of venous thromboembolism after total hip or knee replacement surgery in France, Italy and Spain.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; Cost of Illness; Cost-Benefit Analysis; Dabigatran; Direct Service Costs; Enoxaparin; France; Humans; Italy; Models, Theoretical; Morpholines; Postoperative Complications; Pyridines; Quality of Life; Rivaroxaban; Spain; Thiophenes; Venous Thromboembolism | 2013 |
A head-to-head comparison of periprocedural coagulability under anticoagulation with rivaroxaban versus dabigatran in patients undergoing ablation of atrial fibrillation.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Fibrin Fibrinogen Degradation Products; Humans; Male; Middle Aged; Morpholines; Rivaroxaban; Thiophenes | 2013 |
Point-of-care coagulation testing for assessment of the pharmacodynamic anticoagulant effect of direct oral anticoagulant.
Topics: Adult; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation; Blood Coagulation Tests; Dabigatran; Female; Humans; Male; Middle Aged; Morpholines; Phenprocoumon; Point-of-Care Systems; Rivaroxaban; Thiophenes; Young Adult | 2014 |
Major bleeding with dabigatran and rivaroxaban in patients with atrial fibrillation: a real-world setting.
Topics: Aged; Aged, 80 and over; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Databases, Factual; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Medical Records Systems, Computerized; Middle Aged; Morpholines; Rivaroxaban; Thiophenes | 2014 |
Antithrombotic triple therapy and coagulation activation at the site of thrombus formation: a randomized trial in healthy subjects.
Topics: Adenosine; Administration, Oral; Adult; Anticoagulants; Antithrombin III; Aspirin; Austria; Benzimidazoles; beta-Alanine; beta-Thromboglobulin; Biomarkers; Blood Coagulation; Blood Platelets; Dabigatran; Drug Therapy, Combination; Fibrinolytic Agents; Healthy Volunteers; Humans; International Normalized Ratio; Male; Morpholines; Peptide Fragments; Peptide Hydrolases; Phenprocoumon; Platelet Activation; Platelet Aggregation Inhibitors; Prospective Studies; Prothrombin; Rivaroxaban; Thiophenes; Thrombin; Thrombosis; Ticagrelor; Young Adult | 2014 |
[Comparison of the safety of rivaroxaban versus dabigatran therapy in patients with persistent atrial fibrillation].
Topics: Aged; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Female; Gastrointestinal Diseases; Hemorrhage; Humans; Male; Morpholines; Rivaroxaban; Thiophenes; Thromboembolism | 2014 |
The effect of dabigatran and rivaroxaban on platelet reactivity and inflammatory markers.
Topics: Aged; Aged, 80 and over; Atrial Fibrillation; Biomarkers; Blood Platelets; C-Reactive Protein; Chemokine CCL5; Dabigatran; Female; Humans; Inflammation Mediators; Male; Middle Aged; P-Selectin; Platelet Activation; Rivaroxaban | 2015 |
Comparison of switch-therapy modalities (enoxaparin to rivaroxaban/dabigatran) and enoxaparin monotherapy after hip and knee replacement.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Dabigatran; Enoxaparin; Female; Hemorrhage; Humans; Male; Middle Aged; Postoperative Complications; Prospective Studies; Rivaroxaban; Ultrasonography, Doppler; Venous Thrombosis | 2015 |
Coagulation Factor Concentrates Fail to Restore Alterations in Fibrin Formation Caused by Rivaroxaban or Dabigatran in Studies With Flowing Blood From Treated Healthy Volunteers.
Topics: Adult; Anticoagulants; Blood Coagulation; Blood Coagulation Factors; Dabigatran; Female; Fibrin; Healthy Volunteers; Hemostasis; Humans; Male; Middle Aged; Rivaroxaban; Single-Blind Method; Treatment Failure; Young Adult | 2015 |
Indirect comparison and cost-utility of dabigatran etexilate and rivaroxaban in the treatment and extended anticoagulation of venous thromboembolism in a UK setting.
Topics: Anticoagulants; Cost-Benefit Analysis; Dabigatran; Double-Blind Method; Female; Health Services; Hemorrhage; Humans; Male; Middle Aged; Models, Econometric; Pulmonary Embolism; Quality-Adjusted Life Years; Rivaroxaban; Venous Thromboembolism; Venous Thrombosis; Warfarin | 2016 |
[COMPARATIVE EFFECTIVENESS AND SAFETY OF NEW ORAL ANTICOAGULANTS AND WARFARIN IN PATIENTS WITH AGE-SPECIFIC NON-VALVULAR ATRIAL FIBRILLATION].
Topics: Age Factors; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Drug Monitoring; Female; Humans; International Normalized Ratio; Intracranial Hemorrhages; Male; Middle Aged; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Treatment Outcome; Warfarin | 2015 |
Safety of novel oral anticoagulants in catheter ablation of atrial fibrillation.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Catheter Ablation; Dabigatran; Female; Humans; Male; Middle Aged; Postoperative Hemorrhage; Prospective Studies; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Thromboembolism | 2016 |
Determination of dabigatran and rivaroxaban by ultra-performance liquid chromatography-tandem mass spectrometry and coagulation assays after major orthopaedic surgery.
Topics: Aged; Aged, 80 and over; Anticoagulants; Blood Coagulation; Chromatography, High Pressure Liquid; Dabigatran; Drug Monitoring; Female; Humans; Male; Middle Aged; Orthopedic Procedures; Rivaroxaban; Tandem Mass Spectrometry; Venous Thromboembolism | 2016 |
Strategy of continued vs interrupted novel oral anticoagulant at time of device surgery in patients with moderate to high risk of arterial thromboembolic events: The BRUISE CONTROL-2 trial.
Topics: Administration, Oral; Anticoagulants; Arrhythmias, Cardiac; Canada; Cause of Death; Dabigatran; Defibrillators, Implantable; Dose-Response Relationship, Drug; Hemorrhage; Humans; Incidence; Pacemaker, Artificial; Practice Guidelines as Topic; Preoperative Care; Prospective Studies; Pyrazoles; Pyridones; Rivaroxaban; Survival Rate; Thromboembolism; Warfarin | 2016 |
Adequate Initial Heparin Dosage for Atrial Fibrillation Ablation in Patients Receiving Non-Vitamin K Antagonist Oral Anticoagulants.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Catheter Ablation; Dabigatran; Female; Hemorrhage; Heparin; Humans; Male; Middle Aged; Pyrazoles; Pyridones; Rivaroxaban; Warfarin | 2016 |
Incidence of left atrial abnormalities under treatment with dabigatran, rivaroxaban, and vitamin K antagonists.
Topics: Aged; Atrial Fibrillation; Atrial Flutter; Atrial Function, Left; Dabigatran; Electrocardiography; Female; Heart Atria; Humans; Male; Middle Aged; Rivaroxaban; Thrombosis; Vitamin K | 2016 |
Interindividual variability in dabigatran and rivaroxaban exposure: contribution of ABCB1 genetic polymorphisms and interaction with clarithromycin.
Topics: Adolescent; Adult; Alleles; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Clarithromycin; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Dabigatran; Genotype; Heterozygote; Homozygote; Humans; Male; Middle Aged; Mutation; Polymorphism, Genetic; Rivaroxaban; Young Adult | 2017 |
Point-of-care testing for emergency assessment of coagulation in patients treated with direct oral anticoagulants.
Topics: Anticoagulants; Blood Coagulation Tests; Dabigatran; Factor Xa Inhibitors; Humans; Partial Thromboplastin Time; Point-of-Care Systems; Prospective Studies; Prothrombin Time; Pyrazoles; Pyridones; Rivaroxaban; Thrombin Time | 2017 |
Use of dabigatran and rivaroxaban in non-valvular atrial fibrillation: one-year follow-up experience in an Italian centre.
Topics: Administration, Oral; Aged; Aged, 80 and over; Atrial Fibrillation; Dabigatran; Female; Follow-Up Studies; Humans; Italy; Male; Medication Adherence; Middle Aged; Prospective Studies; Rivaroxaban; Surveys and Questionnaires | 2018 |
[The Choice of Anticoagulant Therapy in Patients With Non-Valvular Atrial Fibrillation and Chronic Kidney Disease].
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Pyridones; Renal Insufficiency, Chronic; Rivaroxaban; Stroke; Warfarin | 2017 |
Factors associated with non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with new-onset atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II).
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Factor Xa Inhibitors; Female; Follow-Up Studies; Humans; Male; Middle Aged; Prospective Studies; Pyrazoles; Pyridones; Registries; Risk Factors; Rivaroxaban; Stroke; Treatment Outcome; Vitamin K; Warfarin | 2017 |
Direct oral anticoagulants in patients undergoing cardioversion: insight from randomized clinical trials.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Electric Countershock; Factor Xa Inhibitors; Hemorrhage; Humans; Incidence; Prospective Studies; Rivaroxaban; Stroke; Thromboembolism; Warfarin | 2017 |
The Perioperative Anticoagulant Use for Surgery Evaluation (PAUSE) Study for Patients on a Direct Oral Anticoagulant Who Need an Elective Surgery or Procedure: Design and Rationale.
Topics: Administration, Oral; Adult; Anticoagulants; Atrial Fibrillation; Canada; Cardiac Surgical Procedures; Cohort Studies; Dabigatran; Female; Hemorrhage; Humans; Male; Perioperative Period; Postoperative Complications; Precision Medicine; Prospective Studies; Pyrazoles; Pyridones; Rivaroxaban | 2017 |
Comparison of clinical characteristics of real-life atrial fibrillation patients treated with vitamin K antagonists, dabigatran, and rivaroxaban: results from the CRAFT study.
Topics: Acenocoumarol; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Hemorrhage; Humans; Male; Middle Aged; Retrospective Studies; Rivaroxaban; Thromboembolism; Warfarin | 2018 |
Impact of BMI on clinical outcomes of NOAC therapy in daily care - Results of the prospective Dresden NOAC Registry (NCT01588119).
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Body Mass Index; Dabigatran; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Male; Obesity; Prospective Studies; Pyrazoles; Pyridines; Pyridones; Registries; Rivaroxaban; Thiazoles; Thromboembolism; Treatment Outcome; Vitamin K | 2018 |
Difference between the Upper and the Lower Gastrointestinal Bleeding in Patients Taking Nonvitamin K Oral Anticoagulants.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Dabigatran; Female; Gastrointestinal Hemorrhage; Humans; Male; Middle Aged; Proton Pump Inhibitors; Pyrazoles; Pyridones; Rivaroxaban | 2018 |
Interrupted versus uninterrupted novel oral anticoagulant peri-implantation of cardiac device: A single-center randomized prospective pilot trial.
Topics: Administration, Oral; Aged; Anticoagulants; Antithrombins; Dabigatran; Factor Xa Inhibitors; Female; Humans; Male; Pacemaker, Artificial; Pilot Projects; Prospective Studies; Prosthesis Implantation; Pyrazoles; Pyridones; Rivaroxaban; Single-Blind Method; Warfarin | 2018 |
Risk of intracranial hemorrhage (RICH) in users of oral antithrombotic drugs: Nationwide pharmacoepidemiological study.
Topics: Adolescent; Adult; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Dabigatran; Female; Fibrinolytic Agents; Humans; Intracranial Hemorrhages; Male; Middle Aged; Norway; Pharmacoepidemiology; Risk Factors; Rivaroxaban; Thrombosis; Warfarin | 2018 |
Differences between activities of coagulation factors after one month of therapy with different direct oral anticoagulant in pulmonary embolism patients.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Blood Coagulation Factors; Dabigatran; Female; Humans; Male; Middle Aged; Pulmonary Embolism; Pyrazoles; Pyridones; Rivaroxaban; Thrombin; Treatment Outcome | 2019 |
Continued vs. interrupted direct oral anticoagulants at the time of device surgery, in patients with moderate to high risk of arterial thrombo-embolic events (BRUISE CONTROL-2).
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Cardiac Pacing, Artificial; Dabigatran; Defibrillators, Implantable; Drug Administration Schedule; Female; Hematoma; Humans; Length of Stay; Male; Middle Aged; Postoperative Complications; Pyrazoles; Pyridones; Reoperation; Rivaroxaban; Thromboembolism | 2018 |
When is it appropriate to stop non-vitamin K antagonist oral anticoagulants before catheter ablation of atrial fibrillation? A multicentre prospective randomized study.
Topics: Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Catheter Ablation; Dabigatran; Drug Administration Schedule; Embolism; Factor Xa Inhibitors; Female; Hemorrhage; Heparin; Humans; Incidence; Intraoperative Care; Male; Middle Aged; Preoperative Care; Prospective Studies; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Whole Blood Coagulation Time | 2019 |
Comparison of anti-inflammatory effects of rivaroxaban vs. dabigatran in patients with non-valvular atrial fibrillation (RIVAL-AF study): multicenter randomized study.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Hemorrhage; Humans; Japan; Male; Middle Aged; Multivariate Analysis; Prospective Studies; Regression Analysis; Rivaroxaban; Severity of Illness Index; Stroke | 2019 |
The daily practice of direct oral anticoagulant use in patients with atrial fibrillation; an observational cohort study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Follow-Up Studies; Humans; Male; Medication Adherence; Middle Aged; Rivaroxaban | 2019 |
Activated clotting time on the day of atrial fibrillation ablation for minimally interrupted and uninterrupted direct oral anticoagulation therapy: Sequential changes, differences among direct oral anticoagulants, and ablation safety outcomes.
Topics: Action Potentials; Aged; Antithrombins; Atrial Fibrillation; Blood Coagulation; Catheter Ablation; Dabigatran; Drug Administration Schedule; Drug Monitoring; Factor Xa Inhibitors; Female; Heart Rate; Humans; Japan; Male; Middle Aged; Predictive Value of Tests; Pyrazoles; Pyridines; Pyridones; Risk Factors; Rivaroxaban; Thiazoles; Time Factors; Treatment Outcome; Whole Blood Coagulation Time | 2019 |
MT in anticoagulated patients: Direct oral anticoagulants versus vitamin K antagonists.
Topics: Aged; Anticoagulants; Dabigatran; Female; Hemorrhage; Humans; Male; Pyrazoles; Pyridones; Registries; Reperfusion; Rivaroxaban; Stroke; Thrombectomy; Treatment Outcome; Vitamin K | 2020 |
Trial of Rivaroxaban in AntiPhospholipid Syndrome (TRAPS): Two-year outcomes after the study closure.
Topics: Administration, Oral; Anticoagulants; Antiphospholipid Syndrome; Atrial Fibrillation; Dabigatran; Humans; Italy; Prospective Studies; Rivaroxaban; Stroke; Warfarin | 2021 |
The risk of stroke/systemic embolism and major bleeding in Asian patients with non-valvular atrial fibrillation treated with non-vitamin K oral anticoagulants compared to warfarin: Results from a real-world data analysis.
Topics: Administration, Oral; Adult; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; Female; Hemorrhage; Humans; Male; Middle Aged; Proportional Hazards Models; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Vitamin K; Warfarin | 2020 |
Comparison of the efficacy of rivaroxaban and dabigatran etexilate in preventing venous thrombosis after arthroplasty: A protocol of randomized controlled trial.
Topics: Administration, Oral; Antithrombins; Arthroplasty; Dabigatran; Humans; Postoperative Complications; Prospective Studies; Randomized Controlled Trials as Topic; Rivaroxaban; Treatment Outcome; Venous Thrombosis | 2021 |
Bleeding complications of thromboprophylaxis with dabigatran, nadroparin or rivaroxaban for 6 weeks after total knee arthroplasty surgery: a randomised pilot study.
Topics: Activities of Daily Living; Anticoagulants; Arthroplasty, Replacement, Knee; Dabigatran; Female; Humans; Nadroparin; Netherlands; Pilot Projects; Postoperative Care; Postoperative Complications; Quality of Life; Rivaroxaban; Treatment Outcome; Venous Thromboembolism | 2021 |
Efficacy and safety of rivaroxaban and ticagrelor in elderly patients with atrial fibrillation undergoing percutaneous coronary intervention.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Coronary Artery Disease; Dabigatran; Drug Therapy, Combination; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Rivaroxaban; Ticagrelor; Treatment Outcome | 2021 |
Appropriate intraprocedural initial heparin dosing in patients undergoing catheter ablation for atrial fibrillation receiving uninterrupted non-vitamin-K antagonist oral anticoagulant treatment.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Catheter Ablation; China; Dabigatran; Double-Blind Method; Drug Administration Schedule; Drug Monitoring; Female; Heparin; Humans; Male; Middle Aged; Postoperative Hemorrhage; Prospective Studies; Risk Assessment; Risk Factors; Rivaroxaban; Stroke; Thromboembolism; Time Factors; Treatment Outcome; Warfarin; Whole Blood Coagulation Time | 2021 |
An emulated target trial analysis based on Medicare data suggested non-inferiority of Dabigatran versus Rivaroxaban.
Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Dabigatran; Female; Humans; Male; Medicare; Rivaroxaban; Stroke; Treatment Outcome; United States | 2021 |
Ciraparantag reverses the anticoagulant activity of apixaban and rivaroxaban in healthy elderly subjects.
Topics: Administration, Oral; Adult; Aged; Anticoagulants; Arginine; Dabigatran; Healthy Volunteers; Humans; Middle Aged; Piperazines; Pyrazoles; Pyridones; Rivaroxaban | 2022 |
Drug Utilization Pattern of Oral Anticoagulants in Patients with Atrial Fibrillation: A Nationwide Population-Based Study in Korea.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Drug Utilization; Humans; Pyridones; Rivaroxaban; Stroke; Warfarin | 2022 |
CytoSorb haemoadsorption for removal of apixaban-A proof-of-concept pilot case for a randomized controlled trial.
Topics: Anticoagulants; Dabigatran; Humans; Pyridones; Rivaroxaban | 2022 |
Safety of apixaban and rivaroxaban compared to warfarin after cardiac surgery.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Cardiac Surgical Procedures; Dabigatran; Hemorrhage; Humans; Prospective Studies; Retrospective Studies; Rivaroxaban; Stroke; Warfarin | 2022 |
Variability in Nonvitamin K Oral Anticoagulant Dose Eligibility and Adjustment According to Renal Formulae and Clinical Outcomes in Patients With Atrial Fibrillation With and Without Chronic Kidney Disease: Insights From ORBIT-AF II.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Renal Insufficiency, Chronic; Rivaroxaban; Stroke | 2023 |
977 other study(ies) available for dabigatran and rivaroxaban
| Article | Year |
|---|---|
Low molecular weight dual inhibitors of factor Xa and fibrinogen binding to GPIIb/IIIa with highly overlapped pharmacophores.
Topics: Dose-Response Relationship, Drug; Factor Xa; Factor Xa Inhibitors; Fibrinogen; Humans; Models, Molecular; Molecular Structure; Molecular Weight; Oxadiazoles; Platelet Glycoprotein GPIIb-IIIa Complex; Protein Binding; Serine Proteases; Serine Proteinase Inhibitors; Structure-Activity Relationship | 2013 |
5-Chlorothiophene-2-carboxylic acid [(S)-2-[2-methyl-3-(2-oxopyrrolidin-1-yl)benzenesulfonylamino]-3-(4-methylpiperazin-1-yl)-3-oxopropyl]amide (SAR107375), a selective and potent orally active dual thrombin and factor Xa inhibitor.
Topics: Animals; Anticoagulants; Crystallography, X-Ray; Drug Design; Factor Xa Inhibitors; Fibrinolytic Agents; Humans; Piperazines; Rats; Sulfonamides; Thrombin; Venous Thrombosis | 2013 |
Structure-based discovery of small molecule hepsin and HGFA protease inhibitors: Evaluation of potency and selectivity derived from distinct binding pockets.
Topics: Amidines; Antineoplastic Agents; Arginine; Benzamidines; Catalytic Domain; Drug Design; Enzyme Assays; Guanidines; High-Throughput Screening Assays; Humans; Kinetics; Molecular Docking Simulation; Neoplasm Proteins; Peptidomimetics; Phenylalanine; Piperazines; Protease Inhibitors; Recombinant Proteins; Serine Endopeptidases; Structure-Activity Relationship; Urea | 2015 |
Acylated 1
Topics: Amines; Anticoagulants; Binding Sites; Blood Coagulation; Catalytic Domain; Cell Line, Tumor; Cell Survival; Factor XIIa; Humans; Inhibitory Concentration 50; Molecular Dynamics Simulation; Platelet Aggregation; Structure-Activity Relationship; Thrombin; Triazoles | 2020 |
Development of oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Azetidines; Benzimidazoles; Benzylamines; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dabigatran; Drug Delivery Systems; Drug Design; Enoxaparin; Factor Xa Inhibitors; Humans; Morpholines; Postoperative Hemorrhage; Pyridines; Rivaroxaban; Thiophenes; Venous Thromboembolism; Venous Thrombosis; Warfarin | 2007 |
[Always more amputations in Germany?].
Topics: Aged; Amputation, Surgical; Anticoagulants; Arterial Occlusive Diseases; Benzimidazoles; Dabigatran; Fibrinolytic Agents; Germany; Humans; Morpholines; Peripheral Vascular Diseases; Pyridines; Rivaroxaban; Thiophenes; Thrombosis | 2008 |
New issues in oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Clinical Trials as Topic; Cytochrome P-450 CYP2C9; Dabigatran; Enoxaparin; Genetic Variation; Humans; Mixed Function Oxygenases; Morpholines; Pharmacogenetics; Polymorphism, Genetic; Pyridines; Rivaroxaban; Thiophenes; Vitamin K Epoxide Reductases; Warfarin | 2008 |
The novel anticoagulants: entering a new era.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; Dabigatran; Heparin; Heparin, Low-Molecular-Weight; Humans; Morpholines; Orthopedic Procedures; Postoperative Complications; Pyridines; Rivaroxaban; Thiophenes; Thromboembolism; Thrombolytic Therapy; Vitamin K | 2009 |
In the pipeline: new oral anticoagulants for the prevention of venous thromboembolism.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; Clinical Trials as Topic; Dabigatran; Fibrinolytic Agents; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2009 |
[New anticoagulants].
Topics: Acute Coronary Syndrome; Anticoagulants; Antithrombins; Benzimidazoles; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Pyridines; Rivaroxaban; Thiophenes; Thromboembolism; Thrombosis | 2009 |
[New agents for the prevention of venous thromboembolism].
Topics: Benzimidazoles; Dabigatran; Enoxaparin; Fibrinolytic Agents; Humans; Morpholines; Pyridines; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; Treatment Outcome; Venous Thromboembolism | 2009 |
[The new oral anticoagulant in the Netherlands].
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; Dabigatran; Drug Interactions; Elective Surgical Procedures; Humans; Morpholines; Netherlands; Patient Selection; Pyridines; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2009 |
Favorable therapeutic index of the direct factor Xa inhibitors, apixaban and rivaroxaban, compared with the thrombin inhibitor dabigatran in rabbits.
Topics: Animals; Benzimidazoles; Blood Coagulation Tests; Dabigatran; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Fibrinolytic Agents; Hemorrhage; Morpholines; Pyrazoles; Pyridines; Pyridones; Rabbits; Rivaroxaban; Thiophenes; Thrombin; Venous Thrombosis | 2009 |
Rivaroxaban and dabigatran etexilate: two new oral anticoagulants for extended postoperative prevention of venous thromboembolism after elective total hip arthroplasty.
Topics: Administration, Oral; Anticoagulants; Arthroplasty, Replacement, Hip; Benzimidazoles; Dabigatran; Elective Surgical Procedures; Humans; Morpholines; Postoperative Complications; Pyridines; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2010 |
New anticoagulants for the prevention of deep venous thrombosis: time to consider cost effectiveness?
Topics: Anticoagulants; Benzimidazoles; Clinical Trials as Topic; Cost-Benefit Analysis; Dabigatran; Economics, Pharmaceutical; Humans; Morpholines; Pyridines; Rivaroxaban; Thiophenes; Venous Thrombosis | 2009 |
A cost-effectiveness model comparing rivaroxaban and dabigatran etexilate with enoxaparin sodium as thromboprophylaxis after total hip and total knee replacement in the irish healthcare setting.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; Cost-Benefit Analysis; Dabigatran; Decision Trees; Enoxaparin; Fibrinolytic Agents; Humans; Ireland; Models, Economic; Monte Carlo Method; Morpholines; Pyridines; Quality-Adjusted Life Years; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2009 |
[Pregnancy and venous thromboembolism. North-American and European guidelines. American College of Chest Physicians].
Topics: Abnormalities, Drug-Induced; Adult; Anticoagulants; Benzimidazoles; Blood Loss, Surgical; Cesarean Section; Contraindications; Dabigatran; Europe; Evidence-Based Medicine; Female; Fetus; Fondaparinux; Heparin; Heparin, Low-Molecular-Weight; Humans; Infant, Newborn; Morpholines; Polysaccharides; Practice Guidelines as Topic; Pregnancy; Pregnancy Complications, Hematologic; Puerperal Disorders; Pyridines; Rivaroxaban; Societies, Medical; Thiophenes; Thrombophilia; United States; Uterine Hemorrhage; Venous Thromboembolism; Warfarin | 2009 |
New agents for orthopaedic thromboprophylaxis: caution essential, but time will tell.
Topics: Anticoagulants; Benzimidazoles; Dabigatran; Enoxaparin; Humans; Morpholines; Orthopedic Procedures; Postoperative Complications; Pyridines; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2009 |
DVT: a new era in anticoagulant therapy.
Topics: Animals; Anticoagulants; Benzimidazoles; Dabigatran; Disease Models, Animal; Factor Xa Inhibitors; Humans; Mice; Mice, Knockout; Morpholines; Pyridines; Rivaroxaban; Thiophenes; Thrombin; Venous Thrombosis | 2010 |
[New oral anticoagulants: prospects].
Topics: Anticoagulants; Benzimidazoles; Clinical Trials as Topic; Dabigatran; Humans; Morpholines; Pyridines; Rivaroxaban; Thiophenes | 2010 |
Apixaban, a direct factor Xa inhibitor, inhibits tissue-factor induced human platelet aggregation in vitro: comparison with direct inhibitors of factor VIIa, XIa and thrombin.
Topics: Adenosine Diphosphate; Anticoagulants; Arginine; Azetidines; Benzimidazoles; Collagen; Dabigatran; Dose-Response Relationship, Drug; Factor VIIa; Factor Xa; Factor Xa Inhibitors; Factor XIa; Humans; Morpholines; Pipecolic Acids; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Sulfonamides; Thiophenes; Thrombin; Thromboplastin; Time Factors | 2010 |
[Anticoagulant therapy in cardiology: yesterday, today, tomorrow].
Topics: Anticoagulants; Benzimidazoles; Carboxypeptidase B2; Cardiovascular Diseases; Clinical Trials, Phase III as Topic; Dabigatran; Fibrinolytic Agents; Humans; Morpholines; Pyridines; Receptor, PAR-1; Rivaroxaban; Thiophenes; Thrombin; Thrombomodulin; Thrombosis; Treatment Outcome; Warfarin | 2010 |
Cost effectiveness of venous thromboembolism pharmacological prophylaxis in total hip and knee replacement: a systematic review.
Topics: Anticoagulants; Antithrombins; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; Clinical Trials as Topic; Cost-Benefit Analysis; Dabigatran; Enoxaparin; Fondaparinux; Heparin, Low-Molecular-Weight; Humans; Models, Economic; Morpholines; Polysaccharides; Postoperative Complications; Pyridines; Quality-Adjusted Life Years; Rivaroxaban; Thiophenes; Treatment Outcome; Venous Thromboembolism | 2010 |
Novel anticoagulants: new evidence for emerging drugs and their potential application in major lower limb surgery.
Topics: Anticoagulants; Benzimidazoles; Clinical Trials as Topic; Dabigatran; Drugs, Investigational; Factor Xa Inhibitors; Humans; Lower Extremity; Morpholines; Orthopedic Procedures; Pyridines; Rivaroxaban; Thiophenes; Thrombin; Venous Thromboembolism | 2011 |
Factor Xa and thrombin as targets for new oral anticoagulants.
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Clinical Trials as Topic; Dabigatran; Drug Discovery; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Thrombin; Venous Thromboembolism; Vitamin K | 2011 |
What do the RE-LY, AVERROES and ROCKET-AF trials tell us for stroke prevention in atrial fibrillation?
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Female; Humans; Male; Morpholines; Practice Guidelines as Topic; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes | 2011 |
New oral anticoagulants for thromboprophylaxis in patients having hip or knee arthroplasty.
Topics: Administration, Oral; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; Cost-Benefit Analysis; Dabigatran; Drug Interactions; Hemorrhage; Humans; Kidney Diseases; Morpholines; Pyridines; Rivaroxaban; Thiophenes; Treatment Outcome; Venous Thromboembolism | 2011 |
Coagulation parameters in patients receiving dabigatran etexilate or rivaroxaban: two observational studies in patients undergoing total hip or total knee replacement.
Topics: Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; Blood Coagulation; Dabigatran; Humans; Male; Middle Aged; Morpholines; Pyridines; Rivaroxaban; Thiophenes | 2011 |
An indirect comparison, via enoxaparin, of rivaroxaban with dabigatran in the prevention of venous thromboembolism after hip or knee replacement.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Dabigatran; Enoxaparin; Female; Health Care Costs; Humans; Male; Middle Aged; Morpholines; Postoperative Complications; Risk; Risk Factors; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2011 |
New oral anticoagulants for venous thromboembolism prophylaxis in orthopaedic surgery.
Topics: Anticoagulants; Antithrombin Proteins; Arthroplasty, Replacement, Knee; Benzimidazoles; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Orthopedic Procedures; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2011 |
Incidence of chronic kidney disease in patients with atrial fibrillation and its relevance for prescribing new oral antithrombotic drugs.
Topics: Administration, Oral; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Biomarkers; Chronic Disease; Creatinine; Dabigatran; Fibrinolytic Agents; Glomerular Filtration Rate; Humans; Incidence; Kidney; Kidney Diseases; Morpholines; Netherlands; Patient Selection; Retrospective Studies; Risk Assessment; Risk Factors; Rivaroxaban; Severity of Illness Index; Thiophenes | 2011 |
[New anticoagulants in the prevention and treatment of venous thromboembolism].
Topics: Administration, Oral; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Drug Costs; Drugs, Investigational; Factor Xa Inhibitors; Humans; Hungary; Morpholines; Oligosaccharides; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Thrombin; Venous Thromboembolism | 2011 |
[Current and future therapies for prophylaxis of thromboembolism in atrial fibrillation].
Topics: Anticoagulants; Antithrombin Proteins; Atrial Fibrillation; Benzimidazoles; Dabigatran; Drug Therapy, Combination; Factor Xa Inhibitors; Fibrinolytic Agents; Guideline Adherence; Hemorrhage; Humans; Intracranial Embolism; Morpholines; Platelet Aggregation Inhibitors; Pyrazoles; Pyridines; Pyridones; Risk Factors; Rivaroxaban; Thiophenes; Vitamin K | 2011 |
[Is the era from the end of warfarin?].
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Phenprocoumon; Rivaroxaban; Thiophenes; Vitamin K | 2011 |
New options in anticoagulation for atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Intention to Treat Analysis; Intracranial Hemorrhages; Morpholines; Rivaroxaban; Thiophenes; Warfarin | 2011 |
New antithrombotic drugs and European approval processes.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Approval; Europe; Fibrinolytic Agents; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes | 2011 |
New anticoagulants: moving on from scientific results to clinical implementation.
Topics: Acute Coronary Syndrome; Anticoagulants; Arthroplasty, Replacement, Hip; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Diet; Drug Interactions; Factor VIIa; Factor Xa Inhibitors; Humans; Kidney; Life Style; Monitoring, Physiologic; Morpholines; Recombinant Proteins; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism; Vitamin K | 2011 |
A new era for anticoagulation in atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Thromboembolism; Warfarin | 2011 |
The future of anticoagulant therapy.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation Disorders; Dabigatran; Drug Approval; Fibrinolytic Agents; Humans; Morpholines; Rivaroxaban; Stroke; Thiophenes | 2012 |
["Xa-tra-xa": opportunities and open questions about new anticoagulants].
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2011 |
Reversal of new oral anticoagulants.
Topics: Anticoagulants; Antidotes; Benzimidazoles; beta-Alanine; Blood Coagulation; Blood Coagulation Factors; Dabigatran; Humans; Male; Morpholines; Rivaroxaban; Thiophenes | 2011 |
The new oral anticoagulants.
Topics: Anticoagulants; Benzimidazoles; Clinical Trials, Phase III as Topic; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes | 2011 |
Heparin-induced thrombocytopenia: in vitro studies on the interaction of dabigatran, rivaroxaban, and low-sulfated heparin, with platelet factor 4 and anti-PF4/heparin antibodies.
Topics: Antibodies; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Cells; Cells, Cultured; Dabigatran; Drug Evaluation, Preclinical; Drug Interactions; HEK293 Cells; Heparin; Humans; Morpholines; Platelet Factor 4; Rivaroxaban; Sulfates; Thiophenes; Thrombocytopenia; Transfection | 2012 |
Lack of an antagonist to reverse the action of dabigatran.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation Factors; Dabigatran; Hemorrhage; Humans; Morpholines; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; Warfarin | 2012 |
Concerns about studies investigating new anticoagulant drugs for stroke prevention in atrial fibrillation.
Topics: Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Vitamin K | 2012 |
[Anticoagulation in atrial fibrillation: a new era has begun].
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thromboembolism | 2012 |
[Pharmacologic heterogeneity of new anticoagulants].
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Contraindications; Dabigatran; Drug Approval; Humans; Kidney; Liver; Morpholines; Postoperative Complications; Pulmonary Embolism; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thromboembolism; United States; United States Food and Drug Administration | 2011 |
[New treatments for venous thromboembolic disease].
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Heparin; Humans; Morpholines; Pulmonary Embolism; Rivaroxaban; Secondary Prevention; Thiophenes; Venous Thrombosis; Warfarin | 2011 |
Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a 'real world' atrial fibrillation population: a modelling analysis based on a nationwide cohort study.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Cohort Studies; Computer Simulation; Dabigatran; Decision Making, Computer-Assisted; Denmark; Humans; Intracranial Hemorrhages; Morpholines; Population Groups; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin | 2012 |
[New anticoagulants].
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Fondaparinux; Humans; Morpholines; Polysaccharides; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes | 2011 |
Anticoagulation prophylaxis in orthopedic surgery: an efficiency frontier approach.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Decision Trees; Drug Costs; Elective Surgical Procedures; Enoxaparin; Female; Humans; Male; Markov Chains; Models, Economic; Morpholines; Postoperative Complications; Pyrazoles; Pyridones; Quality-Adjusted Life Years; Rivaroxaban; State Medicine; Thiophenes; United Kingdom; Venous Thromboembolism | 2012 |
What's the "go to" anticoagulant for stroke prevention in atrial fibrillation?
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes | 2012 |
I recently heard that there are alternative medications to the blood thinner warfarin. What are they, and how are they different?
Topics: Anticoagulants; Benzimidazoles; Cardiovascular Diseases; Dabigatran; Drug Approval; Drug Interactions; Food-Drug Interactions; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiophenes; Warfarin | 2012 |
New directions in anticoagulation.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation Disorders; Clinical Trials as Topic; Dabigatran; Humans; Morpholines; Postoperative Complications; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2012 |
New antithrombotic drugs: a revolution in stroke management.
Topics: Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Drug Approval; Drug Interactions; Drug Therapy, Combination; Fibrinolytic Agents; Humans; Monitoring, Physiologic; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2012 |
[Update on current care guidelines: atrial fibrillation].
Topics: Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Dronedarone; Finland; Humans; Morpholines; Practice Guidelines as Topic; Rivaroxaban; Thiophenes; Warfarin | 2012 |
Medical cost reductions associated with the usage of novel oral anticoagulants vs warfarin among atrial fibrillation patients, based on the RE-LY, ROCKET-AF, and ARISTOTLE trials.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost Control; Dabigatran; Endpoint Determination; Health Expenditures; Humans; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; United States; Warfarin | 2012 |
[Anticoagulant therapeutics: In order not to jeopardize a potential therapeutical progress].
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiophenes | 2012 |
Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Clinical Trials, Phase III as Topic; Dabigatran; Female; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Odds Ratio; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome | 2012 |
[Expanded arsenal in atrial fibrillation: bye-bye marcumar?].
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Approval; Drug Interactions; Drug Substitution; Factor Xa Inhibitors; Germany; Humans; Morpholines; Phenprocoumon; Rivaroxaban; Thiophenes; Thromboembolism | 2012 |
Value-of-information analysis to reduce decision uncertainty associated with the choice of thromboprophylaxis after total hip replacement in the Irish healthcare setting.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Benzimidazoles; Cost-Benefit Analysis; Dabigatran; Decision Making; Enoxaparin; Guidelines as Topic; Health Care Costs; Humans; Ireland; Models, Economic; Morpholines; Pyridines; Quality-Adjusted Life Years; Rivaroxaban; Technology Assessment, Biomedical; Thiophenes; Time Factors; Venous Thromboembolism | 2012 |
Beyond warfarin: the new generation of oral anticoagulants and their implications for the management of dental patients.
Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Biological Availability; Blood Coagulation Tests; Dabigatran; Drug Interactions; Factor Xa Inhibitors; Half-Life; Humans; Morpholines; Narcotics; Oral Hemorrhage; Oral Surgical Procedures; Postoperative Hemorrhage; Rivaroxaban; Thiophenes; Warfarin | 2012 |
Oral anticoagulants for atrial fibrillation: Which one to choose?
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Drug Costs; Drug Substitution; Humans; Morpholines; Pyridines; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2012 |
Reverse engineering for new oral anticoagulants: non-specific reversal agents and the anticoagulant activity of dabigatran and rivaroxaban.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Male; Morpholines; Rivaroxaban; Thiophenes | 2012 |
A clinical decision aid for the selection of antithrombotic therapy for the prevention of stroke due to atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Decision Support Techniques; Drug Costs; Fibrinolytic Agents; Humans; Morpholines; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes | 2012 |
Indirect comparison studies--are they useful? Insights from the novel oral anticoagulants for stroke prevention in atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Female; Humans; Male; Morpholines; Multicenter Studies as Topic; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; Thrombophilia | 2012 |
Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Embolism; Evidence-Based Medicine; Female; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Time Factors; Treatment Outcome; Warfarin | 2012 |
New oral anticoagulant in atrial fibrillation: are they comparable?
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Embolism; Female; Humans; Male; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes | 2012 |
Determination of the anti-F10a or anti-F2a generation action of rivaroxaban or dabigatran.
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Dose-Response Relationship, Drug; Humans; Morpholines; Rivaroxaban; Thiophenes; Thrombin | 2012 |
Head-to-head or indirect comparisons of the novel oral anticoagulants in atrial fibrillation: what's next?
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Female; Humans; Male; Morpholines; Multicenter Studies as Topic; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; Thrombophilia | 2012 |
Concerns about storage and application of dabigatran and rivaroxaban.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Capsules; Dabigatran; Drug Packaging; Drug Stability; Drug Storage; Humans; Humidity; Morpholines; Rivaroxaban; Sunlight; Temperature; Thiophenes | 2013 |
New anticoagulants.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Interactions; Humans; Morpholines; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2012 |
Danger ahead: watch out for indirect comparisons!
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Female; Hemorrhage; Humans; Male; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiophenes | 2012 |
Dabigatran versus rivaroxaban for the prevention of stroke and systemic embolism in atrial fibrillation in Canada. Comparative efficacy and cost-effectiveness.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Canada; Clinical Trials as Topic; Cost-Benefit Analysis; Dabigatran; Embolism; Humans; Markov Chains; Models, Economic; Morpholines; Quality-Adjusted Life Years; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin | 2012 |
Effects on routine coagulation screens and assessment of anticoagulant intensity in patients taking oral dabigatran or rivaroxaban: guidance from the British Committee for Standards in Haematology.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation; Blood Coagulation Tests; Dabigatran; Humans; Morpholines; Risk Assessment; Rivaroxaban; Thiophenes | 2012 |
Catheter ablation of atrial fibrillation: the need for studies to assess the efficacy and safety of novel anticoagulants.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatran; Humans; Morpholines; Risk Factors; Rivaroxaban; Thiophenes; Thromboembolism; United States; Warfarin | 2013 |
Periprocedural anticoagulant management.
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Coronary Restenosis; Dabigatran; Heart Valve Prosthesis; Hemorrhage; Humans; Morpholines; Neoplasms; Perioperative Care; Risk Assessment; Rivaroxaban; Stents; Thiophenes; Venous Thromboembolism; Warfarin | 2012 |
The new oral anticoagulants: a challenge for hospital formularies.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Benzamides; Benzimidazoles; beta-Alanine; Dabigatran; Formularies, Hospital as Topic; Humans; Morpholines; Pennsylvania; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiophenes; Warfarin | 2012 |
Increase in referrals.
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Creatinine; Dabigatran; Dental Service, Hospital; Factor Xa Inhibitors; Humans; Kidney; Morpholines; Referral and Consultation; Rivaroxaban; Thiophenes; Tooth Extraction | 2012 |
[Role of new oral anticoagulants in interventional cardiology].
Topics: Acute Coronary Syndrome; Administration, Oral; Angioplasty, Balloon, Coronary; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation Factors; Cardiac Surgical Procedures; Cardiology; Dabigatran; Humans; Morpholines; Percutaneous Coronary Intervention; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Treatment Outcome | 2012 |
[Introduction].
Topics: Acenocoumarol; Anticoagulants; Benzamides; Benzimidazoles; beta-Alanine; Dabigatran; Heparin; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Thromboembolism; Thrombosis; Warfarin | 2012 |
[New advances in anticoagulation: is it time to forget about heparin and vitamin K antagonists? Yes].
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Heparin; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Venous Thromboembolism; Warfarin | 2012 |
Primary and secondary prevention with new oral anticoagulant drugs for stroke prevention in atrial fibrillation: indirect comparison analysis.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Clinical Trials, Phase III as Topic; Comparative Effectiveness Research; Dabigatran; Dose-Response Relationship, Drug; Drug Monitoring; Female; Hemorrhage; Humans; Male; Morpholines; Pharmacovigilance; Primary Prevention; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Secondary Prevention; Stroke; Thiophenes; Warfarin | 2012 |
New oral anticoagulants.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; Canada; Contraindications; Dabigatran; Drug Dosage Calculations; Drug Interactions; Humans; Morpholines; Postoperative Complications; Pyridines; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism; Venous Thrombosis | 2013 |
[New anticoagulants: better knowledge, better prescriptions].
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Evidence-Based Medicine; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Venous Thromboembolism; Vitamin K | 2012 |
[Management of intracranial hemorrhage during anticoagulant therapy with warfarin or novel anticoagulants].
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Cerebral Hemorrhage; Dabigatran; Humans; Intracranial Embolism; Morpholines; Rivaroxaban; Thiophenes; Warfarin | 2012 |
Rivaroxaban and atrial fibrillation: continue to use warfarin or in some cases, dabigatran.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Interactions; Factor Xa Inhibitors; Humans; Kidney; Morpholines; Rivaroxaban; Thiophenes; Warfarin | 2012 |
Novel methods for assessing oral direct factor Xa and thrombin inhibitors: use of point-of-care testing and urine samples.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Clinical Chemistry Tests; Dabigatran; Factor Xa Inhibitors; Female; Humans; Male; Morpholines; Point-of-Care Systems; Pregnancy; Reproducibility of Results; Rivaroxaban; Thiophenes | 2013 |
Transitions of care in anticoagulation management for patients with atrial fibrillation.
Topics: Administration, Oral; Aftercare; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Continuity of Patient Care; Dabigatran; Drug Monitoring; Drug Substitution; Emergencies; Hemorrhage; Humans; Morpholines; Patient Education as Topic; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2012 |
[Budgetary impact for the National Health System of apixaban prophylaxis of venous thromboembolism in patients undergoing total knee or hip replacement].
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Budgets; Cost Control; Dabigatran; Enoxaparin; Female; Fibrinolytic Agents; Fondaparinux; Hemorrhage; Humans; Morpholines; Polysaccharides; Pulmonary Embolism; Pyrazoles; Pyridones; Rivaroxaban; Spain; State Medicine; Thiophenes; Venous Thromboembolism | 2012 |
Measurement of dabigatran and rivaroxaban in primary prevention of venous thromboembolism in 106 patients, who have undergone major orthopedic surgery: an observational study.
Topics: Aged; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Blood Coagulation Tests; Dabigatran; Female; Humans; Male; Middle Aged; Morpholines; Orthopedic Procedures; Primary Prevention; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2013 |
[Perioperative management in patients receiving newer oral anticoagulant and antiaggregant agents].
Topics: Administration, Oral; Anticoagulants; Dabigatran; Humans; Rivaroxaban; Warfarin | 2012 |
Laboratory assessment of novel oral anticoagulants: method suitability and variability between coagulation laboratories.
Topics: Administration, Oral; Analysis of Variance; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation Tests; Dabigatran; Dose-Response Relationship, Drug; Humans; International Normalized Ratio; Laboratories; Morpholines; Partial Thromboplastin Time; Reproducibility of Results; Rivaroxaban; Thiophenes | 2013 |
[New anticoagulants--should we have a little bit of cold water in the blood?].
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Interactions; Drug Monitoring; Factor Xa Inhibitors; Humans; Medication Adherence; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Warfarin | 2013 |
Novel oral anticoagulants for the prevention of venous thromboembolism in surgical patients.
Topics: Administration, Oral; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Dabigatran; Heparin; Heparin, Low-Molecular-Weight; Humans; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2013 |
Inhibitory effect of apixaban compared with rivaroxaban and dabigatran on thrombin generation assay.
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thrombin; Thrombin Time | 2013 |
Recent advances in antithrombotic therapy for stroke prevention in patients with atrial fibrillation.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Comorbidity; Dabigatran; Hemorrhage; Humans; Morpholines; Platelet Aggregation Inhibitors; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2013 |
Warfarin replacements: good for patients, challenging for laboratories.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation Tests; Dabigatran; Humans; Laboratories; Morpholines; Rivaroxaban; Thiophenes | 2013 |
[New oral anticoagulants in the treatment of venous thromboembolic disease].
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Humans; Morpholines; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2013 |
Venous thromboembolism: prophylactic and therapeutic practice guideline.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Chemoprevention; Dabigatran; Disease Management; Dose-Response Relationship, Drug; Drug Delivery Systems; Drug Monitoring; Drug Substitution; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; International Normalized Ratio; Morpholines; Preoperative Care; Risk Assessment; Risk Factors; Rivaroxaban; Secondary Prevention; Thiophenes; Time Factors; Vena Cava Filters; Venous Thromboembolism | 2013 |
Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cohort Studies; Cost-Benefit Analysis; Dabigatran; Dose-Response Relationship, Drug; Humans; Markov Chains; Models, Statistical; Morpholines; Pyrazoles; Pyridones; Quality-Adjusted Life Years; Risk Factors; Rivaroxaban; Stroke; Thiophenes; United States; Warfarin | 2013 |
[Your patient needs antithrombotics, 2. What do the new substances offer? (interview by Dr. med. Peter Stiefelhagen)].
Topics: Adenosine; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cardiovascular Diseases; Clopidogrel; Dabigatran; Fibrinolytic Agents; Guideline Adherence; Humans; Morpholines; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thromboembolism; Ticagrelor; Ticlopidine; Treatment Outcome | 2013 |
Comparative effectiveness of dabigatran, rivaroxaban, apixaban, and warfarin in the management of patients with nonvalvular atrial fibrillation.
Topics: Age Factors; Aged; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cardiovascular Diseases; Comorbidity; Computer Simulation; Dabigatran; Female; Hemorrhage; Humans; Male; Morpholines; Pyrazoles; Pyridones; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; Time Factors; Warfarin | 2013 |
[Stroke prevention in atrial fibrillation : old and new anticoagulants].
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Vitamin K | 2013 |
Laboratory testing for the new oral anticoagulants: a review of current practice.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation; Blood Coagulation Tests; Dabigatran; Factor X; Humans; Morpholines; Rivaroxaban; Surveys and Questionnaires; Thiophenes | 2013 |
New approaches to reversing oral anticoagulant therapy. Introduction.
Topics: Administration, Oral; Anticoagulants; Antifibrinolytic Agents; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Morpholines; Plasma; Primary Prevention; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thromboembolism; Treatment Outcome; Vitamin K 1 | 2013 |
Pharmacologic interventions for reversing the effects of oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Antifibrinolytic Agents; Antithrombins; Benzimidazoles; beta-Alanine; Blood Coagulation Factors; Blood Loss, Surgical; Dabigatran; Drug Therapy, Combination; Emergencies; Hemorrhage; Humans; International Normalized Ratio; Morpholines; Plasma; Pyrazoles; Pyridones; Rivaroxaban; Surgical Procedures, Operative; Thiophenes; Thromboembolism; Treatment Outcome; Vitamin K 1; Warfarin | 2013 |
Anticoagulant guidelines.
Topics: Anticoagulants; Benzimidazoles; Coumarins; Dabigatran; Dental Care for Chronically Ill; Hemostatic Techniques; Humans; Interprofessional Relations; Morpholines; Oral Hemorrhage; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Pyridines; Rivaroxaban; Thiophenes | 2013 |
Conventional and new oral anticoagulants in the treatment of chest disease and its complications.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Humans; Morpholines; Orthopedic Procedures; Practice Guidelines as Topic; Prognosis; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism; Vitamin K | 2013 |
[Venous thromboembolism. Currently it is worthwhile to use anticoagulants longer].
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Long-Term Care; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Secondary Prevention; Thiophenes; Venous Thromboembolism | 2013 |
[New oral anticoagulants and digestive hemorrhages].
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Female; Gastrointestinal Hemorrhage; Humans; Male; Morpholines; Retrospective Studies; Rivaroxaban; Thiophenes | 2014 |
Contra: "New oral anticoagulants should not be used as 1st choice for secondary stroke prevention in atrial fibrillation".
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Middle Aged; Morpholines; Patient Safety; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Secondary Prevention; Stroke; Thiophenes; Warfarin | 2013 |
Pro: "The novel oral anticoagulants should be used as 1st choice for secondary prevention in patients with atrial fibrillation.".
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Diabetes Complications; Female; Hemorrhage; Humans; Hypertension; Male; Middle Aged; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Secondary Prevention; Stroke; Thiophenes; Warfarin | 2013 |
Perioperative management of patients who are receiving a novel oral anticoagulant.
Topics: Aged; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Male; Morpholines; Perioperative Care; Postoperative Complications; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Thiophenes; Thromboembolism | 2013 |
[New oral anticoagulant agents: the quandary of anticoagulation in the elderly].
Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Interactions; Humans; Medication Adherence; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2013 |
Medical costs in the US of clinical events associated with oral anticoagulant (OAC) use compared to warfarin among non-valvular atrial fibrillation patients ≥75 and <75 years of age, based on the ARISTOTLE, RE-LY, and ROCKET-AF trials.
Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost Savings; Cost-Benefit Analysis; Dabigatran; Drug Costs; Drug Utilization; Female; Humans; Male; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Risk Assessment; Rivaroxaban; Severity of Illness Index; Stroke; Thiophenes; United States; Warfarin | 2013 |
Management of bleeding associated with dabigatran and rivaroxaban: a survey of current practices.
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Data Collection; Female; Hemorrhage; Humans; Male; Morpholines; Practice Patterns, Physicians'; Rivaroxaban; Thiophenes | 2013 |
Should the newer oral anticoagulants be withheld from patients with valvular AF?
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Heart Valve Diseases; Humans; International Normalized Ratio; Morpholines; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2013 |
Atrial fibrillation and anticoagulation management: a wake-up call to practitioners, patients, and policymakers.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2013 |
The promise of pharmacoepidemiology in helping clinicians assess drug risk.
Topics: Administration, Oral; Advertising; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Confounding Factors, Epidemiologic; Dabigatran; Decision Making; Evidence-Based Medicine; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Pharmacoepidemiology; Product Surveillance, Postmarketing; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Research Design; Risk Assessment; Rivaroxaban; Therapeutic Equivalency; Thiophenes; United States; United States Food and Drug Administration; Warfarin | 2013 |
[Differential therapy with the new anticoagulants, 5].
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Approval; Drug Interactions; Germany; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes | 2013 |
New oral anticoagulants for non-valvular atrial fibrillation--safety issues.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome | 2013 |
New oral anticoagulants and risks in ENT.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Otolaryngology; Rivaroxaban; Thiophenes | 2013 |
The gap between trial data and clinical practice -- an analysis of case reports on bleeding complications occurring under dabigatran and rivaroxaban anticoagulation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Female; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin | 2013 |
A comparison of methods for estimating glomerular filtration rate for a population in Hawai'i with non-valvular atrial fibrillation.
Topics: Aged, 80 and over; Anticoagulants; Arginine; Asian People; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Glomerular Filtration Rate; Hawaii; Humans; Male; Morpholines; Pipecolic Acids; Retrospective Studies; Rivaroxaban; Sulfonamides; Thiophenes; Warfarin | 2013 |
Anticoagulation without monitoring.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Monitoring; Hemorrhage; Heparin; Humans; Morpholines; Pharmacovigilance; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thrombosis; Warfarin | 2013 |
Dabigatran and rivaroxaban prescription for atrial fibrillation in Catalonia, Spain: the need to manage the introduction of new drugs.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Utilization; Female; Humans; Male; Middle Aged; Morpholines; Practice Patterns, Physicians'; Rivaroxaban; Spain; Thiophenes | 2014 |
Apixaban, dabigatran, and rivaroxaban versus warfarin for stroke prevention in non-valvular atrial fibrillation: a cost-effectiveness analysis.
Topics: Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Drug Costs; Factor Xa Inhibitors; Health Care Costs; Humans; Italy; Markov Chains; Morpholines; Pyrazoles; Pyridones; Quality of Life; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin | 2014 |
[New direct oral anticoagulants and venous thromboprophylaxis].
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thrombosis | 2013 |
Routine coagulation assays underestimate levels of antithrombin-dependent drugs but not of direct anticoagulant drugs in plasma from patients with cirrhosis.
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Blood Coagulation; Blood Coagulation Tests; Dabigatran; Diagnostic Tests, Routine; Drug Monitoring; Factor Xa Inhibitors; False Negative Reactions; Female; Fondaparinux; Heparin; Heparin, Low-Molecular-Weight; Humans; Liver Cirrhosis; Male; Middle Aged; Morpholines; Polysaccharides; Prothrombin; Rivaroxaban; Sensitivity and Specificity; Thiophenes; Thrombophilia | 2013 |
Comparison of cost-effectiveness of anticoagulation with dabigatran, rivaroxaban and apixaban in patients with non-valvular atrial fibrillation across countries.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Costs and Cost Analysis; Dabigatran; Female; Germany; Humans; Male; Models, Econometric; Morpholines; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Thiophenes | 2014 |
Cost-effectiveness of oral anticoagulants for treatment of atrial fibrillation.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Humans; Models, Statistical; Morpholines; Pyrazoles; Pyridones; Quality-Adjusted Life Years; Rivaroxaban; Thiophenes; United States; Warfarin | 2013 |
New oral anticoagulants: an emergency department overview.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Australia; Benzimidazoles; beta-Alanine; Dabigatran; Emergency Service, Hospital; Humans; Morpholines; Pulmonary Embolism; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Venous Thrombosis | 2013 |
New oral anticoagulants: their role and future.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism; Warfarin | 2013 |
[Experience with rivaroxaban and dabigatran].
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Drug Therapy, Combination; Female; Hemorrhage; Humans; Morpholines; Protein C Deficiency; Rivaroxaban; Thiophenes; Treatment Outcome; Young Adult | 2013 |
Thrombin generation using the calibrated automated thrombinoscope to assess reversibility of dabigatran and rivaroxaban.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Atrial Fibrillation; Automation, Laboratory; Benzimidazoles; beta-Alanine; Blood Coagulation Factors; Dabigatran; Equipment and Supplies; Factor VII; Hemorrhage; Humans; Morpholines; Postoperative Complications; Rivaroxaban; Stroke; Thiophenes; Thrombelastography; Thrombin; Thrombin Time; Venous Thrombosis; Withholding Treatment | 2014 |
How I treat target-specific oral anticoagulant-associated bleeding.
Topics: Administration, Oral; Anticoagulants; Antifibrinolytic Agents; Antithrombins; Benzimidazoles; beta-Alanine; Blood Coagulation Factors; Dabigatran; Drug Monitoring; Factor VIIa; Hemorrhage; Hemostatics; Humans; Morpholines; Pyrazoles; Pyridones; Recombinant Proteins; Renal Dialysis; Rivaroxaban; Thiophenes | 2014 |
Dabigatran, rivaroxaban, apixaban, argatroban and fondaparinux and their effects on coagulation POC and platelet function tests.
Topics: Anticoagulants; Arginine; Artifacts; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Fondaparinux; Humans; Morpholines; Pipecolic Acids; Platelet Function Tests; Point-of-Care Systems; Polysaccharides; Pyrazoles; Pyridones; Rivaroxaban; Sulfonamides; Thiophenes; Thrombelastography; Whole Blood Coagulation Time | 2014 |
New oral anticoagulants for acute venous thromboembolism.
Topics: Acute Disease; Anticoagulants; Benzimidazoles; Dabigatran; Drug Approval; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Treatment Outcome; Venous Thromboembolism | 2014 |
Differential contribution of FXa and thrombin to vascular inflammation in a mouse model of sickle cell disease.
Topics: Anemia, Sickle Cell; Animals; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Bone Marrow Transplantation; Dabigatran; Disease Models, Animal; Factor Xa; Factor Xa Inhibitors; Female; Immunoenzyme Techniques; Inflammation; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Morpholines; Receptor, PAR-1; Receptor, PAR-2; Rivaroxaban; Thiophenes; Thrombin; Vascular Diseases | 2014 |
Treatment with novel oral anticoagulants in a real-world cohort of patients undergoing cardiac rhythm device implantations.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cardiac Pacing, Artificial; Dabigatran; Defibrillators, Implantable; Electric Countershock; Female; Germany; Hematoma; Hemorrhage; Humans; Incidence; Male; Middle Aged; Morpholines; Pacemaker, Artificial; Prospective Studies; Prosthesis Design; Prosthesis Implantation; Risk Factors; Rivaroxaban; Thiophenes; Thromboembolism; Time Factors; Treatment Outcome | 2014 |
Comparative evaluation of direct thrombin and factor Xa inhibitors with antiplatelet agents under flow and static conditions: an in vitro flow chamber model.
Topics: Adenosine Triphosphate; Adult; Anticoagulants; Antithrombins; Aspirin; Benzimidazoles; beta-Alanine; Blood Platelets; Dabigatran; Dose-Response Relationship, Drug; Factor Xa; Factor Xa Inhibitors; Female; Fibrin; Humans; Lab-On-A-Chip Devices; Male; Microscopy, Confocal; Morpholines; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Rivaroxaban; Thiophenes; Thrombin; Thromboplastin; Thrombosis | 2014 |
Comparison of the phase III clinical trial designs of novel oral anticoagulants versus warfarin for the treatment of nonvalvular atrial fibrillation: implications for clinical practice.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Research Design; Rivaroxaban; Thiazoles; Thiophenes; Vitamin K; Warfarin | 2014 |
Differential in vitro inhibition of thrombin generation by anticoagulant drugs in plasma from patients with cirrhosis.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation Tests; Dabigatran; Female; Fondaparinux; Heparin, Low-Molecular-Weight; Humans; Liver Cirrhosis; Male; Middle Aged; Morpholines; Polysaccharides; Rivaroxaban; Thiophenes; Thrombin | 2014 |
Cost-effectiveness of apixaban versus other new oral anticoagulants for stroke prevention in atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Humans; Markov Chains; Models, Economic; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome | 2014 |
Rivaroxaban and dabigatran in patients undergoing catheter ablation of atrial fibrillation.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatran; Drug Prescriptions; Drug Utilization Review; Female; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Portugal; Practice Patterns, Physicians'; Prospective Studies; Risk Assessment; Risk Factors; Rivaroxaban; Thiophenes; Thromboembolism; Time Factors; Treatment Outcome | 2014 |
Safety of short-term use of dabigatran or rivaroxaban for direct-current cardioversion in patients with atrial fibrillation and atrial flutter.
Topics: Administration, Oral; Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Atrial Flutter; Benzimidazoles; beta-Alanine; Dabigatran; Dose-Response Relationship, Drug; Echocardiography, Transesophageal; Electric Countershock; Electrocardiography; Factor Xa Inhibitors; Female; Follow-Up Studies; Humans; Male; Morpholines; Retrospective Studies; Rivaroxaban; Thiophenes; Thromboembolism; Time Factors; Treatment Outcome | 2014 |
Efficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation. An indirect comparison analysis.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Female; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Myocardial Infarction; Precision Medicine; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Survival Analysis; Thiazoles; Thiophenes; Treatment Outcome | 2014 |
Safety of new oral anticoagulants for patients undergoing atrial fibrillation ablation.
Topics: Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatran; Factor Xa Inhibitors; Female; Humans; Male; Middle Aged; Morpholines; Pulmonary Veins; Retrospective Studies; Rivaroxaban; Thiophenes; Thromboembolism; Warfarin | 2014 |
Measurement of the direct oral anticoagulants apixaban, dabigatran, edoxaban, and rivaroxaban in human plasma using turbulent flow liquid chromatography with high-resolution mass spectrometry.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Chromatography, Liquid; Dabigatran; Humans; Mass Spectrometry; Molecular Structure; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes | 2014 |
Insufficient anticoagulation with dabigatran in a patient with short bowel syndrome.
Topics: Administration, Oral; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Biological Availability; Blood Coagulation; Dabigatran; Drug Monitoring; Drug Substitution; Factor Xa Inhibitors; Female; Humans; Infarction, Middle Cerebral Artery; Intestinal Absorption; Morpholines; Predictive Value of Tests; Pyridines; Risk Factors; Rivaroxaban; Short Bowel Syndrome; Thiophenes; Treatment Outcome | 2014 |
Safety of switching from vitamin K antagonists to dabigatran or rivaroxaban in daily care--results from the Dresden NOAC registry.
Topics: Aged; Aged, 80 and over; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Female; Humans; International Normalized Ratio; Male; Middle Aged; Morpholines; Registries; Rivaroxaban; Thiophenes; Vitamin K | 2014 |
Economic evaluation of warfarin, dabigatran, rivaroxaban, and apixaban for stroke prevention in atrial fibrillation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Decision Support Techniques; Humans; Markov Chains; Models, Statistical; Morpholines; Norway; Pyrazoles; Pyridones; Quality-Adjusted Life Years; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2014 |
Triple antithrombotic therapy: risky but sometimes necessary.
Topics: Anticoagulants; Aspirin; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Clopidogrel; Dabigatran; Drug Therapy, Combination; Humans; Morpholines; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Ticlopidine; Vitamin K | 2014 |
Perioperative management of patients on new oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Biological Availability; Clinical Trials as Topic; Dabigatran; Drug Monitoring; Elective Surgical Procedures; Emergencies; Half-Life; Hemorrhage; Humans; Medication Adherence; Morpholines; Preoperative Care; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Time Factors; Warfarin | 2014 |
Urgent monitoring of direct oral anticoagulants in patients with atrial fibrillation: a tentative approach based on routine laboratory tests.
Topics: Administration, Oral; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Humans; Monitoring, Physiologic; Morpholines; Partial Thromboplastin Time; Rivaroxaban; Thiophenes; Thrombin Time | 2014 |
Stroke prevention in patients with atrial fibrillation in France: comparative cost-effectiveness of new oral anticoagulants (apixaban, dabigatran, and rivaroxaban), warfarin, and aspirin.
Topics: Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Comparative Effectiveness Research; Cost-Benefit Analysis; Dabigatran; Factor Xa Inhibitors; Female; France; Humans; Male; Morpholines; Pyrazoles; Pyridones; Quality-Adjusted Life Years; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2014 |
[Rivaroxaban, dabigatran and apixaban: new anticoagulants in operative urology].
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Loss, Surgical; Dabigatran; Humans; Morpholines; Postoperative Hemorrhage; Premedication; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Treatment Outcome; Urologic Surgical Procedures | 2014 |
Patterns of initiation of oral anticoagulants in patients with atrial fibrillation- quality and cost implications.
Topics: Administration, Oral; Adolescent; Adult; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Databases, Factual; Drug Utilization Review; Factor Xa Inhibitors; Fees, Pharmaceutical; Female; Humans; Income; Male; Middle Aged; Morpholines; Multivariate Analysis; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Severity of Illness Index; Sex Factors; Stroke; Thiophenes; United States; Vitamin K; Warfarin; Young Adult | 2014 |
Direct oral anticoagulants--pharmacology, drug interactions, and side effects.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Interactions; Drug Monitoring; Half-Life; Hemorrhage; Humans; Kidney; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Thromboembolism | 2014 |
Direct oral anticoagulants in atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Embolism; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Risk Factors; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Warfarin | 2014 |
Direct oral anticoagulants in acute coronary syndrome.
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Benzimidazoles; Clinical Trials as Topic; Dabigatran; Factor Xa; Factor Xa Inhibitors; Humans; Ischemia; Morpholines; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiophenes | 2014 |
Pharmacoeconomic evaluation of dabigatran, rivaroxaban and apixaban versus enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement in Spain.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Cost-Benefit Analysis; Dabigatran; Decision Trees; Economics, Pharmaceutical; Enoxaparin; Models, Economic; Pyrazoles; Pyridones; Rivaroxaban; Spain; Treatment Outcome; Venous Thromboembolism | 2014 |
An observational case series of dabigatran and rivaroxaban exposures reported to a poison control system.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Benzimidazoles; beta-Alanine; California; Child; Child, Preschool; Dabigatran; Drug Overdose; Female; Humans; Infant; Male; Middle Aged; Morpholines; Poison Control Centers; Prospective Studies; Retrospective Studies; Rivaroxaban; Thiophenes; Young Adult | 2014 |
New oral anticoagulants vs. warfarin treatment: no need for pharmacogenomics?
Topics: Administration, Oral; Anticoagulants; Antithrombins; Aryl Hydrocarbon Hydroxylases; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cytochrome P-450 CYP2C9; Dabigatran; Factor Xa Inhibitors; Genotype; Humans; Morpholines; Pharmacogenetics; Polymorphism, Genetic; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Vitamin K Epoxide Reductases; Warfarin | 2014 |
New oral anticoagulants: a practical guide on prescription, laboratory testing and peri-procedural/bleeding management. Australasian Society of Thrombosis and Haemostasis.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation Tests; Blood Loss, Surgical; Contraindications; Dabigatran; Drug Interactions; Drug Monitoring; Drug Substitution; Elective Surgical Procedures; Emergencies; Hematoma, Epidural, Spinal; Hemorrhage; Humans; Kidney Diseases; Liver Diseases; Morpholines; Patient Selection; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Thrombophilia | 2014 |
Edoxaban in the evolving scenario of non vitamin K antagonist oral anticoagulants imputed placebo analysis and multiple treatment comparisons.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Factor Xa Inhibitors; Humans; Meta-Analysis as Topic; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Vitamin K; Warfarin | 2014 |
Appropriateness of prescribing dabigatran etexilate and rivaroxaban in patients with nonvalvular atrial fibrillation: a prospective study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Female; Hemorrhage; Humans; Inappropriate Prescribing; Male; Middle Aged; Morpholines; Prospective Studies; Pyridines; Rivaroxaban; Thiophenes | 2014 |
Atrial fibrillation choices. Picking an anti-clotting drug.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Food-Drug Interactions; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2014 |
New oral anticoagulants may not be effective to prevent venous thromboembolism in patients with antiphospholipid syndrome.
Topics: Administration, Oral; Adult; Anticoagulants; Antiphospholipid Syndrome; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Female; Humans; Male; Middle Aged; Morpholines; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2014 |
Treatment of atrial fibrillation.
Topics: Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Warfarin | 2014 |
Outcome following intracranial hemorrhage associated with novel oral anticoagulants.
Topics: Aged, 80 and over; Anticoagulants; Antidotes; Blood Coagulation Tests; Dabigatran; Humans; International Normalized Ratio; Intracranial Hemorrhages; Male; Neurologic Examination; Pyrazoles; Pyridones; Rivaroxaban; Tomography, X-Ray Computed; Treatment Outcome | 2015 |
Evaluation of medical costs associated with use of new oral anticoagulants compared with standard therapy among venous thromboembolism patients.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Fees, Pharmaceutical; Health Expenditures; Hemorrhage; Humans; Models, Econometric; Monte Carlo Method; Morpholines; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiazoles; Thiophenes; Venous Thromboembolism | 2014 |
Evaluation of Trends of Inpatient Hospitalisation for Significant Haemorrhage in Patients Anticoagulated for Atrial Fibrillation before and after the Release of Novel Anticoagulants.
Topics: Age Factors; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cohort Studies; Dabigatran; Female; Hemorrhage; Hospitalization; Humans; Male; Morpholines; Rivaroxaban; Thiophenes; Vitamin K | 2015 |
Anticlotting therapy for atrial fibrillation: should you stay with the devil you know? Preventing stroke with warfarin (Coumadin) can be tricky. New anticlotting drugs can help if you accept certain trade-offs--and take them exactly as directed.
Topics: Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Approval; Female; Fibrinolytic Agents; Humans; Male; Morpholines; Patient Education as Topic; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; United States; United States Food and Drug Administration; Warfarin | 2014 |
Peri-procedural interrupted oral anticoagulation for atrial fibrillation ablation: comparison of aspirin, warfarin, dabigatran, and rivaroxaban.
Topics: Administration, Oral; Aged; Algorithms; Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Combined Modality Therapy; Dabigatran; Female; Heparin; Humans; Male; Middle Aged; Morpholines; Postoperative Complications; Radio Waves; Rivaroxaban; Thiophenes; Thromboembolism; Warfarin | 2014 |
Failure of dabigatran and rivaroxaban to prevent thromboembolism in antiphospholipid syndrome: a case series of three patients.
Topics: Adult; Anticoagulants; Antiphospholipid Syndrome; Benzimidazoles; beta-Alanine; Cerebral Infarction; Dabigatran; Drug Substitution; Female; Humans; International Normalized Ratio; Lupus Erythematosus, Systemic; Male; Mesenteric Veins; Middle Aged; Morpholines; Portal Vein; Recurrence; Retrospective Studies; Rivaroxaban; Splenic Vein; Stroke; Thiophenes; Thromboembolism; Thrombophilia; Treatment Failure; Venous Thrombosis; Warfarin | 2014 |
Estimated medical cost reductions associated with use of novel oral anticoagulants vs warfarin in a real-world non-valvular atrial fibrillation patient population.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Health Expenditures; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2014 |
Determination of dabigatran, rivaroxaban and apixaban by ultra-performance liquid chromatography - tandem mass spectrometry (UPLC-MS/MS) and coagulation assays for therapy monitoring of novel direct oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation; Blood Coagulation Tests; Calibration; Chromatography, High Pressure Liquid; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridones; Quality Control; Reference Values; Reproducibility of Results; Rivaroxaban; Tandem Mass Spectrometry; Thiophenes | 2014 |
[New oral anticoagulants are as safe in elderly patients as conventional drugs].
Topics: Administration, Oral; Age Factors; Aged; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Thromboembolism; Treatment Outcome | 2014 |
Eligibility and preference of new oral anticoagulants in patients with atrial fibrillation: comparison between patients with versus without stroke.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Humans; Male; Morpholines; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Research Design; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Warfarin | 2014 |
New oral anticoagulants in the management of venous thromboembolism: a major advance?
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Secondary Prevention; Thiazoles; Thiophenes; Venous Thromboembolism | 2014 |
Simultaneous determination of rivaroxaban and dabigatran levels in human plasma by high-performance liquid chromatography-tandem mass spectrometry.
Topics: Antithrombins; Benzimidazoles; beta-Alanine; Calibration; Chromatography, High Pressure Liquid; Cold Temperature; Dabigatran; Drug Monitoring; Drug Stability; Factor Xa Inhibitors; Humans; Limit of Detection; Linear Models; Molecular Structure; Morpholines; Reference Standards; Reproducibility of Results; Rivaroxaban; Tandem Mass Spectrometry; Thiophenes; Time Factors | 2014 |
Anticoagulant-related gastrointestinal bleeding--could this facilitate early detection of benign or malignant gastrointestinal lesions?
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Early Detection of Cancer; Gastrointestinal Hemorrhage; Gastrointestinal Neoplasms; Humans; Incidence; Morpholines; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Thiophenes; Warfarin | 2014 |
[Cost-effectiveness of apixaban compared to other new oral anticoagulants in patients with non-valvular atrial fibrillation].
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation; Cost-Benefit Analysis; Dabigatran; Drug Monitoring; Hemorrhage; Humans; Models, Statistical; Morpholines; Myocardial Infarction; Prognosis; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Russia; Stroke; Thiophenes; Warfarin | 2014 |
Laboratory monitoring of the non-vitamin K oral anticoagulants.
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Drug Monitoring; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes | 2014 |
Influence of dabigatran and rivaroxaban on routine coagulation assays. A nationwide Belgian survey.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Belgium; Benzimidazoles; beta-Alanine; Biomarkers; Blood Coagulation; Dabigatran; Dose-Response Relationship, Drug; Equipment Design; Fibrinogen; Health Care Surveys; Humans; Laboratory Proficiency Testing; Morpholines; Observer Variation; Partial Thromboplastin Time; Predictive Value of Tests; Prothrombin Time; Quality Indicators, Health Care; Reproducibility of Results; Rivaroxaban; Thiophenes; Time Factors | 2015 |
Non-vitamin K antagonist oral anticoagulation agents in anticoagulant naïve atrial fibrillation patients: Danish nationwide descriptive data 2011-2013.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Comorbidity; Dabigatran; Denmark; Female; Heart Failure; Humans; Male; Middle Aged; Morpholines; Myocardial Infarction; Myocardial Ischemia; Practice Patterns, Physicians'; Pyrazoles; Pyridones; Registries; Renal Insufficiency, Chronic; Rivaroxaban; Sex Factors; Stroke; Thiophenes; Warfarin | 2015 |
Rivaroxaban presents a better pharmacokinetic profile than dabigatran in an obese non-diabetic stroke patient.
Topics: Aged; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Male; Morpholines; Rivaroxaban; Stroke; Thiophenes | 2014 |
Risk of gastrointestinal bleeding with dabigatran: a head-to-head comparative study with rivaroxaban.
Topics: Aged; Aged, 80 and over; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Female; Gastrointestinal Hemorrhage; Humans; Male; Middle Aged; Morpholines; Retrospective Studies; Risk Factors; Rivaroxaban; Thiophenes | 2014 |
Activated protein C resistance testing for factor V Leiden.
Topics: Activated Protein C Resistance; Adult; Antithrombins; Arginine; Benzimidazoles; beta-Alanine; Biological Assay; Blood Coagulation Tests; Child; Dabigatran; Factor V; Factor Xa; False Positive Reactions; Female; Hirudins; Humans; Lupus Coagulation Inhibitor; Morpholines; Peptide Fragments; Pipecolic Acids; Pregnancy; Protein C; Recombinant Proteins; Rivaroxaban; Sulfonamides; Thiophenes; Warfarin | 2014 |
Cost-effectiveness of dabigatran and rivaroxaban compared with warfarin for stroke prevention in patients with atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation; Cost-Benefit Analysis; Dabigatran; Humans; Morpholines; Quality-Adjusted Life Years; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2014 |
Cost effectiveness of new oral anticoagulants for stroke prevention in patients with atrial fibrillation in two different European healthcare settings.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Coumarins; Dabigatran; Humans; Markov Chains; Middle Aged; Morpholines; Netherlands; Pyrazoles; Pyridones; Quality-Adjusted Life Years; Rivaroxaban; Stroke; Thiophenes; United Kingdom | 2014 |
Novel anticoagulants eliminate the need for left atrial appendage exclusion devices.
Topics: Anticoagulants; Atrial Appendage; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Septal Occluder Device; Stroke; Thiazoles; Thiophenes; Unnecessary Procedures; Warfarin | 2014 |
Anticoagulant treatment in German family practices - screening results from a cluster randomized controlled trial.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Coumarins; Dabigatran; Family Practice; Female; Germany; Guideline Adherence; Heart Diseases; Heart Valve Prosthesis; Humans; International Normalized Ratio; Male; Mass Screening; Middle Aged; Morpholines; Practice Guidelines as Topic; Process Assessment, Health Care; Pulmonary Embolism; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Thromboembolism; Thrombosis; Venous Thromboembolism | 2014 |
Help prevent Afib-related stroke. New anticoagulants for atrial fibrillation prove as effective, or even better than, warfarin--and easier to use.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Evaluation; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2014 |
A comparison of bleeding complications between warfarin, dabigatran, and rivaroxaban in patients undergoing cryoballoon ablation.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Comorbidity; Cryosurgery; Dabigatran; Female; Hemorrhage; Humans; Incidence; Male; Morpholines; Retrospective Studies; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin | 2014 |
Approach to the new oral anticoagulants in family practice: part 2: addressing frequently asked questions.
Topics: Acute Disease; Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Family Practice; Hemorrhage; Humans; Morpholines; Preoperative Care; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Time Factors; Venous Thromboembolism | 2014 |
Analysis of the efficacy and safety of new oral anticoagulant drugs in the secondary stroke prevention in patients with AF: single center experience based on 311 patients.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cause of Death; Dabigatran; Female; Hemorrhage; Hospitalization; Humans; Male; Middle Aged; Prospective Studies; Pyrazoles; Pyridones; Rivaroxaban; Secondary Prevention; Sex Factors; Stroke | 2015 |
Evaluating the use of commercial drug-specific calibrators for determining PT and APTT reagent sensitivity to dabigatran and rivaroxaban.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation; Calibration; Chromatography, Liquid; Dabigatran; Dose-Response Relationship, Drug; Drug Labeling; Humans; Morpholines; Partial Thromboplastin Time; Predictive Value of Tests; Prothrombin Time; Reference Standards; Reproducibility of Results; Rivaroxaban; Tandem Mass Spectrometry; Thiophenes; United States | 2015 |
Comparison of the cost-effectiveness of new oral anticoagulants for the prevention of stroke and systemic embolism in atrial fibrillation in a UK setting.
Topics: Anticoagulants; Atrial Fibrillation; Cost-Benefit Analysis; Dabigatran; Embolism; Hemorrhage; Humans; Models, Theoretical; Pyrazoles; Pyridones; Quality-Adjusted Life Years; Rivaroxaban; Stroke; United Kingdom; Warfarin | 2014 |
Comparison of estimated glomerular filtration rate equations for dosing new oral anticoagulants in patients with atrial fibrillation.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Cross-Sectional Studies; Dabigatran; Dose-Response Relationship, Drug; Feeding Behavior; Female; Glomerular Filtration Rate; Humans; Male; Pyrazoles; Pyridones; Renal Insufficiency, Chronic; Rivaroxaban; Stroke | 2015 |
New oral anticoagulants in patients undergoing atrial flutter radiofrequency catheter ablation: an observational study.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Flutter; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatran; Female; Humans; Male; Middle Aged; Morpholines; Pilot Projects; Retrospective Studies; Rivaroxaban; Thiophenes; Treatment Outcome | 2014 |
Transition from apixaban to warfarin--addressing excess stroke, systemic embolism, and major bleeding.
Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; International Normalized Ratio; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Vitamin K; Warfarin | 2015 |
Managing bleeding and emergency reversal of newer oral anticoagulants: a review for primary care providers.
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Hospitalization; Humans; Morpholines; Primary Health Care; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes | 2014 |
The risks of thromboembolism vs. recurrent gastrointestinal bleeding after interruption of systemic anticoagulation in hospitalized inpatients with gastrointestinal bleeding: a prospective study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Benzimidazoles; beta-Alanine; Cohort Studies; Dabigatran; Enoxaparin; Female; Gastrointestinal Hemorrhage; Heparin; Humans; Ischemic Attack, Transient; Longitudinal Studies; Male; Middle Aged; Morpholines; Patient Readmission; Prospective Studies; Pulmonary Embolism; Pyrazoles; Pyridones; Recurrence; Rivaroxaban; Stroke; Thiophenes; Thromboembolism; Venous Thrombosis; Warfarin; Withholding Treatment | 2015 |
Safety of novel oral anticoagulants compared with uninterrupted warfarin for catheter ablation of atrial fibrillation.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatran; Drug Administration Schedule; Female; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin | 2015 |
Measurement of Non-Vitamin K Antagonist Oral Anticoagulants in Patient Plasma Using Heptest-STAT Coagulation Method.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Blood Coagulation; Dabigatran; Dipeptides; Enzyme Assays; Factor Xa Inhibitors; Pyrazoles; Pyridones; Rivaroxaban; Vitamin K; Whole Blood Coagulation Time | 2015 |
[Retrospective study about 73 consecutive patients treated by direct oral anticoagulant and admitted to an emergency room].
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Interactions; Emergency Service, Hospital; Female; France; Hemorrhage; History, Ancient; Hospitalization; Humans; Male; Morpholines; Retrospective Studies; Risk Factors; Rivaroxaban; Stroke; Thiophenes | 2015 |
Comparison of differences in medical costs when new oral anticoagulants are used for the treatment of patients with non-valvular atrial fibrillation and venous thromboembolism vs warfarin or placebo in the US.
Topics: Anticoagulants; Atrial Fibrillation; Cost-Benefit Analysis; Costs and Cost Analysis; Dabigatran; Health Expenditures; Hemorrhage; Humans; Models, Econometric; Myocardial Infarction; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; United States; Venous Thromboembolism; Warfarin | 2015 |
Prevalence of intracardiac thrombi under phenprocoumon, direct oral anticoagulants (dabigatran and rivaroxaban), and bridging therapy in patients with atrial fibrillation and flutter.
Topics: Aged; Anticoagulants; Arrhythmias, Cardiac; Benzimidazoles; beta-Alanine; Cohort Studies; Dabigatran; Electric Countershock; Female; Humans; Male; Middle Aged; Morpholines; Phenprocoumon; Prevalence; Rivaroxaban; Thiophenes; Thrombosis; Vitamin K | 2015 |
Dabigatran and rivaroxaban use in atrial fibrillation patients on hemodialysis.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Databases, Factual; Dose-Response Relationship, Drug; Drug Utilization; Female; Hemorrhage; Hospitalization; Humans; Kidney; Kidney Failure, Chronic; Male; Matched-Pair Analysis; Middle Aged; Morpholines; Poisson Distribution; Practice Patterns, Physicians'; Renal Dialysis; Retrospective Studies; Risk; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2015 |
[Extended options of anticoagulant treatment in thromboembolism].
Topics: Administration, Oral; Aged; Antithrombins; Benzimidazoles; beta-Alanine; Czech Republic; Dabigatran; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Pulmonary Embolism; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thromboembolism; Venous Thrombosis | 2014 |
Novel anticoagulants make life easier for patients with atrial fibrillation. The new drugs have many advantages over Coumadin--but they aren't perfect--and they have no antidotes in case of overdose.
Topics: Anticoagulants; Antidotes; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Warfarin | 2014 |
The management of dental patients taking new generation oral anticoagulants.
Topics: Anesthetics, Local; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Dental Care for Chronically Ill; Drug Interactions; Factor Xa Inhibitors; Hemostatic Techniques; Humans; Morpholines; Oral Surgical Procedures; Postoperative Hemorrhage; Practice Guidelines as Topic; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Warfarin | 2014 |
Defining non-valvular atrial fibrillation while selecting anticoagulation therapy.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Heart Valve Diseases; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes | 2015 |
Novel Oral Anticoagulants for DC Cardioversion Procedures: Utilization and Clinical Outcomes Compared with Warfarin.
Topics: Administration, Oral; Aged; Anticoagulants; Dabigatran; Defibrillators, Implantable; Female; Hemorrhage; Humans; Ischemic Attack, Transient; Male; Middle Aged; Postoperative Complications; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thromboembolism; Treatment Outcome; Warfarin | 2015 |
Risk stratification and stroke prevention therapy care gaps in Canadian atrial fibrillation patients (from the Co-ordinated National Network to Engage Physicians in the Care and Treatment of Patients With Atrial Fibrillation chart audit).
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Canada; Dabigatran; Hemorrhage; Humans; Male; Medical Audit; Morpholines; Predictive Value of Tests; Primary Health Care; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2015 |
[New oral anticoagulants in venous thromboembolism. General practice information on switching, monitoring, pausing].
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Monitoring; Drug Substitution; Half-Life; Hemorrhage; Humans; Kidney Function Tests; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Thromboembolism; Warfarin | 2015 |
Does the Russell Viper Venom time test provide a rapid estimation of the intensity of oral anticoagulation? A cohort study.
Topics: Administration, Oral; Anticoagulants; Dabigatran; Drug Monitoring; Humans; International Normalized Ratio; Mass Spectrometry; Partial Thromboplastin Time; Prothrombin Time; Retrospective Studies; Rivaroxaban; ROC Curve; Sensitivity and Specificity; Thromboembolism; Time Factors; Vitamin K | 2015 |
Are new oral anticoagulant dosing recommendations optimal for all patients?
Topics: Administration, Oral; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes | 2015 |
The effect of dabigatran and rivarovaban on a prothrombinase-based assay for activated protein C resistance: a preliminary study in subjects heterozygous for factor V Leiden.
Topics: Activated Protein C Resistance; Aged; Aged, 80 and over; Antithrombins; Blood Coagulation; Blood Coagulation Tests; Dabigatran; Factor V; Factor Xa Inhibitors; Female; Heterozygote; Humans; Male; Middle Aged; Partial Thromboplastin Time; Rivaroxaban; Thromboplastin | 2015 |
[Prospective study of the new oral anticoagulants in private practice: cautious optimism].
Topics: Administration, Oral; Anticoagulants; Antithrombins; Cardiology; Cardiovascular Diseases; Dabigatran; Factor Xa Inhibitors; Female; France; General Practice; Humans; Male; Middle Aged; Practice Patterns, Physicians'; Prospective Studies; Pyrazoles; Pyridones; Rivaroxaban; Surveys and Questionnaires; Thromboembolism; Treatment Outcome | 2015 |
Rivaroxaban versus warfarin or dabigatran in patients undergoing catheter ablation for atrial fibrillation: A meta-analysis.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Catheter Ablation; Dabigatran; Factor Xa Inhibitors; Humans; Meta-Analysis as Topic; Rivaroxaban; Thromboembolism; Warfarin | 2015 |
Safety of dabigatran or rivaroxaban for thoracoscopic ablation in patients with atrial fibrillation.
Topics: Administration, Oral; Antithrombins; Atrial Fibrillation; Catheter Ablation; Dabigatran; Factor Xa Inhibitors; Female; Follow-Up Studies; Humans; Male; Middle Aged; Retrospective Studies; Rivaroxaban; Thoracoscopy; Thromboembolism; Treatment Outcome | 2015 |
Pros and cons of new oral anticoagulants in the treatment of venous thromboembolism in patients with cancer.
Topics: Anticoagulants; Dabigatran; Heparin, Low-Molecular-Weight; Humans; Neoplasms; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiazoles; Treatment Outcome; Venous Thromboembolism | 2015 |
Cost-effectiveness of anticoagulation in patients with nonvalvular atrial fibrillation with edoxaban compared to warfarin in Germany.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Blood Coagulation; Cost-Benefit Analysis; Dabigatran; Germany; Humans; Pyrazoles; Pyridines; Pyridones; Quality of Life; Quality-Adjusted Life Years; Rivaroxaban; Thiazoles; Warfarin | 2015 |
Safety of early initiation of rivaroxaban or dabigatran after thrombolysis in acute ischemic stroke.
Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Brain Ischemia; Dabigatran; Drug Administration Schedule; Factor Xa Inhibitors; Female; Fibrinolytic Agents; Humans; Intracranial Hemorrhages; Length of Stay; Male; Pilot Projects; Radiography; Recombinant Proteins; Recurrence; Retrospective Studies; Rivaroxaban; Severity of Illness Index; Thrombolytic Therapy; Thrombophilia; Tissue Plasminogen Activator | 2015 |
Net clinical benefit of oral anticoagulants: a multiple criteria decision analysis.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Decision Support Techniques; Embolism; Evidence-Based Medicine; Female; Humans; Intracranial Hemorrhages; Male; Middle Aged; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Research Design; Risk Assessment; Rivaroxaban; Stroke; Warfarin | 2015 |
Cardiology patient page. Patient guide for taking the non-vitamin K antagonist oral anticoagulants for atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Contraindications; Dabigatran; Drug Interactions; Drug Monitoring; Drug Substitution; Female; Hemorrhage; Humans; Kidney Diseases; Kidney Function Tests; Male; Morpholines; Pyrazoles; Pyridines; Pyridones; Risk Factors; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Thrombophilia | 2015 |
Multi-analyte analysis of non-vitamin K antagonist oral anticoagulants in human plasma using tandem mass spectrometry.
Topics: Administration, Oral; Anticoagulants; Chromatography, Liquid; Dabigatran; Humans; Pyrazoles; Pyridones; Quality Control; Rivaroxaban; Tandem Mass Spectrometry; Vitamin K | 2015 |
Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cohort Studies; Dabigatran; Female; Gastrointestinal Hemorrhage; Humans; Incidence; Male; Medicaid; Middle Aged; Morpholines; Patient Selection; Practice Patterns, Physicians'; Proportional Hazards Models; Retrospective Studies; Risk Factors; Rivaroxaban; Thiophenes; United States; Warfarin | 2015 |
Risk of gastrointestinal bleeding associated with oral anticoagulants: population based retrospective cohort study.
Topics: Administration, Oral; Adult; Age Factors; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Gastrointestinal Hemorrhage; Humans; Incidence; Male; Middle Aged; Morpholines; Observational Studies as Topic; Retrospective Studies; Risk Factors; Rivaroxaban; Thiophenes; United States; Warfarin | 2015 |
[Periprocedural management of anticoagulation in patients undergoing atrial fibrillation ablation].
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatran; Humans; Morpholines; Practice Guidelines as Topic; Rivaroxaban; Thiophenes; Thromboembolism | 2015 |
Use of Thromboelastography (TEG) for Detection of New Oral Anticoagulants.
Topics: Adolescent; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Sensitivity and Specificity; Thiophenes; Thrombelastography; Venous Thromboembolism; Young Adult | 2015 |
[Prevention and emergency measures].
Topics: Administration, Oral; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Emergencies; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome | 2015 |
Complications With New Oral Anticoagulants Dabigatran and Rivaroxaban in Cutaneous Surgery.
Topics: Administration, Oral; Aged; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Dermatologic Surgical Procedures; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Minnesota; Mohs Surgery; Morpholines; Retrospective Studies; Risk Factors; Rivaroxaban; Skin Diseases; Thiophenes | 2015 |
[Importance of appropiate clinical management of direct oral anticoagulants].
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Drug Administration Schedule; Drug Monitoring; Hemorrhage; Humans; Retrospective Studies; Rivaroxaban; Spain; Venous Thromboembolism | 2016 |
The Real-World Treatment of Hemorrhages Associated With Dabigatran and Rivaroxaban: A Multicenter Evaluation.
Topics: Aged; Aged, 80 and over; Antithrombins; Blood Coagulation Factors; Coagulants; Cohort Studies; Dabigatran; Epistaxis; Erythrocyte Transfusion; Factor VIIa; Factor VIII; Female; Fibrinogen; Gastrointestinal Hemorrhage; Humans; Intracranial Hemorrhages; Male; Middle Aged; Plasma; Platelet Transfusion; Recombinant Proteins; Retrospective Studies; Rivaroxaban | 2015 |
Attending Physician Attitudes Toward Choice of Oral Anticoagulant for the Treatment of Venous Thromboembolism.
Topics: Administration, Oral; Anticoagulants; Cardiology; Cost-Benefit Analysis; Cross-Sectional Studies; Dabigatran; Health Care Surveys; Hematology; Humans; Internal Medicine; Practice Patterns, Physicians'; Primary Health Care; Rhode Island; Rivaroxaban; Specialization; Venous Thromboembolism; Warfarin | 2015 |
National Trends in Ambulatory Oral Anticoagulant Use.
Topics: Administration, Oral; Adult; Age Factors; Aged; Ambulatory Care; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Humans; Male; Middle Aged; Practice Patterns, Physicians'; Pyrazoles; Pyridones; Rivaroxaban; United States; Venous Thromboembolism; Warfarin; Young Adult | 2015 |
Trends and Characteristics of Emergency Department Patients Prescribed Novel Oral Anticoagulants.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Emergency Service, Hospital; Female; Humans; Intracranial Hemorrhages; Ischemic Attack, Transient; Male; Patient Admission; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Warfarin | 2015 |
Measurement of dabigatran, rivaroxaban and apixaban in samples of plasma, serum and urine, under real life conditions. An international study.
Topics: Anticoagulants; Chromogenic Compounds; Dabigatran; Enzyme Assays; Factor Xa Inhibitors; Humans; Laboratories; Point-of-Care Systems; Pyrazoles; Pyridones; Rivaroxaban | 2016 |
Direct oral anticoagulants in atrial fibrillation: can data from randomized clinical trials be safely transferred to the general population? No.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; Female; Humans; Male; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Treatment Outcome; Warfarin | 2015 |
Modified HAS-BLED Score and Risk of Major Bleeding in Patients Receiving Dabigatran and Rivaroxaban: A Retrospective, Case-Control Study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Case-Control Studies; Dabigatran; Female; Gastrointestinal Hemorrhage; Hemorrhage; Humans; Logistic Models; Male; Retrospective Studies; Risk Assessment; Risk Factors; Rivaroxaban | 2015 |
Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study.
Topics: Adolescent; Adult; Aged; Anticoagulants; Antithrombins; Arterial Occlusive Diseases; Atrial Fibrillation; Dabigatran; Databases, Factual; Factor Xa Inhibitors; Follow-Up Studies; Hemorrhage; Hospitalization; Humans; Middle Aged; Risk; Rivaroxaban; Thromboembolism; Thrombophilia; Vitamin K; Warfarin; Young Adult | 2015 |
Pharmacy quality alliance measure: adherence to non-warfarin oral anticoagulant medications.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Dabigatran; Female; Humans; Male; Middle Aged; Pharmaceutical Services; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban | 2015 |
Medication persistence and discontinuation of rivaroxaban and dabigatran etexilate among patients with non-valvular atrial fibrillation.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Databases, Factual; Female; Humans; Male; Medication Adherence; Propensity Score; Proportional Hazards Models; Retrospective Studies; Rivaroxaban | 2015 |
Use of non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients: insights from a specialist atrial fibrillation clinic.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cardiovascular Diseases; Clinical Audit; Dabigatran; Drug Substitution; Female; Fibrinolytic Agents; Hemorrhage; Humans; Ischemic Attack, Transient; Male; Middle Aged; Pyrazoles; Pyridones; Retrospective Studies; Risk Factors; Rivaroxaban; Stroke; Warfarin | 2015 |
The evolving role of dabigatran etexilate in clinical practice.
Topics: Antithrombins; Arthroplasty, Replacement, Knee; Atrial Fibrillation; Cardiovascular Diseases; Clinical Trials as Topic; Dabigatran; Enoxaparin; Humans; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Venous Thromboembolism | 2015 |
Point-of-Care Testing of Coagulation in Patients Treated With Non-Vitamin K Antagonist Oral Anticoagulants.
Topics: Administration, Oral; Aged; Anticoagulants; Dabigatran; Factor Xa Inhibitors; Female; Humans; Male; Middle Aged; Point-of-Care Testing; Pyrazoles; Pyridones; Rivaroxaban; Stroke | 2015 |
Direct oral anticoagulants (DOACs).
Topics: Administration, Oral; Anticoagulants; Antithrombins; Blood Coagulation; Dabigatran; Drug Costs; Drug Monitoring; Factor Xa Inhibitors; Hemorrhage; Humans; International Normalized Ratio; Patient Selection; Pyrazoles; Pyridines; Pyridones; Risk Factors; Rivaroxaban; Thiazoles | 2015 |
Opportunities for improvement: anticoagulation in patients undergoing total knee or hip replacement.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Dabigatran; Denmark; Female; Follow-Up Studies; Heparin, Low-Molecular-Weight; Humans; Male; Middle Aged; Postoperative Complications; Quality Improvement; Registries; Retrospective Studies; Risk Assessment; Rivaroxaban; Statistics, Nonparametric; Survival Rate; Treatment Outcome; Venous Thromboembolism | 2015 |
Adherence to and persistence with non-vitamin K-antagonist oral anticoagulants: does the number of pills per day matter?
Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Humans; Male; Rivaroxaban | 2015 |
Discontinuation of anticoagulant treatment: from clinical trials to medication persistence.
Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Humans; Male; Rivaroxaban | 2015 |
Peri-procedural management of dabigatran and rivaroxaban: Duration of anticoagulant discontinuation and drug concentrations.
Topics: Aged; Anticoagulants; Antithrombins; Blood Coagulation; Dabigatran; Female; Humans; Male; Prospective Studies; Rivaroxaban | 2015 |
[New oral anticoagulants in patients with atrial fibrillation in a urban health center].
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Drug Utilization; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thrombophilia; Urban Health Services | 2016 |
[Nosebleed in new oral anticoagulant treatment - what should be done?].
Topics: Administration, Oral; Aged; Antithrombins; Atrial Fibrillation; Dabigatran; Drug Administration Schedule; Drug Substitution; Epistaxis; Factor Xa Inhibitors; Humans; Long-Term Care; Male; Middle Aged; Rivaroxaban | 2015 |
Underutilisation of Guideline-based Therapy Primary Prevention among Patients Presenting with AF-related Ischaemic Stroke.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Dabigatran; Dipyridamole; Female; Guideline Adherence; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Primary Prevention; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Ticlopidine; Warfarin | 2015 |
What Do Anticoagulants Say about Microemboli?
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; Female; Humans; Male; Middle Aged; Middle Cerebral Artery; Rivaroxaban; Severity of Illness Index; Treatment Outcome; Ultrasonography, Doppler, Transcranial; Warfarin | 2015 |
Cost-effectiveness of apixaban vs. other new oral anticoagulants for the prevention of stroke: an analysis on patients with non-valvular atrial fibrillation in the Greek healthcare setting.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Cost-Benefit Analysis; Dabigatran; Embolism; Greece; Health Care Costs; Humans; Middle Aged; Pyrazoles; Pyridones; Quality-Adjusted Life Years; Rivaroxaban; Stroke; Warfarin | 2015 |
Adherence to non-vitamin-K-antagonist oral anticoagulant medications based on the Pharmacy Quality Alliance measure.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Cohort Studies; Dabigatran; Female; Humans; Male; Medication Adherence; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban | 2015 |
Different risk factors for bleeding and discontinuation between dabigatran and rivaroxaban.
Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Dabigatran; Drug Substitution; Drug Therapy, Combination; Female; Follow-Up Studies; Hemorrhage; Humans; Incidence; Male; Middle Aged; Multivariate Analysis; Platelet Aggregation Inhibitors; Propensity Score; Risk Factors; Rivaroxaban; Treatment Outcome; Withholding Treatment | 2016 |
Management of acute pulmonary embolism.
Topics: Acute Disease; Age Factors; Ambulatory Care; Anticoagulants; Antithrombins; Comorbidity; Dabigatran; Disease Management; Female; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Hospitalization; Humans; Male; Neoplasms; Practice Guidelines as Topic; Pregnancy; Pregnancy Complications, Cardiovascular; Pulmonary Embolism; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Thrombolytic Therapy; Tissue Plasminogen Activator; Vena Cava Filters; Warfarin | 2015 |
Apixaban, Rivaroxaban, and Dabigatran in Patients Undergoing Atrial Fibrillation Ablation.
Topics: Action Potentials; Administration, Oral; Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Catheter Ablation; Dabigatran; Drug Administration Schedule; Electrophysiologic Techniques, Cardiac; Factor Xa Inhibitors; Female; Heart Rate; Humans; Male; Middle Aged; Phenprocoumon; Postoperative Complications; Pyrazoles; Pyridones; Registries; Rivaroxaban; Stroke; Time Factors; Treatment Outcome | 2016 |
Direct oral anticoagulants and the bleeding patient.
Topics: Antibodies, Monoclonal, Humanized; Anticoagulants; Antidotes; Antifibrinolytic Agents; Antithrombins; Blood Coagulation Factors; Charcoal; Dabigatran; Factor Xa Inhibitors; Half-Life; Hemorrhage; Humans; Pyrazoles; Pyridones; Renal Dialysis; Rivaroxaban; Tranexamic Acid; Warfarin | 2016 |
Initial Experience With Novel Oral Anticoagulants During the First 45 Days After Left Atrial Appendage Closure With the Watchman Device.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Appendage; Cardiac Surgical Procedures; Dabigatran; Echocardiography, Transesophageal; Feasibility Studies; Female; Follow-Up Studies; Humans; Male; Middle Aged; Pilot Projects; Retrospective Studies; Rivaroxaban; Stroke; Survival Rate; Thrombosis; Treatment Outcome | 2015 |
Trends in Prescribing Oral Anticoagulants in Canada, 2008-2014.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Canada; Dabigatran; Humans; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Warfarin | 2015 |
Novel oral anticoagulants vs warfarin for the management of postoperative atrial fibrillation: clinical outcomes and cost analysis.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Blood Component Transfusion; Coronary Artery Bypass; Dabigatran; Drug Costs; Female; Humans; Length of Stay; Male; Pyrazoles; Pyridones; Rivaroxaban; Treatment Outcome; Warfarin | 2015 |
Improving evidence on anticoagulant therapies for venous thromboembolism in children: key challenges and opportunities.
Topics: Adult; Age Factors; Anticoagulants; Child; Child, Preschool; Clinical Trials as Topic; Dabigatran; Disease Management; Evidence-Based Medicine; Heparin, Low-Molecular-Weight; Humans; Infant; Multicenter Studies as Topic; Practice Guidelines as Topic; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Venous Thromboembolism | 2015 |
Emergency admissions for major haemorrhage associated with direct oral anticoagulants.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Emergency Service, Hospital; Female; Gastrointestinal Hemorrhage; Hemodynamics; Hemorrhage; Hemostasis; Humans; Intracranial Hemorrhages; Male; Middle Aged; Patient Admission; Prospective Studies; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Venous Thrombosis | 2015 |
Pharmacokinetics and Pharmacodynamics of the Nonvitamin K Antagonist Oral Anticoagulant Edoxaban When Administered Alone or After Switching from Rivaroxaban or Dabigatran Etexilate in Healthy Subjects.
Topics: Administration, Oral; Adult; Anticoagulants; Area Under Curve; Cross-Over Studies; Dabigatran; Drug Substitution; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Pyridines; Rivaroxaban; Thiazoles; Young Adult | 2016 |
Impact of Variations in Kidney Function on Nonvitamin K Oral Anticoagulant Dosing in Patients With Atrial Fibrillation and Recent Acute Heart Failure.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Cardio-Renal Syndrome; Contraindications; Creatinine; Dabigatran; Factor Xa Inhibitors; Female; Humans; Male; Prospective Studies; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thromboembolism | 2016 |
TRAP-induced platelet aggregation is enhanced in cardiovascular patients receiving dabigatran.
Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Blood Platelets; Dabigatran; Female; Humans; Male; Middle Aged; Platelet Aggregation; Pulmonary Embolism; Receptors, Thrombin; Rivaroxaban; Venous Thrombosis | 2016 |
Comparison of treatment persistence with different oral anticoagulants in patients with atrial fibrillation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Dabigatran; Drug Substitution; Female; Humans; Male; Medication Adherence; Pyrazoles; Pyridones; Rivaroxaban; Warfarin | 2016 |
[Appropriateness of the prescriptions of conventional versus new oral anticoagulants at discharge from a department of internal medicine].
Topics: Acenocoumarol; Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Catheter Ablation; Dabigatran; Drug Prescriptions; Female; Humans; Internal Medicine; Male; Middle Aged; Patient Discharge; Phenprocoumon; Retrospective Studies; Rivaroxaban; Vitamin K | 2016 |
Resident Physicians Choices of Anticoagulation for Stroke Prevention in Patients With Nonvalvular Atrial Fibrillation.
Topics: Administration, Oral; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Atrial Fibrillation; Brain Ischemia; Canada; Dabigatran; Female; Guidelines as Topic; Humans; Internship and Residency; Male; Practice Patterns, Physicians'; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Risk Factors; Rivaroxaban; Stroke; Surveys and Questionnaires; Treatment Outcome; Universities; Warfarin | 2016 |
An early evaluation of bleeding-related hospital readmissions among hospitalized patients with nonvalvular atrial fibrillation treated with direct oral anticoagulants.
Topics: Adolescent; Adult; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Hemorrhage; Hospitalization; Humans; Male; Middle Aged; Patient Readmission; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Warfarin; Young Adult | 2016 |
Quantitation of the Oral Anticoagulants Dabigatran, Rivaroxaban, Apixaban, and Warfarin in Plasma Using Ultra-Performance Liquid Chromatography with Tandem Mass Spectrometry (UPLC-MS/MS).
Topics: Anticoagulants; Chromatography, High Pressure Liquid; Dabigatran; Drug Monitoring; Humans; Pyrazoles; Pyridones; Rivaroxaban; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry; Warfarin | 2016 |
Risk of bleeding and arterial thromboembolism in patients with non-valvular atrial fibrillation either maintained on a vitamin K antagonist or switched to a non-vitamin K-antagonist oral anticoagulant: a retrospective, matched-cohort study.
Topics: Acenocoumarol; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Hemorrhage; Humans; Male; Phenindione; Retrospective Studies; Risk Factors; Rivaroxaban; Stroke; Thromboembolism; Vitamin K; Warfarin | 2015 |
ISTH 2015 Congress.
Topics: Antibodies, Monoclonal, Humanized; Anticoagulants; Arthroscopy; Blood Loss, Surgical; Dabigatran; Factor VIII; Hemophilia A; Humans; Randomized Controlled Trials as Topic; Rivaroxaban; Single-Domain Antibodies; Venous Thromboembolism | 2015 |
UPLC-MRM Mass Spectrometry Method for Measurement of the Coagulation Inhibitors Dabigatran and Rivaroxaban in Human Plasma and Its Comparison with Functional Assays.
Topics: Antithrombins; Biological Assay; Chromatography, Liquid; Dabigatran; Factor Xa Inhibitors; Humans; Limit of Detection; Rivaroxaban; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry; Validation Studies as Topic | 2015 |
Novel oral anticoagulants for atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Cardiology; Dabigatran; Family; Humans; Professional-Patient Relations; Rivaroxaban; Stroke; Thromboembolism; Warfarin | 2015 |
Data on procedural handling and complications of pulmonary vein isolation using the pulmonary vein ablation catheter GOLD®.
Topics: Aged; Antithrombins; Atrial Fibrillation; Catheter Ablation; Dabigatran; Databases, Factual; Electrodes, Implanted; Equipment Design; Europe; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Ischemic Attack, Transient; Male; Middle Aged; Postoperative Complications; Pulmonary Veins; Retrospective Studies; Rivaroxaban; Treatment Outcome | 2016 |
New Target-Specific Oral Anticoagulants and Intracranial Bleeding: Management and Outcome in a Single-Center Case Series.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Dabigatran; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Female; Humans; Intracranial Hemorrhages; Male; Retrospective Studies; Rivaroxaban; Survival Rate; Treatment Outcome | 2016 |
An in-vitro evaluation of direct thrombin inhibitor and factor Xa inhibitor on tissue factor-induced thrombin generation and platelet aggregation: a comparison of dabigatran and rivaroxaban.
Topics: Adult; Antithrombins; Blood Coagulation Tests; Dabigatran; Factor Xa Inhibitors; Female; Humans; Male; Middle Aged; Platelet Aggregation; Rivaroxaban; Thrombin | 2016 |
[Your patient needs an antithrombotic drug. Venous thrombosis of the leg: how and how long anticoagulation?].
Topics: Administration, Oral; Dabigatran; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Substitution; Fibrinolytic Agents; General Practice; Heparin, Low-Molecular-Weight; Humans; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Venous Thrombosis | 2015 |
The safety and persistence of non-vitamin-K-antagonist oral anticoagulants in atrial fibrillation patients treated in a well structured atrial fibrillation clinic.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Cardiovascular Diseases; Dabigatran; Female; Gastrointestinal Hemorrhage; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Patient Safety; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Treatment Outcome; Vitamin K | 2016 |
[Successful direct thrombin inhibitor treatment of a left atrial appendage thrombus developed under rivaroxaban therapy].
Topics: Antithrombins; Atrial Appendage; Atrial Fibrillation; Dabigatran; Echocardiography, Transesophageal; Factor Xa Inhibitors; Heart Diseases; Humans; Male; Methylenetetrahydrofolate Reductase (NADPH2); Middle Aged; Mutation; Rivaroxaban; Thrombosis; Treatment Outcome | 2016 |
Direct new oral anticoagulants in the emergency department: Experience in everyday clinical practice at a Swiss university hospital.
Topics: Aged; Aged, 80 and over; Anticoagulants; Dabigatran; Emergency Service, Hospital; Female; Hemorrhage; Hospitals, University; Humans; Male; Middle Aged; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Severity of Illness Index; Switzerland | 2016 |
Validation of an LC-MS/MS method for the simultaneous quantification of dabigatran, rivaroxaban and apixaban in human plasma.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Blood Chemical Analysis; Chromatography, High Pressure Liquid; Dabigatran; Female; Humans; Male; Pyrazoles; Pyridones; Rivaroxaban; Tandem Mass Spectrometry | 2016 |
Managing patients taking novel oral anticoagulants (NOAs) in dentistry: a discussion paper on clinical implications.
Topics: Administration, Oral; Anticoagulants; Dabigatran; Dental Care; Humans; Pyrazoles; Pyridones; Rivaroxaban | 2016 |
Dabigatran but not rivaroxaban or apixaban treatment decreases fibrinolytic resistance in patients with atrial fibrillation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Carboxypeptidase B2; Dabigatran; Factor Xa Inhibitors; Female; Fibrinolysis; Humans; Male; Pyrazoles; Pyridones; Rivaroxaban; Thrombin | 2016 |
Real-world persistence and adherence to oral anticoagulation for stroke risk reduction in patients with atrial fibrillation.
Topics: Aged; Aged, 80 and over; Atrial Fibrillation; Blood Coagulation; Dabigatran; Databases, Factual; Factor Xa Inhibitors; Female; Follow-Up Studies; Germany; Humans; Logistic Models; Male; Medication Adherence; Middle Aged; Retrospective Studies; Risk Reduction Behavior; Rivaroxaban; Stroke; Vitamin K | 2016 |
An observational study of direct oral anticoagulant awareness indicating inadequate recognition with potential for patient harm.
Topics: Administration, Oral; Anticoagulants; Attitude of Health Personnel; Blood Coagulation; Blood Coagulation Tests; Cardiology; Dabigatran; Electronic Health Records; Health Knowledge, Attitudes, Practice; Humans; Patient Harm; Patient Safety; Practice Patterns, Physicians'; Primary Health Care; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Surveys and Questionnaires; United Kingdom | 2016 |
Uptake of novel oral anticoagulants in Australia.
Topics: Administration, Oral; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Australia; Clinical Trials as Topic; Dabigatran; Female; Humans; Male; Pyrazoles; Pyridones; Retrospective Studies; Risk Factors; Rivaroxaban; Stroke; Veterans | 2016 |
Direct oral anticoagulants in rare venous thrombosis.
Topics: Anticoagulants; Dabigatran; Humans; Pyrazoles; Pyridones; Rivaroxaban; Venous Thrombosis | 2016 |
The Total Incidence of Complications and the Impact of an Anticoagulation Regime on Adverse Events After Cryoballoon Ablation of Atrial Fibrillation: A Single-Center Study of 409 Patients.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Biomarkers; Cryosurgery; Dabigatran; Female; Germany; Humans; Incidence; Inflammation Mediators; Male; Middle Aged; Phenprocoumon; Postoperative Complications; Pulmonary Veins; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Treatment Outcome | 2016 |
Medication utilization evaluation of dabigatran and rivaroxaban within a large, multi-center health system.
Topics: Aged; Aged, 80 and over; Antithrombins; Dabigatran; Drug Utilization Review; Electronic Health Records; Factor Xa Inhibitors; Female; Hemorrhage; Hospitals, University; Humans; Male; Middle Aged; Retrospective Studies; Rivaroxaban | 2016 |
A single test to assay warfarin, dabigatran, rivaroxaban, apixaban, unfractionated heparin, and enoxaparin in plasma.
Topics: Anticoagulants; Blood Coagulation Tests; Blood Donors; Calibration; Dabigatran; Enoxaparin; Factor X; Female; Fondaparinux; Heparin; Humans; International Normalized Ratio; Male; Polysaccharides; Prothrombin; Prothrombin Time; Pyrazoles; Pyridones; Reproducibility of Results; Rivaroxaban; Thromboplastin; Warfarin | 2016 |
[Clinical and economic consequences of using dabigatran or rivaroxaban in patients with non-valvular atrial fibrillation].
Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Drug Costs; Humans; Morpholines; Portugal; Rivaroxaban; Stroke; Warfarin | 2016 |
[Anticoagulants after acute ischemic stroke with atrial fibrillation].
Topics: Anticoagulants; Atrial Fibrillation; Cerebral Hemorrhage; Dabigatran; Deglutition Disorders; Humans; Medical Records; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Assessment; Rivaroxaban; Stroke; Time Factors; Time-to-Treatment; Treatment Outcome; Warfarin | 2016 |
Direct oral anticoagulant drugs (DOAC).
Topics: Administration, Oral; Anticoagulants; Antithrombins; Blood Loss, Surgical; Cataract Extraction; Dabigatran; Eye Hemorrhage; Factor Xa Inhibitors; Humans; Pyrazoles; Pyridones; Rivaroxaban; Warfarin | 2016 |
Dabigatran and rivaroxaban do not affect AA- and ADP-induced platelet aggregation in patients receiving concomitant platelet inhibitors.
Topics: Adenosine Diphosphate; Antithrombins; Arachidonic Acid; Clopidogrel; Dabigatran; Drug Therapy, Combination; Humans; Platelet Aggregation; Platelet Aggregation Inhibitors; Rivaroxaban; Ticlopidine | 2016 |
Heavy menstrual bleeding on Rivaroxaban - Comparison with Apixaban.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Pyrazoles; Pyridones; Rivaroxaban | 2017 |
Novel Oral Anticoagulants and the Risk of Major Hemorrhage in Elderly Patients With Chronic Kidney Disease: A Nested Case-Control Study.
Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Case-Control Studies; Dabigatran; Female; Hemorrhage; Humans; Male; Ontario; Renal Insufficiency, Chronic; Risk; Rivaroxaban; Warfarin | 2016 |
Evaluating the Initiation of Novel Oral Anticoagulants in Medicare Beneficiaries.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Health Expenditures; Humans; Insurance Benefits; Male; Medicare; Middle Aged; Rivaroxaban; Stroke; United States; Warfarin | 2016 |
Cardiology Patient Pages: Antidotes for Bleeding Caused by Novel Oral Anticoagulants.
Topics: Administration, Oral; Antibodies, Monoclonal, Humanized; Antithrombins; Blood Loss, Surgical; Cerebral Hemorrhage; Clinical Trials as Topic; Dabigatran; Drug Approval; Emergencies; Factor Xa; Factor Xa Inhibitors; Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Recombinant Proteins; Rivaroxaban; Thiazoles; United States; United States Food and Drug Administration | 2016 |
Medication adherence to rivaroxaban and dabigatran for stroke prevention in patients with non-valvular atrial fibrillation in the United States.
Topics: Aged; Aged, 80 and over; Atrial Fibrillation; Dabigatran; Female; Humans; Male; Medication Adherence; Middle Aged; Propensity Score; Retrospective Studies; Rivaroxaban; Stroke; Treatment Outcome; United States | 2016 |
Adoption of direct oral anticoagulants for stroke prevention in atrial fibrillation.
Topics: Administration, Oral; Age Factors; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Atrial Flutter; Australia; Dabigatran; Drug Prescriptions; Drug Therapy, Combination; Glomerular Filtration Rate; Humans; Pyrazoles; Pyridones; Retrospective Studies; Risk Factors; Rivaroxaban; Severity of Illness Index; Stroke; Warfarin | 2016 |
Which oral anticoagulant for atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Antidotes; Atrial Fibrillation; Blood Coagulation; Blood Coagulation Tests; Dabigatran; Drug Interactions; Drug Monitoring; Factor Xa Inhibitors; Hemorrhage; Humans; Patient Selection; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Stroke; Treatment Outcome; Warfarin | 2016 |
Comparative Assessment of the Anticoagulant Activity of Rivaroxaban and Dabigatran in Patients With Nonvalvular Atrial Fibrillation: A Noninterventional Study.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Blood Coagulation; Dabigatran; Female; Humans; Male; Middle Aged; Pilot Projects; Rivaroxaban | 2016 |
Laboratory determination of old and new targeted anticoagulant agents for prevention of bleeding and thrombotic events in cancer patients.
Topics: Anticoagulants; Blood Coagulation Tests; Dabigatran; Drug Monitoring; Factor Xa Inhibitors; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; International Normalized Ratio; Neoplasms; Partial Thromboplastin Time; Pyrazoles; Pyridones; Rivaroxaban; Thrombosis; Warfarin | 2016 |
Lupus-anticoagulant testing at NOAC trough levels.
Topics: Administration, Oral; Adult; Anticoagulants; Blood Coagulation Tests; Dabigatran; Dose-Response Relationship, Drug; False Positive Reactions; Humans; Lupus Coagulation Inhibitor; Partial Thromboplastin Time; Prothrombin Time; Pyrazoles; Pyridones; Rivaroxaban | 2016 |
Cost-Effectiveness of Oral Anticoagulants for Ischemic Stroke Prophylaxis Among Nonvalvular Atrial Fibrillation Patients.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Brain Ischemia; Cost-Benefit Analysis; Dabigatran; Humans; Insurance, Health; Middle Aged; Models, Theoretical; Pyrazoles; Pyridines; Pyridones; Quality-Adjusted Life Years; Risk; Rivaroxaban; Severity of Illness Index; Stroke; Thiazoles; Warfarin | 2016 |
Expression of pro-inflammatory genes in human endothelial cells: Comparison of rivaroxaban and dabigatran.
Topics: Antithrombins; Dabigatran; Endothelial Cells; Factor Xa Inhibitors; Human Umbilical Vein Endothelial Cells; Humans; Inflammation; Lactones; Pyridines; Receptor, PAR-1; Rivaroxaban; Thrombin; Transcriptome | 2016 |
Clinical Characteristics, Oral Anticoagulation Patterns, and Outcomes of Medicaid Patients With Atrial Fibrillation: Insights From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF I) Registry.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cause of Death; Dabigatran; DNA-Binding Proteins; Drosophila Proteins; Embolism; Female; Hemorrhage; Humans; Male; Medicaid; Middle Aged; Mortality; Registries; Rivaroxaban; Stroke; Transcription Factors; Treatment Outcome; United States; Warfarin | 2016 |
Comparative study of hemorrhagic and ischemic complications among anticoagulants in patients undergoing cryoballoon ablation for atrial fibrillation.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Brain; Brain Ischemia; Cryosurgery; Dabigatran; Embolism; Female; Hemorrhage; Humans; Incidence; Magnetic Resonance Imaging; Male; Middle Aged; Postoperative Complications; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Warfarin | 2017 |
Direct oral anticoagulant drug level testing in clinical practice: A single institution experience.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antithrombins; Dabigatran; Drug Monitoring; Factor Xa Inhibitors; Female; Humans; Male; Middle Aged; Pyrazoles; Pyridones; Rivaroxaban; Young Adult | 2016 |
Anticoagulants: What is new and what is the standard?
Topics: Administration, Oral; Anticoagulants; Dabigatran; Factor Xa Inhibitors; Humans; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Warfarin | 2016 |
Rivaroxaban versus warfarin and dabigatran in atrial fibrillation: comparative effectiveness and safety in Danish routine care.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Denmark; Female; Hemorrhage; Humans; Male; Middle Aged; Proportional Hazards Models; Prospective Studies; Registries; Rivaroxaban; Stroke; Treatment Outcome; Warfarin | 2016 |
Long-Term Population-Based Cerebral Ischemic Event and Cognitive Outcomes of Direct Oral Anticoagulants Compared With Warfarin Among Long-term Anticoagulated Patients for Atrial Fibrillation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Dementia; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Ischemic Attack, Transient; Male; Middle Aged; Mortality; Multivariate Analysis; Propensity Score; Proportional Hazards Models; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Warfarin | 2016 |
Combined factor IIa and Xa inhibitor therapy for thrombosis whilst on therapeutic anticoagulant.
Topics: Adult; Aged; Anticoagulants; Antithrombins; Arginine; Dabigatran; Factor Xa Inhibitors; Female; Heparin, Low-Molecular-Weight; Humans; Male; Middle Aged; Neoplasms; Pipecolic Acids; Pyrazoles; Pyridones; Recurrence; Rivaroxaban; Sulfonamides; Venous Thrombosis | 2016 |
Clinical trials with direct oral anticoagulants for stroke prevention in atrial fibrillation: how representative are they for real life patients?
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Clinical Trials as Topic; Dabigatran; Female; Humans; Male; Middle Aged; Pyrazoles; Pyridones; Rivaroxaban; Stroke | 2016 |
Risk of Thromboembolic Events in Patients with Non-Valvular Atrial Fibrillation After Dabigatran or Rivaroxaban Discontinuation - Data from the Ljubljana Registry.
Topics: Aged; Antithrombins; Atrial Fibrillation; Dabigatran; Factor Xa Inhibitors; Female; Humans; Incidence; Male; Registries; Risk Factors; Rivaroxaban; Slovenia; Thromboembolism | 2016 |
Intracerebral Hematoma Occurring During Warfarin Versus Non-Vitamin K Antagonist Oral Anticoagulant Therapy.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Brain; Case-Control Studies; Cerebral Hemorrhage; Dabigatran; Factor Xa Inhibitors; Female; Hematoma; Hospital Mortality; Humans; Male; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Tomography, X-Ray Computed; Warfarin | 2016 |
Bleeding in patients with atrial fibrillation treated with dabigatran, rivaroxaban or warfarin: A retrospective population-based cohort study.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Databases, Factual; Female; Gastrointestinal Hemorrhage; Humans; Incidence; Intracranial Hemorrhages; Israel; Male; Middle Aged; Proportional Hazards Models; Retrospective Studies; Rivaroxaban; Stroke; Warfarin | 2016 |
Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Denmark; Drug Administration Schedule; Embolism; Female; Hemorrhage; Humans; Male; Propensity Score; Pyrazoles; Pyridones; Registries; Rivaroxaban; Stroke; Treatment Outcome; Warfarin | 2016 |
Treatment Persistence and Discontinuation with Rivaroxaban, Dabigatran, and Warfarin for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation in the United States.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Humans; Male; Propensity Score; Rivaroxaban; Stroke; Treatment Outcome; United States; Warfarin; Withholding Treatment | 2016 |
Evaluation of Dose-Reduced Direct Oral Anticoagulant Therapy.
Topics: Aged; Aged, 80 and over; Antithrombins; Aspirin; Atrial Fibrillation; Comorbidity; Creatinine; Dabigatran; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Pyrazoles; Pyridones; Renal Insufficiency; Retrospective Studies; Rivaroxaban; Stroke; Venous Thromboembolism | 2016 |
Ophthalmic Complications Associated with Direct Oral Anticoagulant Medications.
Topics: Aged; Aged, 80 and over; Anticoagulants; Dabigatran; Factor Xa Inhibitors; Female; Humans; Hyphema; Male; Pyrazoles; Pyridones; Retinal Hemorrhage; Rivaroxaban; Vitreous Hemorrhage | 2017 |
Vitamin K and non-vitamin K antagonist oral anticoagulants for non-valvular atrial fibrillation in real-life.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Fibrinolytic Agents; Hemorrhage; Humans; Italy; Logistic Models; Male; Middle Aged; Pyrazoles; Pyridones; Rivaroxaban; Severity of Illness Index; Vitamin K | 2016 |
[Clear advice important when fertile women are prescribed NOAC].
Topics: Anticoagulants; Contraindications; Dabigatran; Female; Humans; Patient Education as Topic; Pregnancy; Rivaroxaban | 2016 |
Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation.
Topics: Administration, Oral; Adolescent; Adult; Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Factor Xa Inhibitors; Female; Follow-Up Studies; Hemorrhage; Humans; Male; Middle Aged; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Treatment Outcome; Warfarin; Young Adult | 2016 |
Trauma patients on new oral anticoagulation agents have lower mortality than those on warfarin.
Topics: Administration, Oral; Aged; Anticoagulants; Antithrombins; Connecticut; Dabigatran; Demography; Factor Xa Inhibitors; Female; Humans; Injury Severity Score; Male; Middle Aged; Pyrazoles; Pyridones; Retrospective Studies; Risk Factors; Rivaroxaban; Trauma Centers; Warfarin; Wounds and Injuries | 2016 |
Testing for dabigatran and rivaroxaban by clinical laboratories.
Topics: Anticoagulants; Antithrombins; Blood Coagulation Tests; Calibration; Clinical Laboratory Services; Dabigatran; Factor Xa Inhibitors; Humans; Indicators and Reagents; Observer Variation; Rivaroxaban | 2016 |
Improved persistence with non-vitamin-K oral anticoagulants compared with warfarin in patients with atrial fibrillation: recent Australian experience.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Humans; Male; Middle Aged; Pyrazoles; Pyridones; Rivaroxaban; Warfarin | 2016 |
Managing reversal of direct oral anticoagulants in emergency situations. Anticoagulation Education Task Force White Paper.
Topics: Administration, Oral; Advisory Committees; Antibodies, Monoclonal, Humanized; Anticoagulants; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; Rivaroxaban | 2016 |
PT, aPTT, TT and the hemostatic safety threshold of dabigatran and rivaroxaban.
Topics: Anticoagulants; Antithrombins; Blood Chemical Analysis; Blood Coagulation; Blood Coagulation Tests; Dabigatran; Hemostasis; Humans; Partial Thromboplastin Time; Prothrombin; Rivaroxaban | 2016 |
Non-vitamin K antagonist oral anticoagulation usage according to age among patients with atrial fibrillation: Temporal trends 2011-2015 in Denmark.
Topics: Administration, Oral; Adult; Age Factors; Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Dabigatran; Denmark; Female; Humans; Male; Middle Aged; Practice Patterns, Physicians'; Pyrazoles; Pyridones; Registries; Rivaroxaban | 2016 |
Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin. A propensity score matched analysis.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Hemorrhage; Humans; Male; Middle Aged; Propensity Score; Pyrazoles; Pyridones; Retrospective Studies; Risk; Rivaroxaban; Stroke; Warfarin | 2016 |
Four-factor prothrombin complex concentrate for life-threatening bleeds or emergent surgery: A retrospective evaluation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antifibrinolytic Agents; Blood Coagulation Factors; Cardiac Surgical Procedures; Dabigatran; Emergencies; Female; Gastrointestinal Hemorrhage; Heart Transplantation; Hemorrhage; Hemostatics; Heparin; Humans; Incidence; International Normalized Ratio; Intracranial Hemorrhages; Laparotomy; Male; Middle Aged; Preoperative Care; Pyrazoles; Pyridones; Retrospective Studies; Risk Factors; Rivaroxaban; Surgical Procedures, Operative; Thrombocytopenia; Thromboembolism; Vitamin K; Warfarin | 2016 |
Potential Effect of Substituting Estimated Glomerular Filtration Rate for Estimated Creatinine Clearance for Dosing of Direct Oral Anticoagulants.
Topics: Aged; Aged, 80 and over; Anticoagulants; Creatinine; Dabigatran; Dose-Response Relationship, Drug; Drug Dosage Calculations; Female; Glomerular Filtration Rate; Hemorrhage; Humans; Kidney Function Tests; Male; Metabolic Clearance Rate; Nutrition Surveys; Outcome Assessment, Health Care; Pyridines; Renal Elimination; Rivaroxaban; Thiazoles; United States | 2016 |
Major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban or warfarin: a "real-world" observational study in the United States.
Topics: Adolescent; Adult; Age Distribution; Aged; Aged, 80 and over; Ambulatory Care; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Hemorrhage; Hospitalization; Humans; Male; Middle Aged; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; United States; Warfarin; Young Adult | 2016 |
Safety ad efficacy of direct oral anticoagulants for extended treatment of venous thromboembolism.
Topics: Administration, Oral; Anticoagulants; Aspirin; Dabigatran; Humans; Italy; Pyrazoles; Pyridones; Rivaroxaban; Time Factors; Venous Thromboembolism; Vitamin K; Warfarin | 2016 |
Poor comparability of coagulation screening test with specific measurement in patients receiving direct oral anticoagulants: results from a multicenter/multiplatform study.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Blood Coagulation; Blood Coagulation Tests; Calibration; Dabigatran; Factor Xa; Factor Xa Inhibitors; Female; Humans; Italy; Male; Partial Thromboplastin Time; Prothrombin Time; Pyrazoles; Pyridones; Regression Analysis; Rivaroxaban; Thrombin Time; Treatment Outcome | 2016 |
Gastrointestinal bleeding risk of non-vitamin K oral anticoagulants is similar to warfarin - a Japanese retrospective cohort study
.
Topics: Aged; Aged, 80 and over; Anticoagulants; Cohort Studies; Dabigatran; Drug Therapy, Combination; Female; Gastrointestinal Hemorrhage; Humans; Incidence; Japan; Male; Middle Aged; Platelet Aggregation Inhibitors; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Vitamin K; Warfarin | 2016 |
Severity of renal impairment in patients with heart failure and atrial fibrillation: implications for non-vitamin K antagonist oral anticoagulant dose adjustment.
Topics: Aged; Antithrombins; Atrial Fibrillation; Dabigatran; Factor Xa Inhibitors; Female; Glomerular Filtration Rate; Heart Failure; Humans; Male; Middle Aged; Pyrazoles; Pyridines; Pyridones; Renal Insufficiency, Chronic; Rivaroxaban; Severity of Illness Index; Stroke; Thiazoles | 2016 |
Comparing Stroke and Bleeding with Rivaroxaban and Dabigatran in Atrial Fibrillation: Analysis of the US Medicare Part D Data.
Topics: Aged; Aged, 80 and over; Atrial Fibrillation; Dabigatran; Factor Xa Inhibitors; Female; Fibrinolytic Agents; Hemorrhage; Humans; Insurance Claim Review; Male; Medicare Part D; Rivaroxaban; Stroke; United States | 2017 |
Thromboembolic, Bleeding, and Mortality Risks of Rivaroxaban and Dabigatran in Asians With Nonvalvular Atrial Fibrillation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Asian People; Atrial Fibrillation; Cohort Studies; Dabigatran; Factor Xa Inhibitors; Female; Gastrointestinal Hemorrhage; Humans; Intracranial Hemorrhages; Male; Middle Aged; Retrospective Studies; Risk Assessment; Rivaroxaban; Stroke; Thromboembolism; Warfarin | 2016 |
A nationwide registry study to compare bleeding rates in patients with atrial fibrillation being prescribed oral anticoagulants.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Follow-Up Studies; Hemorrhage; Humans; Incidence; Male; Norway; Prescription Drugs; Pyrazoles; Pyridones; Registries; Retrospective Studies; Rivaroxaban; Survival Rate; Thromboembolism; Warfarin | 2017 |
Stroke, Bleeding, and Mortality Risks in Elderly Medicare Beneficiaries Treated With Dabigatran or Rivaroxaban for Nonvalvular Atrial Fibrillation.
Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Cohort Studies; Dabigatran; Factor Xa Inhibitors; Female; Follow-Up Studies; Gastrointestinal Hemorrhage; Heart Valve Diseases; Humans; Kaplan-Meier Estimate; Male; Medicare; Retrospective Studies; Risk Factors; Rivaroxaban; Stroke; Treatment Outcome; United States | 2016 |
Bleeding risk higher with rivaroxaban than dabigatran for stroke prevention, head-to-head trial shows.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Morpholines; Pyridones; Rivaroxaban; Stroke; Warfarin | 2016 |
Assessment of Web-based education resources informing patients about stroke prevention in atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Fibrinolytic Agents; Hemorrhage; Humans; Internet; Patient Education as Topic; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Stroke; Warfarin | 2016 |
[Safer treatment with serum concentration monitoring of the new anticoagulants?].
Topics: Anticoagulants; Dabigatran; Dose-Response Relationship, Drug; Drug Monitoring; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Hemorrhage; Humans; Pyrazoles; Pyridones; Reference Standards; Risk Factors; Rivaroxaban; Vitamin K | 2016 |
Ischaemic and haemorrhagic stroke associated with non-vitamin K antagonist oral anticoagulants and warfarin use in patients with atrial fibrillation: a nationwide cohort study.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Brain Ischemia; Cohort Studies; Dabigatran; Denmark; Female; Hospitalization; Humans; Intracranial Hemorrhages; Male; Middle Aged; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Vitamin K; Warfarin | 2017 |
Cost-effectiveness of non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with atrial fibrillation at high risk of bleeding and normal kidney function.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cost-Benefit Analysis; Dabigatran; Hemorrhage; Humans; Markov Chains; Pyrazoles; Pyridines; Pyridones; Quality-Adjusted Life Years; Rivaroxaban; Stroke; Thiazoles; Warfarin | 2017 |
Sensitivity of routine coagulation assays to direct oral anticoagulants: patient samples versus commercial drug-specific calibrators.
Topics: Anticoagulants; Blood Coagulation Tests; Calibration; Dabigatran; Drug Monitoring; Humans; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Sensitivity and Specificity | 2016 |
Adherence to Rivaroxaban, Dabigatran, and Apixaban for Stroke Prevention in Incident, Treatment-Naïve Nonvalvular Atrial Fibrillation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Follow-Up Studies; Humans; Insurance Claim Review; Male; Medication Adherence; Middle Aged; Pyrazoles; Pyridones; Rivaroxaban; Stroke; United States | 2016 |
Use of Chronic Oral Anticoagulation and Associated Outcomes Among Patients Undergoing Percutaneous Coronary Intervention.
Topics: Aged; Aged, 80 and over; Angina Pectoris; Anticoagulants; Atrial Fibrillation; Comorbidity; Dabigatran; Databases, Factual; Female; Hospital Mortality; Humans; Kaplan-Meier Estimate; Length of Stay; Logistic Models; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Patient Readmission; Percutaneous Coronary Intervention; Postoperative Hemorrhage; Propensity Score; Proportional Hazards Models; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Stents; Stroke; Thrombosis; Venous Thromboembolism; Warfarin | 2016 |
Use of Oral Anticoagulation in the Management of Atrial Fibrillation in Patients with ESRD: Pro.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Kidney Failure, Chronic; Patient Selection; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Warfarin | 2016 |
Safety and efficacy of contemporary catheter ablation for atrial fibrillation patients with a history of cardioembolic stroke in the era of direct oral anticoagulants.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Catheter Ablation; Dabigatran; Female; Hemorrhage; Humans; Ischemic Attack, Transient; Male; Middle Aged; Pulmonary Veins; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Treatment Outcome; Warfarin | 2017 |
[Gastrointestinal bleeding during treatment with nonvitamin K antagonist oral anticoagulants (NOACs) may be caused by malignant lesions].
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Colonoscopy; Dabigatran; Factor Xa Inhibitors; Female; Gastrointestinal Hemorrhage; Gastrointestinal Neoplasms; Humans; Male; Pilot Projects; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Vitamin K | 2016 |
Stability of direct oral anticoagulants in whole blood and plasma from patients in steady state treatment.
Topics: Administration, Oral; Anticoagulants; Blood Coagulation; Blood Coagulation Tests; Dabigatran; Drug Monitoring; Drug Stability; Humans; Pyrazoles; Pyridones; Rivaroxaban | 2016 |
Development of an UHPLC-UV-Method for Quantification of Direct Oral Anticoagulants: Apixaban, Rivaroxaban, Dabigatran, and its Prodrug Dabigatran Etexilate in Human Serum.
Topics: Administration, Oral; Anticoagulants; Chromatography, High Pressure Liquid; Dabigatran; Dose-Response Relationship, Drug; Humans; Limit of Detection; Prodrugs; Pyrazoles; Pyridones; Reproducibility of Results; Rivaroxaban | 2017 |
Indirect Comparison of Novel Oral Anticoagulants in Women with Nonvalvular Atrial Fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Hemorrhage; Humans; Odds Ratio; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiazoles; Treatment Outcome; Warfarin | 2017 |
Comparative effectiveness of dabigatran and rivaroxaban versus warfarin for the treatment of non-valvular atrial fibrillation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Gastrointestinal Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Rivaroxaban; Warfarin | 2017 |
Efficacy and safety of dabigatran, rivaroxaban, and warfarin for stroke prevention in Chinese patients with atrial fibrillation: the Hong Kong Atrial Fibrillation Project.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Brain Ischemia; Dabigatran; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Hong Kong; Humans; Incidence; Male; Retrospective Studies; Rivaroxaban; Survival Rate; Time Factors; Treatment Outcome; Warfarin | 2017 |
Acute management of stroke patients taking non-vitamin K antagonist oral anticoagulants Addressing Real-world Anticoagulant Management Issues in Stroke (ARAMIS) Registry: Design and rationale.
Topics: Administration, Oral; Adult; Anticoagulants; Antithrombins; Atrial Fibrillation; Cohort Studies; Dabigatran; Emergency Treatment; Female; Humans; Male; Medication Therapy Management; Outcome and Process Assessment, Health Care; Pyrazoles; Pyridines; Pyridones; Quality Improvement; Registries; Rivaroxaban; Stroke; Thiazoles; United States; Warfarin | 2016 |
Bleeding in patients with atrial fibrillation treated with dabigatran, rivaroxaban or warfarin.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Hemorrhage; Humans; Morpholines; Pyrazoles; Rivaroxaban; Warfarin | 2017 |
Direct Comparison of Dabigatran, Rivaroxaban, and Apixaban for Effectiveness and Safety in Nonvalvular Atrial Fibrillation.
Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Cerebral Hemorrhage; Dabigatran; Factor Xa Inhibitors; Female; Humans; Male; Middle Aged; Propensity Score; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; United States | 2016 |
Complications With New Oral Anticoagulants Dabigatran and Rivaroxaban in Cutaneous Surgery.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Dermatologic Surgical Procedures; Hemorrhage; Humans; Morpholines; Pyridones; Rivaroxaban | 2017 |
Cost-Effectiveness Analysis of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation in Taiwan.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cost-Benefit Analysis; Dabigatran; Female; Humans; Male; Middle Aged; Pyrazoles; Pyridones; Quality-Adjusted Life Years; Rivaroxaban; Stroke; Taiwan; Warfarin | 2017 |
The use of direct oral anticoagulants in 56 patients with antiphospholipid syndrome.
Topics: Administration, Oral; Adult; Anticoagulants; Antiphospholipid Syndrome; Dabigatran; Female; Hemorrhage; Humans; Male; Middle Aged; Prospective Studies; Pyrazoles; Pyridones; Rivaroxaban; Thrombosis; Vitamin K; Young Adult | 2017 |
Risk of intraocular hemorrhage with new oral anticoagulants.
Topics: Anticoagulants; Dabigatran; Eye Hemorrhage; Humans; Ocular Hypertension; Odds Ratio; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Stroke; Warfarin | 2017 |
Gastrointestinal Safety of Direct Oral Anticoagulants: A Large Population-Based Study.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Cohort Studies; Dabigatran; Factor Xa Inhibitors; Female; Gastrointestinal Hemorrhage; Humans; Male; Middle Aged; Propensity Score; Proportional Hazards Models; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Young Adult | 2017 |
Direct oral anticoagulants and heparins: laboratory values and pitfalls in 'bridging therapy'.
Topics: Administration, Oral; Anticoagulants; Blood Coagulation; Blood Coagulation Tests; Dabigatran; Dose-Response Relationship, Drug; Drug Interactions; Drug Monitoring; Factor Xa Inhibitors; Heparin; Heparin, Low-Molecular-Weight; Humans; Perioperative Care; Pyrazoles; Pyridones; Rivaroxaban | 2017 |
Safety profile of the direct oral anticoagulants: an analysis of the WHO database of adverse drug reactions.
Topics: Administration, Oral; Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Aged; Anticoagulants; Atrial Fibrillation; Cerebral Hemorrhage; Child; Child, Preschool; Dabigatran; Databases, Factual; Female; Gastrointestinal Hemorrhage; Humans; Infant; Infant, Newborn; Male; Middle Aged; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Stroke; Warfarin; World Health Organization; Young Adult | 2017 |
Non-vitamin K antagonist oral anticoagulants in patients with severe inherited thrombophilia: a series of 33 patients.
Topics: Adult; Anticoagulants; Dabigatran; Female; Humans; Male; Medication Adherence; Middle Aged; Pyrazoles; Pyridones; Recurrence; Rivaroxaban; Thrombophilia; Venous Thromboembolism; Young Adult | 2017 |
[Monitoring of NOAC].
Topics: Administration, Oral; Antibodies, Monoclonal, Humanized; Anticoagulants; Blood Coagulation Tests; Dabigatran; Dose-Response Relationship, Drug; Drug Monitoring; Emergency Service, Hospital; Hemorrhage; Humans; Intensive Care Units; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thromboembolism; Vitamin K | 2017 |
Cost of Hospital Admissions in Medicare Patients With Atrial Fibrillation Taking Warfarin, Dabigatran, or Rivaroxaban.
Topics: Aged; Antithrombins; Atrial Fibrillation; Dabigatran; Factor Xa Inhibitors; Female; Hospital Costs; Humans; Male; Medicare; Patient Admission; Rivaroxaban; Stroke; United States; Warfarin | 2017 |
Use of Intravenous Recombinant Tissue Plasminogen Activator in Patients With Acute Ischemic Stroke Who Take Non-Vitamin K Antagonist Oral Anticoagulants Before Stroke.
Topics: Administration, Intravenous; Aged; Aged, 80 and over; Anticoagulants; Dabigatran; Female; Fibrinolytic Agents; Hemorrhage; Hospital Mortality; Humans; International Normalized Ratio; Male; Pyrazoles; Pyridones; Recombinant Proteins; Registries; Retrospective Studies; Risk Factors; Rivaroxaban; Stroke; Time Factors; Tissue Plasminogen Activator; Treatment Outcome; Warfarin | 2017 |
Microfluidic coagulation assay for monitoring anticoagulant therapy in acute stroke patients.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Automation, Laboratory; Blood Coagulation; Chromatography, High Pressure Liquid; Dabigatran; Drug Monitoring; Female; Humans; Ischemic Attack, Transient; Male; Microfluidic Analytical Techniques; Microscopy, Fluorescence; Middle Aged; Phenprocoumon; Predictive Value of Tests; Pyrazoles; Pyridones; Reproducibility of Results; Rivaroxaban; Stroke; Tandem Mass Spectrometry; Time Factors; Treatment Outcome; Whole Blood Coagulation Time | 2017 |
Permanent discontinuation of non vitamin K oral anticoagulants in real life patients with non-valvular atrial fibrillation.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Dyspepsia; Female; Follow-Up Studies; Hemorrhage; Humans; Italy; Male; Medication Adherence; Middle Aged; Prospective Studies; Pyrazoles; Pyridones; Rivaroxaban; Vitamin K | 2017 |
Trends in oral anticoagulant use in Qatar: a 5-year experience.
Topics: Administration, Oral; Anticoagulants; Dabigatran; Drug Utilization Review; Female; Humans; Male; Prescriptions; Qatar; Rivaroxaban; Warfarin | 2017 |
[Non-vitamin K dependent oral anticoagulants : What is important in intensive care medicine].
Topics: Antibodies, Monoclonal, Humanized; Anticoagulants; Dabigatran; Electric Countershock; Emergency Service, Hospital; Factor Xa Inhibitors; Hemorrhage; Humans; Intensive Care Units; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thrombin; Thromboembolism; Vitamin K | 2017 |
The cost of warfarin treatment for stroke prevention in patients with non-valvular atrial fibrillation in Russia from a collective perspective.
Topics: Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Comorbidity; Dabigatran; Female; Health Behavior; Humans; International Normalized Ratio; Male; Middle Aged; Models, Econometric; Patient Compliance; Patient Satisfaction; Rivaroxaban; Russia; Stroke; Warfarin | 2017 |
Evaluation of the Efficacy and Safety of Direct Oral Anticoagulants in Japanese Patients-Analysis of Pharmaceuticals and Medical Devices Agency Data.
Topics: Administration, Oral; Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Antithrombins; Blood Coagulation; Brain Ischemia; Dabigatran; Databases, Factual; Drug Approval; Factor Xa Inhibitors; Female; Humans; Incidence; Intracranial Hemorrhages; Japan; Male; Middle Aged; Pyrazoles; Pyridones; Retrospective Studies; Risk Assessment; Risk Factors; Rivaroxaban; Time Factors; Treatment Outcome | 2017 |
Italian intersociety consensus on DOAC use in internal medicine.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Clinical Competence; Consensus; Dabigatran; Drug-Related Side Effects and Adverse Reactions; Factor Xa Inhibitors; Food-Drug Interactions; Humans; Internal Medicine; Italy; Liver Diseases; Perioperative Period; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Time Factors; Venous Thromboembolism | 2017 |
Postapproval Observational Studies of Non-Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Data Collection; Gastrointestinal Hemorrhage; Hemorrhage; Humans; Observational Studies as Topic; Patient Selection; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Registries; Rivaroxaban; Stroke; Warfarin | 2017 |
Effect and risk of novel oral anticoagulants versus warfarin in patients with non-valvular atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Rivaroxaban; Stroke; Warfarin | 2017 |
A Comparison of the Rate of Gastrointestinal Bleeding in Patients Taking Non-Vitamin K Antagonist Oral Anticoagulants or Warfarin.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Blood Transfusion; Dabigatran; Female; Gastrointestinal Hemorrhage; Hemoglobins; Humans; Incidence; Male; Pulmonary Embolism; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Venous Thrombosis; Warfarin | 2017 |
Determination of non-Vitamin K oral anticoagulant (NOAC) effects using a new-generation thrombelastography TEG 6s system.
Topics: Adult; Anticoagulants; Antithrombins; Automation; Dabigatran; Drug Monitoring; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Limit of Detection; Male; Middle Aged; Point-of-Care Systems; Pyrazoles; Pyridones; Rivaroxaban; Thrombelastography | 2017 |
[Comparison of the cost-utility of direct oral anticoagulants for the prevention of stroke in patients with atrial fibrillation in Spain].
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Cost-Benefit Analysis; Dabigatran; Female; Humans; Male; Markov Chains; Pyrazoles; Pyridones; Rivaroxaban; Spain; Stroke; Vitamin K | 2017 |
Early non-persistence with dabigatran and rivaroxaban in patients with atrial fibrillation.
Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Dabigatran; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Female; Follow-Up Studies; Humans; Incidence; Male; Ontario; Registries; Retrospective Studies; Rivaroxaban; Stroke; Time Factors; Treatment Outcome | 2017 |
[Real-world data on novel oral anticoagulants: the added value of registries and observational studies. Focus on apixaban].
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Observational Studies as Topic; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Registries; Rivaroxaban; Stroke | 2016 |
Effect of direct oral anticoagulants on the risk of delayed bleeding after gastric endoscopic submucosal dissection.
Topics: Administration, Oral; Aged; Anticoagulants; Antithrombins; Blood Transfusion; Cohort Studies; Dabigatran; Endoscopic Mucosal Resection; Female; Follow-Up Studies; Humans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Postoperative Hemorrhage; Retrospective Studies; Risk Factors; Rivaroxaban; Statistics, Nonparametric; Stomach Neoplasms; Thromboembolism; Treatment Outcome; Warfarin | 2017 |
Thrombotic and bleeding outcomes following perioperative interruption of direct oral anticoagulants in patients with venous thromboembolic disease.
Topics: Administration, Oral; Aged; Antithrombins; Blood Coagulation; Dabigatran; Drug Administration Schedule; Factor Xa Inhibitors; Female; Half-Life; Humans; Male; Middle Aged; Perioperative Care; Postoperative Hemorrhage; Pyrazoles; Pyridones; Recurrence; Retrospective Studies; Risk Assessment; Risk Factors; Rivaroxaban; Surgical Procedures, Operative; Time Factors; Treatment Outcome; Venous Thromboembolism | 2017 |
NOACs for Stroke Prevention in Atrial Fibrillation With Valve Disease: Filling the Gaps.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Heart Valve Diseases; Humans; Rivaroxaban; Stroke | 2017 |
Uptake of non-vitamin K antagonist oral anti coagulants in patients with atrial fibrillation - a prospective cohort study.
Topics: Administration, Oral; Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Factor Xa Inhibitors; Female; Humans; Male; Prospective Studies; Registries; Rivaroxaban; Stroke; Switzerland | 2017 |
Risk of myocardial infarction in patients with atrial fibrillation using vitamin K antagonists, aspirin or direct acting oral anticoagulants.
Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Dabigatran; Female; Fibrinolytic Agents; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Retrospective Studies; Risk Factors; Rivaroxaban; Stroke; Vitamin K | 2017 |
Paramagnetic micro-particles as a tool for rapid quantification of apixaban, dabigatran, edoxaban and rivaroxaban in human plasma by UHPLC-MS/MS.
Topics: Blood Chemical Analysis; Chromatography, High Pressure Liquid; Dabigatran; Humans; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Tandem Mass Spectrometry; Thiazoles | 2017 |
[Incidence, investigation and long-term follow-up of macroscopic hematuria in patients treated with non vitamin K antagonist oral anticoagulant: Insight from a specialist cardiology clinic].
Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Dabigatran; Drug Substitution; Factor Xa Inhibitors; Female; Follow-Up Studies; Hematuria; Humans; Kidney Calculi; Male; Neoplasms; Prostatic Hyperplasia; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban | 2017 |
Volume and Characteristics of Intracerebral Hemorrhage with Direct Oral Anticoagulants in Comparison with Warfarin
.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Blood Coagulation; Cerebral Hemorrhage; Chi-Square Distribution; Cross-Sectional Studies; Dabigatran; Disability Evaluation; Factor Xa Inhibitors; Female; Hematoma; Humans; Japan; Linear Models; Male; Middle Aged; Multivariate Analysis; Patient Discharge; Prospective Studies; Pyrazoles; Pyridones; Registries; Risk Factors; Rivaroxaban; Tomography, X-Ray Computed; Treatment Outcome; Warfarin | 2017 |
Trends in the prescription of novel oral anticoagulants in UK primary care.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Dabigatran; Drug Utilization; Female; Humans; Male; Middle Aged; Practice Patterns, Physicians'; Primary Health Care; Pyrazoles; Pyridones; Rivaroxaban; United Kingdom; Vitamin K | 2017 |
Sex-Specific Comparative Effectiveness of Oral Anticoagulants in Elderly Patients With Newly Diagnosed Atrial Fibrillation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Brain Ischemia; Chi-Square Distribution; Comparative Effectiveness Research; Dabigatran; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Medicare Part D; Multivariate Analysis; Patient Admission; Propensity Score; Proportional Hazards Models; Protective Factors; Retrospective Studies; Risk Assessment; Risk Factors; Rivaroxaban; Sex Factors; Stroke; Treatment Outcome; United States; Warfarin | 2017 |
Management of Severe Bleeding in Patients Treated with Direct Oral Anticoagulants: An Observational Registry Analysis.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Blood Coagulation Factors; Cohort Studies; Dabigatran; Europe; Female; Hemorrhage; Humans; Male; Prospective Studies; Pyrazoles; Pyridones; Registries; Rivaroxaban | 2017 |
Medium- to long-term persistence with non-vitamin-K oral anticoagulants in patients with atrial fibrillation: Australian experience.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Australia; Comorbidity; Dabigatran; Female; Humans; Male; Middle Aged; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Warfarin | 2017 |
Novel oral anticoagulants and trauma: The results of a prospective American Association for the Surgery of Trauma Multi-Institutional Trial.
Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Clopidogrel; Dabigatran; Female; Humans; Injury Severity Score; Intracranial Hemorrhages; Male; Platelet Aggregation Inhibitors; Prospective Studies; Pyrazoles; Pyridones; Rivaroxaban; Ticlopidine; Trauma Centers; Warfarin; Wounds and Injuries; Wounds, Nonpenetrating | 2017 |
Comparative Effectiveness and Safety of Dabigatran and Rivaroxaban in Atrial Fibrillation Patients.
Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Blood Transfusion; Cause of Death; Comparative Effectiveness Research; Dabigatran; Embolism; Factor Xa Inhibitors; Female; Gastrointestinal Hemorrhage; Humans; Intracranial Hemorrhages; Logistic Models; Male; Mortality; Myocardial Infarction; Propensity Score; Proportional Hazards Models; Retrospective Studies; Rivaroxaban; Stroke | 2017 |
Response by Bai et al to Letter Regarding Article, "Rivaroxaban Versus Dabigatran or Warfarin in Real-World Studies of Stroke Prevention in Atrial Fibrillation: Systematic Review and Meta-Analysis".
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Pyridones; Rivaroxaban; Stroke; Warfarin | 2017 |
Letter by Machado-Alba et al Regarding Article, "Rivaroxaban Versus Dabigatran or Warfarin in Real-World Studies of Stroke Prevention in Atrial Fibrillation: Systematic Review and Meta-Analysis".
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Pyridones; Rivaroxaban; Stroke; Warfarin | 2017 |
Different Involvement of OAT in Renal Disposition of Oral Anticoagulants Rivaroxaban, Dabigatran, and Apixaban.
Topics: Animals; Anticoagulants; Biological Transport; Dabigatran; Drug Interactions; Female; Haplorhini; HEK293 Cells; Humans; Kidney; Mice; Mice, Inbred C57BL; Organic Anion Transporters; Pyrazoles; Pyridones; Rats; Rats, Sprague-Dawley; Rivaroxaban | 2017 |
Predictors of Direct Oral Anticoagulants Utilization for Thromboembolism Prevention in Atrial Fibrillation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cross-Sectional Studies; Dabigatran; Female; Humans; Male; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Thromboembolism; Warfarin | 2017 |
Dabigatran Compared With Rivaroxaban vs Warfarin.
Topics: Aged; Atrial Fibrillation; Dabigatran; Humans; Medicare; Rivaroxaban; Stroke; United States; Warfarin | 2017 |
Dabigatran Compared With Rivaroxaban vs Warfarin.
Topics: Aged; Atrial Fibrillation; Dabigatran; Humans; Medicare; Rivaroxaban; Stroke; United States; Warfarin | 2017 |
Dabigatran Compared With Rivaroxaban vs Warfarin.
Topics: Aged; Atrial Fibrillation; Dabigatran; Humans; Medicare; Rivaroxaban; Stroke; United States; Warfarin | 2017 |
Dabigatran Compared With Rivaroxaban vs Warfarin-Reply.
Topics: Aged; Atrial Fibrillation; Dabigatran; Humans; Medicare; Rivaroxaban; Stroke; United States; Warfarin | 2017 |
Dabigatran Compared With Rivaroxaban vs Warfarin-Reply.
Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Rivaroxaban; Warfarin | 2017 |
[Measurement of Prothrombin Fragment 1+2 for the Assessment of Anticoagulant Activity in Patients Treated with Warfarin or Non-vitamin K Antagonist Oral Anticoagulant].
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cerebral Hemorrhage; Dabigatran; Female; Humans; Male; Peptide Fragments; Prothrombin; Rivaroxaban; Warfarin | 2017 |
Initiation of anticoagulation in atrial fibrillation: which factors are associated with choice of anticoagulant?
Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Hemorrhage; Humans; Male; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Stroke; Vitamin K; Warfarin | 2017 |
Antithrombotic Therapy for Venous Thromboembolic Disease.
Topics: Antithrombins; Dabigatran; Humans; Practice Guidelines as Topic; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Review Literature as Topic; Rivaroxaban; Thiazoles; Venous Thromboembolism; Venous Thrombosis; Vitamin K | 2017 |
Comparison of the Incidences of Complications After Second-Generation Cryoballoon Ablation of Atrial Fibrillation Using Vitamin K Antagonists Versus Novel Oral Anticoagulants.
Topics: Ablation Techniques; Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Belgium; Cryosurgery; Dabigatran; Dose-Response Relationship, Drug; Drug Therapy, Combination; Factor Xa Inhibitors; Female; Follow-Up Studies; Humans; Incidence; Intraoperative Period; Italy; Male; Middle Aged; Postoperative Complications; Prognosis; Pyrazoles; Pyridines; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Survival Rate; Thiazoles; Time Factors; Vitamin K | 2017 |
Safety and efficacy of DOACs vs acenocoumarol in patients undergoing catheter ablation of atrial fibrillation.
Topics: Acenocoumarol; Administration, Oral; Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Catheter Ablation; Dabigatran; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Prospective Studies; Pyrazoles; Pyridones; Registries; Risk Factors; Rivaroxaban; Thromboembolism; Time Factors; Treatment Outcome | 2017 |
Non-Vitamin K Antagonist Oral Anticoagulant Dosing in Patients With Atrial Fibrillation and Renal Dysfunction.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Dabigatran; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Female; Follow-Up Studies; Hemorrhage; Humans; Incidence; Male; Middle Aged; Pyrazoles; Pyridones; Renal Insufficiency; Retrospective Studies; Rivaroxaban; Stroke; Time Factors; Treatment Outcome; United States; Vitamin K; Young Adult | 2017 |
Major bleeding risk and healthcare economic outcomes of non-valvular atrial fibrillation patients newly-initiated with oral anticoagulant therapy in the real-world setting.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Comorbidity; Dabigatran; Female; Health Expenditures; Health Resources; Hemorrhage; Humans; Male; Middle Aged; Models, Econometric; Propensity Score; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Warfarin | 2017 |
Effectiveness and Safety of Standard-Dose Nonvitamin K Antagonist Oral Anticoagulants and Warfarin Among Patients With Atrial Fibrillation With a Single Stroke Risk Factor: A Nationwide Cohort Study.
Topics: Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Cohort Studies; Dabigatran; Denmark; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Stroke; Treatment Outcome; Warfarin | 2017 |
Risk of stroke/systemic embolism, major bleeding and associated costs in non-valvular atrial fibrillation patients who initiated apixaban, dabigatran or rivaroxaban compared with warfarin in the United States Medicare population.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Costs and Cost Analysis; Dabigatran; Embolism; Female; Hemorrhage; Humans; Male; Medicare; Proportional Hazards Models; Pyrazoles; Pyridones; Risk; Rivaroxaban; Stroke; United States; Warfarin | 2017 |
Effects of direct oral anticoagulants on lupus anticoagulant assays in a real-life setting.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Biomarkers; Blood Coagulation; Dabigatran; Dose-Response Relationship, Drug; Drug Monitoring; False Positive Reactions; Humans; Lupus Coagulation Inhibitor; Partial Thromboplastin Time; Predictive Value of Tests; Prothrombin Time; Pyrazoles; Pyridones; Reproducibility of Results; Rivaroxaban | 2017 |
Extended use of sulodexide, apixaban, rivaroxaban and dabigatran in venous thromboembolism: indirect comparison of clinical trials.
Topics: Administration, Oral; Anticoagulants; Dabigatran; Glycosaminoglycans; Hemorrhage; Humans; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Venous Thromboembolism | 2017 |
Is it reasonable to use a lower DOACs dose in some patients with VTE? Yes.
Topics: Administration, Oral; Anticoagulants; Dabigatran; Dose-Response Relationship, Drug; Evidence-Based Medicine; Humans; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Venous Thromboembolism; Warfarin | 2017 |
Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Previous Stroke or Transient Ischemic Attack.
Topics: Adolescent; Adult; Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Cerebral Hemorrhage; Cohort Studies; Dabigatran; Factor Xa Inhibitors; Female; Follow-Up Studies; Humans; Ischemic Attack, Transient; Male; Middle Aged; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Treatment Outcome; Warfarin; Young Adult | 2017 |
Shifting to a non-vitamin K antagonist oral anticoagulation agent from vitamin K antagonist in atrial fibrillation.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Denmark; Drug Substitution; Female; Hemorrhage; Humans; Male; Pyrazoles; Pyridones; Registries; Rivaroxaban; Stroke; Vitamin K | 2018 |
Pulmonary embolism in a morbidly obese patient receiving dabigatran.
Topics: Antithrombins; Blood Coagulation; Body Mass Index; Dabigatran; Drug Substitution; Humans; Male; Middle Aged; Obesity, Morbid; Pulmonary Embolism; Risk Factors; Rivaroxaban; Treatment Failure | 2017 |
Non-vitamin K oral anticoagulants are non-inferior for stroke prevention but cause fewer major bleedings than well-managed warfarin: A retrospective register study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Hemorrhage; Humans; Male; Middle Aged; Proportional Hazards Models; Pyrazoles; Pyridines; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Thiazoles; Warfarin | 2017 |
A comparison between vitamin K antagonists and new oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Clinical Trials, Phase III as Topic; Dabigatran; Humans; Intracranial Hemorrhages; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Vitamin K; Warfarin | 2017 |
Apixaban may have lower risk of GI bleeding compared with dabigatran and rivaroxaban in patients with atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Pyrazoles; Pyridones; Rivaroxaban; Stroke | 2017 |
Long-term stroke and bleeding risk in patients with atrial fibrillation treated with oral anticoagulants in contemporary practice: Providing evidence for shared decision-making.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Databases, Factual; Decision Making; Female; Hemorrhage; Humans; Male; Middle Aged; Retrospective Studies; Rivaroxaban; Stroke; Time Factors; Treatment Outcome; Warfarin | 2017 |
Trends in use of warfarin and direct oral anticoagulants in atrial fibrillation in Norway, 2010 to 2015.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Drug Utilization; Female; Humans; Male; Middle Aged; Norway; Pyrazoles; Pyridones; Rivaroxaban; Warfarin; Young Adult | 2017 |
The representativeness of direct oral anticoagulant clinical trials to hospitalized patients with atrial fibrillation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Hospitalization; Humans; Male; Middle Aged; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban | 2017 |
Adherence with direct oral anticoagulants in nonvalvular atrial fibrillation new users and associated factors: a French nationwide cohort study.
Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cohort Studies; Comorbidity; Dabigatran; Databases, Factual; Female; France; Health Care Surveys; Humans; Male; Medication Adherence; Middle Aged; Myocardial Ischemia; Rivaroxaban; Stroke; Vitamin K | 2017 |
Use of direct oral anticoagulants in patients with atrial fibrillation in Scotland: Applying a coherent framework to drug utilisation studies.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Drug Utilization; Female; Humans; Kaplan-Meier Estimate; Male; Medication Adherence; Middle Aged; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Scotland; Warfarin | 2017 |
New oral anticoagulant prescription rate and risk of bleeding in an Italian region.
Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Case-Control Studies; Cross-Over Studies; Dabigatran; Drug Prescriptions; Female; Hemorrhage; Hospitalization; Humans; Italy; Male; Middle Aged; Prevalence; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Sex Factors; Stroke; Time Factors | 2017 |
Dabigatran Therapy Resulting in the Resolution of Rivaroxaban-resistant Left Atrial Appendage Thrombi in Patients with Atrial Fibrillation.
Topics: Aged; Antithrombins; Atrial Appendage; Atrial Fibrillation; Dabigatran; Echocardiography, Transesophageal; Heart Atria; Humans; Male; Rivaroxaban; Thrombosis | 2017 |
Emergency Coagulation Assessment During Treatment With Direct Oral Anticoagulants: Limitations and Solutions.
Topics: Aged; Aged, 80 and over; Antithrombins; Blood Coagulation Disorders; Blood Coagulation Tests; Dabigatran; Emergencies; Factor Xa Inhibitors; Female; Humans; Male; Middle Aged; Partial Thromboplastin Time; Point-of-Care Testing; Prothrombin Time; Pyrazoles; Pyridones; Rivaroxaban; Sensitivity and Specificity; Stroke; Thrombin Time; Thrombolytic Therapy | 2017 |
Direct Oral Anticoagulants Form Thrombus Different From Warfarin in a Microchip Flow Chamber System.
Topics: Administration, Oral; Aged; Anticoagulants; Area Under Curve; Atrial Fibrillation; Dabigatran; Female; Humans; Lab-On-A-Chip Devices; Male; Middle Aged; Pyrazoles; Pyridones; Rivaroxaban; Thrombosis; Warfarin | 2017 |
Evaluation of Direct-Acting Oral Anticoagulant Use in Patients With Cancer.
Topics: Administration, Oral; Aged; Anticoagulants; Cohort Studies; Dabigatran; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Neoplasms; Pyrazoles; Pyridines; Pyridones; Retrospective Studies; Rivaroxaban; Thiazoles; Venous Thromboembolism | 2018 |
Measuring Direct Oral Anticoagulants.
Topics: Administration, Oral; Antithrombins; Blood Coagulation; Dabigatran; Drug Monitoring; Endopeptidases; Factor Xa Inhibitors; Fibrinolytic Agents; Humans; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thrombin Time; Venous Thromboembolism | 2017 |
New Oral Anticoagulants: What Prescribers Should Know; Differences and Similarities between Warfarin and "New Agents" (Dabigatran, Rivaroxaban, Apixaban, Edoxaban) - Review of Indications, Contraindications and Safety of Use.
Topics: Administration, Oral; Anticoagulants; Dabigatran; Diet; Humans; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Warfarin | 2016 |
In nonvalvular AF, DOAC-related risk for GI bleeding was lower with apixaban than dabigatran or rivaroxaban.
Topics: Benzimidazoles; Dabigatran; Humans; Pyrazoles; Pyridones; Rivaroxaban | 2017 |
Replacing warfarin therapy with the newer direct oral anticoagulants, or simply a growth in anticoagulation therapy? Implications for pathology testing.
Topics: Administration, Oral; Anticoagulants; Dabigatran; Humans; Prescriptions; Pyrazoles; Pyridones; Rivaroxaban; Thromboembolism; Warfarin | 2017 |
Treatment of Cryptogenic Stroke with Active Cancer with a New Oral Anticoagulant.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Blood Coagulation; Dabigatran; Dalteparin; Disability Evaluation; Enoxaparin; Female; Hemorrhage; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasms; Recurrence; Registries; Retrospective Studies; Risk Factors; Rivaroxaban; Seoul; Stroke; Time Factors; Treatment Outcome | 2017 |
Apixaban, rivaroxaban, and dabigatran use in patients undergoing catheter ablation for atrial fibrillation using the second-generation cryoballoon.
Topics: Administration, Oral; Aged; Antithrombins; Atrial Fibrillation; Cardiac Catheters; Cerebrovascular Disorders; Cryosurgery; Dabigatran; Drug Administration Schedule; Drug Monitoring; Equipment Design; Factor Xa Inhibitors; Female; Heparin, Low-Molecular-Weight; Humans; International Normalized Ratio; Male; Middle Aged; Phenprocoumon; Postoperative Hemorrhage; Pyrazoles; Pyridones; Retrospective Studies; Risk Factors; Rivaroxaban; Time Factors; Treatment Outcome; Vitamin K | 2017 |
Comparison of effectiveness and safety of treatment with apixaban vs. other oral anticoagulants among elderly nonvalvular atrial fibrillation patients.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Hemorrhage; Humans; Male; Propensity Score; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Warfarin | 2017 |
Major Bleeding Risk During Anticoagulation with Warfarin, Dabigatran, Apixaban, or Rivaroxaban in Patients with Nonvalvular Atrial Fibrillation.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Hemorrhage; Humans; Male; Pyrazoles; Pyridones; Retrospective Studies; Risk; Rivaroxaban; Warfarin | 2017 |
Adherence to Rivaroxaban Compared with Other Oral Anticoagulant Agents Among Patients with Nonvalvular Atrial Fibrillation.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Humans; Male; Medication Adherence; Middle Aged; Propensity Score; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Warfarin | 2017 |
Adherence to Rivaroxaban, Dabigatran, and Apixaban for Stroke Prevention for Newly Diagnosed and Treatment-Naive Atrial Fibrillation Patients: An Update Using 2013-2014 Data.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Humans; Male; Medication Adherence; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke | 2017 |
Direct oral anticoagulant medications in calciphylaxis.
Topics: Adult; Aged; Anticoagulants; Calciphylaxis; Dabigatran; Female; Humans; Male; Middle Aged; Pyrazoles; Pyridones; Renal Insufficiency, Chronic; Retrospective Studies; Rivaroxaban | 2017 |
Bleeding risk of apixaban, dabigatran, and low-dose rivaroxaban compared with warfarin in Japanese patients with non-valvular atrial fibrillation: a propensity matched analysis of administrative claims data.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Female; Hemorrhage; Humans; Japan; Male; Middle Aged; Propensity Score; Proportional Hazards Models; Pyrazoles; Pyridones; Retrospective Studies; Risk; Rivaroxaban; Warfarin | 2017 |
Standard and reduced doses of dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation: a nationwide cohort study.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Denmark; Dose-Response Relationship, Drug; Female; Hemorrhage; Humans; Male; Pyrazoles; Pyridones; Registries; Rivaroxaban; Stroke | 2018 |
Cost-effectiveness analysis of dabigatran versus rivaroxaban for stroke prevention in patients with non-valvular atrial fibrillation using real-world evidence in elderly US Medicare beneficiaries.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Cost-Benefit Analysis; Dabigatran; Humans; Medicare; Rivaroxaban; Stroke; United States | 2018 |
Sex-Specific Associations of Oral Anticoagulant Use and Cardiovascular Outcomes in Patients With Atrial Fibrillation.
Topics: Administration, Oral; Administrative Claims, Healthcare; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cause of Death; Chi-Square Distribution; Dabigatran; Databases, Factual; Female; Heart Failure; Humans; Kaplan-Meier Estimate; Male; Medicare; Multivariate Analysis; Myocardial Infarction; Patient Admission; Propensity Score; Proportional Hazards Models; Retrospective Studies; Risk Factors; Rivaroxaban; Sex Factors; Time Factors; Treatment Outcome; United States; Warfarin | 2017 |
Comparison of the Effectiveness and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Newly Diagnosed Atrial Fibrillation.
Topics: Administration, Oral; Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Dose-Response Relationship, Drug; Embolism; Factor Xa Inhibitors; Female; Follow-Up Studies; Humans; Incidence; Male; Pennsylvania; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Treatment Outcome; Warfarin | 2017 |
Adherence and outcomes to direct oral anticoagulants among patients with atrial fibrillation: findings from the veterans health administration.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Blood Coagulation; Dabigatran; Drug Prescriptions; Factor Xa Inhibitors; Female; Humans; Linear Models; Male; Medication Adherence; Middle Aged; Odds Ratio; Proportional Hazards Models; Pyrazoles; Pyridones; Retrospective Studies; Risk Factors; Rivaroxaban; Stroke; Time Factors; Treatment Outcome; United States; United States Department of Veterans Affairs; Veterans Health | 2017 |
Comparative effectiveness of rivaroxaban versus warfarin or dabigatran for the treatment of patients with non-valvular atrial fibrillation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Blood Coagulation; Comparative Effectiveness Research; Dabigatran; Databases, Factual; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Proportional Hazards Models; Retrospective Studies; Risk Factors; Rivaroxaban; Stroke; Time Factors; Treatment Outcome; Warfarin | 2017 |
Comparison of Prescribing Practices with Direct Acting Oral Anticoagulant Protocols.
Topics: Administration, Oral; Adult; Age Factors; Aged; Algorithms; Anticoagulants; Cohort Studies; Dabigatran; Female; Guideline Adherence; Hemorrhage; Humans; Male; Middle Aged; Off-Label Use; Practice Guidelines as Topic; Practice Patterns, Physicians'; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Thrombosis | 2017 |
Evaluation of dabigatran, rivaroxaban and apixaban target-specific assays in a multicenter French study.
Topics: Anticoagulants; Antithrombins; Dabigatran; France; Humans; Pyrazoles; Pyridones; Rivaroxaban | 2017 |
Oral Anticoagulants to Prevent Stroke in Nonvalvular Atrial Fibrillation in Patients With CKD Stage 5D: An NKF-KDOQI Controversies Report.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Kidney Failure, Chronic; Practice Guidelines as Topic; Pyrazoles; Pyridines; Pyridones; Renal Dialysis; Rivaroxaban; Stroke; Thiazoles; Warfarin | 2017 |
Safety of once- or twice-daily dosing of non-vitamin K antagonist oral anticoagulants (NOACs) in patients with nonvalvular atrial fibrillation: A NOAC-TR study.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Cross-Sectional Studies; Dabigatran; Female; Hemorrhage; Humans; Male; Medication Adherence; Middle Aged; Patient Safety; Pyrazoles; Pyridones; Retrospective Studies; Risk Factors; Rivaroxaban; Stroke; Turkey | 2018 |
Comparison of different oral anticoagulant regimens in patients with atrial fibrillation undergoing ablation or cardioversion.
Topics: Administration, Oral; Aged; Antithrombins; Atrial Fibrillation; Dabigatran; Female; Humans; Incidence; Male; Middle Aged; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thromboembolism | 2017 |
Appropriateness of Dabigatran and Rivaroxaban Prescribing in Qatar: A 5-Year Experience.
Topics: Administration, Oral; Adult; Aged; Antithrombins; Clinical Decision-Making; Cross-Sectional Studies; Dabigatran; Drug Prescriptions; Drug Utilization Review; Factor Xa Inhibitors; Female; Guideline Adherence; Humans; Inappropriate Prescribing; Male; Middle Aged; Practice Guidelines as Topic; Practice Patterns, Physicians'; Qatar; Retrospective Studies; Risk Factors; Rivaroxaban; Time Factors | 2018 |
Oral anticoagulant persistence in patients with non-valvular atrial fibrillation: A cohort study using primary care data in Germany.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Female; Germany; Hemorrhage; Humans; Hypertension; Ischemic Attack, Transient; Male; Primary Health Care; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Stroke; Thromboembolism; Vitamin K | 2017 |
High number of newly initiated direct oral anticoagulant users switch to alternate anticoagulant therapy.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Drug Substitution; Female; Humans; Injections; Male; Middle Aged; Rivaroxaban; Warfarin | 2017 |
Comparison of Treatment Persistence with Dabigatran or Rivaroxaban versus Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients: A Competing Risk Analysis in the French National Health Care Databases.
Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Databases, Factual; Dose-Response Relationship, Drug; Female; France; Hemorrhage; Hospitalization; Humans; International Normalized Ratio; Male; Medication Adherence; Middle Aged; Rivaroxaban; Stroke; Vitamin K | 2018 |
Perioperative complications with new oral anticoagulants dabigatran, apixaban, and rivaroxaban in Mohs micrographic surgery: A retrospective study.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Dabigatran; Female; Humans; Male; Middle Aged; Mohs Surgery; Postoperative Complications; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban | 2017 |
Analysis of Recurrent Stroke Volume and Prognosis between Warfarin and Four Non-Vitamin K Antagonist Oral Anticoagulants' Administration for Secondary Prevention of Stroke.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Humans; Japan; Magnetic Resonance Imaging; Male; Pyrazoles; Pyridines; Pyridones; Recurrence; Retrospective Studies; Risk Factors; Rivaroxaban; Secondary Prevention; Stroke; Thiazoles; Time Factors; Treatment Outcome; Warfarin | 2018 |
Anticoagulation prescribing patterns in patients with cancer.
Topics: Adult; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Enoxaparin; Hemorrhage; Humans; Middle Aged; Neoplasms; Practice Patterns, Physicians'; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Thrombosis; Treatment Outcome; Venous Thromboembolism; Warfarin | 2018 |
Initiation of direct oral anticoagulants versus warfarin for venous thromboembolism: impact on time to hospital discharge.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Dabigatran; Female; Hemorrhage; Humans; Length of Stay; Male; Middle Aged; Patient Readmission; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Venous Thromboembolism; Warfarin | 2018 |
Use of direct oral anticoagulants in the first year after market entry of edoxaban: A Danish nationwide drug utilization study.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Denmark; Drug Utilization; Female; Humans; Male; Middle Aged; Product Surveillance, Postmarketing; Pyrazoles; Pyridines; Pyridones; Registries; Rivaroxaban; Stroke; Thiazoles | 2018 |
Prescribing of NOACs has outnumbered warfarin: exploring how physicians choose anticoagulant treatments.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Cardiovascular Diseases; Clinical Decision-Making; Dabigatran; Drug Monitoring; Drug Resistance; Factor Xa Inhibitors; Focus Groups; General Practitioners; Hemorrhage; Humans; Medical Staff, Hospital; Medication Adherence; Norway; Practice Patterns, Physicians'; Pyrazoles; Pyridones; Qualitative Research; Risk; Rivaroxaban; Warfarin | 2018 |
Renal Outcomes in Anticoagulated Patients With Atrial Fibrillation.
Topics: Acute Kidney Injury; Aged; Anticoagulants; Atrial Fibrillation; Creatinine; Dabigatran; Female; Follow-Up Studies; Glomerular Filtration Rate; Humans; International Normalized Ratio; Kidney Diseases; Male; Middle Aged; Proportional Hazards Models; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Treatment Outcome; United States; Warfarin | 2017 |
Renal Risk Stratification Tool to Guide NOAC Dosing in Patients With Renal Dysfunction.
Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Kidney; Rivaroxaban | 2017 |
Severity of Gastrointestinal Bleeding in Patients Treated with Direct-Acting Oral Anticoagulants.
Topics: Administration, Oral; Aged; Anticoagulants; Arteriovenous Malformations; Aspirin; Blood Transfusion; Case-Control Studies; Dabigatran; Diverticulum; Endoscopy, Gastrointestinal; Female; Gastrointestinal Hemorrhage; Hemorrhoids; Hospitalization; Humans; Male; Middle Aged; Peptic Ulcer; Platelet Aggregation Inhibitors; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Warfarin | 2018 |
Inappropriate doses of direct oral anticoagulants in real-world clinical practice: prevalence and associated factors. A subanalysis of the FANTASIIA Registry.
Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Comorbidity; Dabigatran; Factor Xa Inhibitors; Female; Guideline Adherence; Humans; Inappropriate Prescribing; Logistic Models; Male; Middle Aged; Platelet Aggregation Inhibitors; Pyrazoles; Pyridones; Registries; Retrospective Studies; Rivaroxaban; Stroke; Thromboembolism | 2018 |
Early Recurrence and Major Bleeding in Patients With Acute Ischemic Stroke and Atrial Fibrillation Treated With Non-Vitamin-K Oral Anticoagulants (RAF-NOACs) Study.
Topics: Acute Disease; Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Brain Ischemia; Dabigatran; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Hemorrhage; Humans; Incidence; Male; Middle Aged; Prospective Studies; Pyrazoles; Pyridones; Recurrence; Rivaroxaban; Survival Rate; Time Factors; Treatment Outcome; Vitamin K | 2017 |
Treatment and discharge patterns among patients hospitalized with non-valvular atrial fibrillation transitioning from the inpatient to outpatient setting.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; Female; Hospitalization; Humans; Inpatients; Male; Middle Aged; Outpatients; Patient Discharge; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Warfarin | 2018 |
Association of Novel Oral Antithrombotics With the Risk of Intraocular Bleeding.
Topics: Administration, Oral; Aged; Anticoagulants; Antithrombins; Dabigatran; Dose-Response Relationship, Drug; Eye Hemorrhage; Factor Xa Inhibitors; Female; Follow-Up Studies; Humans; Incidence; Male; Pennsylvania; Prognosis; Retrospective Studies; Risk Assessment; Risk Factors; Rivaroxaban; Thromboembolism; Warfarin | 2018 |
Study protocol for the dabigatran, apixaban, rivaroxaban, edoxaban, warfarin comparative effectiveness research study.
Topics: Anticoagulants; Antithrombins; Comparative Effectiveness Research; Dabigatran; Factor Xa Inhibitors; Humans; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Research Design; Rivaroxaban; Thiazoles; Venous Thrombosis; Warfarin | 2018 |
Outcome of Secondary Stroke Prevention in Patients Taking Non-Vitamin K Antagonist Oral Anticoagulants.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Brain Ischemia; Dabigatran; Female; Humans; Incidence; Kaplan-Meier Estimate; Male; Middle Aged; Proportional Hazards Models; Prospective Studies; Pyrazoles; Pyridones; Recurrence; Risk Factors; Rivaroxaban; Secondary Prevention; Stroke; Time Factors; Treatment Outcome; Warfarin | 2018 |
Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Databases, Factual; Drug Synergism; Hemorrhage; Humans; Pyrazoles; Pyridones; Retrospective Studies; Risk; Rivaroxaban; Taiwan | 2018 |
Effects of Direct Oral Anticoagulants at the Peak Phase, Trough Phase, and After Vascular Injury.
Topics: Aged; Anticoagulants; Antithrombins; Blood Coagulation; Blood Coagulation Factors; Dabigatran; Female; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Punctures; Pyrazoles; Pyridones; Rivaroxaban; Vascular System Injuries; Warfarin | 2018 |
Is There a Preferred Stroke Prevention Strategy for Diabetic Patients with Non-Valvular Atrial Fibrillation? Comparing Warfarin, Dabigatran and Rivaroxaban.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Cohort Studies; Comparative Effectiveness Research; Dabigatran; Databases, Factual; Diabetes Complications; Diabetes Mellitus; Female; Humans; Male; Middle Aged; Patient Safety; Proportional Hazards Models; Risk; Risk Factors; Rivaroxaban; Stroke; Taiwan; Thromboembolism; Treatment Outcome; Warfarin | 2018 |
Bleeding Complications After Use of Novel Oral Anticoagulants in Patients Undergoing Cardiac Surgery.
Topics: Aged; Anticoagulants; Blood Transfusion; Cardiac Surgical Procedures; Critical Care; Dabigatran; Female; Heart Diseases; Humans; Length of Stay; Male; Postoperative Hemorrhage; Pyrazoles; Pyridones; Retrospective Studies; Risk Assessment; Rivaroxaban | 2018 |
Are Screening Tests Reliable to Rule Out Direct Oral Anticoagulant Plasma Levels at Various Thresholds (30, 50, or 100 ng/mL) in Emergency Situations?
Topics: Administration, Oral; Anticoagulants; Dabigatran; Emergency Treatment; Humans; Partial Thromboplastin Time; Pyrazoles; Pyridones; Reference Values; Rivaroxaban; Sensitivity and Specificity; Thrombin Time | 2018 |
Interlaboratory variability in the measurement of direct oral anticoagulants: results from the external quality assessment scheme.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Blood Coagulation Tests; Calibration; Clinical Laboratory Services; Dabigatran; Humans; International Normalized Ratio; Italy; Partial Thromboplastin Time; Prothrombin Time; Pyrazoles; Pyridones; Quality Control; Reproducibility of Results; Rivaroxaban; Surveys and Questionnaires; Thrombin Time | 2018 |
Effectiveness and Safety of Non-Vitamin K Oral Anticoagulants in Comparison to Phenprocoumon: Data from 61,000 Patients with Atrial Fibrillation.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Comorbidity; Dabigatran; Female; Hemorrhage; Humans; Male; Middle Aged; Patient Safety; Phenprocoumon; Proportional Hazards Models; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Treatment Outcome | 2018 |
Intravenous thrombolysis for acute ischaemic stroke in patients on direct oral anticoagulants.
Topics: Administration, Intravenous; Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Blood Coagulation Tests; Brain Ischemia; Dabigatran; Factor Xa Inhibitors; Fibrinolytic Agents; Humans; Retrospective Studies; Rivaroxaban; Stroke; Thrombolytic Therapy | 2018 |
Comparative effectiveness of direct oral anticoagulants and warfarin in patients with cancer and atrial fibrillation.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Databases, Factual; Hemorrhage; Humans; Middle Aged; Neoplasms; Retrospective Studies; Rivaroxaban; Stroke; Treatment Outcome; Venous Thromboembolism; Warfarin; Young Adult | 2018 |
Topics: Anticoagulants; Antithrombins; Clinical Trials as Topic; Dabigatran; Hemorrhage; Pulmonary Embolism; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Survival Analysis; Venous Thrombosis; Warfarin | 2018 |
Initiation and continuation of oral anticoagulant prescriptions for stroke prevention in non-valvular atrial fibrillation: A cohort study in primary care in France.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Comorbidity; Dabigatran; Databases, Factual; Drug Prescriptions; Drug Substitution; Female; France; Humans; Male; Primary Health Care; Proportional Hazards Models; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Stroke; Time Factors; Treatment Outcome | 2018 |
Plasma clot formation and clot lysis to compare effects of different anticoagulation treatments on hemostasis in patients with atrial fibrillation.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Blood Coagulation; Case-Control Studies; Dabigatran; Factor Xa Inhibitors; Female; Fibrin Clot Lysis Time; Heparin, Low-Molecular-Weight; Humans; Linear Models; Male; Middle Aged; Phenprocoumon; Plasma; Pyrazoles; Pyridones; Rivaroxaban; Thromboplastin; Tissue Plasminogen Activator | 2018 |
Kidney function monitoring and nonvitamin K oral anticoagulant dosage in atrial fibrillation.
Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Creatinine; Dabigatran; Drug Monitoring; Factor Xa Inhibitors; Female; Guideline Adherence; Humans; Kidney Function Tests; Male; Multivariate Analysis; Odds Ratio; Practice Guidelines as Topic; Pyrazoles; Pyridones; Registries; Renal Insufficiency; Retrospective Studies; Rivaroxaban; Stroke | 2018 |
International Council for Standardization in Haematology (ICSH) Recommendations for Laboratory Measurement of Direct Oral Anticoagulants.
Topics: Administration, Oral; Anticoagulants; Chromatography; Clinical Laboratory Techniques; Dabigatran; Hematology; Humans; International Cooperation; Mass Spectrometry; Partial Thromboplastin Time; Point-of-Care Testing; Prothrombin; Prothrombin Time; Pyrazoles; Pyridines; Pyridones; Quality Assurance, Health Care; Rivaroxaban; Thiazoles | 2018 |
Evaluation of indications for reduced-dose non-vitamin K antagonist oral anticoagulants in hospitalised patients with atrial fibrillation.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Dabigatran; Female; Humans; Male; Middle Aged; Pyrazoles; Pyridones; Rivaroxaban; Stroke | 2018 |
Screening test for direct oral anticoagulants with the dilute Russell viper venom time.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Biomarkers; Blood Coagulation; Blood Coagulation Tests; Dabigatran; Female; Glomerular Filtration Rate; Humans; Male; Middle Aged; Prothrombin Time; Rivaroxaban; Sensitivity and Specificity | 2018 |
Low drug levels and thrombotic complications in high-risk atrial fibrillation patients treated with direct oral anticoagulants.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Blood Coagulation Tests; Dabigatran; Drug Monitoring; Factor Xa Inhibitors; Female; Humans; Male; Middle Aged; Predictive Value of Tests; Preliminary Data; Pyrazoles; Pyridones; Registries; Risk Assessment; Risk Factors; Rivaroxaban; Thromboembolism; Time Factors; Treatment Outcome | 2018 |
District versus academic hospitals: differences in the clinical characteristics of patients with atrial fibrillation without valvular heart disease treated with oral anticoagulants
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Heart Valve Diseases; Hospitals, District; Hospitals, University; Humans; Male; Middle Aged; Retrospective Studies; Risk Factors; Rivaroxaban; Stroke; Thromboembolism | 2018 |
Quantification of Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in Human Serum by UHPLC-MS/MS-Method Development, Validation, and Application.
Topics: Antithrombins; Chromatography, High Pressure Liquid; Chromatography, Liquid; Dabigatran; Factor Xa Inhibitors; Humans; Pyrazoles; Pyridines; Pyridones; Reproducibility of Results; Rivaroxaban; Tandem Mass Spectrometry; Thiazoles | 2018 |
Length of hospitalization and mortality for bleeding during treatment with warfarin, dabigatran, or rivaroxaban.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Blood Coagulation; Dabigatran; Female; Hemorrhage; Hospitalization; Humans; Intensive Care Units; Length of Stay; Male; Propensity Score; Retrospective Studies; Rivaroxaban; Warfarin | 2018 |
Secondary adherence to non-vitamin-K antagonist oral anticoagulants in patients with atrial fibrillation in Sweden and the Netherlands.
Topics: Administration, Oral; Aged; Antithrombins; Atrial Fibrillation; Dabigatran; Dose-Response Relationship, Drug; Drug Utilization Review; Female; Humans; Male; Medication Adherence; Middle Aged; Netherlands; Pyrazoles; Pyridones; Rivaroxaban; Sweden; Thromboembolism | 2018 |
Tromboc@t Working Group recommendations for management in patients receiving direct oral anticoagulants.
Topics: Administration, Oral; Age Factors; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Embolism; Humans; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Warfarin | 2018 |
Left atrial thrombus and dense spontaneous echocardiographic contrast in patients on continuous direct oral anticoagulant therapy undergoing catheter ablation of atrial fibrillation: Comparison of dabigatran, rivaroxaban, and apixaban.
Topics: Administration, Oral; Aged; Antithrombins; Atrial Fibrillation; Catheter Ablation; Contrast Media; Dabigatran; Dose-Response Relationship, Drug; Echocardiography, Transesophageal; Factor Xa Inhibitors; Female; Heart Atria; Heart Diseases; Humans; Male; Middle Aged; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Thrombosis | 2018 |
Efficacy and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Asians With Nonvalvular Atrial Fibrillation.
Topics: Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Dose-Response Relationship, Drug; Drug Therapy, Combination; Factor Xa Inhibitors; Female; Humans; Incidence; Male; Propensity Score; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Taiwan; Thromboembolism; Treatment Outcome; Warfarin | 2018 |
Safety and Efficacy of Novel Oral Anticoagulants Versus Warfarin in Medicare Beneficiaries With Atrial Fibrillation and Valvular Heart Disease.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Female; Follow-Up Studies; Heart Valve Diseases; Humans; Male; Medicare; Retrospective Studies; Rivaroxaban; Thromboembolism; Treatment Outcome; United States; Warfarin | 2018 |
Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Frail Patients With Nonvalvular Atrial Fibrillation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Dose-Response Relationship, Drug; Drug Therapy, Combination; Factor Xa Inhibitors; Female; Follow-Up Studies; Frail Elderly; Humans; Incidence; Male; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Time Factors; Treatment Outcome; United States; Warfarin | 2018 |
Management of oral anticoagulation in patients with atrial fibrillation: newer agents, newer conundrums?
Topics: Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Humans; Pyrazoles; Pyridones; Rivaroxaban; Stroke | 2018 |
Microbleeds in ischemic vs hemorrhagic strokes on novel oral anticoagulants.
Topics: Aged; Aged, 80 and over; Anticoagulants; Cerebral Hemorrhage; Cerebral Small Vessel Diseases; Comorbidity; Dabigatran; Female; Humans; Magnetic Resonance Imaging; Male; Prospective Studies; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thrombolytic Therapy | 2018 |
Effectiveness and Safety of Direct Oral Anticoagulants and Warfarin, Stratified by Stroke Risk in Patients With Atrial Fibrillation.
Topics: Administration, Oral; Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Dose-Response Relationship, Drug; Drug Therapy, Combination; Factor Xa Inhibitors; Female; Follow-Up Studies; Humans; Incidence; Male; Pyrazoles; Pyridones; Retrospective Studies; Risk Assessment; Risk Factors; Rivaroxaban; Stroke; Survival Rate; Treatment Outcome; United States; Warfarin | 2018 |
Discontinuation risk comparison among 'real-world' newly anticoagulated atrial fibrillation patients: Apixaban, warfarin, dabigatran, or rivaroxaban.
Topics: Adolescent; Adult; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Hemorrhage; Humans; Incidence; Male; Middle Aged; Prognosis; Pyrazoles; Pyridones; Retrospective Studies; Risk Factors; Rivaroxaban; Stroke; United States; Warfarin; Withholding Treatment; Young Adult | 2018 |
Benefit, risk and cost of new oral anticoagulants and warfarin in atrial fibrillation; A multicriteria decision analysis.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Cost-Benefit Analysis; Dabigatran; Decision Support Techniques; Drug Costs; Hemorrhage; Humans; Models, Statistical; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Stroke; Warfarin | 2018 |
Thrombin and factor Xa link the coagulation system with liver fibrosis.
Topics: Actins; Animals; Antithrombins; Blood Coagulation; Cell Line; Cell Shape; Dabigatran; Disease Models, Animal; Factor Xa; Factor Xa Inhibitors; Gene Expression; Hepatic Stellate Cells; Humans; Hydroxyproline; Liver Cirrhosis; Male; Mice, Inbred C57BL; Procollagen; Receptor, PAR-1; Rivaroxaban; Thrombin; Transforming Growth Factor beta | 2018 |
Comparing the Cost Effectiveness of Non-vitamin K Antagonist Oral Anticoagulants with Well-Managed Warfarin for Stroke Prevention in Atrial Fibrillation Patients at High Risk of Bleeding.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Cost-Benefit Analysis; Dabigatran; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Hemorrhage; Humans; Markov Chains; Pyrazoles; Pyridines; Pyridones; Quality-Adjusted Life Years; Risk Adjustment; Rivaroxaban; Stroke; Therapeutic Equivalency; Thiazoles; Warfarin | 2018 |
Predictors of self-reported adherence to direct oral anticoagulation in a population of elderly men and women with non-valvular atrial fibrillation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Caregivers; Dabigatran; Female; Humans; Male; Medication Adherence; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Self Report; Thiazoles | 2018 |
In vitro efficacy of pro- and anticoagulant strategies in compensated and acutely ill patients with cirrhosis.
Topics: Adult; Aged; Anticoagulants; Benzimidazoles; Blood Coagulation Factors; Blood Coagulation Tests; Dabigatran; Factor VIIa; Female; Hemorrhage; Hemostasis; Humans; Liver Cirrhosis; Male; Middle Aged; Plasma; Recombinant Proteins; Rivaroxaban; Thrombin | 2018 |
[Tactics of Selection of Anticoagulant Therapy in Patients With Atrial Fibrillation and Ischemic Heart Disease].
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Myocardial Ischemia; Pyridones; Rivaroxaban; Stroke; Warfarin | 2018 |
Management of major bleeding and outcomes in patients treated with direct oral anticoagulants: results from the START-Event registry.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Blood Coagulation Factors; Dabigatran; Female; Hemorrhage; Humans; Male; Prospective Studies; Pyrazoles; Pyridones; Registries; Rivaroxaban; Treatment Outcome; Ventricular Fibrillation | 2018 |
Dabigatran, rivaroxaban and apixaban vs. high TTR warfarin in atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Humans; Male; Pyrazoles; Pyridones; Rivaroxaban; Warfarin | 2018 |
Effectiveness and Safety of Anticoagulants in Adults with Non-valvular Atrial Fibrillation and Concomitant Coronary/Peripheral Artery Disease.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Coronary Artery Disease; Dabigatran; Embolism; Female; Hemorrhage; Humans; Male; Medicare; Myocardial Infarction; Peripheral Arterial Disease; Proportional Hazards Models; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; United States; Warfarin | 2018 |
In vitro effects of a kaolin-coated hemostatic dressing on anticoagulated blood.
Topics: Adult; Anticoagulants; Antithrombins; Arginine; Bandages; Blood Coagulation; Blood Coagulation Tests; Dabigatran; Factor Xa Inhibitors; Hemostatics; Heparin; Humans; Kaolin; Pipecolic Acids; Platelet Aggregation Inhibitors; Prospective Studies; Rivaroxaban; Sulfonamides; Viscoelastic Substances; Vitamin K | 2018 |
Impact of the Health Insurance Coverage Policy on Oral Anticoagulant Prescription among Patients with Atrial Fibrillation in Korea from 2014 to 2016.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Databases, Factual; Female; Humans; Insurance Coverage; Male; Middle Aged; National Health Programs; Pyrazoles; Pyridones; Republic of Korea; Rivaroxaban; Warfarin | 2018 |
Is the prescription right? A review of non-vitamin K antagonist anticoagulant (NOAC) prescriptions in patients with non-valvular atrial fibrillation. Safe prescribing in atrial fibrillation and evaluation of non-vitamin K oral anticoagulants in stroke pre
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Humans; Inappropriate Prescribing; Male; Medical Audit; Middle Aged; Prescriptions; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke | 2019 |
NOACs Now Mainstream for the Use of Anticoagulation in Non-Valvular Atrial Fibrillation in Australia.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Follow-Up Studies; Humans; Incidence; Pyrazoles; Pyridones; Retrospective Studies; Risk Factors; Rivaroxaban; Stroke; Thrombolytic Therapy; Treatment Outcome; Victoria; Warfarin | 2019 |
Methodological challenges in assessment of current use of warfarin among patients with atrial fibrillation using dispensation data from administrative health care databases.
Topics: Administration, Oral; Administrative Claims, Healthcare; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Databases, Factual; Dose-Response Relationship, Drug; Female; Hemorrhage; Humans; International Normalized Ratio; Male; Pyrazoles; Pyridones; Quebec; Retrospective Studies; Rivaroxaban; Stroke; Warfarin | 2018 |
The risk of acute kidney injury in Asians treated with apixaban, rivaroxaban, dabigatran, or warfarin for non-valvular atrial fibrillation: A nationwide cohort study in Taiwan.
Topics: Acute Kidney Injury; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Asian People; Atrial Fibrillation; Cohort Studies; Dabigatran; Factor Xa Inhibitors; Female; Follow-Up Studies; Humans; Male; Middle Aged; Pyrazoles; Pyridones; Retrospective Studies; Risk Factors; Rivaroxaban; Taiwan; Treatment Outcome; Warfarin | 2018 |
Safety of Direct Oral Anticoagulants and Vitamin K Antagonists in Oldest Old Patients: A Prospective Study.
Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Chronic Disease; Comorbidity; Dabigatran; Dementia; Dicumarol; Disabled Persons; Follow-Up Studies; Hemorrhage; Humans; Mobility Limitation; Prospective Studies; Pyrazoles; Pyridones; Rivaroxaban; Vitamin K | 2018 |
Anticoagulant Activities of Indobufen, an Antiplatelet Drug.
Topics: Animals; Anticoagulants; Blood Coagulation; Blood Coagulation Tests; Dabigatran; Female; Isoindoles; Male; Molecular Structure; Partial Thromboplastin Time; Phenylbutyrates; Platelet Factor 3; Platelet Factor 4; Prothrombin Time; Rabbits; Rats; Rivaroxaban; Thrombin Time | 2018 |
Comparative effectiveness and safety of apixaban, dabigatran, and rivaroxaban in patients with non-valvular atrial fibrillation.
Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Cohort Studies; Dabigatran; Embolism; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Pyrazoles; Pyridones; Registries; Rivaroxaban; Stroke; Treatment Outcome | 2018 |
[in process]
Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Rivaroxaban | 2017 |
Rivaroxaban and dabigatran did not affect clotting profiles in plasma reconstituted with varying levels of autologous platelets to the same degree as heparin when evaluated using thromboelastography.
Topics: Anticoagulants; Blood Coagulation; Blood Coagulation Tests; Blood Platelets; Dabigatran; Heparin; Humans; Rivaroxaban; Thrombelastography | 2018 |
Risks and benefits of direct oral anticoagulants versus warfarin in a real world setting: cohort study in primary care.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Comorbidity; Dabigatran; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Hemorrhage; Humans; Incidence; Male; Patient Safety; Primary Health Care; Prospective Studies; Pyrazoles; Pyridones; Rivaroxaban; Treatment Outcome; Warfarin | 2018 |
Dabigatran, Rivaroxaban, and Warfarin in the Oldest Adults with Atrial Fibrillation in Taiwan.
Topics: Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Databases, Factual; Female; Humans; Male; National Health Programs; Proportional Hazards Models; Retrospective Studies; Rivaroxaban; Taiwan; Treatment Outcome; Warfarin | 2018 |
Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation and Thrombocytopenia.
Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Case-Control Studies; Dabigatran; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Prospective Studies; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Stroke; Thrombocytopenia; Time Factors; Treatment Outcome | 2018 |
Evaluation of Potential Drug-Drug Interactions With Direct Oral Anticoagulants in a Large Urban Hospital.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Dabigatran; Drug Combinations; Drug Interactions; Drug-Related Side Effects and Adverse Reactions; Female; Hemorrhage; Hospitals, Urban; Humans; Male; Middle Aged; Pyridones; Retrospective Studies; Rivaroxaban | 2020 |
Differences in Reported Outcomes in Industry-Funded vs Nonfunded Studies Assessing Thromboprophylaxis After Total Joint Arthroplasty.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Conflict of Interest; Dabigatran; Enoxaparin; Female; Fondaparinux; Health Care Sector; Hemorrhage; Humans; Male; Pulmonary Embolism; Pyrazoles; Pyridones; Rivaroxaban; Venous Thromboembolism; Warfarin | 2018 |
Novel oral anticoagulants in primary care in patients with atrial fibrillation: a cross-sectional comparison before and after their introduction.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Cross-Sectional Studies; Dabigatran; Female; Germany; Humans; Male; Middle Aged; Phenprocoumon; Platelet Aggregation Inhibitors; Primary Health Care; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Young Adult | 2018 |
Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: guidance from the SSC of the ISTH.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Dabigatran; Dalteparin; Factor Xa Inhibitors; Hemorrhage; Humans; Multicenter Studies as Topic; Neoplasms; Observational Studies as Topic; Patient Acceptance of Health Care; Prospective Studies; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Recurrence; Rivaroxaban; Thiazoles; Venous Thromboembolism; Venous Thrombosis | 2018 |
Clarification of the use of rivaroxaban in renal patients.
Topics: Atrial Fibrillation; Dabigatran; Factor Xa Inhibitors; Humans; Renal Dialysis; Rivaroxaban | 2019 |
Role of Hypertension and Other Clinical Variables in Prognostication of Patients Presenting to the Emergency Department With Major Bleeding Events.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Blood Glucose; Blood Transfusion; Cardiovascular Diseases; Creatinine; Dabigatran; Emergency Service, Hospital; Epistaxis; Female; Gastrointestinal Hemorrhage; Hematuria; Hemoptysis; Hemorrhage; Humans; Hypertension; Intracranial Hemorrhages; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Prognosis; Propensity Score; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Severity of Illness Index; Sex Factors; Thiazoles; Warfarin | 2018 |
Estimated Effectiveness and Safety of Nonvitamin K Antagonist Oral Anticoagulants Compared With Optimally Acenocoumarol Anticoagulated "Real-World" in Patients With Atrial Fibrillation.
Topics: Acenocoumarol; Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Factor Xa Inhibitors; Female; Gastrointestinal Hemorrhage; Humans; Intracranial Hemorrhages; Male; Pyrazoles; Pyridones; Rivaroxaban; Spain; Stroke | 2018 |
Appropriateness of non-vitamin K antagonist oral anticoagulant dose in patients with atrial fibrillation in Israel: A population-based study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Humans; Israel; Male; Middle Aged; Pyrazoles; Pyridones; Rivaroxaban; Stroke | 2018 |
All-Cause Mortality Risk with Direct Oral Anticoagulants and Warfarin in the Primary Treatment of Venous Thromboembolism.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Dabigatran; Female; Humans; Male; Middle Aged; Pyrazoles; Pyridines; Pyridones; Retrospective Studies; Risk; Rivaroxaban; Survival Analysis; Thiazoles; Venous Thromboembolism; Warfarin | 2018 |
Measurement of apixaban, dabigatran, edoxaban and rivaroxaban in human plasma using automated online solid-phase extraction combined with ultra-performance liquid chromatography-tandem mass spectrometry and its comparison with coagulation assays.
Topics: Anticoagulants; Automation; Calibration; Chromatography, High Pressure Liquid; Dabigatran; Humans; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Solid Phase Extraction; Tandem Mass Spectrometry; Thiazoles | 2018 |
Risk factors for stroke and choice of oral anticoagulant in atrial fibrillation.
Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Clinical Decision-Making; Dabigatran; Databases, Factual; Female; Humans; Male; Norway; Platelet Aggregation Inhibitors; Pyrazoles; Pyridones; Registries; Risk Factors; Rivaroxaban; Sex Factors; Stroke | 2018 |
The Comparison of Inappropriate-Low-Doses Use among 4 Direct Oral Anticoagulants in Patients with Atrial Fibrillation: From the Database of a Single-Center Registry.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Blood Coagulation; Chi-Square Distribution; Dabigatran; Databases, Factual; Drug Dosage Calculations; Female; Hemorrhage; Humans; Inappropriate Prescribing; Incidence; Japan; Kaplan-Meier Estimate; Logistic Models; Male; Middle Aged; Odds Ratio; Prevalence; Pyrazoles; Pyridines; Pyridones; Registries; Retrospective Studies; Risk Factors; Rivaroxaban; Stroke; Thiazoles; Thromboembolism; Time Factors; Treatment Outcome | 2018 |
Non-vitamin K antagonist oral anticoagulants in patients with an increased risk of bleeding.
Topics: Administration, Oral; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Rivaroxaban; Stroke | 2018 |
Comparing the Efficacy and Safety of Direct Oral Anticoagulants With Warfarin in the Morbidly Obese Population With Atrial Fibrillation.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Drug Therapy, Combination; Female; Hemorrhage; Humans; Incidence; Male; Middle Aged; Obesity, Morbid; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Warfarin; Young Adult | 2019 |
Anticoagulant-associated adverse drug reactions in 2013-15.
Topics: Age Distribution; Anticoagulants; Cerebral Hemorrhage; Comorbidity; Dabigatran; Databases, Factual; Drug Utilization; Drug-Related Side Effects and Adverse Reactions; Female; Hemorrhage; Humans; Male; Pyrazoles; Pyridones; Registries; Risk Factors; Rivaroxaban; Sex Distribution; Time Factors; Warfarin | 2018 |
Trends in Deep Vein Thrombosis Prophylaxis and Deep Vein Thrombosis Rates After Total Hip and Knee Arthroplasty.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Clinical Decision-Making; Dabigatran; Databases, Factual; Enoxaparin; Female; Fondaparinux; Humans; Male; Middle Aged; Postoperative Complications; Retrospective Studies; Rivaroxaban; Venous Thrombosis; Warfarin | 2018 |
Real-world clinical evidence on rivaroxaban, dabigatran, and apixaban compared with vitamin K antagonists in patients with nonvalvular atrial fibrillation: a systematic literature review.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Vitamin K; Warfarin | 2019 |
Drug interaction as a predictor of direct oral anticoagulant drug levels in atrial fibrillation patients.
Topics: Administration, Oral; Adult; Aged; Anticoagulants; ATP Binding Cassette Transporter, Subfamily B, Member 1; Atrial Fibrillation; Cytochrome P-450 CYP3A Inhibitors; Dabigatran; Drug Interactions; Female; Humans; Male; Middle Aged; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban | 2018 |
Pharmacokinetics of anticoagulants apixaban, dabigatran, edoxaban and rivaroxaban in elderly Japanese patients with atrial fibrillation treated in one general hospital.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Dose-Response Relationship, Drug; Female; Humans; Kidney Diseases; Kidney Function Tests; Male; Middle Aged; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles | 2019 |
Comparison of stroke- and bleed-related healthcare resource utilization and costs among patients with newly diagnosed non-valvular atrial fibrillation and newly treated with dabigatran, rivaroxaban, or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Health Care Costs; Hemorrhage; Humans; Male; Medicare; Middle Aged; Patient Acceptance of Health Care; Retrospective Studies; Rivaroxaban; Stroke; United States; Warfarin | 2019 |
[Evaluation of adverse drug reactions associated with direct oral anticoagulants recorded in the Italian Pharmacovigilance Network database using a specifically developed risk index].
Topics: Administration, Oral; Adverse Drug Reaction Reporting Systems; Anticoagulants; Dabigatran; Databases, Factual; Factor Xa Inhibitors; Italy; Pharmacovigilance; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Rivaroxaban; Thiazoles | 2018 |
Management and outcome of epistaxis under direct oral anticoagulants: a comparison with warfarin.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Cohort Studies; Dabigatran; Drug-Related Side Effects and Adverse Reactions; Epistaxis; Female; Follow-Up Studies; Germany; Hospitalization; Humans; Length of Stay; Male; Retrospective Studies; Risk; Rivaroxaban; Treatment Outcome; Warfarin | 2019 |
A simple and fast HPLC-MS/MS method for simultaneous determination of direct oral anticoagulants apixaban, dabigatran, rivaroxaban in human plasma.
Topics: Aged; Aged, 80 and over; Anticoagulants; Chromatography, High Pressure Liquid; Dabigatran; Female; Humans; Linear Models; Male; Pyrazoles; Pyridones; Reproducibility of Results; Rivaroxaban; Sensitivity and Specificity; Tandem Mass Spectrometry | 2018 |
Use of Rivaroxaban in Obesity Cannot be Applied to Use of Dabigatran.
Topics: Anticoagulants; Bariatric Surgery; Dabigatran; Factor Xa Inhibitors; Humans; Obesity; Rivaroxaban | 2018 |
Comparison between specific and nonspecific assay in the evaluation of the anticoagulant effect of the Direct Oral Anticoagulants: Our experience in a cardiovascular hospital.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Blood Coagulation; Blood Coagulation Tests; Dabigatran; Humans; Platelet Membrane Glycoproteins; Pyrazoles; Pyridones; Rivaroxaban | 2019 |
Multianalyte Determination of NOACs Using LC-MS/MS and Comparison with Functional Coagulation Assays.
Topics: Administration, Oral; Anticoagulants; Blood Coagulation; Blood Coagulation Tests; Chromatography, Liquid; Dabigatran; Factor Xa Inhibitors; Humans; Partial Thromboplastin Time; Prothrombin Time; Pulmonary Embolism; Pyrazoles; Pyridones; Rivaroxaban; Tandem Mass Spectrometry; Thrombin; Venous Thrombosis | 2018 |
The risk of delayed intracranial hemorrhage with direct acting oral anticoagulants after trauma: A two-center study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Brain; Brain Injuries, Traumatic; Dabigatran; Female; Humans; Intracranial Hemorrhages; Male; Middle Aged; Neuroimaging; Pyrazoles; Pyridones; Retrospective Studies; Risk; Rivaroxaban; Time Factors; Tomography, X-Ray Computed | 2019 |
Improved Stroke Prevention in Atrial Fibrillation After the Introduction of Non-Vitamin K Antagonist Oral Anticoagulants.
Topics: Administration, Oral; Adult; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Brain Ischemia; Cohort Studies; Dabigatran; Female; Hemorrhage; Humans; Incidence; Male; Middle Aged; Practice Guidelines as Topic; Pyrazoles; Pyridines; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Thiazoles; Warfarin | 2018 |
[Anticoagulant Therapy in Elderly Patients With Atrial Fibrillation].
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Rivaroxaban; Stroke; Warfarin | 2018 |
Oral anticoagulation therapy and subsequent risk of venous thromboembolism in atrial fibrillation patients.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Humans; Male; Middle Aged; Pyrazoles; Pyridones; Rivaroxaban; Venous Thromboembolism | 2019 |
Prior Direct Oral Anticoagulant Therapy is Related to Small Infarct Volume and No Major Artery Occlusion in Patients With Stroke and Non-Valvular Atrial Fibrillation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cerebral Angiography; Dabigatran; Diffusion Magnetic Resonance Imaging; Female; Humans; Infarction, Middle Cerebral Artery; International Normalized Ratio; Logistic Models; Magnetic Resonance Angiography; Male; Multivariate Analysis; Prothrombin Time; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Severity of Illness Index; Stroke; Thiazoles; Warfarin | 2018 |
Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients With Impaired Liver Function: A Retrospective Cohort Study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Cohort Studies; Dabigatran; Factor Xa Inhibitors; Female; Gastrointestinal Hemorrhage; Hemorrhage; Hepatic Insufficiency; Humans; Male; Proportional Hazards Models; Pyrazoles; Pyridines; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Thiazoles; Thromboembolism; Warfarin | 2018 |
Limitations of Specific Coagulation Tests for Direct Oral Anticoagulants: A Critical Analysis.
Topics: Administration, Oral; Aged; Antithrombins; Blood Coagulation; Blood Coagulation Tests; Dabigatran; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Female; Follow-Up Studies; Humans; Male; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Thromboembolism; Thrombolytic Therapy | 2018 |
Efficacy of Direct Acting Oral Anticoagulant Drugs in Treatment of Left Atrial Appendage Thrombus in Patients With Atrial Fibrillation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Appendage; Atrial Fibrillation; Coronary Thrombosis; Dabigatran; Echocardiography, Transesophageal; Female; Humans; Male; Middle Aged; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Treatment Outcome | 2019 |
Real-world comparison of bleeding risks among non-valvular atrial fibrillation patients prescribed apixaban, dabigatran, or rivaroxaban.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Female; Hemorrhage; Humans; Inpatients; Male; Middle Aged; Outpatients; Proportional Hazards Models; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Vitamin K; Warfarin | 2018 |
Antithrombotic efficacy of direct oral anticoagulants on patency rate following microsurgical anastomosis in crushed rat arteries.
Topics: Anastomosis, Surgical; Animals; Dabigatran; Enoxaparin; Factor Xa Inhibitors; Femoral Artery; Male; Microsurgery; Rats; Rats, Wistar; Rivaroxaban; Vascular Patency | 2019 |
Serum Concentrations and Elimination Rates of Direct-Acting Oral Anticoagulants (DOACs) in Older Hip Fracture Patients Hospitalized for Surgery: A Pilot Study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Dabigatran; Female; Hip Fractures; Humans; Male; Pilot Projects; Prospective Studies; Pyrazoles; Pyridones; Rivaroxaban; Warfarin | 2019 |
Ninety-day prognosis of patients receiving direct oral anticoagulants in the early phase of non valvular atrial fibrillation-related acute ischemic stroke: The real life evidence.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Brain Ischemia; Dabigatran; Female; Hemorrhage; Humans; Male; Prognosis; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Secondary Prevention; Thiazoles | 2018 |
Dabigatran Versus Rivaroxaban for Secondary Stroke Prevention in Patients with Atrial Fibrillation Rehabilitated in Skilled Nursing Facilities.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Female; Hemorrhage; Humans; Intracranial Hemorrhages; Ischemic Attack, Transient; Male; Medicare; Myocardial Infarction; Proportional Hazards Models; Retrospective Studies; Rivaroxaban; Secondary Prevention; Skilled Nursing Facilities; Stroke; Thromboembolism; United States | 2018 |
Comparative safety and effectiveness of direct oral anticoagulants in patients with atrial fibrillation in clinical practice in Scotland.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Gastrointestinal Hemorrhage; Humans; Male; Middle Aged; Pulmonary Embolism; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Scotland; Stroke; Treatment Outcome | 2019 |
Direct oral anticoagulant use and subsequent start of proton pump inhibitors as proxy for gastric complaints.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Drug Prescriptions; Female; Gastrointestinal Diseases; Humans; Incidence; Male; Middle Aged; Netherlands; Proportional Hazards Models; Proton Pump Inhibitors; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Stroke | 2018 |
Stroke Severity in Patients on Non-Vitamin K Antagonist Oral Anticoagulants with a Standard or Insufficient Dose.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Disease Progression; Drug Dosage Calculations; Drug Therapy, Combination; Female; Humans; Korea; Male; Middle Aged; Pyrazoles; Pyridones; Rivaroxaban; Severity of Illness Index; Stroke; Treatment Outcome; Warfarin | 2018 |
Effect of low and moderate dose FEIBA to reverse major bleeding in patients on direct oral anticoagulants.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Blood Coagulation Factors; Coagulants; Dabigatran; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Treatment Outcome; Young Adult | 2019 |
Comparison of Drug Switching and Discontinuation Rates in Patients with Nonvalvular Atrial Fibrillation Treated with Direct Oral Anticoagulants in the United States.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Humans; Male; Middle Aged; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Treatment Adherence and Compliance; United States; Warfarin | 2019 |
Comparative Effectiveness and Safety of Standard or Reduced Dose Dabigatran vs. Rivaroxaban in Nonvalvular Atrial Fibrillation.
Topics: Adult; Aged; Aged, 80 and over; Atrial Fibrillation; Cohort Studies; Dabigatran; Databases, Factual; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Female; Follow-Up Studies; Humans; Male; Middle Aged; Mortality; Rivaroxaban; Treatment Outcome; Young Adult | 2019 |
Comparative safety and effectiveness of dabigatran vs. rivaroxaban and apixaban in patients with non-valvular atrial fibrillation: a retrospective study from a large healthcare system.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Comparative Effectiveness Research; Dabigatran; Databases, Factual; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Military Medicine; Pyrazoles; Pyridones; Retrospective Studies; Risk Factors; Rivaroxaban; Stroke; Time Factors; Treatment Outcome; United States; United States Department of Defense; Young Adult | 2019 |
Exploring the effect of factor Xa inhibitors on rotational thromboelastometry: a case series of bleeding patients.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Blood Coagulation; Dabigatran; Drug Monitoring; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Partial Thromboplastin Time; Predictive Value of Tests; Prothrombin Time; Pyrazoles; Pyridones; Reproducibility of Results; Retrospective Studies; Rivaroxaban; Thrombelastography; Treatment Outcome | 2019 |
The importance of time in therapeutic range in switching from vitamin K antagonist to non-vitamin K antagonist oral anticoagulants in atrial fibrillation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Drug Monitoring; Drug Substitution; Factor Xa Inhibitors; Female; Guideline Adherence; Humans; International Normalized Ratio; Logistic Models; Male; Multivariate Analysis; Practice Guidelines as Topic; Rivaroxaban; Stroke; Time Factors; Warfarin | 2019 |
Association of Oral Anticoagulants and Proton Pump Inhibitor Cotherapy With Hospitalization for Upper Gastrointestinal Tract Bleeding.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Dabigatran; Drug Therapy, Combination; Female; Gastrointestinal Hemorrhage; Hospitalization; Humans; Male; Middle Aged; Proton Pump Inhibitors; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Upper Gastrointestinal Tract; Warfarin | 2018 |
[NOAC in combination with platelet antiaggregation in both patients with coronary and peripheral arterial disease].
Topics: Acute Coronary Syndrome; Anticoagulants; Antithrombins; Cardiovascular Diseases; Coronary Artery Disease; Dabigatran; Drug Therapy, Combination; Factor Xa Inhibitors; Humans; Myocardial Infarction; Myocardial Ischemia; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Sweden; Thiazoles | 2018 |
Topics: Anticoagulants; Antithrombins; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; Neoplasms; Perioperative Care; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Venous Thromboembolism; Venous Thrombosis | 2018 |
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Factor Xa Inhibitors; Humans; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiazoles; Warfarin | 2018 |
Topics: Anticoagulants; Antithrombins; Blood Coagulation Tests; Dabigatran; Drug Monitoring; Factor Xa Inhibitors; Humans; Partial Thromboplastin Time; Point-of-Care Testing; Prothrombin Time; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thrombin Time | 2018 |
Effectiveness and Safety of Oral Anticoagulants Among Nonvalvular Atrial Fibrillation Patients.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Humans; Intracranial Hemorrhages; Male; Middle Aged; Proportional Hazards Models; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Treatment Outcome; Warfarin | 2018 |
Higher Incidence of Ischemic Stroke in Patients Taking Novel Oral Anticoagulants.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Brain Ischemia; Cohort Studies; Dabigatran; Female; Humans; Incidence; Intracranial Hemorrhages; Male; Pyrazoles; Pyridines; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Thiazoles; Warfarin | 2018 |
Anticoagulation Therapy for Atrial Fibrillation in Patients With Alzheimer's Disease.
Topics: Aged; Alzheimer Disease; Anticoagulants; Atrial Fibrillation; Cost-Benefit Analysis; Dabigatran; Disease Progression; Health Care Costs; Humans; Pyrazoles; Pyridines; Pyridones; Quality-Adjusted Life Years; Rivaroxaban; Stroke; Thiazoles; Warfarin | 2018 |
Dabigatran as an alternative for atrial thrombosis resistant to rivaroxaban: A case report.
Topics: Antithrombins; Atrial Fibrillation; Dabigatran; Drug Resistance; Heart Atria; Heart Diseases; Humans; Male; Middle Aged; Rivaroxaban; Thrombosis | 2018 |
Hemorrhagic risk and intracranial complications in patients with minor head injury (MHI) taking different oral anticoagulants.
Topics: Aged; Aged, 80 and over; Anticoagulants; Craniocerebral Trauma; Dabigatran; Female; Humans; Intracranial Hemorrhages; Male; Middle Aged; Pyrazoles; Pyridines; Pyridones; Risk; Rivaroxaban; Thiazoles; Vitamin K; Warfarin | 2019 |
Intracerebral hemorrhage associated with warfarin versus non-vitamin K antagonist oral anticoagulants in Asian patients.
Topics: Administration, Oral; Aged; Anticoagulants; Asian People; Atrial Fibrillation; Cerebral Hemorrhage; Dabigatran; Female; Humans; Male; Middle Aged; Odds Ratio; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Warfarin; Young Adult | 2019 |
Assessment of direct oral anticoagulant assay use in clinical practice.
Topics: Anticoagulants; Dabigatran; Decision Making; Drug Monitoring; Factor Xa Inhibitors; Female; Humans; Male; Practice Patterns, Physicians'; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Surgical Procedures, Operative | 2019 |
Safety of radial coronary angiography with uninterrupted direct-acting oral anticoagulant treatment.
Topics: Aged; Anticoagulants; Cardiac Catheterization; Coronary Angiography; Dabigatran; Female; Hematoma; Humans; Male; Middle Aged; Prospective Studies; Pyrazoles; Pyridones; Rivaroxaban; Thrombosis | 2019 |
Direct oral anticoagulants vs non-vitamin K antagonist in atrial fibrillation: A prospective, propensity score adjusted cohort study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Humans; Italy; Male; Propensity Score; Prospective Studies; Pyrazoles; Pyridones; Rivaroxaban; Stroke | 2019 |
Assessment of Outcomes of Treatment With Oral Anticoagulants in Patients With Atrial Fibrillation and Multiple Chronic Conditions: A Comparative Effectiveness Analysis.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Chronic Disease; Comorbidity; Dabigatran; Female; Humans; Male; Proportional Hazards Models; Retrospective Studies; Risk Factors; Rivaroxaban; Stroke; Treatment Outcome; United States; Warfarin | 2018 |
Facing real-life with direct oral anticoagulants in patients with nonvalvular atrial fibrillation: outcomes from the first observational and prospective study in a Spanish population.
Topics: Administration, Oral; Age Factors; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Hemorrhage; Humans; Male; Prospective Studies; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Spain; Stroke; Thiazoles; Treatment Outcome | 2019 |
Laboratory testing for lupus anticoagulant (LA) in patients taking direct oral anticoagulants (DOACs): potential for false positives and false negatives.
Topics: Anticoagulants; Antiphospholipid Syndrome; Blood Coagulation; Blood Coagulation Tests; Dabigatran; False Negative Reactions; False Positive Reactions; Humans; Lupus Coagulation Inhibitor; Prothrombin Time; Rivaroxaban; Thrombophilia | 2019 |
Persistence and outcomes of non-vitamin K antagonist oral anticoagulants versus warfarin in patients with non-valvular atrial fibrillation.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Medication Adherence; Middle Aged; Outcome Assessment, Health Care; Patient Preference; Prospective Studies; Rivaroxaban; Stroke; Warfarin | 2019 |
Horizontal vs. vertical dose reduction of direct oral anticoagulants in patients with non-valvular atrial fibrillation: definition and implications for practice.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Dose-Response Relationship, Drug; Embolism; Humans; Pyrazoles; Pyridines; Pyridones; Research Design; Rivaroxaban; Stroke; Thiazoles | 2019 |
Clinical pharmacist led hospital-wide direct oral anticoagulant stewardship program.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Dabigatran; Drug Utilization Review; Female; Humans; Israel; Male; Medical Overuse; Pharmacists; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban | 2019 |
Bleeding Risk of Add-On Anti-Platelet Agents to Direct Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation (From 2216 Patients in the DIRECT Registry).
Topics: Administration, Oral; Aged; Antithrombins; Atrial Fibrillation; Dabigatran; Drug Therapy, Combination; Factor Xa Inhibitors; Female; Follow-Up Studies; Hemorrhage; Humans; Incidence; Japan; Male; Middle Aged; Platelet Aggregation Inhibitors; Prognosis; Prospective Studies; Pyrazoles; Pyridines; Pyridones; Registries; Rivaroxaban; Thiazoles | 2019 |
Reversal strategies in patients treated with direct oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Antidotes; Dabigatran; Hemorrhage; Humans; Rivaroxaban | 2019 |
Stroke prevention in atrial fibrillation: Closing the gap.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Dabigatran; Health Services Misuse; Hemorrhage; Humans; International Normalized Ratio; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Septal Occluder Device; Stroke; Thiazoles; Warfarin | 2019 |
The effect of DOAC-Stop on lupus anticoagulant testing in plasma samples of venous thromboembolism patients receiving direct oral anticoagulants.
Topics: Administration, Oral; Adult; Anticoagulants; Antiphospholipid Syndrome; Blood Coagulation; Blood Coagulation Tests; Dabigatran; Factor Xa Inhibitors; False Positive Reactions; Female; Humans; Lupus Coagulation Inhibitor; Male; Middle Aged; Partial Thromboplastin Time; Plasma; Prothrombin Time; Pyrazoles; Pyridones; Rivaroxaban; Venous Thromboembolism | 2019 |
Diagnostic and therapeutic approach in adult patients with traumatic brain injury receiving oral anticoagulant therapy: an Austrian interdisciplinary consensus statement.
Topics: Administration, Oral; Anticoagulants; Austria; Brain Injuries, Traumatic; Consensus; Dabigatran; Deamino Arginine Vasopressin; Humans; Interdisciplinary Communication; Partial Thromboplastin Time; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thromboembolism; Tomography, X-Ray Computed; Tranexamic Acid; Treatment Outcome; Vitamin K | 2019 |
Label Adherence for Non-Vitamin K Antagonist Oral Anticoagulants in a Prospective Cohort of Asian Patients with Atrial Fibrillation.
Topics: Administration, Oral; Aged; Anticoagulants; Asian People; Atrial Fibrillation; Dabigatran; Drug Labeling; Female; Humans; Male; Medication Adherence; Middle Aged; Prospective Studies; Pyrazoles; Pyridines; Pyridones; Republic of Korea; Risk Factors; Rivaroxaban; Thiazoles; Vitamin K | 2019 |
Network meta-analysis: a new analysis tool of the experimental evidence.
Topics: Anticoagulants; Antineoplastic Agents; Atrial Fibrillation; Dabigatran; Dasatinib; Data Interpretation, Statistical; Humans; Imatinib Mesylate; Interferons; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Network Meta-Analysis; Pyrimidines; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Warfarin | 2019 |
Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulant and Warfarin in Cirrhotic Patients With Nonvalvular Atrial Fibrillation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Female; Hemorrhage; Humans; Liver Cirrhosis; Male; Middle Aged; Patient Safety; Pyrazoles; Pyridones; Retrospective Studies; Risk Assessment; Risk Factors; Rivaroxaban; Stroke; Taiwan; Thromboembolism; Time Factors; Treatment Outcome; Warfarin | 2019 |
Polish regional differences in patient knowledge on atrial fibrillation and its management as well as in patterns of oral anticoagulant prescription.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Disease Management; Female; Hospitals, District; Hospitals, Teaching; Humans; Male; Patient Education as Topic; Patient Medication Knowledge; Poland; Pyrazoles; Pyridones; Rivaroxaban; Surveys and Questionnaires | 2019 |
Effectiveness and safety of non-vitamin K antagonist oral anticoagulants in octogenarian patients with non-valvular atrial fibrillation.
Topics: Administration, Oral; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Follow-Up Studies; Hemorrhage; Humans; Male; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Treatment Outcome; Warfarin | 2019 |
Cerebral Ischemia in Patients on Direct Oral Anticoagulants.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Brain Ischemia; Dabigatran; Female; Humans; Male; Middle Aged; Registries; Rivaroxaban; Severity of Illness Index; Stroke; Warfarin | 2019 |
Real-world clinical evidence on rivaroxaban, dabigatran, and apixaban compared with -vitamin K antagonists in patients with non-valvular atrial fibrillation: a systematic literature review.
Topics: Atrial Fibrillation; Dabigatran; Humans; Pyrazoles; Pyridones; Rivaroxaban; Vitamin K | 2019 |
Real-world adherence for direct oral anticoagulants in a newly diagnosed atrial fibrillation cohort: does the dosing interval matter?
Topics: Administration, Oral; Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Dabigatran; Databases, Factual; Drug Administration Schedule; Drug Substitution; Factor Xa Inhibitors; Female; Humans; Male; Medication Adherence; Middle Aged; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Time Factors; Treatment Outcome | 2019 |
Changes in Oral Anticoagulation Therapy over One Year in 51,000 Atrial Fibrillation Patients at Risk for Stroke: A Practice-Derived Study.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Drug Substitution; Female; Follow-Up Studies; Germany; Hemorrhage; Humans; Male; Middle Aged; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Vitamin K; Withholding Treatment | 2019 |
Non-Vitamin K Oral Anticoagulants in Comparison to Phenprocoumon in Geriatric and Non-Geriatric Patients with Non-Valvular Atrial Fibrillation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Geriatrics; Germany; Humans; Middle Aged; Phenprocoumon; Proportional Hazards Models; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Vitamin K | 2019 |
[One-year persistence of patients already treated with oral anticoagulants for atrial fibrillation].
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Databases, Factual; Humans; Hungary; Pyrazoles; Pyridones; Rivaroxaban; Treatment Outcome; Vitamin K | 2019 |
Effectiveness and safety of oral anticoagulants in older adults with non-valvular atrial fibrillation and heart failure.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Heart Failure; Humans; Incidence; Kaplan-Meier Estimate; Male; Medicare; Patient Safety; Proportional Hazards Models; Pyrazoles; Pyridones; Retrospective Studies; Risk; Rivaroxaban; Treatment Outcome; United States; Warfarin | 2019 |
Comparative clinical outcomes between direct oral anticoagulants and warfarin among elderly patients with non-valvular atrial fibrillation in the CMS medicare population.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Cardiovascular Diseases; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; Medicare; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Treatment Outcome; United States; Warfarin | 2019 |
The direct oral anticoagulants rivaroxaban and dabigatran do not inhibit orthotopic growth and metastasis of human breast cancer in mice.
Topics: Animals; Anticoagulants; Antithrombins; Breast Neoplasms; Cell Line, Tumor; Dabigatran; Disease Progression; Factor Xa Inhibitors; Female; Humans; Mice; Mice, Inbred NOD; Mice, SCID; Neoplasm Metastasis; Rivaroxaban; Triple Negative Breast Neoplasms; Venous Thromboembolism; Xenograft Model Antitumor Assays | 2019 |
Direct Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation: Update and Periprocedural Management.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Critical Care Nursing; Dabigatran; Female; Humans; Male; Middle Aged; Practice Guidelines as Topic; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Warfarin | 2019 |
Dabigratan-related acute agranulocytosis.
Topics: Agranulocytosis; Atrial Fibrillation; Dabigatran; Follow-Up Studies; Humans; Rivaroxaban | 2019 |
Drug levels and bleeding complications in atrial fibrillation patients treated with direct oral anticoagulants.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Blood Coagulation; Dabigatran; Dose-Response Relationship, Drug; Drug Monitoring; Female; Hemorrhage; Humans; Italy; Male; Middle Aged; Pyrazoles; Pyridones; Registries; Risk Factors; Rivaroxaban; Treatment Outcome | 2019 |
Comparative effectiveness and safety of low-strength and high-strength direct oral anticoagulants compared with warfarin: a sequential cohort study.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Australia; Comparative Effectiveness Research; Dabigatran; Databases, Factual; Female; Hemorrhage; Humans; Logistic Models; Male; Myocardial Infarction; Propensity Score; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Veterans; Warfarin | 2019 |
Real-world 2-year outcome of atrial fibrillation treatment with dabigatran, apixaban, and rivaroxaban in patients with and without chronic kidney disease.
Topics: Administration, Oral; Aged; Atrial Fibrillation; Dabigatran; Factor Xa Inhibitors; Female; Humans; Italy; Male; Middle Aged; Pyrazoles; Pyridones; Registries; Renal Insufficiency, Chronic; Rivaroxaban; Statistics, Nonparametric; Treatment Outcome | 2019 |
Effectiveness and Safety of Four Direct Oral Anticoagulants in Asian Patients With Nonvalvular Atrial Fibrillation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Asian People; Atrial Fibrillation; Dabigatran; Databases, Factual; Female; Hemorrhage; Humans; Male; Middle Aged; Pyrazoles; Pyridines; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Taiwan; Thiazoles; Thromboembolism; Treatment Outcome; Warfarin | 2019 |
Comparisons between Oral Anticoagulants among Older Nonvalvular Atrial Fibrillation Patients.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; Female; Hemorrhage; Humans; Male; Medicare; Proportional Hazards Models; Pyrazoles; Pyridones; Retrospective Studies; Risk Factors; Rivaroxaban; Stroke; Treatment Outcome; United States; Warfarin | 2019 |
Efficacy of Direct Acting Oral Anticoagulants in Treatment of Left Ventricular Thrombus.
Topics: Adult; Aged; Blood Transfusion; Dabigatran; Echocardiography; Epistaxis; Factor Xa Inhibitors; Female; Follow-Up Studies; Gastrointestinal Hemorrhage; Heart Ventricles; Humans; Ischemic Attack, Transient; Male; Middle Aged; Platelet Aggregation Inhibitors; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Thrombosis; Ventricular Dysfunction, Left | 2019 |
Extended treatment with non-vitamin K antagonist oral anticoagulants versus low-molecular-weight heparins in cancer patients following venous thromboembolism. A pilot study.
Topics: Administration, Oral; Aged; Anticoagulants; Antithrombins; Comparative Effectiveness Research; Dabigatran; Drug Administration Schedule; Enoxaparin; Female; Hemorrhage; Humans; Male; Middle Aged; Neoplasms; Pilot Projects; Prospective Studies; Pyrazoles; Pyridones; Recurrence; Risk Factors; Rivaroxaban; Time Factors; Treatment Outcome; Venous Thromboembolism; Vitamin K | 2019 |
Effectiveness and safety of direct oral anticoagulants compared to warfarin in treatment naïve non-valvular atrial fibrillation patients in the US Department of defense population.
Topics: Administration, Oral; Adolescent; Adult; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Hemorrhage; Humans; Male; Middle Aged; Pyrazoles; Pyridones; Retrospective Studies; Risk Assessment; Risk Factors; Rivaroxaban; Stroke; Treatment Outcome; United States; United States Department of Defense; Warfarin; Young Adult | 2019 |
Effectiveness and Safety of Contemporary Oral Anticoagulants Among Asians With Nonvalvular Atrial Fibrillation.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Hemorrhage; Humans; Male; Middle Aged; Republic of Korea; Rivaroxaban; Treatment Outcome; Warfarin | 2019 |
[The Nephrological Aspects of the Use of Rivaroxaban and Other Direct Peroral Anticoagulants in Non-Valvular Atrial Fibrillation].
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Pyridones; Rivaroxaban; Stroke | 2019 |
Real-world efficacy and safety of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Patients; Pyrazoles; Pyridones; Renal Insufficiency, Chronic; Rivaroxaban; Safety | 2019 |
Comparative Real-Life Effectiveness and Safety of Dabigatran or Rivaroxaban vs. Vitamin K Antagonists: A High-Dimensional Propensity Score Matched New Users Cohort Study in the French National Healthcare Data System SNDS.
Topics: Administration, Oral; Aged; Aged, 80 and over; Atrial Fibrillation; Cohort Studies; Dabigatran; Data Systems; Factor Xa Inhibitors; Female; Fibrinolytic Agents; Gastrointestinal Hemorrhage; Humans; Male; Propensity Score; Rivaroxaban; Vitamin K | 2020 |
Renal Function Estimates and Dosing of Direct Oral Anticoagulants in Stroke Patients with Atrial Fibrillation: An Observational Study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Middle Aged; Rivaroxaban; Stroke | 2018 |
Incidence of direct oral anticoagulant use in patients with nonvalvular atrial fibrillation and characteristics of users in 6 European countries (2008-2015): A cross-national drug utilization study.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Databases, Factual; Denmark; Dose-Response Relationship, Drug; Drug Interactions; Drug Utilization; Female; France; Germany; Humans; Longitudinal Studies; Male; Metalloporphyrins; Middle Aged; Netherlands; Pyrazoles; Pyridones; Rivaroxaban; Sex Factors; Spain; United Kingdom; Young Adult | 2019 |
Direct oral anticoagulant- versus vitamin K antagonist-related gastrointestinal bleeding: Insights from a nationwide cohort.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Cohort Studies; Dabigatran; Denmark; Female; Gastrointestinal Hemorrhage; Hospital Mortality; Humans; Logistic Models; Male; Pyrazoles; Pyridones; Rivaroxaban; United States; Vitamin K; Warfarin | 2019 |
Pharmaceutical industry funding of events for healthcare professionals on non-vitamin K oral anticoagulants in Australia: an observational study.
Topics: Anticoagulants; Australia; Cross-Sectional Studies; Dabigatran; Drug Industry; Education, Medical, Continuing; Humans; Practice Patterns, Physicians'; Pyrazoles; Pyridones; Rivaroxaban | 2019 |
Comparative effectiveness of warfarin, dabigatran, rivaroxaban and apixaban in non-valvular atrial fibrillation: A nationwide pharmacoepidemiological study.
Topics: Aged; Atrial Fibrillation; Dabigatran; Female; Follow-Up Studies; Humans; Male; Pyrazoles; Pyridones; Rivaroxaban; Treatment Outcome; Warfarin | 2019 |
Effect of concomitant antiplatelet therapy in patients with nonvalvular atrial fibrillation initiating non-vitamin K antagonists.
Topics: Aged; Aged, 80 and over; Antithrombins; Aspirin; Atrial Fibrillation; Dabigatran; Drug Therapy, Combination; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Mortality; Myocardial Infarction; Platelet Aggregation Inhibitors; Proportional Hazards Models; Purinergic P2Y Receptor Antagonists; Pyrazoles; Pyridines; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Thiazoles | 2019 |
Direct oral anticoagulants in the treatment of cerebral venous sinus thrombosis: a single institution's experience.
Topics: Administration, Oral; Adult; Anticoagulants; Dabigatran; Female; Humans; Male; Middle Aged; Rivaroxaban; Sinus Thrombosis, Intracranial | 2019 |
Safety of direct oral anticoagulants in patients with hereditary hemorrhagic telangiectasia.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Epistaxis; Female; Humans; Male; Middle Aged; Pulmonary Embolism; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Telangiectasia, Hereditary Hemorrhagic; Venous Thromboembolism; Warfarin | 2019 |
Global thromboelastometry in patients receiving direct oral anticoagulants: the RO-DOA study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Blood Coagulation; Blood Coagulation Tests; Dabigatran; Female; Humans; Male; Middle Aged; Pyrazoles; Pyridones; Rivaroxaban; Thrombelastography | 2020 |
The prescription of direct oral anticoagulants in the elderly: An observational study of 19 798 Ambulatory subjects.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Antihypertensive Agents; Blood Cell Count; Blood Coagulation Tests; Chronic Disease; Creatinine; Dabigatran; Drug Prescriptions; Female; France; Humans; Kidney Function Tests; Male; Platelet Aggregation Inhibitors; Practice Patterns, Physicians'; Prospective Studies; Pyrazoles; Pyridones; Rivaroxaban | 2020 |
Appropriateness of initial dose of non-vitamin K antagonist oral anticoagulants in patients with non-valvular atrial fibrillation in the UK.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cross-Sectional Studies; Dabigatran; Female; Humans; Male; Middle Aged; Pyrazoles; Pyridones; Rivaroxaban; Stroke; United Kingdom | 2019 |
Outcome of Anticoagulation Therapy of Left Atrial Thrombus or Sludge in Patients With Nonvalvular Atrial Fibrillation or Flutter.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Drug Therapy, Combination; Echocardiography, Transesophageal; Female; Heart Atria; Humans; Male; Middle Aged; Rivaroxaban; Thrombosis; Treatment Outcome; Warfarin | 2019 |
Discontinuation of non-Vitamin K antagonist oral anticoagulants in patients with non-valvular atrial fibrillation: a population-based cohort study using primary care data from The Health Improvement Network in the UK.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Female; Humans; Kidney Diseases; Male; Medication Adherence; Middle Aged; Pyrazoles; Pyridones; Rivaroxaban; United Kingdom | 2019 |
Reduced dose of rivaroxaban and dabigatran vs. vitamin K antagonists in very elderly patients with atrial fibrillation in a nationwide cohort study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Humans; Rivaroxaban; Stroke; Vitamin K | 2020 |
Safety of cataract surgery in patients treated with the new oral anticoagulants (NOACs).
Topics: Administration, Oral; Aged; Aged, 80 and over; Antithrombins; Blood Loss, Surgical; Dabigatran; Eye Hemorrhage; Factor Xa Inhibitors; Female; Follow-Up Studies; Humans; Incidence; Israel; Male; Middle Aged; Phacoemulsification; Postoperative Hemorrhage; Prospective Studies; Pyrazoles; Pyridones; Rivaroxaban; Thromboembolism | 2019 |
The contribution of real-world evidence to cost-effectiveness analysis: case study of Dabigatran etexilate in France.
Topics: Anticoagulants; Atrial Fibrillation; Cost-Benefit Analysis; Dabigatran; France; Hemorrhage; Humans; Myocardial Infarction; Quality-Adjusted Life Years; Rivaroxaban; Stroke; Warfarin | 2020 |
NOAC Adherence of Patients with Atrial Fibrillation in the Real World: Dosing Frequency Matters?
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Cross-Sectional Studies; Dabigatran; Drug Administration Schedule; Female; Humans; Male; Medication Adherence; Middle Aged; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Surveys and Questionnaires; Thiazoles | 2020 |
Oral Anticoagulation in Patients in the Emergency Department: High Rates of Off-Label Doses, No Difference in Bleeding Rates.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Emergency Service, Hospital; Female; Hemorrhage; Humans; Male; Off-Label Use; Pyrazoles; Pyridines; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Thiazoles; Vitamin K | 2020 |
Effect of rivaroxaban and dabigatran on platelet functions: in vitro study.
Topics: Antithrombins; Dabigatran; Factor Xa Inhibitors; Female; Healthy Volunteers; Humans; Male; Platelet Function Tests; Rivaroxaban | 2019 |
Detecting direct oral anticoagulants in trauma patients using liquid chromatography-mass spectrometry: A novel approach to medication reconciliation.
Topics: Administration, Oral; Aged; Anticoagulants; Chromatography, High Pressure Liquid; Dabigatran; Female; Healthy Volunteers; Humans; Male; Mass Spectrometry; Medication Reconciliation; Prospective Studies; Pyrazoles; Pyridones; Rivaroxaban; Sensitivity and Specificity; Wounds and Injuries | 2020 |
Hematoma Risk After Needle Electromyography in Patients Using Newer Oral Anticoagulants.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Dabigatran; Electromyography; Female; Hematoma; Humans; Male; Middle Aged; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Warfarin | 2021 |
Peri-procedural use of direct anticoagulation agents during cardiac device implantation: vitamin K antagonists vs direct oral anticoagulants.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Defibrillators, Implantable; Female; Humans; Male; Middle Aged; Pyridones; Rivaroxaban; Vitamin K; Warfarin | 2020 |
Association of Anticoagulant Therapy With Risk of Fracture Among Patients With Atrial Fibrillation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Comorbidity; Comparative Effectiveness Research; Dabigatran; Factor Xa Inhibitors; Female; Fractures, Bone; Hip Fractures; Hospitalization; Humans; Incidence; Male; Middle Aged; Osteoporosis; Proportional Hazards Models; Protective Factors; Pyrazoles; Pyridones; Rivaroxaban; Warfarin | 2020 |
Comparing the Effectiveness and Safety of Nonvitamin K Antagonist Oral Anticoagulants and Warfarin in Elderly Asian Patients With Atrial Fibrillation: A Nationwide Cohort Study.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Cohort Studies; Dabigatran; Factor Xa Inhibitors; Female; Humans; Male; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Taiwan; Warfarin | 2020 |
Optimization by response surface methodology of a dispersive magnetic solid phase extraction exploiting magnetic graphene nanocomposite coupled with UHPLC-PDA for simultaneous determination of new oral anticoagulants (NAOs) in human plasma.
Topics: Anticoagulants; Chromatography, High Pressure Liquid; Dabigatran; Graphite; Humans; Limit of Detection; Magnetite Nanoparticles; Nanocomposites; Plasma; Pyrazoles; Pyridones; Rivaroxaban; Solid Phase Extraction | 2020 |
Direct comparisons of effectiveness and safety of treatment with Apixaban, Dabigatran and Rivaroxaban in atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke | 2020 |
[How to maintain an adherence to oral anticoagulant in a patient with atrial fibrillation?]
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Rivaroxaban; Stroke; Warfarin | 2019 |
Safety and Effectiveness of Dabigatran and Other Direct Oral Anticoagulants Compared With Warfarin in Patients With Atrial Fibrillation.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Cohort Studies; Dabigatran; Female; Hemorrhage; Humans; Longitudinal Studies; Male; Middle Aged; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Warfarin; Young Adult | 2020 |
Rivaroxaban and Dabigatran for Suppression of Mechanical Heart Valve-Induced Thrombin Generation.
Topics: Antithrombins; Dabigatran; Factor Xa Inhibitors; Heart Diseases; Heart Valve Prosthesis; Humans; Rivaroxaban; Thrombin; Thrombosis | 2020 |
Challenges in stroke prevention among very elderly patients with atrial fibrillation: discerning facts from prejudices.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Humans; Prejudice; Rivaroxaban; Stroke; Vitamin K | 2020 |
Using the PCI-IS Method to Simultaneously Estimate Blood Volume and Quantify Nonvitamin K Antagonist Oral Anticoagulant Concentrations in Dried Blood Spots.
Topics: Administration, Oral; Anticoagulants; Blood Volume; Chromatography, Liquid; Dabigatran; Dried Blood Spot Testing; Humans; Pyrazoles; Pyridones; Rivaroxaban; Tandem Mass Spectrometry; Vitamin K | 2020 |
Risk of Osteoporosis in Patients With Atrial Fibrillation Using Non-Vitamin K Antagonist Oral Anticoagulants or Warfarin.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Databases, Factual; Factor Xa Inhibitors; Female; Humans; Male; Middle Aged; Osteoporosis; Pyrazoles; Pyridones; Retrospective Studies; Risk Assessment; Risk Factors; Rivaroxaban; Taiwan; Treatment Outcome; Warfarin | 2020 |
Effects of anticoagulant drugs on wound healing process in a rat model: a comparative study.
Topics: Administration, Cutaneous; Administration, Oral; Animals; Anticoagulants; Dabigatran; Enoxaparin; Female; Models, Animal; Random Allocation; Rats; Rats, Sprague-Dawley; Rivaroxaban; Saline Solution; Single-Blind Method; Skin; Treatment Outcome; Wound Healing; Wounds and Injuries | 2020 |
Cost-effectiveness of Dabigatran Compared With Rivaroxaban for Prevention of Stroke and Systemic Embolism in Patients With Atrial Fibrillation in China.
Topics: Aged; Anticoagulants; Atrial Fibrillation; China; Cost-Benefit Analysis; Dabigatran; Embolism; Female; Humans; Male; Markov Chains; Models, Economic; Quality-Adjusted Life Years; Rivaroxaban; Stroke; Treatment Outcome | 2020 |
Comparison of dabigatran, rivaroxaban, and apixaban for effectiveness and safety in atrial fibrillation: a nationwide cohort study.
Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Dabigatran; Databases, Factual; Embolism; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Incidence; Male; Middle Aged; Norway; Patient Safety; Pyrazoles; Pyridones; Registries; Risk Assessment; Risk Factors; Rivaroxaban; Stroke; Time Factors; Treatment Outcome | 2020 |
[Pharmaco-utilization and outcomes in patients treated with oral anticoagulants from 2014 to 2015: evidences from administrative databases of the Romagna Local Health Unit].
Topics: Administration, Oral; Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Cause of Death; Comorbidity; Dabigatran; Databases, Factual; Female; Hemorrhage; Humans; Male; Medication Adherence; Platelet Aggregation Inhibitors; Propensity Score; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Thromboembolism; Warfarin | 2020 |
Effectiveness and Safety of Direct Oral Anticoagulants versus Warfarin in Obese Patients with Acute Venous Thromboembolism.
Topics: Administration, Oral; Aged; Anticoagulants; Cohort Studies; Dabigatran; Female; Humans; Male; Middle Aged; Obesity, Morbid; Pulmonary Embolism; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Treatment Outcome; Venous Thromboembolism; Warfarin | 2020 |
Outcome of non-vitamin K oral anticoagulants in the treatment of left atrial/left atrial appendage thrombus in patients with nonvalvular atrial fibrillation.
Topics: Administration, Oral; Aged; Antithrombins; Atrial Appendage; Atrial Fibrillation; Dabigatran; Factor Xa Inhibitors; Female; Humans; Male; Middle Aged; Retrospective Studies; Rivaroxaban; Stroke; Thrombosis; Time Factors; Treatment Outcome | 2020 |
Development, validation and application of a new HPLC-DAD method for simultaneous quantification of apixaban, dabigatran, edoxaban and rivaroxaban in human plasma.
Topics: Anticoagulants; Chromatography, High Pressure Liquid; Dabigatran; Humans; Plasma; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Solid Phase Extraction; Spectrophotometry; Thiazoles | 2020 |
Fracture risks among patients with atrial fibrillation receiving different oral anticoagulants: a real-world nationwide cohort study.
Topics: Administration, Oral; Adult; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Humans; Retrospective Studies; Rivaroxaban; Stroke; Taiwan | 2020 |
Characteristics and outcomes in patients with atrial fibrillation receiving direct oral anticoagulants in off-label doses.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Dabigatran; Databases, Factual; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Medicare; Off-Label Use; Practice Patterns, Physicians'; Retrospective Studies; Risk Assessment; Risk Factors; Rivaroxaban; Stroke; Thromboembolism; Time Factors; Treatment Outcome; United States | 2020 |
Risk of major bleeding among users of direct oral anticoagulants combined with interacting drugs: A population-based nested case-control study.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Case-Control Studies; Dabigatran; Hemorrhage; Humans; Pharmaceutical Preparations; Pyridones; Rivaroxaban | 2020 |
Comparison of Traumatic Intracranial Hemorrhage Expansion and Outcomes Among Patients on Direct Oral Anticoagulants Versus Vitamin k Antagonists.
Topics: Accidental Falls; Aged; Aged, 80 and over; Anticoagulants; Antifibrinolytic Agents; Antithrombins; Blood Coagulation Factors; Coagulants; Dabigatran; Disease Progression; Factor Xa Inhibitors; Female; Glasgow Outcome Scale; Humans; Intracranial Hemorrhage, Traumatic; Length of Stay; Male; Middle Aged; Mortality; Neurosurgical Procedures; Plasma; Platelet Transfusion; Pyrazoles; Pyridines; Pyridones; Retrospective Studies; Rivaroxaban; Thiazoles; Vitamin K; Warfarin | 2020 |
Simultaneous Determination of Dabigatran, Rivaroxaban, and Apixaban in Human Plasma by Liquid Chromatography/Tandem Mass Spectrometry.
Topics: Anticoagulants; Chromatography, Liquid; Dabigatran; Drug Monitoring; Humans; Pyrazoles; Pyridones; Reproducibility of Results; Rivaroxaban; Tandem Mass Spectrometry | 2020 |
Analytical verification and comparison of chromogenic assays for dabigatran, rivaroxaban and apixaban determination on BCSXP and STA Compact Max analysers.
Topics: Anticoagulants; Blood Coagulation Tests; Dabigatran; Humans; Pyrazoles; Pyridones; Rivaroxaban | 2020 |
Effects of rivaroxaban and dabigatran on global hemostasis in patients with atrial fibrillation.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Hemostasis; Humans; Male; Rivaroxaban | 2020 |
INVITED COMMENTARY.
Topics: Dabigatran; Heart Valves; Rivaroxaban; Thrombin | 2020 |
Trends of ambulatory oral anticoagulant prescription in five major cities of China, 2012-2017.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Ambulatory Care; Ambulatory Care Facilities; Anticoagulants; China; Cities; Dabigatran; Drug Prescriptions; Female; Health Expenditures; Humans; Male; Middle Aged; Rivaroxaban; Warfarin; Young Adult | 2020 |
The Protective Effect of Dabigatran and Rivaroxaban on DNA Oxidative Changes in a Model of Vascular Endothelial Damage with Oxidized Cholesterol.
Topics: Anticoagulants; Antioxidants; Cholesterol; Dabigatran; DNA Damage; Human Umbilical Vein Endothelial Cells; Humans; Oxidative Stress; Rivaroxaban | 2020 |
Anticoagulant-related gastrointestinal bleeding: a real-life data analysis on bleeding profiles, frequency and etiology of patients receiving direct oral anticoagulants versus vitamin K antagonists.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Dabigatran; Female; Gastrointestinal Hemorrhage; Humans; Male; Middle Aged; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Vitamin K; Young Adult | 2019 |
Comment on-Switching from vitamin K antagonist to dabigatran in atrial fibrillation: differences according to dose: reply.
Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Rivaroxaban; Vitamin K | 2021 |
Comments on-Switching from vitamin K antagonist to dabigatran in atrial fibrillation: differences according to dose.
Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Rivaroxaban; Vitamin K | 2021 |
Trends in anticoagulant prescribing: a review of local policies in English primary care.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Drug Utilization; England; Female; Humans; Male; Practice Patterns, Physicians'; Primary Health Care; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; State Medicine; Stroke; Thiazoles; Warfarin | 2020 |
Management of epistaxis in patients on novel oral anticoagulation therapy.
Topics: Administration, Oral; Aged; Antibodies, Monoclonal, Humanized; Anticoagulants; Antidotes; Antithrombins; Arginine; Awareness; Dabigatran; Epistaxis; Factor Xa; Factor Xa Inhibitors; First Aid; Humans; Male; Piperazines; Prevalence; Recombinant Proteins; Rivaroxaban; Severity of Illness Index | 2020 |
Current clinician perspective on non-vitamin K antagonist oral anticoagulant use in challenging clinical cases.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cardiologists; Clinical Trials, Phase III as Topic; Consensus; Dabigatran; Disease Management; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Female; Humans; Male; Middle Aged; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiazoles; Vitamin K; Warfarin | 2020 |
The management of patients with acute ischemic stroke while on direct oral anticoagulants (DOACs): data from an Italian cohort and a proposed algorithm.
Topics: Aged; Aged, 80 and over; Atrial Fibrillation; Dabigatran; Disease Management; Drug Monitoring; Factor Xa Inhibitors; Female; Humans; Ischemic Stroke; Italy; Male; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban | 2020 |
Profile of Patients Diagnosed With Acute Venous Thromboembolism in Routine Clinical Practice: The RE-COVERY DVT/PE™ Study.
Topics: Administration, Oral; Adult; Age Distribution; Aged; Anticoagulants; Asia; Comorbidity; Cross-Sectional Studies; Dabigatran; Diabetes Mellitus; Europe; Factor Xa Inhibitors; Female; Fondaparinux; Heparin; Humans; Hypertension; Latin America; Male; Middle Aged; Middle East; Neoplasms; Postoperative Complications; Practice Patterns, Physicians'; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Venous Thromboembolism; Venous Thrombosis; Wounds and Injuries | 2020 |
Risk of Cardiovascular Events and Mortality Among Elderly Patients With Reduced GFR Receiving Direct Oral Anticoagulants.
Topics: Aged; Aged, 80 and over; Antithrombins; Brain Ischemia; Cause of Death; Comorbidity; Dabigatran; Female; Glomerular Filtration Rate; Hemorrhage; Humans; Male; Mortality; Myocardial Infarction; Myocardial Revascularization; Ontario; Procedures and Techniques Utilization; Propensity Score; Proportional Hazards Models; Pyrazoles; Pyridones; Renal Insufficiency, Chronic; Retrospective Studies; Rivaroxaban; Thrombophilia; Vitamin K | 2020 |
Safety and effectiveness of non-vitamin K oral anticoagulants versus warfarin in real-world patients with non-valvular atrial fibrillation: a retrospective analysis of contemporary Japanese administrative claims data.
Topics: Administration, Oral; Administrative Claims, Healthcare; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Electronic Health Records; Female; Hemorrhage; Humans; Japan; Male; Middle Aged; Patient Safety; Pyrazoles; Pyridines; Pyridones; Retrospective Studies; Risk Assessment; Risk Factors; Rivaroxaban; Stroke; Thiazoles; Time Factors; Treatment Outcome; Vitamin K; Warfarin | 2020 |
Real-World Direct Comparison of the Effectiveness and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Medicare Beneficiaries With Atrial Fibrillation.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Female; Hemorrhage; Humans; Ischemic Attack, Transient; Male; Medicare; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; United States; Warfarin | 2020 |
Association of different oral anticoagulants use with renal function worsening in patients with atrial fibrillation: A multicentre cohort study.
Topics: Administration, Oral; Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Female; Humans; Kidney Diseases; Male; Middle Aged; Prospective Studies; Rivaroxaban; Stroke | 2020 |
Regarding the publication "Rivaroxaban versus warfarin in patients with non-valvular atrial fibrillation and stage IV-V chronic kidney disease".
Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Renal Insufficiency, Chronic; Rivaroxaban; Warfarin | 2020 |
Effects of rivaroxaban and dabigatran on local expression of coagulation and inflammatory factors within human aortic stenotic valves.
Topics: Aged; Antithrombins; Aortic Valve; Aortic Valve Stenosis; Blood Coagulation Factors; Cells, Cultured; Dabigatran; Factor Xa Inhibitors; Female; Humans; Inflammation Mediators; Male; Middle Aged; Rivaroxaban; Severity of Illness Index; Signal Transduction | 2020 |
[Stroke Prevention in Patients with Atrial Fibrillation in Real Clinical Practice, Emphasis on Efficacy and Safety of Anticoagulant Therapy].
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Pyridones; Retrospective Studies; Rivaroxaban; Stroke | 2020 |
Assessment of direct oral anticoagulants administered as potentially inappropriate medications to elderly inpatients.
Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; China; Creatinine; Cross-Sectional Studies; Dabigatran; Hemorrhage; Humans; Inappropriate Prescribing; Inpatients; Length of Stay; Male; Polypharmacy; Retrospective Studies; Risk Factors; Rivaroxaban; Thromboembolism | 2020 |
Major bleeding risk associated with oral anticoagulant in real clinical practice. A multicentre 3-year period population-based prospective cohort study.
Topics: Administration, Oral; Adult; Aged; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Female; Hemorrhage; Humans; Prospective Studies; Rivaroxaban; Stroke; Vitamin K | 2020 |
Association Between Treatment With Apixaban, Dabigatran, Rivaroxaban, or Warfarin and Risk for Osteoporotic Fractures Among Patients With Atrial Fibrillation: A Population-Based Cohort Study.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Female; Follow-Up Studies; Hip Fractures; Hong Kong; Humans; Male; Osteoporotic Fractures; Pyrazoles; Pyridones; Rivaroxaban; Spinal Fractures; Stroke; Warfarin | 2020 |
Direct acting oral anticoagulants and alopecia: to go further with data mining in pharmacovigilance databases.
Topics: Administration, Oral; Alopecia; Anticoagulants; Dabigatran; Data Mining; Databases, Factual; Humans; Minoxidil; Pharmacovigilance; Platelet-Rich Plasma; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles | 2020 |
Mechanical Heart Valves Require Warfarin: No News Is Good News?
Topics: Anticoagulants; Dabigatran; Family Characteristics; Heart Valve Prosthesis; Heart Valves; Humans; Rivaroxaban; Thrombin; Warfarin | 2020 |
Remaining activity of temporary interrupted direct oral anticoagulants and its impact on intra-ablation heparinization in patients with atrial fibrillation: Comparisons across four drugs and two dose regimens.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Pharmaceutical Preparations; Pyridones; Rivaroxaban; Stroke | 2020 |
The speed of adoption of new drugs and prescription volume after the amendments in reimbursement coverage: the case of non-vitamin K antagonist oral anticoagulants in South Korea.
Topics: Adult; Aged; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Drug Prescriptions; Health Expenditures; Humans; Interrupted Time Series Analysis; Middle Aged; National Health Programs; Practice Patterns, Physicians'; Primary Health Care; Pyrazoles; Pyridones; Republic of Korea; Retrospective Studies; Rivaroxaban | 2020 |
Association Between Nonvitamin K Antagonist Oral Anticoagulants or Warfarin and Liver Injury: A Cohort Study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Chemical and Drug Induced Liver Injury; Cohort Studies; Dabigatran; Databases, Factual; Female; Humans; Male; Middle Aged; Propensity Score; Pyrazoles; Pyridones; Risk; Rivaroxaban; Warfarin | 2020 |
Risk of Hospitalization With Hemorrhage Among Older Adults Taking Clarithromycin vs Azithromycin and Direct Oral Anticoagulants.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Azithromycin; Clarithromycin; Dabigatran; Drug Interactions; Factor Xa Inhibitors; Female; Hemorrhage; Hospitalization; Humans; Male; Pyrazoles; Pyridones; Retrospective Studies; Risk Factors; Rivaroxaban | 2020 |
Clinical outcomes of nonvitamin K oral anticoagulants and acenocoumarol for stroke prevention in contemporary practice: A population-based propensity-weighted cohort study.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Atrial Fibrillation; Brain Ischemia; Cohort Studies; Dabigatran; Humans; India; Netherlands; Retrospective Studies; Rivaroxaban; Spain; Stroke | 2021 |
Comparative Safety and Effectiveness of Oral Anticoagulants in Nonvalvular Atrial Fibrillation: The NAXOS Study.
Topics: Adult; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; Factor Xa Inhibitors; Female; Humans; Male; Middle Aged; Rivaroxaban; Stroke; Warfarin | 2020 |
Safe chest tube placement in a patient with tension pneumothorax receiving rivaroxaban therapy for non-valvular atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Chest Tubes; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; Male; Middle Aged; Pneumothorax; Respiratory Insufficiency; Rivaroxaban; Thoracostomy; Treatment Outcome | 2020 |
Does the CHA2DS2-VASc scale sufficiently predict the risk of left atrial appendage thrombus in patients with diagnosed atrial fibrillation treated with non-vitamin K oral anticoagulants?
Topics: Aged; Atrial Appendage; Atrial Fibrillation; Dabigatran; Echocardiography, Transesophageal; Factor Xa Inhibitors; Female; Humans; Male; Middle Aged; Pyrazoles; Pyridones; Risk Assessment; Risk Factors; Rivaroxaban; Thromboembolism | 2020 |
Oral anticoagulants for nonvalvular atrial fibrillation in frail elderly patients: insights from the ARISTOPHANES study.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Cause of Death; Dabigatran; Frail Elderly; Hemorrhage; Humans; Propensity Score; Pyrazoles; Pyridones; Retrospective Studies; Risk Factors; Rivaroxaban; Stroke; United States; Vitamin K; Warfarin | 2021 |
Comparison of the Efficacy and Safety of Direct Oral Anticoagulants and Warfarin After Bioprosthetic Valve Replacements.
Topics: Administration, Oral; Aged; Anticoagulants; Bioprosthesis; Dabigatran; Female; Heart Valve Prosthesis; Hemorrhage; Humans; Male; Middle Aged; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Thromboembolism; Warfarin | 2020 |
Comparing risk of major bleeding between users of different oral anticoagulants in patients with nonvalvular atrial fibrillation.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Female; Germany; Hemorrhage; Humans; Male; Rivaroxaban; Spain; Stroke; Vitamin K | 2021 |
In Vitro Evaluation of Pro- and Anticoagulant Drugs in Children with End-Stage Liver Disease Undergoing Liver Transplantation.
Topics: Anticoagulants; Blood Coagulation; Blood Coagulation Factors; Child; Child, Preschool; Dabigatran; End Stage Liver Disease; Female; Hemostatics; Heparin; Humans; Liver Transplantation; Male; Rivaroxaban | 2020 |
Activated prothrombin complex concentrates for direct oral anticoagulant-associated bleeding or urgent surgery: Hemostatic and thrombotic outcomes.
Topics: Administration, Oral; Anticoagulants; Blood Coagulation Factors; Dabigatran; Hemorrhage; Hemostasis; Hemostatics; Humans; Retrospective Studies; Rivaroxaban | 2020 |
[Antithrombotic Therapy in Patients with Acute Coronary Syndrome and Atrial Fibrillation].
Topics: Acute Coronary Syndrome; Acute Disease; Aspirin; Atrial Fibrillation; Clopidogrel; Combined Modality Therapy; Cyclophosphamide; Dabigatran; Drug Therapy, Combination; Fibrinolytic Agents; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Risk Factors; Rivaroxaban; Stents; Stroke; Vitamin K | 2020 |
Oral anticoagulants and risk of acute liver injury in patients with nonvalvular atrial fibrillation: a propensity-weighted nationwide cohort study.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Alcoholism; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Female; France; Humans; Liver Failure, Acute; Male; Middle Aged; Propensity Score; Proportional Hazards Models; Pyrazoles; Pyridones; Risk; Rivaroxaban; Young Adult | 2020 |
A Prospective Cohort Comparative Study of Rivaroxaban, Dabigatran, and Apixaban Oral Thromboprophylaxis in 2431 Hip and Knee Arthroplasty Patients: Primary Efficacy Outcomes and Safety Profile.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Dabigatran; Humans; Prospective Studies; Pyrazoles; Pyridones; Rivaroxaban; Venous Thromboembolism | 2020 |
Electrophysiological effects of non-vitamin K antagonist oral anticoagulants on atrial repolarizing potassium channels.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Potassium Channels; Pyridones; Rivaroxaban; Stroke | 2020 |
Influence of anticoagulants on the risk of delayed bleeding after gastric endoscopic submucosal dissection: a multicenter retrospective study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Dabigatran; Endoscopic Mucosal Resection; Female; Humans; Japan; Male; Middle Aged; Postoperative Complications; Postoperative Hemorrhage; Pyrazoles; Pyridines; Pyridones; Retrospective Studies; Rivaroxaban; Stomach; Stomach Neoplasms; Thiazoles; Thromboembolism; Warfarin | 2021 |
Predictors of preprocedural direct oral anticoagulant levels in patients having an elective surgery or procedure.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Humans; Rivaroxaban | 2020 |
Intra-procedural anticoagulation and post-procedural hemoglobin fall in atrial fibrillation ablation with minimally interrupted direct oral anticoagulants: comparisons across 4 drugs.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Catheter Ablation; Dabigatran; Hemoglobins; Humans; Pharmaceutical Preparations; Rivaroxaban | 2021 |
Monitoring DOACs with a Novel Dielectric Microsensor: A Clinical Study.
Topics: Aged; Aged, 80 and over; Blood Coagulation; Blood Coagulation Tests; Dabigatran; Drug Monitoring; Equipment Design; Factor Xa Inhibitors; Female; Humans; Male; Middle Aged; Pyrazoles; Pyridones; Rivaroxaban | 2021 |
Effectiveness and Safety of Direct Oral Anticoagulants in the Secondary Stroke Prevention of Elderly Patients: Ljubljana Registry of Secondary Stroke Prevention.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; Female; Hemorrhage; Humans; Incidence; Ischemic Attack, Transient; Male; Middle Aged; Pyrazoles; Pyridones; Registries; Rivaroxaban; Secondary Prevention; Stroke | 2020 |
[Pharmacogenomic Research in Direct Oral Anticoagulants].
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Pharmacogenetics; Rivaroxaban | 2020 |
A Survey of Direct Oral Anticoagulant Cessation in General Surgery and Outcomes in Patients with Nonvalvular Atrial Fibrillation.
Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Blood Loss, Surgical; Carotid Artery Diseases; Cerebral Infarction; Dabigatran; Digestive System Surgical Procedures; Elective Surgical Procedures; Embolism; Endoscopy; Factor Xa Inhibitors; Female; Humans; Male; Myocardial Infarction; Orthopedic Procedures; Perioperative Care; Postoperative Complications; Postoperative Hemorrhage; Pyrazoles; Pyridines; Pyridones; Retrospective Studies; Rivaroxaban; Thiazoles; Thromboembolism; Urologic Surgical Procedures; Vascular Surgical Procedures | 2020 |
Direct oral anticoagulants in the prevention of stroke in breast cancer patients with atrial fibrillation during adjuvant endocrine therapy: A cohort study.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Breast Neoplasms; Cohort Studies; Dabigatran; Female; Humans; Middle Aged; Prospective Studies; Pyridones; Rivaroxaban; Stroke | 2021 |
Antithrombotic management and outcomes of patients with atrial fibrillation treated with NOACs early at the time of market introduction: Main results from the PREFER in AF Prolongation Registry.
Topics: Administration, Oral; Aged; Atrial Fibrillation; Dabigatran; Europe; Factor Xa Inhibitors; Female; Humans; Male; Prospective Studies; Pyrazoles; Pyridones; Registries; Rivaroxaban | 2021 |
Predictors of Bleeding in the Perioperative Anticoagulant Use for Surgery Evaluation Study.
Topics: Aged; Atrial Fibrillation; Blood Loss, Surgical; Dabigatran; Elective Surgical Procedures; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Medication Therapy Management; Perioperative Care; Pyrazoles; Pyridones; Risk Adjustment; Rivaroxaban; Stroke | 2020 |
Position paper on the safety/efficacy profile of direct oral anticoagulants in patients with chronic kidney disease. Consensus document from the SIN, FCSA and SISET.
Topics: Administration, Oral; Antidotes; Antithrombins; Atrial Fibrillation; Cohort Studies; Dabigatran; Drug Interactions; Drug Monitoring; Glomerular Filtration Rate; Hemorrhage; Humans; Kidney; Metabolic Clearance Rate; Observational Studies as Topic; Polypharmacy; Practice Guidelines as Topic; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Rivaroxaban; Stroke; Thiazoles | 2020 |
Postpolypectomy bleeding of colorectal polyps in patients with continuous warfarin and short-term interruption of direct oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Colonic Polyps; Dabigatran; Hemorrhage; Humans; Male; Pyridones; Rivaroxaban; Warfarin | 2021 |
Therapeutic Drug Monitoring of Direct Oral Anticoagulants May Increase Their Benefit-Risk Ratio.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antithrombins; Blood Coagulation; Chromatography, High Pressure Liquid; Dabigatran; Drug Monitoring; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Patient Safety; Predictive Value of Tests; Prospective Studies; Risk Assessment; Risk Factors; Rivaroxaban; Tandem Mass Spectrometry; Thrombosis; Treatment Outcome | 2020 |
Prescribers' compliance with summary of product characteristics of dabigatran, rivaroxaban and apixaban-A European comparative drug utilization study.
Topics: Anticoagulants; Contraindications, Drug; Dabigatran; Drug Interactions; Drug Prescriptions; Drug Utilization; Humans; Pyrazoles; Pyridones; Rivaroxaban | 2021 |
Effects of dabigatran and rivaroxaban on stroke severity according to the results of routine coagulation tests.
Topics: Acute Disease; Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Brain Ischemia; Dabigatran; Factor Xa Inhibitors; Female; Follow-Up Studies; Humans; Male; Middle Aged; Partial Thromboplastin Time; Prognosis; Prothrombin Time; Retrospective Studies; Rivaroxaban; Severity of Illness Index; Stroke | 2020 |
Thrombotic complications with interruption of direct oral anticoagulants in dermatologic surgery.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Dermatologic Surgical Procedures; Female; Humans; Ischemic Attack, Transient; Male; Perioperative Care; Postoperative Hemorrhage; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban | 2021 |
Association of anticoagulant therapy with risk of dementia among patients with atrial fibrillation.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Dementia; Female; Humans; Male; Pyridones; Rivaroxaban; Stroke | 2021 |
[Comparative efficacy and safety of direct oral anticoagulants in patients with atrial fibrillation and chronic kidney disease].
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Pyridones; Renal Insufficiency, Chronic; Rivaroxaban; Stroke; Treatment Outcome | 2020 |
Patterns of anticoagulation therapy in atrial fibrillation: results from a large real-life single-center registry.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Proportional Hazards Models; Pyrazoles; Pyridones; Registries; Retrospective Studies; Risk Factors; Rivaroxaban; Stroke; Survival Rate; Warfarin; Young Adult | 2020 |
Switching across direct oral anticoagulants: a real-life-setting pilot prospective study.
Topics: Age Factors; Aged; Aged, 80 and over; Cardiovascular Diseases; Dabigatran; Drug Monitoring; Drug Substitution; Drug-Related Side Effects and Adverse Reactions; Factor Xa Inhibitors; Female; Heart Disease Risk Factors; Humans; Italy; Long Term Adverse Effects; Male; Medication Therapy Management; Risk Adjustment; Rivaroxaban | 2021 |
Observations on clot properties in atrial fibrillation: Relation to renal function and choice of anticoagulant.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Pyridones; Rivaroxaban; Stroke; Thrombosis; Warfarin | 2021 |
Heavy menstrual bleeding in women on oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Humans; Menorrhagia; Pyridones; Retrospective Studies; Rivaroxaban | 2021 |
Short-Term Cessation of Dabigatran Causes a Paradoxical Prothrombotic State.
Topics: Aged; Aged, 80 and over; Animals; Antithrombins; Arachidonic Acid; Aspirin; Carotid Artery Thrombosis; Cerebral Infarction; Chlorides; Computed Tomography Angiography; Dabigatran; Deprescriptions; Factor Xa Inhibitors; Female; Ferric Compounds; Humans; Ischemic Stroke; Magnetic Resonance Angiography; Male; Mean Platelet Volume; Mice; Noxae; Pilot Projects; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Count; Pyrazoles; Pyridones; Rivaroxaban; Severity of Illness Index; Substance Withdrawal Syndrome; Thrombin; Thrombophilia; X-Ray Microtomography | 2021 |
Factors influencing oral anticoagulant use in patients newly diagnosed with atrial fibrillation.
Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Australia; Dabigatran; Factor Xa Inhibitors; Female; General Practice; Geography; Humans; Logistic Models; Male; Middle Aged; Practice Patterns, Physicians'; Pyrazoles; Pyridones; Rivaroxaban; Sex Factors; Stroke; Warfarin | 2021 |
Differences in risk factors for anticoagulant-related nephropathy between warfarin and direct oral anticoagulants: Analysis of the Japanese adverse drug event report database.
Topics: Administration, Oral; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Drug-Related Side Effects and Adverse Reactions; Humans; Japan; Male; Risk Factors; Rivaroxaban; Stroke; Warfarin | 2021 |
Long-Term Risk of Major Adverse Cardiac Events in Atrial Fibrillation Patients on Direct Oral Anticoagulants.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Female; Heart Failure; Humans; Male; Medication Adherence; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Prospective Studies; Rivaroxaban | 2021 |
Non-warfarin oral anticoagulant copayments and adherence in atrial fibrillation: A population-based cohort study.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Cohort Studies; Dabigatran; Databases, Factual; Deductibles and Coinsurance; Drug Costs; Factor Xa Inhibitors; Female; Humans; Male; Medicare Part C; Medication Adherence; Middle Aged; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Sample Size; Stroke; Thiazoles; United States; Warfarin | 2021 |
A Real-world Experience of the Safety and Efficacy of Non-vitamin K Oral Anticoagulants Versus Warfarin in Patients with Non-valvular Atrial Fibrillation-A Single-centre Retrospective Cohort Study in Singapore.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Male; Middle Aged; Retrospective Studies; Rivaroxaban; Singapore; Stroke; Vitamin K; Warfarin; Young Adult | 2020 |
Cost-effectiveness analysis of dabigatran, rivaroxaban and warfarin in the prevention of stroke in patients with atrial fibrillation in China.
Topics: Anticoagulants; Atrial Fibrillation; China; Cost-Benefit Analysis; Dabigatran; Humans; Quality-Adjusted Life Years; Rivaroxaban; Stroke; Warfarin | 2021 |
Effectiveness and safety of non-vitamin K antagonist oral anticoagulants in Asian patients with atrial fibrillation and valvular heart disease.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Heart Valve Diseases; Humans; Retrospective Studies; Rivaroxaban; Stroke; Treatment Outcome | 2021 |
Bleeding Risk of Direct Oral Anticoagulants in Patients With Heart Failure And Atrial Fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Heart Failure; Humans; Retrospective Studies; Rivaroxaban; Stroke | 2021 |
Idarucizumab Reversal of Dabigatran in Patients with Acute Ischemic Stroke and Intracranial Hemorrhage: Comparison with Non-idarucizumab-Treated Patients.
Topics: Administration, Intravenous; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antithrombins; Dabigatran; Factor Xa Inhibitors; Female; Humans; Intracranial Hemorrhages; Ischemic Stroke; Male; Middle Aged; Prospective Studies; Pyrazoles; Pyridones; Rivaroxaban; Treatment Outcome | 2021 |
Direct oral anticoagulant plasma level measurement in clinical practice: A French single-institution retrospective study.
Topics: Administration, Oral; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; France; Humans; Pharmaceutical Preparations; Pyridones; Retrospective Studies; Rivaroxaban | 2021 |
Risks of post-colonoscopic polypectomy bleeding and thromboembolism with warfarin and direct oral anticoagulants: a population-based analysis.
Topics: Aged; Anticoagulants; Blood Transfusion; Cohort Studies; Colonic Polyps; Colonoscopy; Dabigatran; Factor Xa Inhibitors; Gastrointestinal Hemorrhage; Hong Kong; Humans; Male; Postoperative Complications; Pyrazoles; Pyridones; Retrospective Studies; Risk Assessment; Rivaroxaban; Thromboembolism; Warfarin | 2022 |
Predicting major bleeding among hospitalized patients using oral anticoagulants for atrial fibrillation after discharge.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Databases, Factual; Female; Gastrointestinal Hemorrhage; Hemorrhage; Hospitalization; Humans; Intracranial Hemorrhages; Male; Pyrazoles; Pyridones; Regression Analysis; Rivaroxaban; Warfarin | 2021 |
Current status of oral anticoagulant adherence in Japanese patients with atrial fibrillation: A claims database analysis.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Japan; Pyridones; Retrospective Studies; Rivaroxaban; Stroke | 2021 |
Comparative study of adverse drug reactions among direct-acting oral anticoagulants and vitamin K antagonists using the EudraVigilance database.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Dabigatran; Databases, Factual; Drug-Related Side Effects and Adverse Reactions; Female; Gastrointestinal Diseases; Humans; Male; Middle Aged; Pharmacovigilance; Pyrazoles; Pyridones; Rivaroxaban; Vitamin K; Young Adult | 2021 |
Clinical and Economic Outcomes Among Nonvalvular Atrial Fibrillation Patients With Coronary Artery Disease and/or Peripheral Artery Disease.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cause of Death; Coronary Artery Disease; Dabigatran; Embolism; Female; Health Care Costs; Hemorrhage; Humans; Male; Mortality; Myocardial Infarction; Peripheral Arterial Disease; Propensity Score; Proportional Hazards Models; Pyrazoles; Pyridones; Rivaroxaban; Stroke; United States; Warfarin | 2021 |
[Effect of anticoagulant therapy on the course of COVID-19 in comorbid patients].
Topics: Acetylcysteine; Aged; Aged, 80 and over; Anticoagulants; Antiviral Agents; Atrial Fibrillation; Azithromycin; Cohort Studies; Comorbidity; Coronary Disease; COVID-19; COVID-19 Drug Treatment; Dabigatran; Disseminated Intravascular Coagulation; Female; Humans; Hypertension; Indoles; Interferon alpha-2; Intracranial Arteriosclerosis; Male; Middle Aged; Pyrazoles; Pyridones; Rivaroxaban; SARS-CoV-2; Severity of Illness Index; Survival Analysis | 2021 |
Treatment with the direct oral anticoagulants (DOACs) apixaban and rivaroxaban associated with significant worsening of behavioural and psychological symptoms of dementia (BPSD).
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Dabigatran; Dementia; Humans; Pyrazoles; Pyridones; Rivaroxaban | 2021 |
Real-life data of major and minor bleeding events with direct oral anticoagulants in the one-year follow-up period: The NOAC-TURK study.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Follow-Up Studies; Hemorrhage; Humans; Middle Aged; Prospective Studies; Pyridones; Rivaroxaban; Stroke | 2021 |
The Use of Novel Non-Vitamin K Antagonist Oral Anticoagulants Following Closure of the Left Atrial Appendage: Preliminary Results of Clinical Follow-Up.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Appendage; Atrial Fibrillation; Dabigatran; Female; Humans; Male; Middle Aged; Retrospective Studies; Rivaroxaban | 2021 |
Proton Pump Inhibitor Co-Therapy in Patients with Atrial Fibrillation Treated with Oral Anticoagulants and a Prior History of Upper Gastrointestinal Tract Bleeding.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Gastrointestinal Hemorrhage; Humans; Proton Pump Inhibitors; Rivaroxaban; Stroke; Upper Gastrointestinal Tract; Warfarin | 2022 |
Real-world effectiveness and safety of rivaroxaban versus warfarin among non-valvular atrial fibrillation patients with obesity in a US population.
Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Obesity; Retrospective Studies; Rivaroxaban; Stroke; Treatment Outcome; Warfarin | 2021 |
Treatment with direct oral anticoagulants or warfarin and the risk for incident diabetes among patients with atrial fibrillation: a population-based cohort study.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Databases, Factual; Diabetes Mellitus; Factor Xa Inhibitors; Female; Hong Kong; Humans; Incidence; Male; Middle Aged; Pyrazoles; Pyridones; Retrospective Studies; Risk Assessment; Risk Factors; Rivaroxaban; Sex Factors; Time Factors; Treatment Outcome; Warfarin | 2021 |
Effectiveness and Safety of Direct Oral Anticoagulants Versus Warfarin in Patients With Valvular Atrial Fibrillation : A Population-Based Cohort Study.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cerebral Hemorrhage; Comparative Effectiveness Research; Dabigatran; Embolism; Female; Follow-Up Studies; Gastrointestinal Hemorrhage; Humans; Ischemic Stroke; Male; Propensity Score; Pyrazoles; Pyridones; Retrospective Studies; Risk Factors; Rivaroxaban; Treatment Outcome; Warfarin | 2021 |
Burden of oral anticoagulation in embolic stroke of undetermined source without atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Aspirin; Clinical Trials as Topic; Cost-Benefit Analysis; Dabigatran; Drug Costs; Embolic Stroke; Hemorrhage; Humans; Ischemic Stroke; Models, Economic; Recurrence; Retrospective Studies; Risk Assessment; Risk Factors; Rivaroxaban; Secondary Prevention; Time Factors; Treatment Outcome | 2021 |
Comment on the article by Toorop et al.: "The relationship between DOAC levels and clinical outcomes: The measures tell the tale".
Topics: Dabigatran; Humans; Rivaroxaban | 2021 |
Adherence to direct oral anticoagulant treatment for atrial fibrillation in the Netherlands: A surveillance study.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Medication Adherence; Middle Aged; Netherlands; Pyridones; Rivaroxaban; Stroke | 2021 |
[Efficiency of the Decision-Making Module in the Personalized Choice of an Anticoagulant].
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Middle Aged; Pyridones; Rivaroxaban; Stroke; Warfarin | 2021 |
Adverse Events Associated With the Addition of Aspirin to Direct Oral Anticoagulant Therapy Without a Clear Indication.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Dabigatran; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Pyrazoles; Pyridines; Pyridones; Registries; Rivaroxaban; Thiazoles; Venous Thromboembolism | 2021 |
2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Pyridones; Rivaroxaban; Stroke | 2021 |
Acute liver failure after changing oral anticoagulant from apixaban to rivaroxaban.
Topics: Administration, Oral; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Liver Failure, Acute; Male; Pyrazoles; Pyridones; Rivaroxaban | 2021 |
[Is one DOAC better than another?]
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Drug Administration Schedule; Female; Hemorrhage; Humans; Male; Pyrazoles; Pyridones; Rivaroxaban; Thromboembolism; Treatment Outcome | 2021 |
How lower doses of direct oral anticoagulants are interpreted in clinical practice: a national survey of the Italian Atherosclerosis, Thrombosis and Vascular Biology (ATVB) Study Group.
Topics: Administration, Oral; Anticoagulants; Atherosclerosis; Atrial Fibrillation; Dabigatran; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Humans; Italy; Pyrazoles; Pyridines; Pyridones; Renal Insufficiency; Rivaroxaban; Surveys and Questionnaires; Thiazoles; Thrombosis; Treatment Outcome | 2021 |
Comparison of potential pharmacokinetic drug interactions in patients with atrial fibrillation and changing from warfarin to non-vitamin K oral anticoagulant therapy.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Vitamin K; Warfarin | 2021 |
Use of Non-Vitamin K Antagonist Oral Anticoagulants Among Patients with Nonvalvular Atrial Fibrillation and Multimorbidity.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Multimorbidity; Retrospective Studies; Rivaroxaban; Stroke | 2021 |
Effectiveness and safety of oral anticoagulants in elderly patients with atrial fibrillation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Embolism; Female; Hemorrhage; Humans; Male; Rivaroxaban; Stroke; Warfarin | 2022 |
RHEDAR study: Determination of the risk of gastrointestinal hemorrhage in treatment with dabigatran, acenocoumarol and rivaroxaban.
Topics: Acenocoumarol; Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Clopidogrel; Dabigatran; Female; Gastrointestinal Hemorrhage; Humans; Male; Retrospective Studies; Rivaroxaban; Warfarin | 2021 |
Topics: Administration, Oral; Aged; Aged, 80 and over; Alzheimer Disease; Angiotensin II; Animals; Antithrombins; Atrial Fibrillation; Body Mass Index; Catheter Ablation; Cohort Studies; Dabigatran; Dogs; Embolism; Factor Xa Inhibitors; Female; Genotype; Hemorrhage; Humans; Hypertension; Hypertrophy, Left Ventricular; Incidence; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 3; Middle Aged; Norepinephrine; Obesity; Polymorphism, Single Nucleotide; Retrospective Studies; Rivaroxaban; Stroke; Sympathectomy | 2017 |
Dose specific effectiveness and safety of DOACs in patients with non-valvular atrial fibrillation: A Canadian retrospective cohort study.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Canada; Cohort Studies; Dabigatran; Humans; Pyridones; Retrospective Studies; Rivaroxaban; Stroke | 2021 |
Risk of Severe Abnormal Uterine Bleeding Associated with Rivaroxaban Compared with Apixaban, Dabigatran and Warfarin.
Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Humans; Male; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Uterine Hemorrhage; Warfarin | 2021 |
Laboratory assessment of the direct oral anticoagulants: who can benefit?
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Brain Ischemia; Dabigatran; Humans; Laboratories; Pyridones; Rivaroxaban; Stroke | 2021 |
Use of oral anticoagulants in patients with valvular atrial fibrillation: findings from the NCDR PINNACLE Registry.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Humans; Male; Practice Patterns, Physicians'; Pyrazoles; Pyridines; Pyridones; Registries; Risk Factors; Rivaroxaban; Stroke; Thiazoles; Warfarin | 2021 |
Evaluation of Prescribing Practices and Outcomes Using Direct-acting Oral Anticoagulants After Cardiac Surgery.
Topics: Administration, Oral; Adult; Anticoagulants; Atrial Fibrillation; Cardiac Surgical Procedures; Dabigatran; Factor Xa Inhibitors; Humans; Pyridones; Retrospective Studies; Rivaroxaban; Stroke | 2021 |
The debated issue of direct oral anticoagulants correct dosing: When even the reviewer is confused.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Pyridones; Rivaroxaban; Stroke | 2021 |
Persistence and adherence to non-vitamin K antagonist oral anticoagulant treatment in patients with atrial fibrillation across five Western European countries.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Pyridones; Rivaroxaban; Stroke; Warfarin | 2021 |
Evaluation of rivaroxaban-, apixaban- and dabigatran-associated hemorrhagic events using the FDA-Adverse event reporting system (FAERS) database.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Warfarin | 2021 |
Bleeding complications in patients with gastrointestinal cancer and atrial fibrillation treated with oral anticoagulants.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cohort Studies; Confidence Intervals; Dabigatran; Denmark; Factor Xa Inhibitors; Female; Gastrointestinal Neoplasms; Hemorrhage; Humans; Male; Proportional Hazards Models; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Warfarin | 2021 |
Incidence of abnormal uterine bleeding in a multicenter implementation study using apixaban and rivaroxaban to treat venous thromboembolism.
Topics: Anticoagulants; Dabigatran; Female; Humans; Incidence; Pyrazoles; Pyridones; Rivaroxaban; Uterine Hemorrhage; Venous Thromboembolism | 2021 |
Impact of a commercially available DOAC absorbent on two integrated procedures for lupus anticoagulant detection.
Topics: Administration, Oral; Anticoagulants; Antiphospholipid Syndrome; Dabigatran; Humans; Lupus Coagulation Inhibitor; Pyridones; Rivaroxaban | 2021 |
Interlaboratory Performance in Measurement of Dabigatran and Rivaroxaban.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Blood Coagulation Tests; Dabigatran; Humans; Partial Thromboplastin Time; Pyrazoles; Pyridones; Rivaroxaban | 2022 |
Potential Dexamethasone-Direct Oral Anticoagulant Drug Interaction: Is This a Concern in COVID?
Topics: Administration, Oral; Animals; Anticoagulants; COVID-19 Drug Treatment; Dabigatran; Dexamethasone; Drug Interactions; Humans; Pyridones; Rivaroxaban; SARS-CoV-2 | 2022 |
Risk of upper gastrointestinal bleeding in patients on oral anticoagulant and proton pump inhibitor co-therapy.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Databases, Factual; Female; Gastrointestinal Hemorrhage; Humans; Incidence; Ischemic Stroke; Male; Middle Aged; Proton Pump Inhibitors; Republic of Korea; Risk; Rivaroxaban; Upper Gastrointestinal Tract; Warfarin | 2021 |
Comparison of Low-Dose Direct Acting Anticoagulant and Warfarin in patients Aged ≥80 years With Atrial Fibrillation.
Topics: Age Factors; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Intracranial Hemorrhages; Male; Multivariate Analysis; Platelet Aggregation Inhibitors; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Warfarin | 2021 |
Kidney, limb and ophthalmic complications, and death in patients with nonvalvular atrial fibrillation and type 2 diabetes prescribed rivaroxaban or warfarin: an electronic health record analysis.
Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Diabetes Mellitus, Type 2; Electronic Health Records; Eye Diseases; Humans; Kidney; Kidney Diseases; Retrospective Studies; Rivaroxaban; Stroke; Treatment Outcome; Warfarin | 2021 |
Direct Oral Anticoagulants Plasma Levels in Patients with Atrial Fibrillation at the Time of Bleeding: A Pilot Prospective Study.
Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Case-Control Studies; Dabigatran; Drug Monitoring; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Pilot Projects; Prospective Studies; Pyrazoles; Pyridones; Rivaroxaban; Time Factors; Treatment Outcome | 2021 |
Differences in activated clotting time and total unfractionated heparin dose during pulmonary vein isolation in patients on different anticoagulation therapy.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Catheter Ablation; Dabigatran; Female; Heparin; Humans; Middle Aged; Pulmonary Veins; Pyridones; Rivaroxaban | 2021 |
Effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in atrial fibrillation: a Scandinavian population-based cohort study.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Embolism; Female; Hemorrhage; Humans; Male; Rivaroxaban; Stroke; Warfarin | 2022 |
Pharmacokinetics of Direct Oral Anticoagulants in Emergency Situations: Results of the Prospective Observational RADOA-Registry.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Prospective Studies; Pyridones; Registries; Rivaroxaban | 2022 |
Evaluation of the in vitro stability of direct oral anticoagulants in blood samples under different storage conditions.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Blood Specimen Collection; Dabigatran; Humans; Middle Aged; Preservation, Biological; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles | 2021 |
Frailty and Clinical Outcomes of Direct Oral Anticoagulants Versus Warfarin in Older Adults With Atrial Fibrillation : A Cohort Study.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Frail Elderly; Humans; Male; Massachusetts; Medicare; Propensity Score; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; United States; Warfarin | 2021 |
Appropriateness of inpatient dosing of direct oral anticoagulants for atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Australia; Cross-Sectional Studies; Dabigatran; Humans; Inpatients; Pyridones; Retrospective Studies; Rivaroxaban; Stroke | 2022 |
[Atrial fibrillation in old age: risk management and features of the use of direct oral anticoagulants].
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Pyridones; Risk Management; Rivaroxaban; Russia; Stroke | 2021 |
Nonvitamin K Antagonist Oral Anticoagulant in Patients With Venous Thromboembolism and Polycythemia Vera or Essential Thrombocythemia: A Cohort Study.
Topics: Administration, Oral; Aged; Antithrombins; Dabigatran; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Polycythemia Vera; Pyrazoles; Pyridones; Recurrence; Risk Assessment; Risk Factors; Rivaroxaban; Secondary Prevention; Thrombocythemia, Essential; Time Factors; Treatment Outcome; Venous Thromboembolism | 2021 |
Risk of major bleeding and thromboembolism in Asian patients with nonvalvular atrial fibrillation using direct oral anticoagulants versus warfarin.
Topics: Administration, Oral; Anticoagulants; Asian People; Atrial Fibrillation; Cohort Studies; Dabigatran; Hemorrhage; Humans; Retrospective Studies; Rivaroxaban; Stroke; Thromboembolism; Warfarin | 2022 |
Determinants for under- and overdosing of direct oral anticoagulants and physicians' implementation of clinical pharmacists' recommendations.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Body Weight; Cross-Sectional Studies; Dabigatran; Humans; Pharmacists; Physicians; Retrospective Studies; Rivaroxaban; Stroke | 2022 |
Pharmacokinetics of Direct Oral Anticoagulants in Patients With Atrial Fibrillation and Extreme Obesity.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Humans; Male; Obesity; Rivaroxaban; Stroke | 2021 |
Derivation and validation of predictors of oral anticoagulant-related adverse events in seniors transitioning from hospital to home.
Topics: Administration, Oral; Adult; Aftercare; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Hospitals; Humans; Ontario; Patient Discharge; Pyridones; Retrospective Studies; Rivaroxaban | 2021 |
Oral Anticoagulants for Nonvalvular Atrial Fibrillation in Patients With High Risk of Gastrointestinal Bleeding.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Female; Gastrointestinal Hemorrhage; Humans; Male; Pyrazoles; Pyridones; Retrospective Studies; Risk Factors; Rivaroxaban; Treatment Outcome; United States; Warfarin | 2021 |
Dabigatran-induced oesophagitis improved by switching medication to apixaban.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Esophagitis; Humans; Pyrazoles; Pyridones; Rivaroxaban; Stroke | 2021 |
The Risk of Acute Kidney Injury with Oral Anticoagulants in Elderly Adults with Atrial Fibrillation.
Topics: Acute Kidney Injury; Age Factors; Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Comorbidity; Dabigatran; Databases, Factual; Factor Xa Inhibitors; Female; Glomerular Filtration Rate; Humans; Male; Ontario; Pyrazoles; Pyridones; Risk Assessment; Risk Factors; Rivaroxaban; Time Factors; Treatment Outcome; Warfarin | 2021 |
A retrospective study of indications and consequences of monitoring direct oral anticoagulant plasma concentrations on patient care in a university hospital: The Retro-AOD study.
Topics: Administration, Oral; Anticoagulants; Dabigatran; Hospitals; Humans; Patient Care; Pyridones; Retrospective Studies; Rivaroxaban | 2021 |
Addendum to British Society for Haematology guideline on the investigation, management and prevention of venous thrombosis in children (Br. J. Haematol. 2011; 154: 196-207).
Topics: Anticoagulants; Child; Dabigatran; Disease Management; Humans; Rivaroxaban; Venous Thrombosis | 2021 |
Mortality associated with the use of non-vitamin K antagonist oral anticoagulants in cancer patients: Dabigatran versus rivaroxaban.
Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Cause of Death; Dabigatran; Female; Gastrointestinal Hemorrhage; Hemorrhage; Humans; Male; Middle Aged; Neoplasms; Rivaroxaban; Taiwan; Venous Thromboembolism | 2021 |
Comparison of the Safety and Effectiveness of Four Direct Oral Anticoagulants in Japanese Patients with Nonvalvular Atrial Fibrillation Using Real-World Data.
Topics: Administration, Oral; Administrative Claims, Healthcare; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Hemorrhage; Humans; Ischemic Attack, Transient; Ischemic Stroke; Japan; Male; Middle Aged; Pyrazoles; Pyridines; Pyridones; Retrospective Studies; Rivaroxaban; Thiazoles | 2021 |
Direct Oral Anticoagulants and Non-valvular Atrial Fibrillation: Compliance with Dose Level Guidelines in Patients Aged 80 Years and Over.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Pyridones; Retrospective Studies; Rivaroxaban; Stroke | 2021 |
Novel bleeding prediction model in atrial fibrillation patients on new oral anticoagulants.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Bayes Theorem; Dabigatran; Hemorrhage; Humans; Hypertension; Male; Platelet Aggregation Inhibitors; Rivaroxaban; Stroke | 2022 |
Adverse events in patients taking apixaban or rivaroxaban who have undergone bariatric surgery: a retrospective case series.
Topics: Administration, Oral; Adult; Anticoagulants; Atrial Fibrillation; Bariatric Surgery; Dabigatran; Hemorrhage; Humans; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Thromboembolism; Thrombosis | 2022 |
Adherence and persistence to rivaroxaban in non-valvular atrial fibrillation patients receiving 30- or 90-day supply prescription fills.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Medicare; Medication Adherence; Prescriptions; Retrospective Studies; Rivaroxaban; Stroke; United States | 2022 |
Thromboembolic and bleeding complications following primary total knee arthroplasty : a Danish nationwide cohort study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antithrombins; Arthroplasty, Replacement, Knee; Dabigatran; Dalteparin; Denmark; Female; Fibrinolytic Agents; Follow-Up Studies; Humans; Male; Middle Aged; Perioperative Care; Postoperative Complications; Postoperative Hemorrhage; Proportional Hazards Models; Registries; Rivaroxaban; Tinzaparin; Venous Thromboembolism; Young Adult | 2021 |
Rivaroxaban Is Associated With Higher Rates of Gastrointestinal Bleeding Than Other Direct Oral Anticoagulants : A Nationwide Propensity Score-Weighted Study.
Topics: Aged; Cohort Studies; Dabigatran; Digestive System Diseases; Factor Xa Inhibitors; Female; Follow-Up Studies; Gastrointestinal Hemorrhage; Humans; Iceland; Male; Propensity Score; Pyrazoles; Pyridones; Rivaroxaban; Ulcer | 2021 |
"I just didn't want to trust it at all": Atrial fibrillation patient's treatment experience of rivaroxaban and warfarin.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; COVID-19; Dabigatran; Humans; Rivaroxaban; Stroke; Trust; Warfarin | 2022 |
Assessment of exposure to direct oral anticoagulants in elderly hospitalised patients.
Topics: Age Factors; Aged; Aged, 80 and over; Dabigatran; Drug Monitoring; Factor Xa Inhibitors; Female; Hospitalization; Humans; Male; Pyrazoles; Pyridones; Rivaroxaban; Thrombosis | 2021 |
Inter- and intra-individual concentrations of direct oral anticoagulants: The KIDOAC study.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Blood Coagulation Tests; Dabigatran; Humans; Male; Pyridones; Rivaroxaban | 2022 |
Non-persistence to Oral Anticoagulation Treatment in Patients with Non-valvular Atrial Fibrillation in the USA.
Topics: Administration, Oral; Adult; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Medicare; Pyridones; Rivaroxaban; Stroke; United States; Warfarin | 2022 |
Direct Oral Anticoagulants: Overcoming the Challenges of Managing Venous Thromboembolism in Children.
Topics: Anticoagulants; Child; Clinical Trials as Topic; Dabigatran; Factor Xa Inhibitors; Humans; Risk Factors; Rivaroxaban; Venous Thromboembolism; Vitamin K | 2022 |
Defining the duration of the dispensation of oral anticoagulants in administrative healthcare databases.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Delivery of Health Care; Humans; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke | 2022 |
Renal outcomes in Asian patients receiving oral anticoagulants for non-valvular atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Creatinine; Dabigatran; Humans; Kidney; Retrospective Studies; Rivaroxaban; Stroke; Warfarin | 2022 |
Safety and efficacy of low-dose non-vitamin K antagonist oral anticoagulants versus warfarin after left atrial appendage closure with the Watchman device.
Topics: Administration, Oral; Anticoagulants; Atrial Appendage; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Rivaroxaban; Stroke; Thrombosis; Treatment Outcome; Warfarin | 2022 |
Development and validation of an analytical method for the determination of direct oral anticoagulants (DOAC) and the direct thrombin-inhibitor argatroban by HPLC-MS/MS.
Topics: Administration, Oral; Aged; Anticoagulants; Antithrombins; Arginine; Chromatography, High Pressure Liquid; Dabigatran; Humans; Pipecolic Acids; Pyridones; Rivaroxaban; Sulfonamides; Tandem Mass Spectrometry; Thrombin | 2022 |
A retrospective study on the evaluation of the appropriateness of oral anticoagulant therapy for patients with atrial fibrillation.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; China; Dabigatran; Female; Hemorrhage; Hospitals; Humans; Inappropriate Prescribing; Male; Middle Aged; Retrospective Studies; Risk Factors; Rivaroxaban | 2021 |
Comparison of clinical outcomes of edoxaban versus apixaban, dabigatran, rivaroxaban, and vitamin K antagonists in patients with atrial fibrillation in Germany: A real-world cohort study.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Humans; Pyrazoles; Pyridines; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Thiazoles; Vitamin K | 2022 |
Cost-effectiveness of anticoagulants for preventing stroke in patients with non-valvular atrial fibrillation in mainland China.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Cost-Benefit Analysis; Dabigatran; Humans; Pyridones; Rivaroxaban; Stroke; Warfarin | 2022 |
Thrombotic events and rebleeding after hemorrhage in patients taking direct oral anticoagulants for non-valvular atrial fibrillation.
Topics: Aged; Aged, 80 and over; Atrial Fibrillation; Dabigatran; Factor Xa Inhibitors; Female; Gastrointestinal Hemorrhage; Hemorrhage; Humans; Male; Pyrazoles; Pyridines; Pyridones; Retrospective Studies; Rivaroxaban; Thiazoles; Thrombosis | 2021 |
[ANMCO Position paper: Prescription appropriateness of direct oral anticoagulants for stroke and systemic thromboembolis with non-valvular atrial fibrillation].
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Prescriptions; Pyridones; Rivaroxaban; Stroke | 2021 |
Direct Oral Anticoagulants in Cardiac Amyloidosis-Associated Heart Failure and Atrial Fibrillation.
Topics: Aged; Aged, 80 and over; Amyloidosis; Anticoagulants; Antithrombins; Atrial Fibrillation; Cardiomyopathies; Dabigatran; Factor Xa Inhibitors; Female; Heart Failure; Humans; Male; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Warfarin | 2022 |
Bleeding Risk Following Systemic Fluconazole or Topical Azoles in Patients with Atrial Fibrillation on Apixaban, Rivaroxaban, or Dabigatran.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Azoles; Cross-Over Studies; Dabigatran; Fluconazole; Hemorrhage; Humans; Pyrazoles; Pyridones; Rivaroxaban; Stroke | 2022 |
Impact of different renal function equations on direct oral anticoagulant concentrations.
Topics: Adult; Aged; Aged, 80 and over; Antithrombins; Creatinine; Cystatin C; Dabigatran; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Female; Glomerular Filtration Rate; Humans; Male; Middle Aged; Pyrazoles; Pyridones; Rivaroxaban; Vitamin K | 2021 |
Can Machine Learning from Real-World Data Support Drug Treatment Decisions? A Prediction Modeling Case for Direct Oral Anticoagulants.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Machine Learning; Retrospective Studies; Rivaroxaban; Stroke | 2022 |
Choice of oral anticoagulant prescribed by general practices in Wales: Application of Dirichlet regression and linked data.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Pyridones; Rivaroxaban; Semantic Web; Stroke; Wales | 2022 |
Different Kinetics of Activated Clotting Time Among Uninterrupted Oral Anticoagulants During Catheter Ablation Procedure.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Catheter Ablation; Dabigatran; Heparin; Humans; Kinetics; Pyridones; Rivaroxaban; Treatment Outcome; Warfarin | 2022 |
Guideline-discordant dosing of direct-acting oral anticoagulants in the veterans health administration.
Topics: Aged; Atrial Fibrillation; Dabigatran; Factor Xa Inhibitors; Humans; Rivaroxaban; Veterans Health | 2021 |
Differential effect of direct oral anticoagulants on thrombin generation and fibrinolysis in patients with atrial fibrillation and venous thromboembolism.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Fibrin Clot Lysis Time; Fibrinolysis; Humans; Rivaroxaban; Thrombin; Tissue Plasminogen Activator; Venous Thromboembolism | 2022 |
Case series of massive direct oral anticoagulant ingestion-Treatment and pharmacokinetics data.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Charcoal; Cohort Studies; Dabigatran; Eating; Hemorrhage; Humans; Middle Aged; Pyridones; Rivaroxaban | 2022 |
Appropriate dosing of the individual direct oral anticoagulants in atrial fibrillation: Differences in the questions to be answered.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Rivaroxaban | 2022 |
Newly developed modified diluted prothrombin time reagent: A multi-centre validation in patients with non-valvular atrial fibrillation under direct oral anticoagulant therapy.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Indicators and Reagents; Prothrombin Time; Pyridones; Rivaroxaban; Stroke | 2022 |
Thrombin in complex with dabigatran can still interact with PAR-1 via exosite-I and instigate loss of vascular integrity.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Factor Xa; Factor Xa Inhibitors; Humans; Receptor, PAR-1; Rivaroxaban; Thrombin | 2022 |
A Multicenter Retrospective Evaluation of Direct Oral Anticoagulants for the Treatment of Heparin-Induced Thrombocytopenia.
Topics: Administration, Oral; Adult; Anticoagulants; Dabigatran; Hemorrhage; Humans; Retrospective Studies; Rivaroxaban; Thrombocytopenia; Thrombosis | 2022 |
Anticoagulation in Pediatric Patients.
Topics: Administration, Oral; Anticoagulants; Blood Coagulation; Child; Dabigatran; Humans; Rivaroxaban; Venous Thromboembolism | 2022 |
Serum or Plasma for Quantification of Direct Oral Anticoagulants?
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Citrates; Dabigatran; Edetic Acid; Factor X; Humans; Pyridones; Rivaroxaban; Stroke | 2022 |
Plasma levels of direct oral anticoagulants in atrial fibrillation patients at the time of embolic stroke: a pilot prospective multicenter study.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Embolic Stroke; Factor Xa Inhibitors; Humans; Prospective Studies; Pyridones; Rivaroxaban; Stroke | 2022 |
Topics: Dabigatran; Hemorrhage; Humans; Rivaroxaban | 2022 |
DOAC Dipstick Testing Can Reliably Exclude the Presence of Clinically Relevant DOAC Concentrations in Circulation.
Topics: Administration, Oral; Aged; Anticoagulants; Antithrombins; Cohort Studies; Dabigatran; Factor Xa Inhibitors; Female; Humans; Prospective Studies; Pyridones; Rivaroxaban | 2022 |
Impact of Drug Interactions on Major Bleed Rates in Patients Taking Direct Oral Anticoagulants.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Dabigatran; Drug Interactions; Hemorrhage; Humans; Retrospective Studies; Rivaroxaban | 2023 |
Use of Apixaban in Atrial Fibrillation With Ritonavir-Boosted Antiretroviral Therapy: A Case Report.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; HIV Infections; Humans; Male; Pyridones; Ritonavir; Rivaroxaban; Stroke; Warfarin | 2023 |
Apixaban has superior effectiveness and safety compared to rivaroxaban in patients with commercial healthcare coverage: A population-based analysis in response to CVS 2022 formulary changes.
Topics: Anticoagulants; Dabigatran; Delivery of Health Care; Humans; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke | 2022 |
Monitoring of direct oral anticoagulants plasma levels for secondary stroke prevention.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Female; Humans; Ischemic Stroke; Male; Pyridones; Rivaroxaban; Stroke | 2022 |
Tyrosine kinase inhibitors and direct oral anticoagulants: In vitro evaluation of drug-drug interaction mediated by P-glycoprotein.
Topics: Administration, Oral; Anticoagulants; ATP Binding Cassette Transporter, Subfamily B, Member 1; Axitinib; Crizotinib; Dabigatran; Drug Interactions; Humans; Imatinib Mesylate; Neoplasms; Protein Kinase Inhibitors; Pyrazoles; Pyridones; Rivaroxaban | 2022 |
Switching of oral anticoagulants in atrial fibrillation: a cohort study using Australian general practice data.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Australia; Cohort Studies; Dabigatran; General Practice; Humans; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Warfarin | 2022 |
Comparative effectiveness and safety of non-vitamin K antagonists for atrial fibrillation in clinical practice: GLORIA-AF Registry.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Clinical Trials, Phase III as Topic; Dabigatran; Hemorrhage; Humans; Myocardial Infarction; Prospective Studies; Pyridones; Registries; Rivaroxaban; Stroke | 2022 |
Intracranial Hemorrhage Following Anticoagulant Treatment in Denmark: Spontaneous Adverse Drug Reaction Reports Versus Real-World Data.
Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Denmark; Drug-Related Side Effects and Adverse Reactions; Humans; Intracranial Hemorrhages; Pyridones; Rivaroxaban; Warfarin | 2022 |
Anticoagulation in Atrial Fibrillation Associated with Mitral Stenosis.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Factor Xa Inhibitors; Female; Humans; Mitral Valve Stenosis; Rivaroxaban; Stroke; Vitamin K; Warfarin | 2022 |
Obesity Paradox in Atrial Fibrillation and its Relation with the New Oral Anticoagulants.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Factor Xa Inhibitors; Humans; Obesity; Pyridones; Rivaroxaban; Stroke; Thrombin | 2022 |
Rivaroxaban vs Apixaban and Ischemic or Hemorrhagic Events in Patients With Atrial Fibrillation-Reply.
Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Fibrinolytic Agents; Hemorrhage; Humans; Ischemia; Pyrazoles; Pyridones; Rivaroxaban; Stroke | 2022 |
Rivaroxaban vs Apixaban and Ischemic or Hemorrhagic Events in Patients With Atrial Fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Ischemia; Pyrazoles; Pyridones; Rivaroxaban; Stroke | 2022 |
Rivaroxaban Reduces the Dabigatran Dose Required for Anticoagulation During Simulated Cardiopulmonary Bypass.
Topics: Anticoagulants; Cardiopulmonary Bypass; Dabigatran; Fibrin; Heparin; Humans; Rivaroxaban; Thrombosis | 2022 |
Frequency of hemorrhage after tooth extraction in patients treated with a direct oral anticoagulant: A multicenter cross-sectional study.
Topics: Administration, Oral; Adult; Anticoagulants; Atrial Fibrillation; Cross-Sectional Studies; Dabigatran; Hemorrhage; Humans; Male; Prospective Studies; Pyridones; Rivaroxaban; Tooth Extraction; Warfarin | 2022 |
Warfarin is associated with higher rates of epistaxis compared to direct oral anticoagulants: A nationwide propensity score-weighted study.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Epistaxis; Humans; Propensity Score; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Warfarin | 2022 |
The non-vitamin K antagonist oral anticoagulants and heparin-induced prolongation of the activated coagulation time.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Heparin; Humans; Pyridones; Rivaroxaban | 2022 |
Risk of intracranial hemorrhage between different direct oral anticoagulants in older patients seen in the emergency department with a head injury: A population-based cohort study.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Cohort Studies; Craniocerebral Trauma; Dabigatran; Emergency Service, Hospital; Humans; Intracranial Hemorrhages; Ontario; Pyridones; Retrospective Studies; Rivaroxaban | 2022 |
Pharmacological Difference Between Platelet Aggregations in Cardioembolic Stroke Patients with Direct Oral Anticoagulants: A Pilot Study.
Topics: Adenosine Diphosphate; Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Embolic Stroke; Factor Xa Inhibitors; Humans; Pilot Projects; Platelet Aggregation; Pyridones; Retrospective Studies; Rivaroxaban | 2022 |
Simvastatin, but Not Atorvastatin, Is Associated with Higher Peak Rivaroxaban Serum Levels and Bleeding: an Asian Cohort Study from Singapore.
Topics: Anticoagulants; Asian People; Atorvastatin; Atrial Fibrillation; Cohort Studies; Dabigatran; Drug Therapy, Combination; Hemorrhage; Humans; Rivaroxaban; Simvastatin; Singapore; Stroke | 2023 |
Expression of anti and pro-inflammatory genes in human endothelial cells activated by 25-hydroxycholesterol: A comparison of rivaroxaban and dabigatran.
Topics: Administration, Oral; Anticoagulants; Atherosclerosis; Atrial Fibrillation; Cytokines; Dabigatran; Endothelial Cells; Human Umbilical Vein Endothelial Cells; Humans; Hydroxycholesterols; Interleukin-18; Interleukin-23; Oxysterols; Rivaroxaban; RNA, Messenger; Transforming Growth Factor beta | 2022 |
Effectiveness and safety of oral anticoagulants in non-valvular atrial fibrillation patients with prior bleeding events: a retrospective analysis of administrative claims databases.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; Female; Hemorrhage; Humans; Male; Retrospective Studies; Rivaroxaban; Stroke; Warfarin | 2022 |
Impact of the COVID-19 pandemic on England's national prescriptions of oral vitamin K antagonist (VKA) and direct-acting oral anticoagulants (DOACs): an interrupted time series analysis (January 2019-February 2021).
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; COVID-19; Dabigatran; England; Factor Xa Inhibitors; Fibrinolytic Agents; Humans; Interrupted Time Series Analysis; Pandemics; Prescriptions; Pyridones; Rivaroxaban; Stroke; Vitamin K; Warfarin | 2022 |
Thromboembolic Events While Taking Direct Oral Anticoagulants: An Analysis of Post-market WHO Database Reports from 2012 to 2020.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Pulmonary Embolism; Pyridones; Reproducibility of Results; Rivaroxaban; Venous Thromboembolism; Venous Thrombosis; World Health Organization | 2022 |
Time Trends and Treatment Pathways in Prescribing Individual Oral Anticoagulants in Patients with Nonvalvular Atrial Fibrillation: An Observational Study of More than Three Million Patients from Europe and the United States.
Topics: Administration, Oral; Adult; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; France; Humans; Rivaroxaban; Stroke; United States | 2022 |
The changing use of anticoagulants in New Zealand.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; New Zealand; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Warfarin | 2022 |
Performance of a Qualitative Point-of-Care Strip Test to Detect DOAC Exposure at the Emergency Department: A Cohort-Type Cross-Sectional Diagnostic Accuracy Study.
Topics: Administration, Oral; Anticoagulants; Cross-Sectional Studies; Dabigatran; Emergencies; Emergency Service, Hospital; Factor Xa; Factor Xa Inhibitors; Humans; Point-of-Care Systems; Point-of-Care Testing; Prospective Studies; Pyridones; Rivaroxaban; Thrombin | 2022 |
A retrospective cohort study of the effectiveness and safety of dabigatran versus rivaroxaban in overweight patients with nonvalvular atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Overweight; Prospective Studies; Retrospective Studies; Rivaroxaban; Stroke; Warfarin | 2022 |
Drugs for treatment and prevention of venous thromboembolism.
Topics: Anticoagulants; Dabigatran; Humans; Pyridones; Rivaroxaban; Venous Thromboembolism | 2022 |
Comparison table: Some oral anticoagulants for VTE.
Topics: Administration, Oral; Anticoagulants; Dabigatran; Humans; Pyridones; Rivaroxaban; Venous Thromboembolism | 2022 |
A cohort study to assess risk of cutaneous small vessel vasculitis among users of different oral anticoagulants.
Topics: Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Humans; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Vasculitis; Warfarin | 2022 |
Differences in the predictors of left atrial appendage thrombus between men and women treated with dabigatran or rivaroxaban.
Topics: Anticoagulants; Atrial Appendage; Atrial Fibrillation; Dabigatran; Female; Heart Diseases; Humans; Male; Retrospective Studies; Rivaroxaban; Thrombosis | 2022 |
A new model to predict the risk of major gastrointestinal bleeding in patients on direct oral anticoagulants (dabigatran and rivaroxaban).
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Gastrointestinal Agents; Gastrointestinal Hemorrhage; Humans; Retrospective Studies; Rivaroxaban | 2023 |
Risk of stroke/systemic embolism, major bleeding, and associated costs in non-valvular atrial fibrillation patients who initiated apixaban, dabigatran, or rivaroxaban compared with warfarin in the United States medicare population: updated analysis.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; Hemorrhage; Humans; Medicare; Pyridones; Rivaroxaban; Stroke; United States; Warfarin | 2022 |
Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation and Valve Replacement or Repair.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Ischemic Stroke; Medicare; Pyridones; Rivaroxaban; Stroke; United States; Warfarin | 2022 |
Apixaban versus other anticoagulants in patients with nonvalvular fibrillation: a comparison of all-cause and event-related costs in real-life setting in France.
Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; France; Hemorrhage; Humans; Retrospective Studies; Rivaroxaban; Stroke | 2023 |
Protocolized management of bleeding in hospitals in The Netherlands in patients treated with direct oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Dabigatran; Hemorrhage; Hospitals; Humans; Netherlands; Pyridones; Rivaroxaban | 2023 |
Intravenous Thrombolysis With Alteplase at 0.6 mg/kg in Patients With Ischemic Stroke Taking Direct Oral Anticoagulants.
Topics: Administration, Intravenous; Aged; Anticoagulants; Dabigatran; Female; Humans; Intracranial Hemorrhages; Ischemic Stroke; Male; Rivaroxaban; Thrombolytic Therapy; Tissue Plasminogen Activator; Treatment Outcome | 2022 |
[Reversal agents for severe bleeding associated with direct oral anticoagulants].
Topics: Administration, Oral; Anticoagulants; Dabigatran; Hemorrhage; Heparin; Humans; Rivaroxaban; Vitamin K | 2022 |
Application of Activators Ecarin and Factor Xa in Thrombelastography for Measurement of Anticoagulant Effect of Direct Oral Anticoagulants Using TEG 5000.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Dabigatran; Factor Xa; Factor Xa Inhibitors; Fibrinogen; Hemorrhage; Humans; Kaolin; Male; Pyridones; Rivaroxaban; Thrombelastography | 2022 |
Effect of tramadol and DOACs with special attention to dabigatran on concomitant use, on the risk of mayor bleeding using BIFAP database in Spain.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Gastrointestinal Hemorrhage; Humans; Rivaroxaban; Spain; Stroke; Tramadol | 2023 |
Coagulation assays and direct oral anticoagulant levels among patients having an elective surgery or procedure.
Topics: Administration, Oral; Anticoagulants; Blood Coagulation Tests; Dabigatran; Humans; Partial Thromboplastin Time; Pyrazoles; Pyridones; Rivaroxaban | 2022 |
Bleeding risk of oral anticoagulants in liver cirrhosis.
Topics: Administration, Oral; Adolescent; Adult; Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Liver Cirrhosis; New Zealand; Retrospective Studies; Rivaroxaban; Stroke; Warfarin | 2022 |
Comparison of Dabigatran Versus Warfarin Treatment for the Prevention of New Cerebral Lesions in Valvular Atrial Fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Rivaroxaban; Stroke; Warfarin | 2022 |
Reply to the Comment on "Comparison of Dabigatran Versus Warfarin Treatment for Prevention of New Cerebral Lesions in Valvular Atrial Fibrillation".
Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Rivaroxaban; Warfarin | 2022 |
Nine-Year Trends in Prevention of Thromboembolic Complications in Elderly Patients with Atrial Fibrillation Treated with NOACs.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Hemorrhage; Humans; Hypertension; Male; Pyridones; Rivaroxaban; Stroke; Thromboembolism | 2022 |
Do Patients with Atrial Fibrillation and a History of Ischemic Stroke Overuse Reduced Doses of NOACs?-Results of the Polish Atrial Fibrillation (POL-AF) Registry.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Fibrinolytic Agents; Humans; Ischemic Stroke; Poland; Prospective Studies; Pyridones; Registries; Rivaroxaban | 2022 |
Using primary care data to assess comparative effectiveness and safety of apixaban and rivaroxaban in patients with nonvalvular atrial fibrillation in the UK: an observational cohort study.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Hemorrhage; Humans; Ischemic Attack, Transient; Myocardial Infarction; Primary Health Care; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; United Kingdom; Warfarin | 2022 |
Comparative non-persistence in the first year of treatment with oral anticoagulants in patients with atrial fibrillation: A French comprehensive nationwide study.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Retrospective Studies; Rivaroxaban; Stroke | 2022 |
Protocols for perioperative management of direct oral anticoagulants in hospitals: opportunities for improvement.
Topics: Administration, Oral; Anticoagulants; Antidotes; Atrial Fibrillation; Dabigatran; Hemorrhage; Hospitals; Humans; Pyridones; Rivaroxaban | 2023 |
Comparative Effectiveness and Safety Between Apixaban, Dabigatran, Edoxaban, and Rivaroxaban Among Patients With Atrial Fibrillation : A Multinational Population-Based Cohort Study.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Clinical Trials as Topic; Cohort Studies; Dabigatran; Embolism; Humans; Ischemic Stroke; Renal Insufficiency, Chronic; Rivaroxaban; United States | 2022 |
Head-to-head efficacy and safety of rivaroxaban, apixaban, and dabigatran in an observational nationwide targeted trial.
Topics: Anticoagulants; Atrial Fibrillation; Brain Ischemia; Dabigatran; Gastrointestinal Hemorrhage; Humans; Retrospective Studies; Rivaroxaban; Stroke | 2022 |
Trends in direct oral anticoagulant (DOAC) prescribing in English primary care (2014-2019).
Topics: Administration, Oral; Adolescent; Adult; Anticoagulants; Atrial Fibrillation; Dabigatran; Factor Xa Inhibitors; Humans; Male; Primary Health Care; Pyridones; Retrospective Studies; Rivaroxaban; Stroke | 2023 |
Proportion of Patients on Warfarin Therapy Who Are Eligible for Conversion to a Direct Oral Anticoagulant in the Setting of COVID-19.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; COVID-19; Cross-Sectional Studies; Dabigatran; Humans; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Warfarin | 2023 |
Assessment of DOAC in GEriatrics (Adage Study): Rivaroxaban/Apixaban Concentrations and Thrombin Generation Profiles in NVAF Very Elderly Patients.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Humans; Prospective Studies; Pyridones; Rivaroxaban; Stroke; Thrombin | 2023 |
Direct Oral Anticoagulant (DOAC) Dosing in Patients with Non-valvular Atrial Fibrillation (NVAF) in the United Kingdom: A Retrospective Cohort Study Using CPRD Gold Database.
Topics: Administration, Oral; Adult; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Male; Pyridones; Retrospective Studies; Rivaroxaban; Stroke | 2023 |
Trends in utilization, reimbursement, and price for DOACs and warfarin in the US Medicaid population from 2000 to 2020.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Medicaid; Retrospective Studies; Rivaroxaban; United States; Warfarin | 2023 |
Trends of use and factors that determine the choice of oral anticoagulants in women and men with atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Hemorrhage; Humans; Male; Renal Insufficiency, Chronic; Rivaroxaban; Warfarin | 2022 |
Predictors of use of direct oral anticoagulants in acute pulmonary embolism.
Topics: Acute Disease; Anticoagulants; Dabigatran; Fibrinolytic Agents; Hemorrhage; Humans; Pulmonary Embolism; Rivaroxaban | 2022 |
Periprocedural Management of Patients With Atrial Fibrillation Receiving a Direct Oral Anticoagulant Undergoing a Digestive Endoscopy.
Topics: Administration, Oral; Adult; Anticoagulants; Atrial Fibrillation; Child; Cohort Studies; Dabigatran; Endoscopy, Gastrointestinal; Female; Gastrointestinal Hemorrhage; Humans; Male; Rivaroxaban | 2023 |
Drug-drug interactions with direct oral anticoagulants: development of a consensus list for ambulatory care.
Topics: Administration, Oral; Anticoagulants; Consensus; Dabigatran; Drug Interactions; Humans; Rivaroxaban | 2023 |
Delaying clinical events among patients with non-valvular atrial fibrillation treated with oral anticoagulants: Insights from the ARISTOPHANES study.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; Hemorrhage; Humans; Medicare; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; United States; Warfarin | 2023 |
Impact of increased kidney function on clinical and biological outcomes in real-world patients treated with Direct Oral Anticoagulants.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Factor Xa Inhibitors; Heparin, Low-Molecular-Weight; Humans; Kidney; Prospective Studies; Pyridones; Rivaroxaban | 2022 |
Safety of direct oral anticoagulants in patients with advanced solid tumors receiving anti-VEGF agents: a retrospective study.
Topics: Administration, Oral; Aged; Anticoagulants; Bevacizumab; Dabigatran; Female; Hemorrhage; Humans; Neoplasms; Pulmonary Embolism; Retrospective Studies; Rivaroxaban | 2022 |
Effectiveness and Safety of Direct Oral Anticoagulants Among Patients with Non-valvular Atrial Fibrillation and Multimorbidity.
Topics: Administration, Oral; Adult; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; Hemorrhage; Humans; Medicare; Multimorbidity; Pyridones; Risk Assessment; Rivaroxaban; Stroke; United States; Warfarin | 2023 |
The dose-response of direct oral anticoagulants is non-linear at plasma levels below 100 ng/ml.
Topics: Administration, Oral; Anticoagulants; Dabigatran; Humans; Plasma; Pyridones; Rivaroxaban | 2023 |
Comparison of the effectiveness and safety of direct oral anticoagulants: a nationwide propensity score-weighted study.
Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Myocardial Infarction; Propensity Score; Rivaroxaban; Stroke | 2023 |
Drug-drug interaction between dexamethasone and direct-acting oral anticoagulants: a nested case-control study in the National COVID Cohort Collaborative (N3C).
Topics: Administration, Oral; Adult; Anticoagulants; Atrial Fibrillation; Case-Control Studies; COVID-19; COVID-19 Drug Treatment; Dabigatran; Dexamethasone; Drug Interactions; Factor Xa Inhibitors; Humans; Pyridones; Retrospective Studies; Rivaroxaban | 2022 |
Comparison of the real-life clinical outcomes of warfarin with effective time in therapeutic range and non-vitamin K antagonist oral anticoagulants: Insight from the AFTER-2 trial.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Ischemic Attack, Transient; Pyridones; Rivaroxaban; Stroke; Warfarin | 2023 |
Comparison of medication adherence to different oral anticoagulants: population-based cohort study.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Female; Humans; Medication Adherence; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Warfarin | 2023 |
Reduced dose direct oral anticoagulants compared with warfarin with high time in therapeutic range in nonvalvular atrial fibrillation.
Topics: Administration, Oral; Adolescent; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Gastrointestinal Hemorrhage; Humans; Pyridones; Rivaroxaban; Stroke; Warfarin | 2023 |
Comparison of the Treatment Persistence Among 4 Direct Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation: A 5-Year Retrospective Cohort Study.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Pyridones; Retrospective Studies; Rivaroxaban; Stroke | 2023 |
Just DOAC: Use of direct-acting oral anticoagulants in pediatrics.
Topics: Administration, Oral; Anticoagulants; Child; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; Rivaroxaban; Venous Thromboembolism | 2023 |
Physiologically-based pharmacokinetic modeling to predict drug-drug interactions of dabigatran etexilate and rivaroxaban in the Chinese older adults.
Topics: Administration, Oral; Aged; Anticoagulants; ATP Binding Cassette Transporter, Subfamily B, Member 1; China; Clarithromycin; Dabigatran; Drug Interactions; East Asian People; Humans; Rivaroxaban; Verapamil | 2023 |
Safety Signal Evaluation of a Risk of Syncope and Dizziness Not Related to Bleeding or Stroke in Direct Oral Anticoagulant-treated Patients.
Topics: Administration, Oral; Adult; Anticoagulants; Atrial Fibrillation; Dabigatran; Dizziness; Hemorrhage; Humans; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Syncope | 2023 |
Retrospective analysis of gastrointestinal bleedings with direct oral anticoagulants reported to EudraVigilance.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Gastrointestinal Hemorrhage; Humans; Male; Retrospective Studies; Rivaroxaban; Stroke | 2023 |
Healthcare Resource Utilization and Costs of Rivaroxaban Versus Warfarin Among Non-valvular Atrial Fibrillation (NVAF) Patients with Diabetes in a US Population.
Topics: Adult; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Diabetes Mellitus; Female; Humans; Male; Patient Acceptance of Health Care; Retrospective Studies; Rivaroxaban; Stroke; United States; Warfarin | 2023 |
Integrating Real-World Evidence in Economic Evaluation of Oral Anticoagulants for Stroke Prevention in Non-valvular Atrial Fibrillation in a Developing Country.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Cost-Benefit Analysis; Dabigatran; Developing Countries; Humans; Pyridones; Rivaroxaban; Stroke; Warfarin | 2023 |
Comparative Effectiveness and Safety of Direct Oral Anticoagulants and Warfarin in Patients With Atrial Fibrillation and Chronic Liver Disease: A Nationwide Cohort Study.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Embolism; Hemorrhage; Humans; Ischemic Stroke; Liver Diseases; Retrospective Studies; Rivaroxaban; Stroke; Warfarin | 2023 |
Evolving Trends in Consumption of Direct Oral Anticoagulants in 65 Countries/Regions from 2008 to 2019.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Pyridones; Rivaroxaban; Stroke | 2023 |
Identifying treatment heterogeneity in atrial fibrillation using a novel causal machine learning method.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Humans; Ischemic Stroke; Pyridones; Rivaroxaban; Stroke; Warfarin | 2023 |
Real-World Evaluation of Anticoagulant Treatment Patterns in Patients with Atrial Fibrillation: Data from Multicenter ROTA Study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; Female; Humans; Male; Middle Aged; Prospective Studies; Pyridones; Rivaroxaban; Stroke; Vitamin K; Young Adult | 2023 |
Comparing the risk of dementia in subjects with atrial fibrillation using non-vitamin K antagonist oral anticoagulants versus vitamin K antagonists: a Belgian nationwide cohort study.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Belgium; Cohort Studies; Dabigatran; Dementia; Humans; Rivaroxaban; Stroke | 2023 |
Comparative Effectiveness and Safety of Oral Anticoagulants by Dementia Status in Older Patients With Atrial Fibrillation.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Comparative Effectiveness Research; Dabigatran; Dementia; Female; Hemorrhage; Humans; Ischemic Stroke; Male; Medicare; Retrospective Studies; Rivaroxaban; United States; Warfarin | 2023 |
Reversal agents for current and forthcoming direct oral anticoagulants.
Topics: Administration, Oral; Aged; Anticoagulants; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; Recombinant Proteins; Rivaroxaban; Vitamin K | 2023 |
Adherence and clinical outcomes for twice-daily versus once-daily dosing of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: Is dosing frequency important?
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Pyridones; Rivaroxaban; Stroke | 2023 |
A high-throughput liquid chromatography-tandem mass spectrometry method for simultaneous determination of direct oral anticoagulants in human plasma.
Topics: Anticoagulants; Chromatography, High Pressure Liquid; Chromatography, Liquid; Dabigatran; Humans; Reproducibility of Results; Rivaroxaban; Tandem Mass Spectrometry | 2023 |
Dabigatran Dosing Proposal for Adults With Atrial Fibrillation: Stress-Testing Renal Function Range in Real World Patients.
Topics: Administration, Oral; Adult; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; Dabigatran; Humans; Kidney; Rivaroxaban; Stroke; Warfarin | 2023 |
Cost-Effectiveness of Direct Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation in Hong Kong.
Topics: Anticoagulants; Atrial Fibrillation; Cost-Benefit Analysis; Dabigatran; Hong Kong; Humans; Rivaroxaban; Warfarin | 2023 |
Efficacy and Safety of Direct Oral Anticoagulants in Patients With Atrial Fibrillation Combined With Hypertension: A Multicenter, Retrospective Cohort Study.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Hypertension; Retrospective Studies; Rivaroxaban; Stroke; Thromboembolism; Warfarin | 2023 |
Direct oral anticoagulants: patient reported adherence and minor bleedings.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Patient Reported Outcome Measures; Pyridones; Rivaroxaban; Stroke | 2023 |
Impact of Direct Oral Anticoagulant Concentration on Clinical Outcomes in Asian Patients with Atrial Fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Pyridones; Rivaroxaban; Stroke; Treatment Outcome | 2023 |
Effectiveness and safety of secondary prevention of non-vitamin K oral anticoagulants use by drug type in Asian patients.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; Hemorrhage; Humans; Ischemic Stroke; Retrospective Studies; Rivaroxaban; Secondary Prevention; Stroke; Thromboembolism; Vitamin K; Warfarin | 2023 |
[Increased menstrual bleeding among direct oral anticoagulant users].
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Hemorrhage; Humans; Menorrhagia; Middle Aged; Rivaroxaban | 2023 |
DOAC Dosing Discordance Using Different Estimates of Kidney Function and Outcomes.
Topics: Administration, Oral; Adult; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Kidney; Pyridones; Renal Insufficiency, Chronic; Retrospective Studies; Rivaroxaban; Stroke; Thromboembolism | 2023 |
Prevalence and bleeding risk associated with the concomitant use of direct oral anticoagulants and antiarrhythmic drugs in patients with atrial fibrillation, based on the French healthcare insurance database.
Topics: Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Delivery of Health Care; Hemorrhage; Humans; Male; Prevalence; Pyridones; Rivaroxaban; Stroke | 2023 |
Safety and mortality outcomes for direct oral anticoagulants in renal transplant recipients.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Gastrointestinal Hemorrhage; Humans; Kidney Transplantation; Retrospective Studies; Rivaroxaban; Stroke; Warfarin | 2023 |
OKL-1111, A modified cyclodextrin as a potential universal reversal agent for anticoagulants.
Topics: Administration, Oral; Animals; Anticoagulants; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Rabbits; Rats; Rivaroxaban; Thrombin | 2023 |
Risk for Bleeding-Related Hospitalizations During Use of Amiodarone With Apixaban or Rivaroxaban in Patients With Atrial Fibrillation : A Retrospective Cohort Study.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; Female; Flecainide; Hemorrhage; Hospitalization; Humans; Ischemic Stroke; Male; Medicare; Retrospective Studies; Rivaroxaban; Sotalol; Stroke; United States | 2023 |
The efficacy of direct oral anticoagulants in patients on concomitant treatment with levetiracetam.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Humans; Levetiracetam; Male; Pyridones; Rivaroxaban; Stroke; Venous Thromboembolism | 2023 |
A Real-World Evaluation of Primary Medication Nonadherence in Patients with Nonvalvular Atrial Fibrillation Prescribed Oral Anticoagulants in the United States.
Topics: Administration, Oral; Adult; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Medication Adherence; Retrospective Studies; Rivaroxaban; Stroke; United States; Warfarin | 2023 |
Effectiveness and safety of Dabigatran 110 mg versus 150 mg for Stroke Prevention in Patients with Atrial Fibrillation at High Bleeding Risk.
Topics: Administration, Oral; Adult; Anticoagulants; Atrial Fibrillation; Creatinine; Dabigatran; Embolism; Hemorrhage; Humans; Pyridones; Rivaroxaban; Stroke; Treatment Outcome | 2023 |
ORal anticoaGulants in diAbetic and Nondiabetic patients with nOn-valvular atrial fibrillatioN (ORGANON).
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Diabetes Mellitus; Hemorrhage; Humans; Rivaroxaban; Stroke | 2023 |
Utilization outcomes of direct oral anticoagulants in Medicare patients.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Medicare; Retrospective Studies; Rivaroxaban; United States; Venous Thromboembolism; Warfarin | 2023 |
Comparison of bleeding and ischemic events with apixaban vs. rivaroxaban in triple antithrombotic therapy regimens.
Topics: Adult; Anticoagulants; Atrial Fibrillation; Dabigatran; Fibrinolytic Agents; Hemorrhage; Humans; Pyridones; Retrospective Studies; Rivaroxaban; Stroke | 2023 |
Baseline Characteristics and 3-Year Outcome of Nonvalvular Atrial Fibrillation Patients Treated with the Four Direct Oral Anticoagulants (DOACs).
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Hemorrhage; Humans; Male; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Thromboembolism | 2023 |
Safety and efficacy of oral anticoagulants in extreme weights.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Obesity; Pyridones; Rivaroxaban; Thinness; Venous Thromboembolism; Warfarin | 2023 |
Comparison of the efficacy and safety between rivaroxaban and dabigatran in the treatment of acute portal vein thrombosis in cirrhosis.
Topics: Administration, Oral; Anticoagulants; Dabigatran; End Stage Liver Disease; Hemorrhage; Humans; Liver Cirrhosis; Portal Vein; Retrospective Studies; Rivaroxaban; Severity of Illness Index; Treatment Outcome; Venous Thrombosis | 2023 |
Clinical comprehensive evaluation of direct oral anticoagulants for patients with atrial fibrillation in China.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Pyridones; Rivaroxaban; Stroke; Warfarin | 2023 |
Real-world data emulating randomized controlled trials of non-vitamin K antagonist oral anticoagulants in patients with venous thromboembolism.
Topics: Administration, Oral; Aged; Anticoagulants; Dabigatran; Female; Humans; Male; Middle Aged; Randomized Controlled Trials as Topic; Rivaroxaban; Venous Thromboembolism | 2023 |
Characteristics of patients with atrial fibrillation treated with direct oral anticoagulants and new insights into inappropriate dosing: results from the French National Prospective Registry: PAFF.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Kidney Failure, Chronic; Registries; Retrospective Studies; Rivaroxaban; Stroke | 2023 |
Utilization of direct oral anticoagulants in a Saudi tertiary hospital: a retrospective cohort study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Humans; Male; Middle Aged; Pulmonary Embolism; Retrospective Studies; Rivaroxaban; Saudi Arabia; Stroke; Tertiary Care Centers; Venous Thrombosis | 2023 |
Benefits and Harms of Standard Versus Reduced-Dose Direct Oral Anticoagulant Therapy for Older Adults With Multiple Morbidities and Atrial Fibrillation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Medicare; Morbidity; Retrospective Studies; Rivaroxaban; Stroke; United States | 2023 |
Gastrointestinal bleeding with direct oral anticoagulants in patients with atrial fibrillation and anaemia.
Topics: Administration, Oral; Anemia; Anticoagulants; Atrial Fibrillation; Dabigatran; Gastrointestinal Hemorrhage; Humans; Pyridones; Rivaroxaban; Stroke | 2023 |
Comparing Efficacy and Safety Between Patients With Atrial Fibrillation Taking Direct Oral Anticoagulants or Warfarin After Direct Oral Anticoagulant Failure.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Ischemic Stroke; Retrospective Studies; Rivaroxaban; Stroke; Subarachnoid Hemorrhage; Vitamin K; Warfarin | 2023 |